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Abstract  
 
MICAL from the “Molecule Interacting with CasL” indicates a family of cytoplasmic multidomain 
proteins conserved from insects to humans, which participates in the control of cytoskeleton dynamics. A 
unique feature of MICAL proteins is the presence of a catalytic N-terminal flavoprotein 
monoonoxygenase-like (MO) domain that is followed by several protein interaction domains, namely: a 
calponin homology (CH) domain, a LIM domain and a C-terminal region containing potential coiled-coil 
motifs. 
In neurons MICAL1 is an essential component for the transduction of the semaphorin signaling 
downstream of plexin by catalyzing a NADPH-dependent F-actin depolymerization through the N-
terminal flavoprotein domain. But it may also control integrin pathway and microtubules assembly 
through interaction with CasL and CRMP, respectively and apoptosis through interaction with NDR1. 
The MICAL2 and MICAL3 isoforms are implicated in vesicles trafficking and gene transcription.  
The aim of this project is to contribute to define the function of human MICAL1 by characterizing the 
catalytic properties of the MO domain and how they are modulated by its CH, LIM and C-terminal 
domains and, eventually, by its interacting proteins.     
The human MICAL1 form containing the isolated MO domain (55.1 kDa; pI 9) and the form 
comprising both the MO and the CH domains (MOCH; 68.5 kDa; pI 7.7) have been produced according 
to the procedures available in the laboratory, which were further optimized. The full-length MICAL1 
(MICAL; 119 kDa; pI, 6.2) and the form lacking the C-terminal region (MOCHLIM; 86.4 kDa; pI, 6.7) 
were produced in E.coli cells and their purification protocols were set-up exploiting the engineered C-
terminal His6-tag. All the purified MICAL forms are stable and greater than 95% homogeneous.  
MICAL forms are isolated with the correct complement of FAD bound to the MO domain and zinc 
ions bound to the LIM domain, which predicts the formation of two zinc fingers. The absorption spectra 
of all MICAL forms are similar to each other, with an extinction coefficient at 458 nm of ≈8.1 mM-1cm-1 
similar to that previously determined for the isolated MO domain, indicating that the CH, LIM and C-
terminal regions do not alter the conformation of the catalytic domain. However, the LIM domain causes 
MOCHLIM to oligomerize to yield dimers, trimers and higher order aggregates, while the full-length 
protein yielded stable dimers as opposed to the monomeric state of MO and MOCH forms.  
All MICAL forms catalyze a NADPH oxidase (H2O2-producing) activity, which is associated with the 
MO domain. By combining steady-state kinetic measurements of the reaction as a function of pH and of 
solvent viscosity we concluded that the CH, LIM and C-terminal domains lead to a progressive lowering 
of the catalytic efficiency (MO, ≈165 s-1mM-1; MOCH, ≈18.5 s-1mM-1; MOCHLIM, ≈15 s-1mM-1; 
MICAL, ≈0.75 s-1mM-1) of the reaction due to an increase of Km for NADPH from ≈20 μM (MO), to 
≈130 μM (MOCH), ≈230 μM (MOCHLIM) and ≈370 μM (MICAL). The 200-fold drop of the catalytic 
efficiency of the full-length MICAL compared to that of MO is also due to a ≈10-fold decrease of kcat. 
The study of the pH and viscosity dependence of the NADPH oxidase reaction of MICAL forms led us to 
conclude that the observed changes in the values of the kinetic parameters are not due to changes in rate 
determining steps of the reaction taking place within MO. The increase of KNADPH correlates with a 
decrease of the positive charge of the protein due to the acidity of the CH, LIM and C-terminal domains.  
The 10-fold drop of kcat observed with full-length MICAL is consistent with the proposal of an 
autoinhibitory role of the C-terminal region on MICAL catalytic activity. Our experiments reveal that is 
likely due to a conformational equilibrium between an inactive and an active conformation of MICAL, 
which is shifted 9:1 toward the inactive conformation in solution. The position of the C-terminal region is 
crucial to make the protein fully inactive .  
All MICAL forms are able to depolymerize F-actin in the presence of NADPH as observed by 
monitoring the decrease of fluorescence of pyrenyl-actin and of the average radius of F-actin solution by 
dynamic light scattering. F-actin leads to an approximately 5-10-fold increase of the maximum rate of the 
NADPH consumption for all MICAL forms (MO, 20 s
-1
; MOCH, 26 s
-1
; MOCHLIM, 15 s
-1
; MICAL, 8 s
-
1
) compared to that measured in its absence. The presence of F-actin leads to a lowering of the Km for 
NADPH to similar values (11-50 μM) for all the four forms. The apparent Km for F-actin is similar (≈4 
μM) for MO, MOCH and MOCHLIM, but 10-fold higher for MICAL (≈30 μM). Also this effect can be 
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explained by the conformational equilibrium between an inactive and an active conformation of the full-
length MICAL. The actin binding site on the MO domain may be physically accessible to F-actin only 
when MICAL is in the active conformation, subtracting it from the inactive/active conformational 
equilibrium. In this case, the high apparent Km for actin of MICAL would reflect the coupled equilibria 
between inactive/active conformations and complex formation between actin and MICAL in the active 
conformation.  
In all cases, the amount of NADPH oxidized during the reaction exceeds that of total actin present, 
suggesting a case of substrate recycling or an enhancement of the NADPH oxidase activity of MICAL 
forms when actin is bound. This finding is in contrast with the proposal that MICAL forms catalyze a 
(slow) NADPH oxidase activity when isolated but a fast and specific hydroxylation of actin Met44 (and 
Met 47) in the presence of F-actin, which leads to filament depolymerization (Hung et al. (2013) Nat Cell 
Biol., 15, 1445-1454).  Mass spectrometry analyses of actin samples treated with MICAL forms and 
NADPH support the hypothesis that actin depolymerization is mediated by the H2O2 released by the 
enhanced NADPH oxidase activity of MICAL in complex with actin. A maximum of two residues are 
oxidized per actin molecule among which are Met44 and Met47 but also several other Met and Trp 
residues are oxidized with similar probability. 
Overall it appears that MICAL in the free state can catalyze a basal NADPH oxidase reaction even in 
the cell. This activity is enhanced when the fraction of MICAL in the catalytically active state binds to 
actin leading to its depolymerization. Interaction of MICAL C-terminus with the cytoplasmic side of 
plexin upon semaphorin signaling would shift the equilibrium of inactive/active conformations toward the 
active form favoring the interaction with actin in proximity of plexin and its local depolymerization.  
With purified MICAL forms now available, it will possible to identify its interactors and to study their 
effect on its activities. As a first step in this direction we produced and purified a CRMP1 form that was 
found to cooperate with MICAL1 in determining COS7 cells collapse in response to semaphorin 
signaling. We demonstrated that CRMP1 and MICAL1 MO and MOCH interact, but in a complex way: 
at low ionic strength the interaction, which is largely non specific due to the strong opposite charges of 
the proteins,  leads to inhibition of the MO and MOCH NADPH oxidase activity; at higher ionic strength, 
where non specific interactions are removed, CRMP stimulates the NADPH oxidase activity of MO and 
MOCH and competes with actin for binding MICAL, but the effect is mild.  
These preliminary experiments support the hypothesis that actin and microtubules dynamics may be 
linked through MICAL-CRMP interaction. More importantly, they show the feasibility of detailed in 
vitro studies for the identification of MICAL interacting proteins and their mutual modulatory effect. This 
approach, along with the detailed mechanistic studies of MICAL reactions thanks to the availability of 
various MICAL forms, will also open the way to the identification of molecules able to inhibit MICAL 
that could be beneficial to combat diseases in which MICAL has been implicated such as 
neurodegeneration, cancer and even vasculo- and cardiogenesis.    
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Abbreviations 
2-ME, 2-mercaptoethanol; BrPAPS, 2-(5-bromo-2-pyridiylazo)-5-[N-n-propyl-N-(3-
sulfopropyl)amino]phenol; ABP, actin binding protein; CasL, Crk (p38)-associated substrate-related protein; 
CH, calponine homology; Cc, critical concentration; CRMP, collapsin response mediator protein; DLS, 
dynamic light scattering; D-MICAL, Drosophila melanogaster MICAL; DTT, dithiothreitol; FAD, flavin 
adenine dinucleotide; FMN, flavin mononucleotide; F-actin, filamentous actin; G-actin, globular actin; 
HEPES, (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid; LIM, domain found in Lin11, Isl-1 and Mec-
3 proteins; MALDI-TOF, matrix-assisted laser desorption ionization - time of flight mass spectrometry; 
MICAL, the molecule interacting with CasL; MO, monooxygenase domain; MOCH, truncated MICAL form 
comprising the MO and CH domains; MOCHLIM, truncated MICAL form comprising the MO, CH and LIM 
domains; MRTF-A, myocardin-related transcription factor-A; MS, mass spectrometry; MST1, mammalian 
Ste-20-like kinase; NADPH, nicotinamide adenine dinucleotide phosphate; NDR, nuclear Dbf2-related 
kinases; PHBH, p-hydroxybenzoate hydroxylase; PMSF, phenylmethanesulfonyl fluoride; PVDF, 
polyvinylidene difluoride; Rab, Ras-related protein Rab; SDS, sodium dodecyl sulfate; SRF, serum response 
factor; TCA, trichloroacetic acid. 
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1. Introduction 
MICAL1 is a member of a family of cytoplasmic multidomain proteins conserved from insect to human, 
which participate in the control of cytoskeleton dynamics in a variety of fundamental cellular processes, 
such cell migration and differentiation, cell-cell contacts, vesicle trafficking and axon growth (Hung et 
al., 2011; Zhou et al., 2011; Vanoni et al., 2012). Three MICAL proteins have been identified in 
mammals, MICAL1-3; while in drosophila only a single gene has been identified encoding MICAL 
(Terman et al., 2002).   
A common and unique feature of MICAL proteins is the presence of a putative N-terminal catalytic 
flavoprotein domain that is followed by several protein-protein interactions domains, namely: a calponin 
homology (CH) domain, a LIM domain, a Pro-rich and coiled-coil regions (Figure 1.1). The position of 
such domains and the length of the interdomain regions differ for MICAL1, MICAL2 and MICAL3 
(Figure 1.1; see Chapter 2).  
MICAL1 and MICAL3 are ubiquitously expressed in the nervous system, while MICAL2 expression 
showed greater spatio-temporal selectively (Pasterkamp et al., 2006). MICAL proteins are also expressed 
in the heart, lung, kidney, liver, thymus, muscles, bone marrow and brain (Ashida et al., 2006; Fischer et 
al., 2005; Suzuki et al., 2002; Xue et al., 2011). MICAL1-3 mainly localize to the cytosol and a small 
fraction is associated with plasma membrane.   
In mammals two proteins related to MICAL have been identified. They show sequence similarity with 
MICAL1-3, but they lack the N-terminal flavoprotein domain, leading to define them as MICAL-like1 
and MICAL-like2 (Sharma et al., 2010). They are encoded by different genes and they are also conserved 
from insects to humans. MICAL-like1 has been identified as a EHD1 (protein-binding EH domain 1) 
interactor through the NPF (asparagine-proline-phenylanine) motif. EDH1 is responsible for receptor 
recycling during endocytosis. MICAL-like1 and EDH1 colocalize at the membrane of the endoplasmic 
reticulum (ER). Their interaction is necessary for the traslocation of EDH1 to ER and therefore, to 
promote endocytosis of the receptors (Rahaieng et al., 2010). MICAL-like1 is also an effector of Rab8 
(Ras-related protein Rab-8A) protein that mediates vesicles secretion from the Golgi to the plasma 
membrane (Rahajeng et al., 2010). MICAL-like2 protein is also involved in vescicular trafficking as an 
effector of Rab13 (Ras-related protein Rab13 precursor) (Yamamura et al., 2008). MICAL-like2 lacks the 
NPF motif and the interaction with Rab13 takes place at its C-terminus resulting in the colocalization of 
the proteins near the perinuclear membrane and at cellular tight junctions. MICAL-like2 can also interact 
with E-cadeherin promoting its recycling (Yamamura et al., 2008). 
The biological roles of MICAL proteins has been studied by using genetic and cell biology approaches, 
but a solid knowledge of their mechanism of action is still missing.  
In the effort to fill this void, in this work we shall present the characterization of the catalytic properties 
of the N-terminal flavoprotein domain of human MICAL1 and how there are modulated by the CH and 
LIM domains and the C-terminal region, as an extension of the work previously done (Zucchini et al., 
2011).  
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Each chapter is introduced by a survey of the relevant literature to complement the present introduction 
(Chapter 1) and is followed by a brief discussion. The overall discussion of our results and the 
conclusions are in Chapter 9. The Materials and Methods employed are gathered in Chapter 10.  
More specifically:  
Chapter 2: deals with the comparison of MICAL and MICAL-like proteins and the analysis of the three-
dimensional structure of the N-terminal flavoprotein domain of mouse MICAL1, which allowed us to (i) 
plan the protein engineering experiments for the production of the full-length protein and of the truncated 
forms lacking the LIM domain (MOCH) and the C-terminal region (MOCHLIM); (ii) gain insight on the 
mechanism of action of MICAL and highlight potentially key residues. 
Chapter 3: describes the engineering of the full-length human MICAL1 and the form lacking the C-
terminal region for the expression of C-terminal His6-tagged proteins in E.coli cells to facilitate their 
purification. 
Chapter 4: focus on the set-up and optimization of the purification procedures to obtain soluble and 
homogeneous preparations of MICAL forms in quantities sufficient for their characterization.  
Chapter 5: reports on the structural analysis of MICAL forms by determining (i) the N-terminal sequence; 
(ii) the mass of the intact proteins; (iii) the amounts of FAD and zinc ions associated to the N-terminal 
flavoprotein domain and to the LIM domain, respectively and (iv) the stability of the proteins 
preparations.  
Chapter 6: the studies of the NADPH oxidase activity of MICAL forms under steady-state conditions to 
determine the effect of (i)  the CH, LIM and C-terminal domains;  (ii) the ionic strength, (iii) the pH and 
(iv) the solvent viscosity on the kinetic parameters (kcat, KNADPH and kcat/KNADPH ) of the catalyzed reaction 
by MICAL forms.  
Chapter 7: deals with the studies of the NADPH-dependent F-actin depolymerizing activity of MICAL 
forms by determine (i) steady-steady kinetic parameters (kcat, KNADPH and apparent Km for F-actin); (ii) the 
intact mass of actin treated with MICAL and NADPH; and (iii) the modified actin residues by mass 
spectrometry.    
Chapter 8: the expression and purification of mouse CRMP1 forms, which has been proposed to be an 
interactor and even a possible substrate of the N-terminal flavoprotein domain of MICAL1 (Schmidt et 
al., 2008). The mouse CRMP1 form comprising residues 8-525 was purified in quantities sufficient to (i) 
study its interaction with MO and MOCH forms of MICAL and (ii) its effect on their NADPH oxidase 
activity under various conditions.  
 
1.1. MICAL1 as a CasL interactor  
MICAL1 protein was initially identified during the search of CasL (from Crk p38-associated substrate-
related protein) interactors among proteins expressed from a thymus cDNA library, from which the 
acronym Molecule Interacting with CasL was derived (Suzuki et al., 2002). CasL, also known as hEF1 
(enhancer of filamentation 1) and NEDD9 (neural precursor expressed developmentally down-regulated 
protein 9), is a docking protein of the Cas family of proteins, and plays important roles in several cellular 
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functions, such as interleukin-2 production and cellular migration by leading to the formation of focal cell 
adhesion (Suzuki et al., 2002). MICAL1 was proposed to bind the SH3 domain of CasL through its Pro-
rich region, as demonstrated by co-localization and co-immunoprecipitation experiments (Suzuki et al., 
2002). Using same methods Suzuki et al., (2002) also demonstrated that the C-terminal region of 
MICAL1 can interact with vimentin, which is the main component of intermediate filaments of the 
cytoskeleton (Suzuki et al., 2002). Therefore, it was proposed that MICAL1 participates in the cascade of 
events that follow β1 integrin and/or T cell receptor stimulation by interacting with CasL, providing a 
physical link with cytoskeleton proteins (Suzuki et al., 2002; Vanoni et al., 2012).  
 
1.2. MICAL in the context of axon growth 
At about the same time MICAL was also found among the intracellular components of the semaphorin-
plexin pathway as a novel PlexA interactor in an embryonic Drosophila cDNA library (Terman et al., 
2002). Upon the discovery of MICAL several genetic and cellular biology studies have been made to 
identify the role of MICALs in cells. A great deal of work was done with Drosophila to elucidate MICAL 
function in the semaphorin-plexin signaling pathway in the context of axon growth (Terman et al., 2002). 
The semaphorin signaling pathway leads to a reorganization of the cytoskeleton. During neuronal 
development, the axon receives a multitude of extracellular signals that guide the directionality of its 
growth (Figure 1.2) (Schmidt et al., 2009).  
Among the molecules responsible for axon guidance, are the semaphorins. Semaphorins function as 
axonal repellents, but they are also involved in other important cellular events such as morphogenesis and 
organ homeostasis. They also mediate the release of cytokines. Semaphorins are implicated in different 
neurodegenerative diseases and cancer (Tamagnone et al., 2004). Seven classes of semaphorins have been 
identified, comprising soluble and membrane proteins and they are highly conserved from insects to 
humans. Their conserved N-terminal domain is responsible for the interaction with their plexin receptors. 
The functional role of the semaphorins has been extensively studied using Drosophila as model organism. 
The interaction between Sema3A and PlexA leads to axon cone growth collapse (Pasterkamp and 
Kolodkin 2003). Drosophila mutants obtained by inactivation of the single MICAL gene showed a 
phenotype similar to that observed by inactivation of Sema3A (Figure 1.3; Terman et al., 2002). The 
same phenotype was also observed by introducing the drastic G-to-W substitution in the consensus 
sequence for FAD-binding in the N-terminal domain of MICAL, indicating that the flavoprotein domain 
is essential for MICAL function (Terman et al., 2002). The introduction of point mutations in the 
Drosophila MICAL gene also caused alterations of myofilaments organization and synaptic structure 
(Beuchle et al., 2007; Figures 1.4 and 1.5). 
MICALs participate also in the Sox14-regulated dendritic pruning (Kirilly et al., 2009). In this context, 
Sox14 transcription factor is essential for dendritric pruning by promoting MICAL expression (Kirilly et 
al., 2009). These observations confirm the role of MICAL in neuronal regulation.     
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1.3. MICAL and actin cytoskeleton organization  
The importance of the catalytic domain for MICAL function was also demonstrated in mammalian 
neuronal and non-neuronal cells (Giridharan et al., 2012).  
Overexpression and siRNA-mediated knock down of MICAL1-3 in mammalian cells had a significant 
impact on the organization of actin filaments (Giridharan et al., 2012). Changes on the organization of 
actin filaments to yield filopodia-like protusions were observed when MICAL2 was overexpressed, while 
no changes were observed upon overexpression of MICAL1 and MICAL3 (Giridharan et al., 2012). 
Instead, when HeLa cells were transfected with the isolated N-terminal flavoprotein domain of MICAL1 
and MICAL3, the number of actin filaments was reduced (Giridharan et al., 2012). In addition, the 
isolated N-terminal domain of MICAL1 affected also the organization of microtubules (Giridharan et al., 
2012), probably in an indirect way as demonstrated by the fact the Drosophila MICAL was not able to 
directly interact in vitro with microtubules (Hung et al., 2011). On the other hand, depletion of MICAL1 
and MICAL2 led to an increase of filopodia-like protusions at the cell periphery, while depletion of 
MICAL3 caused an increase of stress fibers and cell size (Giridharan et al., 2012). MICAL2 localizes to 
plasma membrane in HeLa cells and its overexpression correlated with the loss of actin stress fibers as 
well as actin in filopodia-like structures at the cell periphery (Giridharan et al., 2012). The same cell 
phenotype was observed when the isolated N-terminal catalytic domain of MICAL2 was overexpressed, 
indicating that the flavoprotein domain of MICAL2 is required and sufficient for actin stress fiber loss 
(Giridharan et al., 2012).  
MICAL3 has been found among Rab8A (Ras-related protein Rab-8A) interactors (Grigoriev et al., 2011). 
Rab8A protein is involved in the vesicles trafficking from the trans-Golgi to plasma membrane. Rab8A is 
associated with exocytotic vesicles by interacting with Rab6 (Ras-related protein Rab6-A) protein. Rab8A 
forms a complex with MICAL3 through the C-terminal region of MICAL. Other residues in such region 
mediate also the interaction with ELK (ETS domain-containing protein ELK-1) protein, which is 
important for the docking and fusion of exocytotic vesicles (Grigoriev et al., 2011). Rab8A-ELK-
MICAL3 proteins can form a triple complex in transfected HeLa cells, in which the interaction between 
Rab8A and ELK is more efficient when MICAL3 is present (Grigoriev et al., 2012). These results 
indicate a functional role of MICAL3 in the trafficking of vesicles. Moreover, as observed for MICAL1 
and MICAL2, the N-terminal flavoprotein domain of MICAL3 is essential for its function. The 
substitution of G to W in the consensus sequence for FAD binding led to an increase of the number of 
secretory vesicles in the cytosol that failed to fuse with the plasma membrane (Grigoriev et al., 2011). As 
discussed above, MICAL-like proteins are also involved in vesicle trafficking, but they do not have any 
enzymatic activity and they exert their function through protein-proteins interactions (Sharma et al., 
2011).   
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Figure 1.1. Domain organization of MICAL forms. The boundaries of the monooxygenase-like (MO), calponin 
homology (CH) and LIM domains, Pro- and Glu-rich region and coiled coil region are referred to the human forms.  
 
 
 
 
Figure 1.2. Axon guidance.  During neuronal development the direction of axon extension is guided by attractive 
and/or repulsive signals (Zhou et al., 2010).  
 
 
 
Figure 1.3. Role of MICAL during neuronal development. Development of wild-type Drosophila neurons and 
mutant loss of function for MICAL (MICAL LOF), in which the control of axons growth is lost (Termann et al., 
2002).  
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Figure 1.4. Role of MICAL in the organization of actin filaments in Drosophila muscle cells. Confocal images of 
wild type muscle cells (panels A-C) and of MICAL mutants (panels D-F). The larvas were stained with phalloidin-
Cy3 (red) for the visualization of actin and anti-MHC (green) for myosin. The arrowheads indicate the synaptic 
boutons. 
 
 
 
Figure 1.5. Organization of postsynaptic ultrastructures in Drosophila MICAL mutants. Electron micrographs 
depicting a cross-section through synaptic boutons on muscle 6 in a wild-type (A) and MICAL mutant larva (B). 
Active zones (arrowhead), mitochondria (asterisk) and the subsynaptic reticulum (SSR) are marked. Panels A1 and 
B1: zone containing electron-dense membrane thickenings (arrow) and synaptic vesicles attached to a T-bar 
(arrowhead). Panels A2 and B2:  Enlargement of the postsynaptic area consisting of multiply folded membranes of 
the SSR (Beuchle et al., 2007).   
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1.4. MICAL and apoptosis 
MICAL1 participates also in other cellular processes besides axon cone growth. In fact, it has been 
demonstrated that MICAL1 is involved in apoptosis by interacting with NDR (nuclear Dbf2-related) 
kinases (Zhou et al., 2011).  NDR kinase is involved in cell proliferation, mitosis and apoptosis in 
response to several signalling pathways. Deletion of NDR in mouse T cells caused an unregulated cells 
apoptosis with consequent lymphoma development in mice (Cornils et al., 2010). NDR is activated upon 
phosphorylation of Thr444 by MST1 kinase (mammalian Ste-20-like kinase 1) in response to cell death 
receptor stimulation. MST1 binds the C-terminal region of NDR1 and at the same region takes place the 
interaction with MICAL1 (Zhou et al., 2011). In this case, MICAL functions as a scaffold protein by 
interacting with NDR through its region spanning from the LIM domain to the C-terminus. Thus, 
MICAL1 sequesters NDR preventing its interaction with MST1 and therefore, its phosphorylation. As a 
result cell apoptosis is inhibited (Zhou et al., 2011).   
 
1.5. Hypotheses on MICAL mechanism of action  
From the data obtained by genetic, molecular and cellular biology studies, several hypotheses on MICAL 
mechanism of action have been made (Terman et al., 2002).  
Several proteins have been identified as MICAL interactors, namely: GTPases, GTPase-activating 
proteins, GTP-binding proteins (Weide et al., 2003), CasL (Suzuki et al., 2002), CRMP (Schmidt et al., 
2008) and NDR (Zhou et al., 2011) (Figure 1.6). These observations led to propose that MICAL simply 
acts as a scaffold protein through its conserved protein-protein interaction domains to recruit and/or 
modulate the activity of interactors (Figure 1.7) (REF). This hypothesis  can explain the way in which 
MICAL1 interferes with CasL, CRMP and NDR functions.  
The scaffold model can also be applied to MICAL-like proteins that lack the catalytic domain and thus 
exert their functions through their protein-protein interaction domains (Sharma et al., 2011).  
However, several of such studies also demonstrated the essentiality of the N-terminal flavoprotein domain 
of MICAL for its role in the control of the cytoskeleton dynamics leading to other hypotheses on its 
mechanism of action.  
In 2005 the three-dimensional structure of the isolated flavoprotein domain of mouse MICAL1 has been 
solved (Nadella et al., 2005; Siebold et al., 2005; Chapter 2) confirming the similarity of the N-terminal 
domain to p-hydroxybenzoate hydroxylase (PHBH), which is the prototype of the FAD-dependent 
monooxygenases class of flavoproteins that catalyze the hydroxylation of aromatic compounds. The 
structure of the flavoprotein domain also suggested that its substrate could be an acidic protein, such as 
actin. On the basis of the similarity with flavoproteins of the monooxygenase class, the N-terminal 
domain of MICAL will be indicated as MO without actually implying that it catalyzes an hydroxylation 
reaction (see Chapter 6 and 7 for further discussion).  
 In this respect, several experiments have been carried out with the N-terminal domain of Drosophila, 
MICAL and with the forms comprising also the CH domain (MOCH), with the MO domain of mouse 
MICAL2 (Palfey et al., 2012), MOCH form of mouse MICAL1-2 (Lee et al., 2013) and with the isolated 
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MO domain of human MICAL1 (Zucchini et al., 2011). As will be described in Chapter 7, MICAL forms 
are able to catalyze a NADPH-dependent F-actin depolymerizing activity supporting this hypothesis.      
The similarity of N-terminal domain to flavoproteins of the oxidase and monooxygenase classes led to the 
proposal that MICAL may catalyze: (i) an oxidase activity on a small molecule coupled to production of 
H2O2; (ii) an oxidase or monooxygenase activity on the side chain of its protein-substrate and (iii) a 
NAD(P)H oxidase activity with the production of H2O2 as a signaling molecule for the activation of the 
downstream events (Terman et al., 2002; Nadella et al., 2005; Vanoni et al., 2012; Figure 1.7).  
 
1.6. Regulation of MICAL1 activity 
In the context of actin depolymerization, it has been proposed that MICAL1 would become active only 
upon its interaction with plexin in response to semaphorin signal (Figure 1.8). In support of this 
hypothesis are the experiments carried out in COS7 and HeLa cells (Schmidt et al., 2008; Giridharan et 
al., 2012).  The H2O2 produced by MICAL in the presence of NADPH was significantly reduced in the 
total cell extracts of COS7 cells expressing the full-length MICAL1 compared to that observed in extracts 
of cells transfected with truncated forms of MICAL1 (Schimdt et al., 2008; Chapter 8).  
This observation led to the proposal of an inhibitory role of the C-terminal domain of MICAL1 on the 
activity of the MO domain (Schmidt et al., 2008).   
The C-terminal domain of MICAL2 seems to have no effect on the activity of the enzyme, as deduced 
indirectly from the analysis of the amount of actin stress fibers, which was similar to that observed in 
HeLa cells expressing the truncated forms of MICAL2 comprising the MO, CH and LIM domains 
(Giridharan et al., 2012). The generation of chimera MICAL1-MICAL2 (composed by the MO, CH 
domains of MICAL1 and the C-terminal LIM domain of MICAL2) and MICAL2-MICAL1 (composed 
by the MO and CH domains of MICAL2 and the LIM and C-terminal domain of MICAL1) proteins, 
revealed that the C-terminal domain of MICAL1 was also able to interact with the MO domain of 
MICAL2 reducing its activity as deduced from the absence of changes on the organization of actin 
filaments in HeLa cells (Figure 1. 9, panels B-G; Giridharan et al., 2012). Thus, it has been proposed that 
the C-terminal region of MICAL1 has an autoinhibitory function to maintain MICAL in a inactive form 
until it binds to plexin in response to semaphorin/plexin complex formation (Figure 1.8) (Schmidt et al., 
2008; Giridharan et al., 2012). 
However, these experiments were limited to the analysis of the effect of human MICAL1-2 forms on the 
cytoskeleton (actin) organization on cells (Giridharan et al., 2012) or measuring the H2O2 produced in 
lysates of cells expressing truncated and full-length mouse MICAL1 (Schmidt et al., 2008) in a semi-
quantitative way. Thus, the precise molecular mechanism by which the C-terminal domain controls the 
activity of the N-terminal flavoprotein domain is still missing. In this respect, the expression and 
purification of full-length human MICAL1, which will be described in Chapter 4, has allowed us to carry 
out in vitro experiments with the isolated protein to better understand how the C-terminal region 
modulates the activities of the N-terminal monooxygenase like domain (Chapters 6 and 7).    
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Figure 1.6. Schematic representation of the domain organization of human MICAL1 with regions responsible for the 
binding with interactor proteins are indicated. (The colour scheme is the same as that used in Figure 1.1). 
 
 
 
 
 
 
 
Figure 1.7. Possible mechanisms of MICAL1 function. Schematic representation of the possible mechanism of 
MICAL1 action upon its activation by interacting with plexin receptor in response to semaphorin signaling (the 
scheme is based on Kolodkin et al., 2007; Vanoni et al., 2012).  
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Figure 1.8. Proposed mechanism of activation of MICAL1. Schematic representations of :the possible mechanism of 
MICAL1 activation upon its interaction with the plexin receptor in response to semaphorin signaling (the domain 
colour code is the same as that used in Figure 1.1). 
 
 
 
Figure 1.9. Inhibitory function of the C-terminal region of human MICAL1. Panel A: The domain organization of 
wild-type human MICAL1 and -2 and chimeras HA-MICAL1-MICAL2, HA-MICAL2-MICAL1 is shown. HeLa 
cells have been transiently trasfected with chimeric MICAL1-MICAL2 (panels B-D) and MICAL2-MICAL1 
(panels E-G) forms. Cells were fixed 18 h after the transfection and incubated with anti-HA antibody (panels B and 
E) to localize MICAL forms, followed by incubation with phalloidin conjugated antibody (panels C and F) for actin 
detection. Panels D and G show the merge of the images of panels B-C and E-F, respectively.  Insets and arrows 
show partial colocalization of the MICAL1–MICAL2 chimera with actin stress fibers. Scale bar: 10 μm. (Giridaran 
et al., 2012). 
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1.7. MICAL and disease 
The mechanisms controlling cytoskeleton dynamics are far from being completely understood. In this 
context, understanding the molecular details of semaphorin-plexin pathway is of interest to modulate their 
action in pathological conditions, such as in neurodegenerative diseases, in cell mestatization and 
angiogenesis in cancer, pathogen infection (Vanoni et al., 2012 REF). Several observations on MICAL 
expression and function support its biomedical relevance. Inhibition of semaphorins seemed to prevent 
early events occurring in neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS) and to 
promote axon regeneration (Kikushi et al., 2003; Kaneko et al., 2006; Schmidt et al., 2009). In rat models 
of spinal cord injuries, the expression levels of MICAL forms are increased (Pasterkamp et al., 2005), 
supporting the hypothesis that inhibition of MICAL activity would have the same effect as that observed 
for semaphorins inhibition. Overexpression of alternative splicing variants of MICAL2 is associated with 
particular aggressive prostate cancers forms (Ashida et al., 2006). The cancer cells growth was lowered 
by decreasing the expression level of MICAL2 variants with small RNA interfering technology (Ashida 
et al., 2006). Recently, MICAL proteins have been also related to melanoma cancer (Loria et al., 2015). 
Moreover, studies carried out using zebrafish as model organism demonstrated the role of MICALs 
during cardiovascular development (Xue et al., 2012). Thus, determining MICAL mechanism of action 
can provide information for the understanding of the semaphorin pathway as well as a way to interfere 
and regulate with such fundamental cellular process.  
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2. Sequence and structural analyses of MICAL proteins.  
2.1. Primary structure of MICALs 
MICAL proteins are conserved from insect to humans. Insects contain a single gene encoding MICAL. In 
Drosophila there are three MICAL isoforms, the so called long, medium and short variants, originated by 
alternative splicing (Termann et al 2002). Three different genes encoding MICAL have been found in the 
model organism zebrafish (Danio Rerio) (Xue et al., 2011). Also in mammals three MICAL proteins, 
MICAL1, MICAL2 and MICAL3, have been identified and they are encoded by three different genes 
(Termann et al., 2002); several splicing variants have been predicted (Friedburg et at., 2008) (Table 2.1 A).  
As part of our studies of MICAL1, a comparative analysis of MICAL’s primary structures was carried out. 
MICAL1-3 proteins are related to each other. Analysis of their primary structure led to identify several 
domains, namely: a FAD-containing domain, a calponin homology (CH) domain, a LIM (from the three gene 
products Lin-11, Isl-1 and Mec-3) domain and Coiled-Coil motifs. The position of the FAD-containing and 
CH domains is conserved at the N-terminus in the three MICAL forms. Instead, the position of the LIM 
domain and of the Coiled-Coil regions, as well as the presence of additional conserved regions distinguish 
MICAL1 from MICAL2 and MICAL3.  
The primary structures of representative MICAL forms are shown in Figure 2.1 (Vanoni et al., 2012). The 
sequence analyses and annotations have been done also on the basis of information deriving from structural 
studies (Nadella et al., 2005; Siebold et al., 2005; Sun et al., 2006). In the text and in Figure 2.1 the residue 
numbering is given for mouse MICAL1, for which high resolution structural models are available (Nadella et 
al., 2005; Siebold et al., 2005).  
The N-terminal region (residues 1-498) of MICALs showed sequence similarity to FAD-containing aromatic 
hydroxylase, of which  p-hydroxybenzoate hydroxylase (PHBH) is the prototype (Entsch et al., 2005; 
McDonald and Palfey 2010). This hypothesis was confirmed by the determination of the three-dimensional 
structure of the isolated N-terminal domain of mouse MICAL1 (Nadella et al., 2005; Siebold et al., 2005).  
The first ≈80 residues of the N-terminal domain form a subdomain, which has not counterpart in PHBH and 
contains several conserved basic residues (bold and highlighted in blue in Figure 2.1, panel A).  Regions 
matching the consensus sequence for the formation of a Rossman fold (Wierenga et al., 1986) for FAD 
binding and the so called “second FAD binding region” identified by Eggink et al. (Eggink et al., 1990) are 
also conserved in all MICALs (residues in bold and highlighted in yellow in Figure 2.1, panel A), as are the 
residues important for NADPH binding (Wang et al., 2002; Siebold et al., 2005; in red and bold in Figure 
2.1, panel A). Instead, other residues are conserved only within each MICAL1-3 class and can be used for 
their classification of MICAL proteins. In the N-terminal domain of Drosophila MICAL an additional 40 
residue segment precedes such region, but it is not conserved among insect MICALs (Figure 8.1, panel A).    
The calponin homology (CH) domain (residues 509-614) follows the flavoprotein domain. MICALs contain 
a type 2 CH domain (see below) based on sequence and structural analyses (Sun et al., 2006). In Figure 2.1 
the underlined sequence corresponds to the conserved hydrophobic residues that form the core of the domain 
(Sun et al., 2006; Ishida et al., 2008); in bold are residues conserved in MICALs. The type 2 CH domains 
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contain the acting binding site (ABS) and phosphatidylinositol (4,5)-bisphosphate (PIP2) binding site  are 
conserved in the CH domain of MICALs (Figure 2.1, panel A in which the ABS and PIP2 binding site have 
been identified according to Gimona et al., 2002).   
The LIM domain (residues 677-742) was identified by the presence of the CX2CX16-23HX2CX2CX16-23CX2C 
consensus sequence in all MICALs, with the conservation of the Cys and His residues responsible for the 
coordination of two zinc ions (highlighted in purple in Figure 2.1, panel B).  
The interdomain region between the CH and LIM domains of MICAL2 is longer than those of MICAL1 and 
3 (Figure 1.1). Within this region the formation of a coiled-coil motif has been predicted. The coiled coil 
region of MICAL1 and 3 has been identified at the C-terminus of the proteins.  
A unique feature of MICAL1 is the presence of a Pro-rich region (PPKPP, indicated in orange in Figure 2.1, 
panel C) typical of proteins that interact with the SH3 domains. Several Pro-rich region can be found in 
MICAL2 and 3 (Figure 2.1, panels C and E), but at different positions.  
All MICALs contain a Glu-rich region (shown in green in Figure 2.1, panel D), which varies for the length 
and can contribute to protein-protein interactions.  
The C-terminal region of MICAL may form coiled-coil structures and it has been proposed to be related to 
proteins of Ezrin, radizin and moesin (ERM) family (Terman et al., 2002). The number of heptad repeats of 
hydrophobic residues and their distribution differ in MICAL1-3 (residues highlighted in grey in Figure 2.1, 
panel E). One coiled-coil motif of MICAL1 (residues 964-986) corresponds to the leucine zipper identified 
by Suzuki et al. (2002; bold and highlighted in grey in Figure 2.1, panel E). This region has the consensus 
sequence (S/TXV) for the formation of a PDZ binding motif as found (Termann  et al. 2002; Beuchle et al., 
2007), but our comparison of multiple sequences does not allow to confirm the hypothesis (Figure 2.1, panel 
E). 
Sequence comparison of MICAL-like proteins (Table 2.1 B) has been also done. In mammals two different 
genes encode for MICAL-like1 and MICAL-like2 proteins, while Drosophila contains a single gene 
encoding a MICAL-like protein. The proteins differ from MICALs mainly for the absence of the N-terminal 
flavoprotein domain. They also contain the CH and LIM domains and the C-terminal region forming coiled-
coil motifs. In addition, MICAL-like proteins are characterized by the presence of the asparagine-proline-
phenylalanine (NPF) signature sequence, at which the interaction with EDH1 protein takes place (Sharma et 
al., 2010; Chapter 1).  
The primary structure of the representative MICAL-like proteins is shown in Figure 2.2 in comparison with 
that of the isolated domain of human MICAL1.  
In the CH domain the hydrophobic residues stabilizing its three-dimensional structure are conserved in both 
MICAL-like1 and MICAL-like2, as the residues responsible for actin (ABS) and PIP2 binding (Figure 2.2, 
panel A).  
Zebrafish MICAL-like2 contains an additional ≈80 residues segment between the CH and LIM domain, 
while Drosophila lacks ≈30 residues in the interdomain region when compared to the other MICAL-like 
proteins (Figure 2.2, panel A).  
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The Cys and His residues of the LIM domain for the binding of the zincs ion are conserved, as are the other 
residues that also in this case do not show similarity with those of human MICAL1 (Figure 2.2, panel B).  
In human MICAL1 a Pro- and Glu-rich regions following the LIM domain is present (Figure 2.1, panels C 
and D), corresponding regions can also be found in MICAL-like proteins (Figure 2.2, panels D and E).  
MICAL-like1 proteins can be identified by the presence of two NPF motifs following the LIM domain, 
which are also found in the Drosophila MICAL-like protein (Figure 2.2, panels E and F).  
In the C-terminal region several hydrophobic residues can form coiled-coil motifs, as found for MICAL 
proteins, but the hypothetical leucine zipper identified in human MICAL1 (Figure 2.1, panel E) has not a 
counterpart in MICAL-like proteins (Figure 2.2, panel G).     
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Table 2.1. Summary of MICAL (A) and MICAL-like (B) sequences from databanks. The putative full-length protein was 
selected when several isoforms for each one of the predicted proteins exists on the basis of sequence comparison using 
BLAST (blast.ncbi.nlm.nhi.gov/Blast). 
 
A 
Protein Organism Chromosome Nucleotide Protein Length Gene ID UniPro/ 
  Location   residues  SwissProt 
MICAL1 human 6q21 NM_022765 NP_073602 1067 64780 Q8TDZ2 
MICAL2 human 11p15 NM_014632 NP_055447 1124 9645 O94851 
MICAL3 human 22q11.21 NM_015241 NP_056056 2002 57553 Q7RTP6 
MICAL1 mouse 10B1-B2 NM_138315 NP_612188 1048 171580 Q8VDP3 
MICAL2 mouse 7E3 NM_001193305 NP_001180234 1102 320878 8QBML1 
MICAL3 mouse 6F1 NM_001270475 NP_001257404 1993 194401 Q8CJ19 
MICAL1 rat 20q12 NM_001106397 NP_001099867 1047 294520 D3ZBP4 
MICAL2 rat 1q33  EDM_17817 1103 365352 D4A1F2-2 
MICAL3 rat 4q42 NM_001191085 NP_001178014 1997 362427  
MICAL1 guinea pig - XM_003466042 XP_003466090 1058 100715118 H0V032 
MICAL2 guinea pig - XM_003465749 XP_003465749 1105 100735168  
MICAL3 guinea pig - XM_003461762 XP_003461810 2005 100726239  
MICAL1 macaque 4 XM_002803949 XP_002803995 1065 698737  
MICAL2 macaque 14  EEH23095 1124 701439  
MICAL3 macaque 10 XM_001103660 XP_001103660 2001 710292  
MICAL1 D.rerio 23 XM_003201226 XP_003201274 1214 568573 E7F9T0 
MICAL2 D.rerio 25 JX291155 AFS28884 1120 569564  
MICAL3 D.rerio 18   1994 567456 F1QH17.2 
MICAL drosophila 3R AF520715 AAM55244 4723 41225 Q86BA1 
MICAL A.egyptis 1 CH477341 XP_001650895.1 3542 157109953  
 
B 
Protein Organism Chromosome Nucleotide Protein Length Gene ID UniPro/ 
  Location   residues  SwissProt
MICAL-like1 human 22q.13 NM_033386.3 NP_203744.1 863 85377 Q8N3F8 
MICAL-like2 human 2p22.3 NM_182924.3 NP_891554.1 904 79778 Q8IY33 
MICAL-like1 mouse 15 NM_177461.1 NP_803412.1 870 27008 Q8BGT6 
MICAL-like2 mouse 5G2 NM_174850.3 NP_777275.2 1009 231830  
MICAL-like1 rat 7q34 XM_006242043.2 XP_006242105.1 861 362958  
MICAL-like2 rat 12q11 XM_006248975.2 XP_006249037.1 1006 288515  
MICAL-like1 D.rerio 6 XM_001922140.4 XP_001922175.2 867 100149741  
MICAL-like2 D.rerio 3 XM_005164196.2 XP_005164253.1 802 327198  
MICAL-like1 guinea pig 6 XM_005003841.2 XP_005003898.1 844 100724657  
MICAL-like2 guinea pig  XM_003469926.3 XP_003469974.2 888 100732572  
MICAL-like drosophila 69F5 NM_140364.3 NP_648621.1 1010 39475  
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A 
MO  
humanMICAL2        -----------------------------------------MGENEDEKQAQAGQVFENFVQASTCKGTL 29    
macaqueMICAL2      -----------------------------------------MGENEDEKQAQAGQVFENFVQASTCKGTL 29    
guinea_pigMICAL2   -----------------------------------------MGENEDEKQAQAGQVFENFVQAATCKGTL 29    
mouseMICAL2        -----------------------------------------MGENEDEKQAQASQVFENFVQATTCKGTL 29    
ratMICAL2          -----------------------------------------MGENEDEKQAQASQVFENFVQATTCKGTL 29    
humanMICAL3        -----------------------------------------MEERKHETMNPAHVLFDRFVQATTCKGTL 29    
ratMICAL3          -----------------------------------------MEERKQETTNQAHVLFDRFVQATTCKGTL 29   
mouseMICAL3        -----------------------------------------MEERKQETTNQAHVLFDRFVQATTCKGTL 29    
D.rerioMICAL3      -------------------------------------MGDGGVNAVGEGVNQSHMLFDRFVQATTCKGTL 33 
A.aegyptiMICAL1    ---------------------------------------MNPAISEHEAASLAAEMFDHFCAATTMRQIL 31    
humanMICAL1        ------------------------------------------MASPT-STNPAHAHFESFLQAQLCQDVL 27    
macaqueMICAL1      ------------------------------------------MASPT-STNPAHAHFESFLQAQLCQDVL 27    
guinea_pigMICAL1   ------------------------------------------MASSS-SPNPAHAHFESFLQAQLCQDVL 27    
mouseMICAL1        ------------------------------------------MASPA-STNPAHDHFETFVQAQLCQDVL 27    
ratMICAL1          ------------------------------------------MASPT-STNPAHDHFETFVQAQLCQDVL 27    
D.rerioMICAL1      ------------------------------------------MVNPLDSVNPSHALFEGFVQAQTCKETQ 28    
DrosophilaMICAL    MSRQHQRHHQQHHHLPPHQQPQQQMPQQQQQLTAQQQQQQQLLMAEHAAAAEAAELFDLLCVATTMRQIL 70                                                                                                 
                                                                           *:    *  
                ADP binding 
                                                                              ----------- 
humanMICAL2        QAFNILTRHLDLDPLDHRNFYSKLKSKVTTWKAKALWYKLDKRGSHKEYKRGKSCTNTKCLIVGGGPCGL 99    
macaqueMICAL2      QAFNILTRHLDLDPLDHRNFYSKLKSKVTTWKAKALWYKLDKRGSHKEYKRGKSCMNTKCLIVGGGPCGL 99    
guinea_pigMICAL2   QAFNTLTRLLDLDPLDHRNFYSKLKSKVTTWKAKALWYKLDKRGSHKEYKRGKACMNTKCLIVGGGPCGL 99    
mouseMICAL2        QAFNILTCLLDLDPLDHRNFYSQLKSKVNTWKAKALWHKLDKRGSHKEYKRGKACSNTKCLIVGGGPCGL 99    
ratMICAL2          QAFNILTCLLDLDPLDHRNFYTQLKSKVNTWKAKALWHKLDKRGSHKEYKRGKACSNTKCLIVGGGPCGL 99    
humanMICAL3        KAFQELCDHLELKPKDYRSFYHKLKSKLNYWKAKALWAKLDKRGSHKDYKKGKACTNTKCLIIGAGPCGL 99    
ratMICAL3          RAFQELCDHLELKPKDYRSFYHKLKSKLNYWKAKALWAKLDKRGSHKDYKKGKACTNTKCLIIGAGPCGL 99    
mouseMICAL3        RAFQELCDHLELKPKDYRSFYHKLKSKLNYWKAKALWAKLDKRGSHKDYKKGKACTNTKCLIIGAGPCGL 99    
D.rerioMICAL3      KAFQELCDFLELKPNEYRVFYHKLKSKLNYWKAKALWAKLDKRASHKEYKKGRACANTKCLIIGAGPCGL 103  
A.aegyptiMICAL1    GLYRNMCDILNLRPGPLNEFYPKFKAKIRNWKAQALWKKFDARASHRVYNKGTAASGTRVLVIGAGPCGL 101   
humanMICAL1        SSFQELCGALGLEPGGGLPQYHKIKDQLNYWSAKSLWTKLDKRAGQPVYQQGRACTSTKCLVVGAGPCGL 97    
macaqueMICAL1      SSFQELCGALGLEPGGGLPQYHKIKDQLNYWSAKSLWTKLDKRAGQPVYQQGRACTSTKCLVVGAGPCGL 97    
guinea_pigMICAL1   SSFRELCGALGVEPGCGLPQYHKIKAQLNYWSAKSLWAKLDKRASQPVYQQGQACTSTKCLVVGAGPCGL 97    
mouseMICAL1        SSFQGLCRALGVESGGGLSQYHKIKAQLNYWSAKSLWAKLDKRASQPVYQQGQACTNTKCLVVGAGPCGL 97    
ratMICAL1          SSFQGLCRALGVESGGGLPQYHKIKAQLNYWSAKSLWAKLDKRASQPAYQQGQACTNTKCLVVGAGPCGL 97    
D.rerioMICAL1      QNFTELCRHLQVDPKDYKHFYSKLKDRLNYWKAKDLWQKIDKRAAHPDYDQGKACHQNKCLVLGAGPCGL 98    
DrosophilaMICAL    ALHRAMCEAVGLRPSPLNDFYPRLKAKVRSWKAQALWKKFDARAAHRVYGKGAACTGTRVLVIGAGPCGL 140   
                        :   :          *  :*  :  * *  ** * * *:    *  *      : *::*:***** 
 
                   -----------------nn   n/piii                               i 
humanMICAL2        RTAIELAYLGAKVVVVEKRDSFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGSIDHISIRQLQLILFKV 169   
macaqueMICAL2      RTAIELAYLGAKVVVVEKRDTFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGSIDHISIRQLQLILFKV 169   
guinea_pigMICAL2   RTAIELAYLGAKVVVVEKRDTFSRNNVLHLWPYTIHDLRGLGAKKFYGKFCAGSIDHISIRQLQLILFKV 169   
mouseMICAL2        RTAIELAYLGAKVVVVEKRDTFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGSIDHISIRQLQLILFKV 169   
ratMICAL2          RTAIELAYLGAKVVVVEKRDTFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGSIDHISIRQLQLILFKV 169   
humanMICAL3        RTAIDLSLLGAKVVVIEKRDAFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGAIDHISIRQLQLILLKV 169   
ratMICAL3          RTAIDLSLLGAKVVVIEKRDAFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGAIDHISIRQLQLILLKV 169   
mouseMICAL3        RTAIDLSLLGAKVVVIEKRDAFSRNNVLHLWPFTIHDLRGLGAKKFYGKFCAGAIDHISIRQLQLILLKV 169   
D.rerioMICAL3      RTAIELGFLGAKVVLLEKRDAFSRNNVLHLWPFTIQDLRGLGAKKFYGKFCAGAIDHISIRQLQLMLLKV 173 
A.aegyptiMICAL1    RTAIEAQLLGAKVVVVEKRDRISRNNVLHLWPFLITDLKALGAKKFYGKFCAGSIDHISIRQLQCILLKV 171   
humanMICAL1        RVAVELALLGARVVLVEKRTKFSRHNVLHLWPFTIHDLRALGAKKFYGRFCTGTLDHISIRQLQLLLLKV 167   
macaqueMICAL1      RVAVELALLGARVVLVEKRTKFSRHNVLHLWPFTIHDLRALGAKKFYGRFCTGTLDHISIRQLQLLLLKV 167   
guinea_pigMICAL1   RAAVELALLGARVVLVEKRTKFSRHNVLHLWPFTIHDLRALGAKKFYGRFCTGTLDHISIRQLQLLLLKV 167   
mouseMICAL1        RAAVELALLGARVVLVEKRIKFSRHNVLHLWPFTIHDLRALGAKKFYGRFCTGTLDHISIRQLQLLLLKV 167   
ratMICAL1          RAAVELALLGARVVLVEKRTKFSRHNVLHLWPFTIHDLRALGAKKFYGRFCTGTLDHISIRQLQLLLLKV 167   
D.rerioMICAL1      RTAIELALLGAQVVVLEKRSSFTRNNVLHLWPFTIKDLLNLGAKKFYGRFCSGSIHHISIRQLQLILLKV 168   
DrosophilaMICAL    RTAIEAQLLGAKVVVLEKRDRITRNNVLHLWPFVITDLRNLGAKKFYGKFCAGSIDHISIRQLQCMLLKV 210   
                   * *:::  *** **::***    * ******** * **: ********:** * : ******** :* * 
 
A                            
 
 
                               Ado                                      AMP n n 
humanMICAL2        ALMLGVEIHVNVEFVKVLEPPEDQENQKIGWRAEFLPTD-HSLSEFEFDVIIGADGRRNTLEGFRRKEFR 238   
macaqueMICAL2      ALMLGVEIHVNVEFVKVLEPPEDQENQKIGWRAEFLPAD-HSLSEFEFDVIIGADGRRNTLEGFRRKEFR 238   
guinea_pigMICAL2   ALMLGVEIHVNVEFVKVLEPPEDQENQKIGWRADFLPAD-HPLSEFEFDVIIGADGRRNTLEGFRRKEFR 238   
mouseMICAL2        ALMLGVEVHVNVEFVRVLEPPEDQENQKVGWRAEFLPAD-HALSDFEFDVIIGADGHRNTLEGFRRKEFR 238   
ratMICAL2          ALMLGVEIHVNVEFVRVREPPKDQENRKIGWRAEFLPAD-HALSNFEFDVIIGADGHRNTLEGFRRKEFR 238   
humanMICAL3        ALILGIEIHVNVEFQGLIQPPEDQENERIGWRALVHPKT-HPVSEYEFEVIIGGDGRRNTLEGFRRKEFR 238   
ratMICAL3          ALILGIEIHVNVEFQGLVQPPEDQENERIGWRALVHPKT-HPVSEYEFEVIIGGDGRRNTLEGFRRKEFR 238   
mouseMICAL3        ALILGIEIHVNVEFQGLVQPPEDQENERIGWRALVHPKT-HPVSEYEFEVIIGGDGRRNTLEGFRRKEFR 238   
D.rerioMICAL3      ALLLGIEIHVNVEFKGLIEPPEDQENERIGWRAEVHPRT-HPVNELEFDVIIGADGRRNTLSGFRRKEFR 242 
A.aegyptiMICAL1    ALLLGVEVHEGLSFIRELEPKDG-----CGWRAAVSPED-HAVSHYEFDVLIGADGKRNTLEGFKRKEFR 235   
humanMICAL1        ALLLGVEIHWGVTFTGLQPPPRK----GSGWRAQLQPNPPAQLANYEFDVLISAAGGKFVPEGFKVREMR 233   
macaqueMICAL1      VLLLGVEIHWGVTFTGLQPPPRK----GSGWRAQLQPNPPAQLANYEFDVLISAAGGKFVPEGFKVREMR 233   
guinea_pigMICAL1   ALLLGVEIHWGVTFTGLQPPLRK----GSGWRAQLQPKPPDQLANYEFDVLISAAGSKFVPEGFTVREMR 233   
mouseMICAL1        ALLLGVEIHWGVKFTGLQPPPRK----GSGWRAQLQPNPPAQLASYEFDVLISAAGGKFVPEGFTIREMR 233   
ratMICAL1          ALLLGVEIHWGFTFTGLQPPPKK----GSGWRARIQPSPPAQLASYEFDVLISAGGGKFVPEGFTIREMR 233   
D.rerioMICAL1      ALFLGVEVHTGVAFEGLNEPSG-----SAGWRANVSPKS-HPVADFQFDVFISAGGGKYVPDGFKIKELR 232   
DrosophilaMICAL    ALLLGVEIHEGVSFDHAVEPSGD----GGGWRAAVTPAD-HPVSHYEFDVLIGADGKRNMLD-FRRKEFR 274   
                   ** **:*:*  : *     *         ****   *     :  : *:* * * * :   * *  :* *  
 
                                                                              i 
 
humanMICAL2        GKLAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYYKDCTHYFVMTAKKQSL 308  
macaqueMICAL2      GKLAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYYKDCTHYFVMTAKKQSL 308   
guinea_pigMICAL2   GKLAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYYKDCTHYFVMTAKKQSL 308   
mouseMICAL2        GKLAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYYKDSTHYFVMTAKKQSL 308   
ratMICAL2          GKLAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYYKDSTHYFVMTAKKQSL 308   
humanMICAL3        GKLAIAITANFINRNTTAEAKVEEISGVAFIFNQKFFQELREATGIDLENIVYYKDDTHYFVMTAKKQSL 308   
ratMICAL3          GKLAIAITANFINRNTTAEAKVEEISGVAFIFNQKFFQELREATGIDLENIVYYKDDTHYFVMTAKKQSL 308   
mouseMICAL3        GKLAIAITANFINRNTTAEAKVEEISGVAFIFNQKFFQELREATGIDLENIVYYKDDTHYFVMTAKKQSL 308   
D.rerioMICAL3      GKLAIAITANFINRNTTAEAKVEEISGVAFIFNQKFFQDLREATGIDLENIVYYKDDTHYFVMTAKKQSL 312 
A.aegyptiMICAL1    GKLAIAITANFINKKTEAEAKVEEISGVAFIFNQSFFKELYQTTGIDLENIVYYKDETHYFVMTAKKHSL 305   
humanMICAL1        GKLAIGITANFVNGRTVEETQVPEISGVARIYNQSFFQSLLKATGIDLENIVYYKDDTHYFVMTAKKQCL 303   
macaqueMICAL1      GKLAIGITANFVNGRTVEETQVPEISGVARIYNQSFFQSLLKATGIDLENIVYYKDDTHYFVMTAKKQCL 303   
guinea_pigMICAL1   GKLAIGITANFVNRRTAEETQVPEISGVARIYNQKFFQSLLKATGIDLENIVYYKDDTHYFVMTAKKQCL 303   
mouseMICAL1        GKLAIGITANFVNGRTVEETQVPEISGVARIYNQKFFQSLLKATGIDLENIVYYKDETHYFVMTAKKQCL 303   
ratMICAL1          GKLAIGITANFVNGRTVEETQVPEISGVARIYNQKFFQSLLKATGIDLENIVYYKDDTHYFVMTAKKQCL 303   
D.rerioMICAL1      GKLAIGITANFVNRHTKQEAQVQEISGVARIYNQQFFQALQSEIGVDLENIVYYKDDTHYFVMTAKKASL 302   
DrosophilaMICAL    GKLAIAITANFINKKTEAEAKVEEISGVAFIFNQAFFKELYGKTGIDLENIVYYKDETHYFVMTAKKHSL 344   
                   *****:*****:*  *  *  * ****** * ** **  *    *:********** **********  * 
       
                                                                      n            n 
humanMICAL2        LDKGVIINDYIDTEMLLCAENVNQDNLLSYAREAADFATNYQLPSLDFAMNHYGQPDVAMFDFTCMYASE 378   
macaqueMICAL2      LDKGVIINDYIDTEMLLCAENVNQDNLLSYAREAADFATNYQLPSLDFAMNHYGQPDVAMFDFTCMYASE 378   
guinea_pigMICAL2   LDKGVIINDCIDTELLLCAENVNQDNLLSYAREAADFATNYQLPSLDFAINHYGQPDVAMFDFTSMYASE 378   
mouseMICAL2        LDKGVILNDYIDTEMLLCSENVNQDNLLSYAREAADFATNYQLPSLDFAINHNGQPDVAMFDFTSMYASE 378   
ratMICAL2          LDKGVILNDYIDTEMLLCAENVNQDNLLSYAREAADFATNYQLPSLDFAINHNGQPDVAMFDFTSMYASE 378   
humanMICAL3        LDKGVILHDYADTELLLSRENVDQEALLSYAREAADFSTQQQLPSLDFAINHYGQPDVAMFDFTCMYASE 378   
ratMICAL3          LDKGVILHDYTDTELLLSRENVDQEALLNYAREAADFSTQQQLPSLDFAINHYGQPDVAMFDFTCMYASE 378   
mouseMICAL3        LDKGVILHDYTDTELLLSRENVDQEALLNYAREAADFSTQQQLPSLDFAINHYGQPDVAMFDFTCMYASE 378   
D.rerioMICAL3      LEKGVILHDYADTEMLLSRANVDQKALLSYAREAADFSTNHQLPKLDFAINHYGQPDVAMFDFTCMYASE 382 
A.aegyptiMICAL1    LDKGVIIQDYGDPAELLSSANVDTSKLLDYAREAANFSTKYQMPNLEFAVNHYGKPDVAMFDFTSMFAAD 375   
humanMICAL1        LRLGVLRQDWPDTNRLLGSANVVPEALQRFTRAAADFATHGKLGKLEFAQDAHGQPDVSAFDFTSMMRAE 373   
macaqueMICAL1      LRLGVLRQDWPDTDRLLGSANVVPEALQRFARAAADFATHGKLGKLEFAQDAHRQPDVSAFDFTSMLRAE 373   
guinea_pigMICAL1   LRLGVLRQDRLETEQLLSSANVVPEALQRFVRAAADFATNGKLGKLEFAQDARGRPDISAFDFTSMLRAE 373   
mouseMICAL1        LRLGVLRQDLSETDQLLGKANVVPEALQRFARAAADFATHGKLGKLEFAQDARGRPDVAAFDFTSMMRAE 373   
ratMICAL1          LRLGVLRQDLPETDQLLGKANVVPEALQQFARAAADFATQGKLGKLEFAQDARGRPDVAAFDFTSMMRSE 373   
D.rerioMICAL1      LKKGVIKQDFSDADKLLAPSNVNQEALQDYAFEACDFSTEHLLPNLEFAKNHKGQADVAMFDFTCMQRAE 372   
DrosophilaMICAL    IDKGVIIEDMADPGELLAPANVDTQKLHDYAREAAEFSTQYQMPNLEFAVNHYGKPDVAMFDFTSMFAAE 414   
                   :  **:  *  :   **   **    *   :  * :* *   :  *:**    *  *:*:**** *   : 
 20 
 
 
 
 
                            FAD-II binding 
                            -----------      i 
humanMICAL2        NAALVRERQAHQLLVALVGDSLLEPFWPMGTGCARGFLAAFDTAWMVKSWNQG-TPPLELLAERESLYRL 447   
macaqueMICAL2      NAALVRERQSHQLLVALVGDSLLEPFWPMGTGCARGFLAAFDTAWMVKNWNQG-TPPLELLAERESLYRL 447   
guinea_pigMICAL2   NAALVRERQGHPLLVALVGDSLLEPFWPMGTGCARGFLAAFDTAWMVKSWDQG-TPPLEVLAERESLYRL 447   
mouseMICAL2        NAALMRERQAHQLLVALVGDSLLEPFWPMGTGCARGFLAAFDTAWMVKSWDQG-TPPLEVLAERESLYRL 447   
ratMICAL2          NAALMRERQAHQLLVALVGDSLLEPFWPMGTGCARGFLAAFDTAWMVKSWDQG-TPPLEVLAERESLYRL 447   
humanMICAL3        NAALVREQNGHQLLVALVGDSLLEPFWPMGTGIARGFLAAMDSAWMVRSWSLG-TSPLEVLAERESIYRL 447   
ratMICAL3          NAALVREQNGHQLLVALVGDSLLEPFWPMGTGIARGFLAAMDSAWMVRSWSLG-TSPLEVLAERESIYRL 447   
mouseMICAL3        NAALVREQNGHQLLVALVGDSLLEPFWPMGTGIARGFLAAMDSAWMVRSWSLG-TSPLEVLAERESIYRL 447   
D.rerioMICAL3      NAALVRQRNGHKLLVALVGDSLLEPFWPMGTGIARGFLAAMDSAWMVRSWAHG-SSPLEVLAERESIYRL 451 
A.aegyptiMICAL1    NSCKITVRKNYRLLSCLVGDSLLEPFWPTGSGCARGFLSSMDAAYAIKLFSNSKNSALGVIAQRESIYRL 445   
humanMICAL1        SSARVQEKHGARLLLGLVGDCLVEPFWPLGTGVARGFLAAFDAAWMVKRWAEG-AESLEVLAERESLYQL 442   
macaqueMICAL1      SSARVQEKHGARLLLGLVGDCLVEPFWPLGTGVARGFLAAFDAAWMVKRWAEG-AEPLEVLAERESLYQL 442   
guinea_pigMICAL1   CSARVQEKHGARLLLGLVGDCLVEPFWPLGTGVARGFLAAFDAAWMVKRWAEG-TEPLEVLAERESLYQL 442   
mouseMICAL1        SSARVQEKHGARLLLGLVGDCLVEPFWPLGTGVARGFLAAFDAAWMVKRWAEG-AGPLEVLAERESLYQL 442   
ratMICAL1          SSARIQEKHGARLLLGLVGDCLVEPFWPLGTGVARGFLAAFDAAWMVKRWAEG-TGPLELLAERESLYQL 442   
D.rerioMICAL1      SASLVKERNGKRLLIGLVGDSLVEPFWPLGTGIARGFLGAFDAAWMVRSWGKG-VQPMEVLAERESVYQL 441   
DrosophilaMICAL    MSCRVIVRKGARLMQCLVGDSLLEPFWPTGSGCARGFLSSMDAAYAIKLWSNPQNSTLGVLAQRESIYRL 484   
                       :       *:  **** *:***** * * *****   * *  ::         : :** ***:* * 
                                                                                    
                                                                                   CH --- 
humanMICAL2        LPQTTPENINKNFEQYTLDPGTRYPNLNSHCVRPHQVKHLYITKEL-E-HYPLERLGSVRRSVNLSRKES 515  
macaqueMICAL2      LPQTTPENINKNFEQYTLDPGTRYPNLNSHCVRPHQVKHLYITKEL-E-HYPLERLGSVRRSVNLSRRES 515   
guinea_pigMICAL2   LPQTTPENINKNFEQYTLDPGTRYPNLNSHCVRPHQVKHLYVTKEL-D-YHPLERFNSLRRSVNLSRRES 515   
mouseMICAL2        LPQTTPENINKNFEQYTLDPATRYPNLNLHCVRPHQVKHLYITKEM-D-RFPLERWGSVRRSVSLSRRES 515   
ratMICAL2          LPQTTPENINKNFEQYTLDPATRYPNLNVHCVRPHQVKHLYITKEM-D-RFPLERWGSVRRSASLSRRES 515   
humanMICAL3        LPQTTPENVSKNFSQYSIDPVTRYPNINVNFLRPSQVRHLYDTGETKDIHLEMESLVNSRTTPKLTRNES 517   
ratMICAL3          LPQTTPENVSKNFSQYSIDPVTRYPNININFLRPSQVRHLYDSGESKDIHLEMENLVNSRTTPKLTRNES 517   
mouseMICAL3        LPQTTPENVSKNFSQYSIDPVTRYPNININFLRPSQVRHLYDSGETKDIHLEMENMVNPRTTPKLTRNES 517   
D.rerioMICAL3      LPQTTPENVSKNFSQYSVDPTTRYPNISLHQVRPNQVRHLLDTGETRDLRVDLENVVNS-STPKLTRNES 520 
A.aegyptiMICAL1    LAQTTPENLHRDIGAYTLDPSTRYPNLNKSSVNMIQVKHLLDTDDLALLDQMFLDTNALTAGPEVIVTKR 515   
humanMICAL1        LSQTSPENMHRNVAQYGLDPATRYPNLNLRAVTPNQVRDLYDVLAKEPVQRNNDKTDTGM-PATGSAGTQ 511   
macaqueMICAL1      LSQTSPENMHRNVAQYGLDPATRYPNLNLRAVTPNQVRDLYDVLTKEPVQRN-DKTDAGM-PTTGSAGTQ 510   
guinea_pigMICAL1   LSQTSPENMHRNVAQYGLDPASRYPNLNLKAVTPNQVRDLYDVVAKGPVPKKNDKPNRGN-PTTGSAGTQ 511   
mouseMICAL1        LSQTSPENMHRNVAQYGLDPATRYPNLNLRAVTPNQVQDLYDMMDKEHAQRKSDEPDSRK-TTTGSAGT- 510   
ratMICAL1          LSQTSPENMHRNVAQYGLDPATRYPNLNLRAVTPNQVQDLYDIMDKEHARKKSDETDARK-TTTGSAGT- 510   
D.rerioMICAL1      LSQTTPENTSKNYMAYSIDPSTRYPNINLSSIKPRQVKRLYEAEEQESKPNKLKKPDIKAKPRKDSMKRL 511   
DrosophilaMICAL    LNQTTPDTLQRDISAYTVDPATRYPNLNRESVNSWQVKHLVDTDDPSILEQTFMDTHALQTPHLDTPGRR 554   
                   * ** *:   :    * :**  ******   :   **  *                         :                   
                                 
                              ABS             PIP2        
                              --------- ------------------ 
humanMICAL2        DIRP-------SKLLTWCQQQTEGYQHVN-VTDLTTSWRSGLALCAIIHRFRPELINFDSLNEDDAVENN 577   
macaqueMICAL2      DIRP-------SKLLTWCQQQTEGYQHVN-VTDLTTSWRSGLALCAIIHRFRPELINFDSLNEDDAVENN 577   
guinea_pigMICAL2   DIQP-------SKLLTWCQQQTEGYQHVN-VTDLTTSWRSGLALCAIIHRFRPELINFDSLNEDDAVKNN 577   
mouseMICAL2        DIRP-------NKLLTWCQQQTKGYQHVR-VTDLTTSWRSGLALCAIIHSFRPELINFDSLNEDDAVENN 577   
ratMICAL2          DIRP-------NKLLTWCQQQTKGYQHVR-VTDLTTSWRSGLALCAIIHSFRPELINFDSLNENDVVENN 577   
humanMICAL3        VARS-------SKLLGWCQRQTDGYAGVN-VTDLTMSWKSGLALCAIIHRYRPDLIDFDSLDEQNVEKNN 579   
ratMICAL3          VARS-------SKLLGWCQRQTDGYSGVN-VTDLTMSWKSGLALCAIIHRYRPDLIDFDSLDEQNVEQNN 579   
mouseMICAL3        VARS-------SKLLGWCQRQTEGYSGVN-VTDLTMSWKSGLALCAIIHRYRPDLIDFDSLDEQNVEKNN 579   
D.rerioMICAL3      IVRS-------SKLLNWCQRQTEGYRGVS-VSDLTTSWKSGLALCALIHRYRPDLIDFESLDEKDVEKNN 582 
A.aegyptiMICAL1    KRRTNDTVPLGTVLLRWVKSQLKGNDFVQELTDAAQCFTNGRVLCTLINRYRPDLVNLDELDGCGPDECN 585   
humanMICAL1        -----------EELLRWCQEQTAGYPGVH-VSDLSSSWADGLALCALVYRLQPGLLEPSELQGLGALEAT 569   
macaqueMICAL1      -----------EELLRWCQEQTAGYPGVH-VSDLSSSWTDGLALCALVHRLQPGLLEPSELQGLGALEAT 568   
guinea_pigMICAL1   -----------EELLHWCQEKTAGYPGVH-VTDLSSSWADGRALCALVHRLQPSLLGPSEVQDMGALEAT 569   
mouseMICAL1        -----------EELLHWCQEQTAGFPGVH-VTDFSSSWADGLALCALVHHLQPGLLEPSELQGMGALEAT 568   
ratMICAL1          -----------EELLHWCQEQTAGFPGVS-VTDFSSSWADGRALCALVHRLQPGLLEPSELQGMSALEAT 568   
D.rerioMICAL1      -----------EELLSWCQKNTVGYEHVK-VKDLSESWRSGLALCALIHSFRPELVDMSALDEYNIIKNN 569   
DrosophilaMICAL    KRRSGDLLPQGATLLRWISAQLHSYQFIPELKEASDVFRNGRVLCALINRYRPDLIDYAATKDMSPVECN 624   
                                ** *       :  :  : :    :  * :** ::    * *:               
 
 
 
 
 
                     
humanMICAL2        QLAFDVAEREFGIPPVTTGKEMASAQEPDKLSMVMYLSKFYELFRGTPLRPVDSWRKNYGENADLSLAKS 647   
macaqueMICAL2      QLAFDVAEREFGIPPVTTGREMVSAQEPDELSMVMYLSKFYELFRGTPLRPVDSWRKNYGENADLSLAKS 647   
guinea_pigMICAL2   QLAFDVAEREFGIPPVTTGKEMASVQEPDKLSMVMYLSKFYELFRGTPLRPVDSWRKSYGENADLSFAKS 647   
mouseMICAL2        QLAFDVAKREFGILPVTTGKEMASTQEPDKLSMVMYLSKFYELFRGTPLRPMDSWRKNYGENADFGLGKT 647   
ratMICAL2          QLAFDVAKREFGILPVTTGKEMASTQEPDKLSMVMYLSKFYELFRGTPLRPMDSRRKNYGENADFGLGKT 647   
humanMICAL3        QLAFDIAEKELGISPIMTGKEMASVGEPDKLSMVMYLTQFYEMFKDSLPSSDTLDLNAEEKAVLIASTRS 649   
ratMICAL3          QLAFDIAEKELGISPIMTGKEMASVGEPDKLSMVMYLTQFYEMFKDSLSSSDTLDLNAEEKAVLIASTKS 649   
mouseMICAL3        QLAFDIAEKELGISPIMTGKEMASVGEPDKLSMVMYLTQFYEMFKDSLSSSDTLDLNAEEKAVLIASTKS 649   
D.rerioMICAL3      QLAFDVAEREFGISPIMTGKEMSVVVEPDKLSMVMYLSQFYEMFKDTVPPGENQNLSPEEKAALIASTKS 652 
A.aegyptiMICAL1    ELAISIFEDHLAIPRIMSGQESLTLAGVDSKLWLNYLEQICEVFRGEIPHVKHPKLDYAEFKQKQQIDSM 655   
humanMICAL1        AWALKVAENELGITPVVSAQAVVAG--SDPLGLIAYLSHFHSAFKSMAHSPGPVSQASPGTSSAVLFLSK 637   
macaqueMICAL1      AWALKVAEHELGITPVVSAQAVVAG--SDPLGLIAYLSHFHSAFKSTAHSPGPVSQASPGTSSAVLFLGK 636   
guinea_pigMICAL1   TWALRAAEHELGITPVVSAQAVVAG--SDPLGLIAYLSHFHSAFKNTPNSPGPVNQGSPGTSSAVLFLGK 637   
mouseMICAL1        TWALRVAEHELGITPVLSAQAVMAG--SDPLGLIAYLSHFHSAFKNTSHSSGLVSQPSGTPSAILFLGKL 636   
ratMICAL1          AWALRVAEYELGIIPVLSAQAVVAG--SDPLGLIAYLSHFHSAFKNTPHSSGLVSQPHGTPSAILFLGKL 636   
D.rerioMICAL1      KLAFDLMEKEFGITPIMRPGDMMTCGKIDQLSMVVYLTQIRNALTEKDTPAAQSNTLSLSRKRSAVAFLN 639   
DrosophilaMICAL    ELSFAVLERELHIDRVMSAKQSLDLTELESRIWLNYLDQICDLFRGEIPHIKHPKMDFSDLRQKYRINHT 694 
                         :   *  *  :            :    : **   
 
B 
                                         LIM 
human_MICAL2       SRLPSPDTSPDLESMRKSFPLNLGGSDTCYFCKKRVYVMERLSAEGHFFHRECFRCSICATTLRLAAYTF 1043   
macaqueMICAL2      HRPKAQATSPDLESMRKSFPLNLGGSDTCYFCKKRVYVMERLSAEGHFFHRECFRCSVCATTLRLAAYTF 1043   
guinea_pigMICAL2   HRPKAQATSPDLESIRKAFPPNLGGCDTCYFCKKRVYVMERLSAEGHFFHRECFCCSICATTLRLATYAF 1047   
mouseMICAL2        HRPKTQATSPDLESPRKAFPLSLGGRDTCYFCKKRVYMIERLSAEGHFFHQECFRCSVCSATLRLAAYAF 1021   
ratMICAL2          ENTRNPSALKQESLRKAEFPLSLGGRDTCYFCKKRVYVMERLSAEGHFFHRECFRCSVCAAILRVAAYAF 795   
mouseMICAL3        NAPAQSTGVRRQGSIKKEFPQNLGGSDTCYFCQKRVYVMERLSAEGKFFHRSCFKCEYCATTLRLSAYAY 805   
ratMICAL3          NAPAQSTGVRRQGSIKKEFPQNLGGSDTCYFCQKRVYVMERLSAEGKFFHRSCFKCDYCATTLRLSAYAY 805   
humanMICAL3        NAPAQSIGIRRQGSMKKEFPQNLGGSDTCYFCQKRVYVMERLSAEGKFFHRSCFKCEYCATTLRLSAYAY 805   
D.rerioMICAL3      NAPTQSTGLKRQGSFRKEFPQNIGGSDVCFFCRKRVYVMERLSAEGKFFHRSCFKCDYCGTTLRLSSYAF 815 
DrosophilaMICAL1   TTNTNNTVIPKSSSKVALAFKKQAASEKCRFCKQTVYPMEKTTVEGLVLHRNCLKCHHCHTNLRLGGYAF 1115   
A.aegyptiMICAL1    QQQQQQQSSQKSTSKAALVLTSSGVAEKCHFCKQRVYLMEKISAENLTLHRSCLKCHHCHTNLRLGGYAF 1050   
humanMICAL1        STEVPPDPEPGVPLTPPSQHQEAGAGDLCALCGEHLYVLERLCVNGHFFHRSCFRCHTCEATLWPGGYEQ 738   
macaqueMICAL1      STEVPPDPEPGVPLTPPSQHQEAGAGDLCALCGEHLYVLERLCVDGHFFHRSCFRCHTCEATLWPGGYEQ 737   
guinea_pigMICAL1   RTEEPPAPESRGPLVPPPQQQEADARGLCALCGEHLYILERFCVDGHFFHRSCFRCHACEATLWPGGYGQ 738   
mouseMICAl1        EEPPVSEPSMSPNTPELSEHQEAGAEELCELCGKHLYILERFCVDGHFFHRSCFCCHTCEATLWPGGYGQ 724   
ratMICAL1          CTEEPPVSEPSVPPALPSEHEEAGAEDVCELCGKRLYILERFCVDGHFFHRGCFCCRTCEATLRPGGYGQ 722   
D.rerioMICAL1      GPRQMKEKEEKKDVKEESLSSETSACEPCYFCKKHLYVVERESAEGKFFHRSCFNCFQCGSTLRQGGYSF 729   
                                               *  *   :*::*:        ** *  *  *   *    * 
 
human_MICAL2       DCDE—-GKFYCKPHFIHCKTNSKQRKRRAE---------------------------------------- 1071   
macaqueMICAL2      DCDE-—GKFYCKPHFIHCKTNSKQRKRRAE---------------------------------------- 1071   
guinea_pigMICAL2   DCEE-—GKFYCKPHFIHCKANSKQRKRWTE---------------------------------------- 1075   
mouseMICAL2        DCDE—-GKFYCKPHFVHCKTSSKQRKRRAE---------------------------------------- 1057   
ratMICAL2          DCDE—-GKFYCKLHFAHCKTSSKQRKRRAE---------------------------------------- 823   
mouseMICAL3        DIED--EFSPNFWTSASYHVP------------------------------------------------- 824   
ratMICAL3          DIED—-GKFYCKPRYCYRLSGYAQRKRPAVA--PLSGKEAKGPLQDGPTADTNGLASAATSSAERSPGAS 871   
humanMICAL3        DIED—-GKFYCKPHYCYRLSGYAQRKRPAVA--PLSGKEAKGPLQDGATTDANGRANAVASSTERTPGSG 871   
D.rerioMICAL3      DVED—-GKFYCKPHYCYRLSGVAQRKRPAPAAAPANAKEPQVLAVSPNTVDAPGQAITTQTPAERRPSET 883 
DrosophilaMICAL1   DRDDPQGRLYCTQHFRLPPKPLPQRTNKARKSAAAQPASPAVPPTAGSVPTAAATSEHMDTTPPRDQVDL 1185   
A.aegyptiMICAL1    DRDDPEGKFYCTQHFKLPSKTYNKPVPKKSLTRTPQADKQPLAAAAAVASTTQPSTPDSKSSGFINFNLL 1120   
humanMICAL1        HPGD--GHFYCLQH--LPQTDHKKEGSDRGPESPELPTPSENSMPPGLSTPTASQEGAGPVPDPSQPTRR 804  
macaqueMICAL1      HPGD--GHFYCLQH--LPQPDHKEEGSDGGPESPELPTPSENSMPPGLSTPTASQEGVGPVPDPSQPTRR 803   
guinea_pigMICAL1   HP-D--GHFYCLQH--LPGTDHKKDIMDGGSTSPELPTPDANSVPPGPLTPTAPQEEASPIPCPRQPARR 803   
mouseMICAl1        HPGD--GHFYCLQH—-LPQEDQKEADNNGSLESQELPTPGDSNMQPDPSSPPVTRV--SPVPSPSQPARR 788   
ratMICAL1          YPGD--GYFYCLQH--LPQEDQKEADNNGSPENQELPTPGDSTTQSGPSSPVPPVTEASPVPSPSQPARR 788   
D.rerioMICAL       HSDN--GRFYCELHSLAEEEEGDEGHGGAQNHTENGSKEDKNGETTAASSPPAHLSIKRKGSYKISVDPD 797                     
 21 
 
C                                                                       
   PXXP 
humanMICAL1           PTRRQIRLSSPERQRLSSLN---LTPDPEMEPPPKPPRSCSALAR-HALESSFVGWGLPV 857 
macaqueMICAL1         PTRRRIHLSSLERQRLSSLN---LTPDPEMEPPPKPPRSCSALAR-HALESSFVGWGLPV 862 
guinea_pigMICAL1      PARRLIRLSSPERQRLSSLD---INPSPEMEPPPKPPRSCSALAR-EALEGSFVGWGMPA 855 
mouseMICAL1           PARRLIRLSSLERLRLSSLN---IIPDSGAEPPPKPPRSCSDLAR-ESLKSSFVGWGVPV 840 
ratMICAL1             PARRLIRLSSVERLRLSSLN---IIPDSGVEPPPKPPRSCLDLAQ-ESLKSSFMGWGVLR 840 
humanMICAL3           LHGSSSNMKTLGSQSFNTSDSAMLTPPSS-PPPPPPPGEEPATLR-RKLREAEPNASVVP 1487 
ratMICAL3             PIRSQPVALPEARSPTSPTS--SLQPESLLA-PPTPPTPPSTQLP-ICSQPQPSSDASIP 1274 
D.rerioMICAL3         LNGSVTTSQTAASDSYNNSDSTMLTPPSS--PPPPPPREEPACLQNKKSQPRTPVSPPQP 1508                     
D.rerioMICAL1         KISVDPDFDESTEFPAPDQ----EPPDLEESHQPPKPSELSAENTNMENQQHNINPVPAP 847 
DrosophilaMICAL       FSSSSPQLYIHKPHHLAAAH---PSALDDQTPPPIPPLPLNYQRSDDESYANETREHKKQ 4542 
                                                       *  *                           
 
D 
                 Glu-rich 
humanMICAL1        SPQALVAMEKEEKESPFSSEEEEEDVPLDSDVEQALQTFMEK------------TWRRTLLRRAKEEE--  921 
macaqueMICAL1      GPQALVA----EEEESSSSSEEEEDVPLDSDVEQALQTFAKTSGTMNDYP----TWRRTLLRRAKEEE--  919 
guinea_pigMICAL1   SLPVF---EAMEEEESSSDNEEEEDDDEPLDPDLEQALQTMAKNAGTMD--KYPTWRRTLLRHAKEEE--  919 
mouseMICAL1        APQVPEAIEKGDDEEEEEEEEEEEEEPLPPLEPELEQTLLTLAKNPGAMT-KYPTWRRTLMRRAKEEE--  908 
ratMICAL1          APQVPEAIEKGEEEEEEEEEEEEEEEELPPPLALEVEQSLLTLAKNSGDMTKYPTWRRTLMRRAKEEE--  908 
humanMICAL3        AEEDVASSSSESEMEEEGEEEEEEPRLPPSDLGGVPWKEAVRIHALLKGKSEEELEASKSFGPGNEEEEE  996  
ratMICAL3          TEEDAASSSSESEM-EEEEEEDEEDQLPTSDLGGVPWKEAVRIHALLKGRSEEELEASKNFEP---EEEE  992 
D.rerioMICAL3      TDIEEGSSSSESDMEEEDEDAEAAG---PSDLGGVPWKEAVELHAKLKGESDPGADDDGLHDGDGEMDED  1006 
D.rerioMICAL1      AGQSQPDQYVSEDDNEDDEDEDEEDLQAEHYLDCEGADFEFSDSEKRNLKRMKTLERKAKMTEIQRF---  1060 
mouseMICAL3        KDKKEKDSDGAGKRRKTSQSEEEE--PPRSYKGERPTLVSTLTDRRMDAAVGNQNKVKYMATQLLAKFEE  735 
                                       *:**                                               
 
humanMICAL1        ----------------------------------------------------------------------   
macaqueMICAL1      ----------------------------------------------------------------------   
guinea_pigMICAL1   ----------------------------------------------------------------------   
mouseMICAL1        ----------------------------------------------------------------------   
ratMICAL1          ----------------------------------------------------------------------   
humanMICAL3        EEEEYEEEEEEDYDEEEEESSEAGNQRLQQVMHAADPLEIQADVHWTHIREREEEERMAPASESSASGAP  1066 
ratMICAL3          EEEEYEDDEEE-YDEEEEESSEAGNKRLQQIITAADPLAIQADVHWTHIREREEEERMLPPSESSTSRAP  1061 
D.rerioMICAL3      EEE--EEDEEDEDEEEEEESSEARNLQIQQAIHPVDPLDIQMESHQAEGVLEMPSVSPLGSLTQPTSSTA  1081 
D.rerioMICAL1      ----------------------------------------------------------------------   
mouseMICAL3        ----------------------------------------------------------------------   
 
 
E 
                                 CC 
humanMICAL1          -----------------------MKRFCKAQTIQRRLNEIEAALRELEAEGVKLELALRRQSSSPEQQKK 968 
macaqueMICAL1        -----------------------MKRFRKAQTIQRRLNEIEGALRELEAEGVKLELALRRQSSSPEQQKK 966 
guinea_pigMICAL1     -----------------------MKRFCKAQTIQRRLNEIEAALRELEAEGVKLELALRSQSTSPEQQKK 966 
mouseMICAL1          -----------------------MKRFCKAQAIQRRLNEIEATMRELEAEGTKLELALRKESSSPEQQKK 955 
ratMICAL1            -----------------------MKRFCKAQAIQRRLNEIEAAMRELETEGMKLEVALRKESSSPEKQKK 955 
humanMICAL3          EELNAKLTRRVQKAARRQAKQEELKRLHRAQIIQRQLQQVEERQRRLEERGVAVEKALRGEAGMGKKDDP 1890 
ratMICAL3            EELSAKLTRRVQKAARRQAKQEELKRLHRAQIIQRQLEQVEEKQRQLEERGVAVEKALRGEAGMGKKDDP 1886 
D.rerioMICAL3        EELNAKLTRRVQKAARRQAKQEELKRLHRAQIIQRQLQQVEEKQRQLEERGVAVEKALRGEAGMGKKDDP 1915 
D.rerioMICAL1        FSDSEKRNLKRMKTLERKAKMTEIQRFHKAQSIQRRLEEIEVTFKELEEKGVELERALRGETGTG---DE 1100 
DrosophilaMICAL      SYANETREHKKQRAISKASRQAELKRLRIAQEIQREQEEIEVQLKDLEARGVLIEKALRGEAQNIENLDA 4600 
humanMICAL2          LSGVLWRLQQVEEKILQKRAQNLANREFHTKNIKEKAAHLASMFGHGDFPQNKLLSKGLSHTHPPSPPSR 905 
macaqueMICAL2        LSGVLWRLQQVEEKILQKRAQNLANREFHTKNIKEKAAHLASMFGHGDFPQNKLLSKGLSHTHPPSPPSC 905 
guinea_pigMICAL2     LSGVLRRLQQVEEKILQKRAQNLANREFHQKNIKEKAAHLASMFGHGDFPQNKLLSKGPSHTHPPSPPPC 907 
mouseMICAL2          LSGVLRRLQQVEEKVLQKRAQNLANREFHTKNIKEKAAHLASMFGHGDLPQDKLLSKRVPHAHPPSPPSC 904 
ratMICAL2            QGFNNLEELPAFSSRSLGSSQEYAKESGNQNKVKYMANQLLAKFEENTRNPS-ALKQESLRKAEFPLSLG 749 
mouseMICAL3          KTSQSEEEEPPRSYKGERPTLVSTLTDRRMDAAVGNQNKVKYMATQLLAKFEENAPAQSTGVRRQGSIKK 752 
A.aegyptiMICAL1      ---------------------------------------------------------------------- 
 
 
 
 
 
 
                                  Leu zipper 
                             ----------------------                                  
humanMICAL1          LWVGQLLQLVDKKNSLVAEEAELMITVQELNLEEKQWQLDQELRGYMNREENLKTAADRQAEDQVLRKLV 1038  
macaqueMICAL1        LWVGQLLQLVDKKNSLVAEEAELMITVQELNLEEKQWQLDQELRGYMNREETLKTAADRQAEDQVLRKLV 1036  
guinea_pigMICAL1     LWLEQLLQLVQKKNSLVAEEAELMITVQELDLEEKQWQLDHELRGYMNREETLKTAEDRQAEDEILRKLV 1036  
mouseMICAL1          LWLDQLLRLIQKKNSLVTEEAELMITVQELDLEEKQRQLDHELRGYMNREETMKTEADLQSENQVLRKLL 1025 
ratMICAL1            LWLEQLLQLIQKKNSLVTEEAELMITVQELDLEEKQRQLDHEFRG-INREETLKTQADRLSEDRVLRKLL 1024  
humanMICAL3          KLMQEWFKLVQEKNAMVRYESELMIFARELELEDRQSRLQQELRERMAVEDHLKTEEELSEEKQILNEML 1961  
ratMICAL3            KLMQEWFKLVQEKNAMVRYESELMIFARELELEDRQSRLQQELRERMAVEDHLKTEEELSEEKKILNEML 1956  
D.rerioMICAL3        KLMQEWFKLVQEKNALVRYESELMIFARELELEDRQSRLQQELRERMAIDDHLKTEEELAEEKQILNEML 1985 
D.rerioMICAL1        EIIDQWIELVQEKNNLLSEESDLMVASRQLELEDKQSMLEMELRRYMEMDDSEKSPEQQKHEAEILQEML 1170  
DrosophilaMICAL      KLLKELLEIWRNITALKKRDEELTIRQQELQLEYRHAQLKEELNLRLSCNKLDKSSADVAAEGAILNEML 4676  
humanMICAL2          LKQQREEEATWQEQEAPRRDTPTESSC—-AVAAIGTLEGSPPVHFSLPVLHPLLG*               1124 
macaqueMICAL2        LKQQREEEATWQEQEAPLRDTPTESSC—-AVAAIGTLEGSPPVHFSLPVLHPLLG*               1124  
guinea_pigMICAL      LKQEQEEEGTWQEQEGPRRDTATESSC—-AVAAVSTPEGSPPVHFSLPVLHPLLG*               1128  
mouseMICAL2          LNQQREEEGTWQEQEAPRRDVPTESSC-—AVAAISTPEGSPPVRFSLPVLHPLLG*               1102  
ratMICAL2            LNQQREEEGTWPEQEAARRDVPAESSC--AVAAISTPEGSPPGISTSFFRKALSWPLRLTRGLLNLPQSL 891 
mouseMICAL3          FSPNFWTSASYHVPVALPATVMPMC----LYHPSQVLVCLEGGPAFMSPVLFNDTNS------------- 864  
A.aegyptiMICAL1      KTKPKPEALTKVDPKLELMMTTLTEPAEVLEQTD-LSKDSSLLNASSCDLPDIVNITKKQAIEAQPALKI 2939  
                             :      :             :                                                               
 
humanMICAL1          DLVNQRDALIRFQEERRLSELALGTGAQG*                                         1067 
macaqueMICAL1        DLVNQRDALIRLQEERRLSELALGIGAQG*                                         1065 
guinea_pigMICAL1     EVVNQRDALIRFREECRLSELA*                                                1058 
mouseMICAL1          EVVNQRDALIQFQEERRLREMPA*                                               1048 
ratMICAL1            DVVNQRDALIQFQEERRLREMPV*                                               1047 
humanMICAL3          EVVEQRDSLVALLEEQRLREREEDKDLEAAMLSKGFSLNWS*                             2002 
ratMICAL3            EVVEQRDSLVALLEEQRLREKEEDKDLEAAMLCKGFSLDWS*                             1997 
D.rerioMICAL3        EVVEQRDSLVALLEEQRLREREEDKDLEAVMLSKGFNLNWA*                             2026 
D.rerioMICAL1        DVVDMRDSLVAFLEEKRLKEVNDQFNSSLDAKRRSTTASQVHWE*                          1214      
DrosophilaMICAL      EIVAKRAALRPTASQLDLTAAGSASTSAEATGIKLTGQPHDHEESII*                       4723 
ratMICAL2            LRWMQGLLQAAGHHVRDNAHNYCFMFELLSLGLLLLWAFSEVLAAMYRESEESLESIRSWLLRFVPVKLQ*961        
A.aegyptiMICAL1      LDHTEKIKQITSHIPQEIQVYTLHTEDHKPAEPQPSTSGVTSDYASILKDISSGLMGTDIVEPVFYEPPPT3009 
 
A.aegyptiMICAL1 IDRKPKSDFTTYKQILQDKAREPAEHNSQQPQRPLRKPKPTERSVSPAVAGRPFDNSICIDPWRAKRSSSI 3081 
A.aegyptiMICAL1 ENLVVEQVFVKKDDKVVDTFYIVPEQQKKLKRRSKSFDRLQVPGYSGRRHSKKSLEELRDFGFDIEPPGTC 3152 
A.aegyptiMICAL1 KNLVNPRLRHLNFDESDEDLSSLRNNRRRENLRKCQSSTDTSKLDVEASRVDIDRESPIPRSTDFSKWEAI 3223 
A.aegyptiMICAL1 LDRGIPYYKEPPVHKKEDIKSLERKLEDLKTECKPRRKISGKTPAIPKDYDPEEYVPRINRRALDTYDVPD 3294 
A.aegyptiMICAL1 SDLPKWYDPDEYVPRAQRNHAFDHEIPVSSAVRSRRLNEFDIPTSSTSRPQRSSAYEIDVPISRTGGRYYP 3365 
A.aegyptiMICAL1 EPLHLDDLPMTHTLPKSKITSSHVPYTSSRTYDLPSRDVPRTRYSHRPTADSGTIVNRSQRLHEKANKYIR 3436 
A.aegyptiMICAL1 SQVTKNDPNPYIREMLENESDDDAYPITTSTSHRVPITTSSFHPISTYGTSGSAAMSRIATKAITQPSRMT 3507 
A.aegyptiMICAL1 HYTRKDVPSSSGSGSRSYRRGGGDHHDRRDNCTIS*                                    3542 
 
 
 
Figure 2.1. Sequence comparison of MICAL forms. Regions corresponding to the 
monooxygenase (MO) and calponin homology (CH) domains (panel A), LIM domain 
(panel B), Pro-rich (panel C) and Glu-rich region (panel D) and coiled coil regions 
(panel E) of selected MICAL sequences (Table 2.1) have been aligned with ClustalW2 
(Goujon 2010). The output reflects the degree of sequence similarity among the 
proteins. Sequence annotation: cyan, basic residues in the N-terminal basic region and 
conserved residues are in bold; yellow, residues involved in FAD binding as indicated 
in the sequence; in bold are the residues matching the ADP binding region and second 
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FAD consensus sequence; residues involved in the interaction with the isoallosaxine 
ring (i), pyrophosphate (p) adenosine (Ado) and AMP regions of FAD are also 
indicated. Red, residues proposed to be responsible of NADPH binding as deduced 
from the comparison with pHBH. The red stars below the aligned sequences indicate 
the conserved region of MO domain of MICALs. In the CH domain the underlined 
residues are those forming the hydrophobic core based on the structure of the CH 
domain of human MICAL1 (Sun et al., 2006). The regions implied in the binding of 
actin (ABS) and PIP2 (PIP2) as defined by Gimona et al., 2002 and Sun et al., 2006, are 
also indicated. Residues matching the consensus sequence for ABS are in bold and for 
PIP2 binding are in bold and in italic. The conserved Cys and His residues of the 
consensus sequence of the LIM domain are in bold and highlighted in purple. The Pro-
rich regions are in bold and orange. The Glu-rich regions are in bold and green. The 
residues that potentially form coiled-coil motifs (CC) are highlighted in grey and those 
forming the putative leucine zipper are in bold. *, identical residues; :, conserved 
residues.  
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A 
                                            CH   ___ABS  _  ______PIP2______ 
humanMICAL1                -------GSAGTQEELLRWCQEQTAGYPGVHVSDLSSSWADGLALCALVY 548 
humanMICAL-like1           -------MAGPRG-ALLAWCRRQCEGYRGVEIRDLSSSFRDGLAFCAILH 42 
guinea_pigMICAL-like1      -------MAGPRG-ALLSWCRRQCEGYGGVEIRDLSSSFRDGLAFCAILH 42 
mouseMICAL-like1           -------MAGPRG-ALLAWCRRQCEGYRGVDIRDLSSSFRDGLAFCAILH 42 
ratMICAL-like1             --MWGVRPSGERGSTAGAWSQGGAPSSSRSPATRAGRGGDGGGGRPWPAH 48 
D.rerioMICAL-like1         --------MGSLK-ALQDWCRNQCASYNNVDITNMTSSFRDGLAFCAIIH 41 
humanMICAL-like2           ---------MAAIRALQQWCRQQCEGYRDVNICNMTTSFRDGLAFCAILH 41 
guinea_pigMICAL-like2      ---------MAAIKALQQWCRQQCEGYRDVDITNMTTSFRDGLAFCAILH 41 
mouseMICAL-like2           ---------MAAIKALQEWCRQQCEGYRDVSITNMTTSFRDGLAFCAILH 41 
ratMICAL-like2             ---------MAAIKALQEWCRQQCEGYRDVSITNMTTSFRDGLAFCAILH 41 
D.rerioMICAL-like2         ---------MAAIKALQQWCKIQCEGYRDVAISNMSMSFRDGLAFCALIH 41 
drosophilaMICAL-like       MSDRRGTKVGTGTKALEYWCRVVTQGYNGVKVENMTTSWRNGLAFCAIIH 50 
                                          .  *..          .  .        .    .*                                            
 
humanMICAL1                RLQPGLLEPSELQGLGALEATAWALKVAENELGITPVVSAQAVVAGSDPL 598 
humanMICAL-like1           RHRPDLLDFDSLSKDNVFENNRLAFEVAEKELGIPALLDPNDMVSMSVPD 92 
guinea_pigMICAL-like1      RHRPDLLDFDSLSKDNVFENNRLAFEVAEKELGIPALLDPNDMVSMSVPD 92 
mouseMICAL-like1           RHRPDLLDFQSLSKENVFENNRLAFEVAEKELGIPALLDPNDMVSMSVPD 92 
ratMICAL-like1             NEDSGPRDFQSLSKENVFENNRLAFEVAEKELGIPALLDPNDMVSMSVPD 98 
D.rerioMICAL-like1         RHRPDLIDFDSLSKENVFENNRLAFEVAERELGIPALLDAEDMVSMSVPD 91 
humanMICAL-like2           RHRPDLINFSALKKENIYENNKLAFRVAEEHLGIPALLDAEDMVALKVPD 91 
guinea_pigMICAL-like2      RHRPDLINYSALRKENIYENNKLAFSVAEEHLGIPALLDAEDMVALKVPD 91 
mouseMICAL-like2           RHRPDLINFSALRKENIYENNKLAFQVAEEQLGIPALLDAEDMVALKVPD 91 
ratMICAL-like2             RHRPDLINFNALRKENIYENNKLAFQVAEEQLGIPALLDAEDMVALKIPD 91 
D.rerioMICAL-like2         KFRPDLINFESLSKDNVYYNNHLAFRVAEDHLGIPALLDAEDMVALPVPD 91 
drosophilaMICAL-like       HFRPDLIDFDRLKADDIYENNDLAFTTAEKYLGIPALLDAADMVSYEVPD 100 
                                           .. **  **  **  ********  ***    **                        
 
humanMICAL1                --GLIAYLSHFHSAFKSMAHSPGPVSQASPGTSSAVLFLSK--------- 637 
humanMICAL-like1           CLSIMTYVSQYYNHFCSPGQAGVSPPRKGLAPCSPPSVAPTPVE-PEDVA 141 
guinea_pigMICAL-like1      CLSIMTYVSQYYHHFTSPGQAGVSPSRKELTASSPPLVAPSPAE-PGDET 141 
mouseMICAL-like1           CLSIMTYVSQYYNHFTSSGQAAASPPKPGKDPAPPSPTSTSPAVQPGEEA 142 
ratMICAL-like1             CLSIMTYVSQYYNHFTSSGQAAASPPKPGKDPAAPSPTSTSPAVQPGEEA 148 
D.rerioMICAL-like1         RLSIITYVSQYYNFFTNKSHTVSKCIKSPSSSGYIRSAIKRPLASPEDRD 141 
humanMICAL-like2           RLSILTYVSQYYNYFHGRSPIGGMAGVKRASEDSEEEPSGKK-APVQAAK 140 
guinea_pigMICAL-like2      RLSILTYVSQYYNYFHGRSPIGGMAGIKRPPSDPEEEPSGKK-APSTPAK 140 
mouseMICAL-like2           RLSILTYVSQYYNYFHGRSPIGGMAGIKRPSSDSTEELSGKK-GLSQPAK 140 
ratMICAL-like2             RLSILTYVSQYYNYFHGRSPIGGMAGMKRPSSDSTEELSGKKKVPSQPAK 141 
D.rerioMICAL-like2         RLSILTYVSQYYNYFHGRSPIGGVGGIKRHAEDSKEVPSEKKNLPVVAKL 134 
drosophilaMICAL-like       RLSILTYLSQFYKVLG-KSLKHPKPEEPLGEESEPPQKVMHIVGMPRRDK 149 
                            ***.*****.* 
 
B                                                                                                        
                                      LIM 
humanMICAL                 -------------------STEVPPDPEPGVPLTPPSQHQEAGAGDLCAL 699 
humanMICAL-like1           QGEELSSGSLSEQGTGQTP-------------------------SSTCAA 166 
guinea_pigMICAL-like1      QSEELSSGSLSEQGAQRAP-------------------------SSTCAA 166 
mouseMICAL-like1           QGDDLSPDSLSEQGKQQPP-------------------------SSACAA 167 
ratMICAL-like1             QGDDLSPDSLSEQGKPQPP-------------------------SSACAA 173 
D.rerioMICAL-like1         AHNESGAD---IQPKRSTL-------------------------SSTCSA 163 
humanMICAL-like2           LPSPAPARKPPLSPAQTNPVVQRRNEGAGGPPPKTDQALAGSLVSSTCGV 190 
guinea_pigMICAL-like2      LPSSAPAQALPAPAARTSSMAQRMD---GG--PKAAQTVAGSAVSSTCAV 185 
mouseMICAL-like2           LPSPAQTQRSPLSPARTNPVVQRNEGGSQRPSPKAAPGTAGSSVSSICGV 190 
ratMICAL-like2             LSSPVPTQRLPLSPARTNPVVQRNEGVSERPSPKAAPGTVGSSVSSICGV 191 
D.rerioMICAL-like2         KSPGPKCVQAPVTPLRARSPQPHREAEKVSKSVLVETSNKTGTLNSECAV 241 
drosophilaMICAL-like       -----------------------------------------------CQK 152 
                                                                          *.. 
                                                                            
 
 
humanMICAL1                CGEHLYVLERLCVNGHFFHRSCFRCHTCEATLWPGGYEQHPGDGHFYCLQ 749 
humanMICAL-like1           CQQHVHLVQRYLADGRLYHRHCFRCRRCSSTLLPGAYENGPEEGTFVCAE 216 
guinea_pigMICAL-like1      CQQHVHLVQRYLAEGRLYHRHCFRCRQCSGTLLPGAYKSGPEAGTFVCAE 216 
mouseMICAL-like1           CGQRVHLVQRYLAEGRLYHRHCFRCRQCSSTLVPGSYSSGPEEGTFVCAE 217 
ratMICAL-like1             CGQRVHLVQRYLAEGRLYHRHCFRCRQCSSTLVPGSYSSGPEEGTFVCAE 223 
D.rerioMICAL-like1         CGKHVHLVQRILVDGKLYHRNCFRCRECSRTLLPGSYKFTEDPGALVCTH 213 
humanMICAL-like2           CGKHVHLVQRHLADGRLYHRSCFRCKQCSCTLHSGAYKATGEPGTFVCTS 240 
guinea_pigMICAL-like2      CGKHVHLVQRHLVDGRLYHRSCFKCKQCSSTLRSGAYRATGEPGIYVCTS 235 
mouseMICAL-like2           CGKHVHLVQRHLADGRLYHRSCFRCKQCSSTLHSGAYRATGEPGVFVCTH 240 
ratMICAL-like2             CGKHVHLVQRHLADGRLYHRSCFRCKQCSSTLHSGAYRATGEPGVFVCTH 241 
D.rerioMICAL-like2         CGNHVHLVQRHLVDGKLYHRSCYKCSVCYGTLKSGAYKLGSDTGSLVCTI 291 
drosophilaMICAL-like       CNLPVFLAERVLVGKRAYHRTCLKCARCSSLLTPGSFYETEVNNIYCCET 202 
                           *   * *        ..*** *..*  *                   * 
humanMICAL1                HLPQTDHKKEGSDRGPESPELPTPSENSMPPGLSTPTASQEGAGPVPDPS 799 
humanMICAL-like1           HCARLGPGTRSGTRPGPFSQPKQQHQQQLAEDAKDVPGG--GPSSSAPAG 264 
guinea_pigMICAL-like1      RCTRLGPGGQAGARPGPPSQPKP---QQLAEEARDGEEG--GPSSSVAAG 261 
mouseMICAL-like1           RCTRLGPGSRSGTRLLSQQRQQP-----AAAEAKDAEDN--DPSLSVAAV 260 
ratMICAL-like1             RCTRLGLGGRSGTRPLSLQKQQPA----AAAEAKDGEDS--DLSKSVVVV 267 
D.rerioMICAL-like1         HFTRSASTNQNGHSDMSNRLAKLT---TSAEDPLCGNDSEISPQRDEEKT 260 
humanMICAL-like2           HLPAAASASPKLTGLVPRQPGAMGVDSRTSCSPQKAQEAN-------KAR 283 
guinea_pigMICAL-like2      HHSRATSANTALPALTSKQPAATPVDAGAPSVLQKTQEMNGLREAAPKAQ 285 
mouseMICAL-like2           HSSEVTSVSPKSSNLASRKPGGVTADTRPFGVSWTVQEANG-EGTPLRVR 289 
ratMICAL-like2             HSSEAVSVSPKLSNLASRQPGGGIADTRPIGVSQKVLETNG-EATPLRAR 290 
D.rerioMICAL-like2         HQHGQNGFKPTVKPFKSSGFTVSDLVAKSEREDQSPSQRYISVLSAPIKA 341 
drosophilaMICAL-like       CPDEESEPESDILKLKTTTTDSPNDKQMVAQSSDYSEAEDKQEDLEDNDI 252 
 
                                                                                                        
C 
 
humanMICAL-like1           A-EADGPKASPEARPQIPTKP---RVPGKLQE------------------ 292 
guinea_pigMICAL-like1      ------RKAVPEARPHVPTKP---PLPGKPQE------------------ 284 
mouseMICAL-like1           A-EADRLQASSEVQFHTPTKP---PLPSKPQE------------------ 288 
ratMICAL-like1             AAEADGLQASSEVQPHTLTKP---PLPSKPQD------------------ 296 
D.rerioMICAL-like1         SELEERLRKQTDSKSKVETEEGANPFDESEEEDRDIQQEDLKSATDVANG 310 
humanMICAL-like2           PSAWEPAAGNSPARASVPAAPNPAATSATS-------------------- 313 
guinea_pigMICAL-like2      PVAHRPVVGNTTAKGFARITSEPPASTVP--------------------- 314 
mouseMICAL-like2           TAAWEHAGGNTTAKGFVQTELKPPSTSQV--------------------- 318 
ratMICAL-like2             TAAWEHAGGNRAAKGFVQTELTPPATSRV--------------------- 319 
D.rerioMICAL-like2         --------------------------------------------------  
drosophilaMICAL-like       RTTDKPENFQPPSNKDEQNNELTINPVNPILSEERKISFIPLDEEDGGLI 302 
 
                                                                         
humanMICAL-like1           -------LASPPAGRPTPAPRKASESTTPAPPTPRPRSSLQQENLVEQAG 335 
guinea_pigMICAL-like1      -------LSSPVSGRPTPAPRKASDSMAPTPPTPRPRSSLQQDSTAEQGG 327 
mouseMICAL-like1           -------LASPPGGRPTPAPRKASESSALTPPTPRPRSSLQQDGTVEQSV 331 
ratMICAL-like1             -------LASPPVSRPTPAPRKASESSALTPPTPRPRSSLQQDGMVEQSV 339 
D.rerioMICAL-like1         DTPSTSVKSTAAESRPVPAPRRVLEPSPAPRPVPRLRRSRISESIT---V 357 
humanMICAL-like2           ---------VHVRSPARP--SESRLAPTPTEGKVRPRVTNSSPMGWSSAA 352 
guinea_pigMICAL-like2      ---------IQVGSPAGPRLPANPVASLLEHSTASTHVTGRSPMGRTSHA 355 
mouseMICAL-like2           ----------HVGSSAGPKLPTITVTTTSVTSKALTHVTNSSPIGWSSPA 358 
ratMICAL-like2             ----------HVGSPAGPRLPMSTVTTTSANSKATTHVTNSSPVGWSSSA 359 
D.rerioMICAL-like2         --------------------------------------------------  
DrosophilaMICAL-like       EQYNKSTTPVKPAIPEKPKVSTLPLDDEQHAGVEQNNDLAVSPENDIPKE 352 
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D 
 
humanMICAL1                --------------------PTRRQIRLSSPERQRLSSLNLTPDPEMEPP 830 
humanMICAL-like1           SSSLVNGRLHELPVPKPRG-TPKPSEGTPAPRKDPPWITLVQAEPKKKPA 384 
guinea_pigMICAL-like1      SGGLVNGRLQEPPVPKPRG-TPKLSERTPPARKDPPWITLVQAEPKKKPA 376 
mouseMICAL-like1           SSGLVNGRLQEPPVPKPRG-TPKLSERMAAPRKDPPWITLVQTEPKKKPA 380 
ratMICAL-like1             SGDLVNGRLQELPVPKPRG-TPKLSERMTAPRKDPPWITLVQTEPKKKPA 388 
D.rerioMICAL-like1         NGDPDQTQTPQVPVPKERMHSPARKAGDTPKPKDPPWLALVQSETKRKPA 407 
humanMICAL-like2           PCT-AAAASHPAVPPSAPDPRPATPQGGGAPRVAAPQTTLSSSSTSAATV 401 
guinea_pigMICAL-like2      QYP-ATNSSR--SAPSIPEPCPATPQGLGPPRVSTSVTKLGLNSASPGAA 402 
mouseMICAL-like2           QSSPANFNSRPVVSPSARNTHLPGSQGQTAS--KGVKTQLNLNSESSNTA 406 
ratMICAL-like2             QSSTGTSGSRPVVSPSALGAHLSVPQGQAAS--KGVKTQLNSSTDSSSTA 407 
D.rerioMICAL-like2         -----------------------------VP----RPVELSLAQQS---- 354 
drosophilaMICAL-like       KLKISSVSIYLEDDRLVVDAIHPDNLDKQEALNNTSDALIPESQEAPIPE 402    
  
                          Pro-rich 
humanMICAL1                PKPPRSCSALARHALESSFVGWGLPVSPQALVAM---------------- 856 
humanMICAL-like1_human     PLPPSSSPGPPSQDSRQVENGGTEEVAQPSPTASL--------------- 419 
guinea_pigMICAL-like1      PLPPGS-PRPPSRGSRQEENGTVEEVTPRGPAAGS--------------- 410 
mouseMICAL-like1           PQPPSSGPGPLSQAYRQVEDGGLEEQTQKSSGTEP--------------- 415 
ratMICAL-like1             PLPPSSGPGPLSQASRQVENGGLEEKTQKSPAAEP--------------- 423 
D.rerioMICAL-like1         PRPPTGTAVPPSTGASPSRK---EETSRPS-------------------- 434 
humanMICAL-like2           DPPAWTPSASRTQQARNKFFQTSAVPPG---------------------- 429 
guinea_pigMICAL-like2      DPPAWTPSATRTQQARERFFQSPAAPT----------------------- 429 
mouseMICAL-like2           VTPAWTSSASKTQQAREKFFQTPPSAPAPASAPAP-APTSKVPTVVTVPT 455 
ratMICAL-like2             PTPAWTSSSSRTQQAREKFFHNLSPAPAPAPASSSSSHASRVPTVVTAPS 457 
D.rerioMICAL-like2         ----WTSSAQRTQAARQKFFQSCAPATE---------------------- 378 
drosophilaMICAL-like       NNTQVAIKPEDHISPRKENKIFSNTESCSKQEGVLPKQMDLESPKDKVIE 452 
                                                                                                               
E 
                Glu-rich 
humanMICAL1                EKESPFSSEEEEEDVPLDSDVEQALQTFMEKTWRRTLLRRAKEEE----- 921  
humanMICAL-like1           ESKPYNPFEEEEEDKEEEAP------------------------------ 439  
guinea_pigMICAL-like1      EPRTYNPFEDEEE-VEEPSP------------------------------ 429  
mouseMICAL-like1           EPKPYNPFEEEEEEEGEPAPPVPSPS------------------------ 441  
ratMICAL-like1             EPKPYNPFEEEEEEE----------------------------------- 438  
D.rerioMICAL-like1         --TPPNPFENEEEEE----------------------------------- 447 
humanMICAL-like2           TSLSGRGPTPSLVLS----------------------------------- 444 
guinea_pigMICAL-like2      SGPVGQTPAPANAPF----------------------------------- 444 
mouseMICAL-like2           SKVPNVVTAPTSKVP--TVVTVPTSKVPTVVSAPTSKVPTVVSAPTSKVP 503 
ratMICAL-like2             GKVSPLVNTSTSKVPSATVVTVPTSKASTVVTAPTSKAPTVVTVPISKAP 507 
D.rerioMICAL-like2         LQPNTKPPLGPAEPS----------------------------------- 393 
drosophilaMICAL-like       YPEDLNPFKDDDSSKGANPFD----------------------------- 480  
   
 
F 
                                                                                                                                                    
humanMICAL-like1           ------------------AAPSLATSPALGHPESTPKSLHPWYGITP-TS 470 
guinea_pigMICAL-like1      ------------------AAPSPAPSPAQAPSECTPKSLHPWYGITP-TS 460 
mouseMICAL-like1           ----------LAPPVPSPSPAPPVPSPAPAPSEATPKSLHPWYGITP-TS 480 
ratMICAL-like1             -----------------EASVPAVPSPAPAPPETTPKSLHPWYNITP-TS 470 
D.rerioMICAL-like1         -------------------ESELGPEDVPGPVVAS----HPWYGITHSTE 474 
humanMICAL-like2           ------------KDSSKEQARNFLKQALSALEEAGAPAPGRPSPATAAVP 482 
guinea_pigMICAL-like2      ------------RDSSREQALSFLKKALSGVEAAGAQAPGKSSPAMNSCP 482 
mouseMICAL-like2           ASKVSPVVDAPAQESSREQALSVLRKALPALTGSGTQAPNRSFPATSSVL 603 
ratMICAL-like2             ASKVSGVVDNPAQESSREQALSVLRKALPGLTRAGSQAPSRSSPATSSVL 607 
D.rerioMICAL-like2         --------------------------NLKVQEKEGNRALANGNPLHEGNA 417 
drosophilaMICAL-like       -------------SSDDEVELLKAIPAQQSKGKVVPPRPPPPKIGLSSIS 517 
 
 
humanMICAL-like1           SPKTKKRPAPRAPSASPLALHASRLS----HSEPPSATPSPALSVESLSS 516 
guinea_pigMICAL-like1      SPKTKKRPAPRAPSASPLALHASRLS----HSEPPSATPSPALSVESLAS 506 
mouseMICAL-like1           SPKTKKRPAPRAPSASPLAIHASRLS----HSEPPSATPSPALSVESLSS 526 
ratMICAL-like1             SPKTKKRPAPKAPSASPLVLHASRLS----HSEPPSATPSPALSVESLSS 516 
D.rerioMICAL-like1         VPGGDAGKQSPARSESPISIRRKKRP----APKAPNSSTSAFPSSQTSSP 520 
humanMICAL-like2           SSQPKTEAPQASPLAKPLQSSSPRVLGLPSRMEPPAPLSTSSTSQASALP 532 
guinea_pigMICAL-like2      ----KTEGPKAVPSGKPLQSDAPHTLSSTSRTEPSARLSVGSTSQVGKSP 528 
mouseMICAL-like2           VTLPKNEVPQKVPSDK-LSALTTQTPNFTIKLEPSAPVNVGN---TAVFL 649 
ratMICAL-like2             ITLPKNEVPPKVPSAK-LSHSTTQAFSPTPKMEPTAPLSVGSTSWTSVSL 656 
D.rerioMICAL-like2         NNNNALNSDPRAKSQVKISCSSAEVSTWRQELHVRDSKGRSSYQAAPSSP 467 
drosophilaMICAL-like       NPSEKPHSSPTLSHGKKMPMPTPRISISKTQTPAKPMTHQGQKSSISSSS 567 
                                        
 
humanMICAL-like1           ES----ASQTAGAELLEPPAVPKSSSEPAVHAP-------GTPG---NPV 552 
guinea_pigMICAL-like1      ES----CSQMAAGELLEPPAVPKSSSEPAVHAP-------GTPG---NSA 542 
mouseMICAL-like1           ES----SSHTANAEPLEPPAVPKSSSDPAVHVP-------GTPGTSGNSV 565 
ratMICAL-like1             ES----SSHTANTEPSEPPAVPKSSSDPAVHVP-------GTPGTSANSV 555 
D.rerioMICAL-like1         ASSLALSTESLSSSSSDYSAVPQKAAANEQDHL-------FTKSVS-EPS 562 
humanMICAL-like2           PAGRRNLAESSGVGRVGAGSRPKPEAPMAKGKSTTLTQDMSTSLQEGQED 582 
guinea_pigMICAL-like2      -------ATSSGVIKEGTGSRLKPEAPTAKGP--------STSPQQSQED 563 
mouseMICAL-like2           QAGKKSPSISPRVGKTSVGSRPQAEVAGVKGP--------GPISQEGQEE 691 
ratMICAL-like2             QAGKKSPGISPGIGKTSAVSRPQAEVK---GP--------GPTSQEGQEE 695 
D.rerioMICAL-like2         ---AIISSGGGMNGKESL-YLSAISKESSRPPSLLQTTAKASANDVQSYD 504 
drosophilaMICAL-like       SEHLNSIRTFDRGADDRGSSISLPSANGPRKPLR---ASVGSPLRSEESS 614 
 
 
humanMICAL-like1           SLSTNSSLASSGELVEPRVEQMPQASPGLAPRTRGSSGPQ-------PAK 595 
guinea_pigMICAL-like1      SLSAHSSLSSSGELVQPSVEQTPQA------RTRGSPGPQ-------PAK 579 
mouseMICAL-like1           TPSANSSLSSSGELGQPSGEQMLQA------RTKGSAGTH-------STK 602 
ratMICAL-like1             TPSAHSSLSSSGELGQPSGEQMPQA------RTRGSPGTH-------STK 592 
D.rerioMICAL-like1         INTPASALSQKAELQPRCSPNLSPP-----PPPPTNTSSA-------PAT 600 
humanMICAL-like2           GPAGWRANLKPVDRRSPAERTLKPKEPRALAEPRAGEAPR------KVSG 626 
guinea_pigMICAL-like2      GPEGWRARLKPVEKKPPAGRAQEPKEPRVPAEPKAGEAPVAPRTPVQVSG 613 
mouseMICAL-like2           GPEGWRARLKPVDKKTPAGRSLEQKEP-VLAEPRIGDTSR------KASS 734 
ratMICAL-like2             GPEGWRARLKPVDK-----RALEQKEP-VLAEPRAGDTPR------KASS 733 
D.rerioMICAL-like2         APADWR--SKPKAAPNGP-RLNRSPDIAKDVPLTCGENKDLKVQDSQAFM 560 
drosophilaMICAL-like       PTTSLSSITSPMRKKRQAPLPPIQTDFDSDPGFSKLSDEQKALLHTQLKA 664 
 
 
humanMICAL-like1           PCSGATPTPLLLVGD-RSPVPSPGSSSPQLQVKSSCKENPFNRKPS---- 640 
guinea_pigMICAL-like1      PCSGAAATP-LLVGD-RSPAPSPGSSSP--QLQSSCKENPFNRKPS---- 621 
mouseMICAL-like1           PFSGATPTPFLLAGD-RNPAPPVGSASPQLQIKSSCKENPFNRKPS---- 647 
ratMICAL-like1             PFSGATPTPFLLAGDQKSPAPPMGSSSPQMLIKSSCKENPFNRKPS---- 638 
D.rerioMICAL-like1         PQTNRSARPPSLSAG---LKITPTSQTPGTPGKRTCKENPFNRKTT---- 643 
humanMICAL-like2           SFAGSVHITLTPVRPDRTPRPASPGPSLPARSPSPPRRRRLAVPAS---- 672 
guinea_pigMICAL-like2      HVQVGVQITLTPVQPEQTLAHAGPGTKLPEASPSSSSRRRLAIPPS---- 659 
mouseMICAL-like2           SSDSSVHITLTSIQHKRKPCPAGSGPSPAALSPSPSHRKKLAVPPS---- 780 
ratMICAL-like2             SSDSSIHITLTPIQQKRTPCLADSGSSLAAPSP-PSRRKKLVVPPT---- 778 
D.rerioMICAL-like2         -------------------------------------------------- 578 
drosophilaMICAL-like       PNLGDSTRRLIPLDQSLLSDEATESSNYDESLSTSNADEEVNVVYRRILV 714 
                                                                             
humanMICAL-like1           PAASPATKKATKGSKPVRPPAPGHG------------------------F 666 
guinea_pigMICAL-like1      PAASPTAKKATKGPKPARPPAPGHG------------------------F 647 
mouseMICAL-like1           PSASPTVRKATKGAKPVRPPAPGHG------------------------F 673 
ratMICAL-like1             PSTSPTVRKATKGAKPVRPPAPGHG------------------------F 664 
D.rerioMICAL-like1         TSANSFVSRPPKGPRPARPPAPGHG------------------------F 669 
humanMICAL-like2           LDVCDNWLRPEPPGQEARVQSWKEEEKKPHLQGKPGRPLSPANVPALPGE 722 
guinea_pigMICAL-like2      LDISANWLQSEPSEQEAQVQSWKE---KPHSQDKPGRPSALAGIPASPEK 706 
mouseMICAL-like2           LDVSADWLQPEPKKQEDGTRSCKE--EKSPTRWSRERSAVLDSGLAPPGE 828 
ratMICAL-like2             LDVSADWLQPELKKQDDQTRSCK---EKTATWGTRESSAILDNDLVSPDE 825 
D.rerioMICAL-like2         -------------------------------------------------- 617 
drosophilaMICAL-like       PPTQPENTVERSKEDQKSPIVYNDFDRNVSPLGHNKSTHGKWKRRKGPAP 764 
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G 
                CC 
humanMICAL-like1           PLIKRKVQADQYIPEEDIHGEMDTIERRLDALEHRGVLLEEKLRGGL--- 713 
guinea_pigMICAL-like1      PLIKRKVQADQYVPEEDIYGEMDAIERQLDALEHRGVLLEEKLRGGA--- 694 
mouseMICAL-like1           PLIKRKVQADQYIPEEDIYGEMDNIERQLDALEHSGVLLEEKLRGGA--- 720 
ratMICAL-like1             PLIKRKVQADQYIPEEDIYGEMDSIERQLDALEHSGVLLEEKLRGGA--- 711 
D.rerioMICAL-like1         PLIKRKVQSDQFIPVEDIHVEMSDLEKRLDELEHRGVDLEKSLRECS--- 716 
humanMICAL-like2           TVTSPVRLHPDYLSPEEIQRQLQDIERRLDALELRGVELEKRLRAAE--- 769 
guinea_pigMICAL-like2      TVSSPIRLHPDYVPQEEIERQLQDIERQLDALELRGVALEQQLRAAD--- 753 
mouseMICAL-like2           AVTSPVRLHPDYIPQEELQRQLQDIESQLDALELRGVELEKRLRAAE--- 875 
ratMICAL-like2             AVTSPVRLHPNYISQEELQRQLQDIERQLDALELRGVELEKRLRAAE--- 872 
D.rerioMICAL-like2         -----------YITPEQISKELQDIENNLNDLENEGVELEWKLRVYEE-- 661 
drosophilaMICAL-like       AVPIPPRKVLQRLPLQEIRHEFEIIAVQQLGLEKQGVILEKMIRDRCERS 814 
                                       .    *      *      **  ** **  .*                            
humanMICAL-like1           ----------------NEGREDDMLVDWFKLIHEKHLLVRRESELIYVFK 747 
guinea_pigMICAL-like1      ----------------SEGREDAMLVDWFKLIHEKHLLVRRESELIYIFK 728 
mouseMICAL-like1           ----------------NEGSEDDMLVDWFKLIHEKHLLVRRESELIYVFK 754 
ratMICAL-like1             ----------------NEGSEDDMLVDWFKLIHEKHLLVRRESELIYVFK 745 
D.rerioMICAL-like1         ----------------NDEEEEHLLVDWFTLIHEKHLLVRREAELVYTAK 750 
humanMICAL-like2           ----------------GDDAEDSLMVDWFWLIHEKQLLLRQESELMYKSK 803 
guinea_pigMICAL-like2      ----------------GAAEEDDLMVAWFRLVHEKQLLLRQESELMYKSK 787 
mouseMICAL-like2           ----------------GDASEDSLMVDWFRLIHEKQLLLRLESELMYKSK 909 
ratMICAL-like2             ----------------GDASEDGLMVDWFRLIHEKQLLLRRESELMYKSK 906 
D.rerioMICAL-like2         -------------EGHGDILMDPLMVDWFNLIRKKQSYIRRESELMYIAR 698 
drosophilaMICAL-like       LDATDTDGPESAEVLTNSKEVEDLILQLFELVNEKNELFRRQAELMYLRR 864 
                                                  ..     *.       *   **.*  . 
           
humanMICAL-like1           QQNLEQRQADVEYELRCLLNKPEKDWTEEDRAREKVLMQELVTLIEQRNA 797 
guinea_pigMICAL-like1      QQNLEQRQADVEYELRCLLNKPEKDWTEEDKSREKVLLQELMTLIEQRNA 778 
mouseMICAL-like1           QQNLEQRQADVEFELRCLLNKPEKDWTDEDRAREKVLMQELMTLIEQRDA 804 
ratMICAL-like1             QQNLEQRQADVEFELRCLLNKPEKDWTDDDRAREKVLMQELMTLIEQRDA 795 
D.rerioMICAL-like1         QQNLEERQADVEYELRCLLNKPEKEWTSEDKDREKQLMADLVTIIEQRNQ 800 
humanMICAL-like2           AQRLEEQQLDIEGELRRLMAKPEALKSLQERRREQELLEQYVSTVNDRSD 853 
guinea_pigMICAL-like2      TQRLEERQQDLEGELRRLMAKPEYLKTPQDQRREQELLSQYVSTVNDRSD 837 
mouseMICAL-like2           DQRLEEQQLDLQGELRRLMDKPEGLKSPQDRQREQELLSQYVNTVNDRSD 959 
ratMICAL-like2             DQCLEERQLDLQGELRRLMEKPEGLKSPQDRKREQELLNQYVNTVNDRSD 956 
D.rerioMICAL-like2         TQDLEEQQPGVEGELRRLINKPEHLKTLNEKKRETELLNRLMKIVNDRNA 748 
drosophilaMICAL-like       QHRLEQEQADIEHEIRVLMGQPEHNKTDSDKAHEEVLINRLVKVVEMRNE 914 
                              **     .   ** *.              *  *.      .                             
 
humanMICAL-like1           IINCLDEDRQREEEEDKMLEAMIKKKEFQREAEPEGKKKGKFKTMKMLKL 847 
guinea_pigMICAL-like1      IVNCLDEDRQREEEEDKMLEAMIKRKEFQKEAESEGKKKGKFKTIKVLKM 828 
mouseMICAL-like1           IVNCLDEDRQREEEEDKMLETMIKKKDFQREAESDSKKKGKFKTIKVLKF 854 
ratMICAL-like1             IVNCLDEDRQREEEEDKMLETMIKKKDFQREAESDSKKKGKFKTMKVLKL 845 
D.rerioMICAL-like1         IVNNIDIDRQREEEEDKLVAAMLKKKDFHGQGEQK-KKSGKFKPMKVLKR 849 
humanMICAL-like2           IVDSLDEDRLREQEEDQMLRDMIEKLGLQ-------RKKSKFRLSKIWSP 896 
guinea_pigMICAL-like2      IVDILDEDRLREKEEDQVLQDMIQRLDLQ-------KKKPKFRLSKIWGT 880 
mouseMICAL-like2           IVDFLDEDRLREQEEDQMLENMIQNLGLQ-------RKKSKSFLSKIWSS 1002 
ratMICAL-like2             IVDNLDEDRLREQEEDQMLESMIQNLGLQ-------RKKSKSFLSKIWSS 999 
D.rerioMICAL-like2         IVEGLEEDRIREEEEDQQLNEMMQRLGLQK-----FKNKRKSSFSKLFRR 793 
drosophilaMICAL-like       VIDSLETDRVREAREDMSIKNRLHIYNSEREEPPAHPRSADKSSKKLSKK 964 
                           ..  .     ** ***  .   .                       .  
 
humanMICAL-like1           LGNKRD-AKSKSPRDKS*                             863 
guinea_pigMICAL-like1      LGNKRD-TKSKSPGDKS*                             844 
mouseMICAL-like1           LGNKRE-AKSKAPGDKS*                             870 
ratMICAL-like1             LGNKRD-AKSKAPTGKS*                             861 
D.rerioMICAL-like1         LSTKNEGVKDNSPRKENS*                            867 
humanMICAL-like2           KSKSSPSQ*                                      904 
guinea_pigMICAL-like2      KNKGAPQE*                                      888 
mouseMICAL-like2           KSKSGQA*                                       1009 
ratMICAL-like2             KSKSGQT*                                       1006 
D.rerioMICAL-like2         RSKKASMGE*                                     802 
drosophilaMICAL-like       ERKKLKEENKLGKGKKSDLDKDVDESEQAPALEKVKKKRNLFFLKM 1010 
 
 
 
 
Figure 2.2. Sequence comparison of MICAL-like proteins. Annotation is as in Figure 
2.1; the NPF sequence is shown in bold and blue.    
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2.2. Three-dimensional structures of MICAL domains.  
The N-terminal domain of MICAL, which shows sequence similarity with FAD-containing aromatic 
hydroxylase (Figure 2.3, panel A), which is essential for several its functions.  
In 2005, two independent groups (Nadella et al., 2005; Siebold et al., 2005) solved the three-dimensional 
structure of the isolated N-terminal domain of the mouse MICAL1 with an His6-tag at the N-terminus of 
the protein (residues 1-498). In one case (Nadella et al., 2005) to favor the formation of ordered crystals 
Lys141 and Lys142, which were eventually found at the protein surface, were mutated to alanine (Nadella 
et al., 2005; PDB ID 2BRA, 2 Å resolution). Instead, no mutations were introduced to solve the structure 
of the isolated N-terminal domain of mouse MICAL1 in the oxidized and reduced state by Siebold et al., 
(2005; PDBID 2BRY; 2C4C, 1.45 Å resolution). As expected, the structures of the as-isolated (oxidized) 
proteins are similar to each other. A homodimer was found in the crystallographic asymmetric unit, 
although the protein is monomeric in solution (Nadella et al., 2005; Siebold et al., 2005; Vanoni et al., 
2012).  
The N-terminal domain of MICAL had a compact fold with an N-terminal four-helix bundle (residues 1-
86) followed by the core region (87-442) and few disordered segments (Figure 2.3, panel B). The core 
region showed a fold similar to that of p-hydroxybenzoate hydroxylase (PHBH, PDB ID 1PBE), phenol 
hydroxylase (1PN0) and of several FAD-containing oxidases and monooxygenases. In the N-terminal 
flavoprotein domain of MICAL the larger portion (residues 86-234 and 367-444) contains the FAD and 
NADPH binding regions (Figure 2.3, panel A). The region between residues 235 and 366 forms the 
smaller lobe of the protein, which completes the active site. This region was defined as the 
monooxygenase domain by Siebold et al. (2005), but we will indicate it as the cap domain in order to 
adopt the nomenclature used for PHBH (Schreuder et al., 1989). 
The topology of the N-terminal domain of MICAL is simplified compared to that of PHBH in which the 
polypeptide chain passes several times between the FAD- and substrate-binding domains (Figure 2.3, 
panels B-C and E). In MICAL, only a long two-stranded β-sheets (β 9 and 15, Figures 2.3, panel B and 
2.4) connects the two domains. The C-terminus, which links the N-terminal domain to the CH domain, 
and the N-terminal region (residues 1-86) have no counterpart in PHBH. Several basic residues are 
present in the first 86 residues (H11, H13, H49, K50, K52, K61, K66, K(or R) 69, R(or K)70, K(or R)86, 
Figures 2.1, panel A) and in addition to several conserved residues of the FAD domain. They form one 
extended patch of basic potential on one face of the protein (Figure 2.5, panels A and B) (Vanoni et al., 
2012). Due to its location and to the acidity of several cytoskeletal proteins, including actin, the N-
terminal 1–85 basic region of MICAL has been proposed to be important to promote the interaction with 
the putative protein substrate (Nadella et al., 2005; Siebold et al., 2005; Vanoni et al., 2012).   
On the opposite face of the protein a second basic patch is found (Figure 2.5, panels A and B), in which 
several basic residues are conserved among MICALs (K115, R116, R121, H122, R158, K221, R356 in 
Figure 2.1, panel A). Structural comparison of the N-terminal domain of MICAL with PHBH reveals that 
this second positively charged region may define the NADPH binding site (Figures 2.3, panel A and 2.5, 
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panels A and B; Vanoni et al., 2012). NADPH binds to PHBH in an extended conformation (Wang et al., 
2002) stabilized by interactions with residues R33, Q34, R42, H162, R269, I164 that could correspond to 
K115, R116, R121, K221, V223 and S368 of MICAL (Figure 2.3, panel A). FAD also assumes an 
extended conformation with its adenylate moiety bound to the Rossman fold identified by the GXGXXG 
motif at position 91-96 of MICAL (Figures 2.1, panel A; 2.3, panel A and 2.4; Wierenga et al., 1986, 
1979; Schreuder et al., 1989;) and its ribityl 3’OH is bound to residues 384-390 corresponding to 
Eggink’s second FAD consensus sequence (Figure 2.1, panel A). The dimethylbenzene and the 
pyrimidine ring of FAD are both exposed to the solvent on the two opposite faces of the protein.  
The side chain of the conserved Trp400 stacks against the re face of the isoalloxazine ring of FAD and 
must undergo conformational changes to allow FAD reduction following NADPH binding. The si face of 
the isoalloxazine ring makes van der Walls interactions with Ile157 and a complex network of hydrogen 
bonds through its N5 with Asn123, Asn243, Thr291, Tyr293 and Asp360 (Siebold et al., 2005; Vanoni et 
al., 2012; Figure 2.5, panel C).  
Incubation of the crystals containing the N-terminal domain of mouse MICAL1 with NADPH led to 
determine its structure in the reduced redox state (Siebold et al., 2005; PDB ID 2C4C, 1.45 Å resolution), 
which corresponds to the “flavin in” conformation of PHBH (Figures 2.4 and 2.5) as opposed to the 
conformation similar to the “flavin out” state of PHBH observed in the oxidized MICAL forms (Nadella, 
et al., 2005; Siebold et al., 2005; Vanoni et al., 2012). No NADP(H) was bound to the protein preventing 
the identification of its binding site. The rotation (≈20°C) of the C1-C2 bond of ribityl side chain of FAD 
led to the switch from the “out” to the “in” conformation. When the flavin is in the “in” conformation it is 
shielded from the solvent at the interface between the FAD and cap domain (Figures 2.4 and 2.5). The 
stacking interaction between the flavin and Trp400 is lost and also the polypeptide chain undergoes 
conformational changes in the secondary structure elements in the cap domain (Figures 2.4 and 2.5). The 
difference of the relative position of FAD and cap domain of the oxidized and reduced N-terminal domain 
of MICAL is larger than that observed for PHBH (Figure 2.4 and 2.5). The conformational changes from 
the “out” to the “in” state of flavin leads to the formation of a channel connecting the protein surface to 
the active site (Figure 2.5, panels A and B). In this conformation the reactive C4a and N5 positions of 
FAD become exposed to the solvent. The residues that define the channel are conserved in MICALs 
suggesting an important role for MICAL function (Figure 2.1, panel A). The channel is located on the 
same side of the positively charged N-terminal region of the protein (Figure 2.5, panels A and B), which, 
in addition to the presence of the CH and LIM domains supports the hypothesis that the substrate of the 
N-terminal flavoprotein domain of MICAL could be the side-chain of an acidic protein. The side-chain of 
the protein substrate could reach the active site of MICAL through the tunnel when protein is the “flavin 
in” conformation upon its reduction by NADPH. Base on the similarity with PHBH the side-chain could 
be modified by specific hydroxylation. However, the hypothesis that the flavoprotein domain acts through 
a NADPH oxidase activity should not be discussed.   
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Figure 2.3. Sequence comparison between the N-terminal flavoprotein domain of mouse MICAL1 and p-
hydroxybenzoate hydroxylase. Panel A: The 83-440 region of mouse MICAL1 is compared with the full-length 
Pseudomonas fluorescens p-hydroxybenzoate hydroxylase. The secondary structure elements are indicated (β 
strands, α helices and β turns (TT). The alignment takes into the account the three-dimensional structures of the 
proteins (2BRA (Nadella et al., 2005); 2BRY (Siebold et al., 2005) for mouse MICAL1 and 1 PBE (Schreuder et al., 
1989) for PHBH). Colour code: highlighted in yellow, conserved residues in the consensus sequence of the binding 
site of the adenylate portion of FAD and in the second consensus sequence for FAD binding (Eggink et al., 1990 ); 
red, PHBH residues involved in the binding of NADPH (n) and conserved residues of MICAL in equivalent position 
(Vanoni et al., 2012). The topology of the N-terminal domain of mouse MICAL1 (panel B) and of PHBH (panel C) 
is shown, in which the shaded area indicates the region that is deleted in MICAL1 isoform b. Note that this species 
has not been experimentally detected in cells. Solvent-accessible surface of MICAL (panel D) and of PHBH (panel 
E) with their unique parts are shown in purple for MICAL and in cyan for  PHBH (Siebold et al ., 2005). 
A
B C
D E
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Figure 2.3 Comparison of the primary, secondary and ternary structures of the flavoprotein 
monooxygenase-like domain of mouse MICAL1. Left panel: Sequence of the N-terminal domain 
of human MICAL1, in which the residues corresponding to secondary structure elements are 
identified based on its three-dimensional structure. Right panel: The structures of the “as 
isolated” mouse MICAL1 monooxygenase domain in the oxidized (“flavin out”) state (2BRY, 
chain A, MICAL-MOox) and of the NADPH-reduced (“flavin in”) species (2C4C, chain A, 
MICAL MOred) as determined by Siebold et al. (2005) are shown in two orientations. Color 
scheme is as follows: blue, residues 1–85; red, residues 86–177, 208–217; coral, 178–208; grey, 
218–237 (β9) and 366–375 (β15); green, 238–365; dark red, 376–442; dark grey, 443–489. FAD, 
Trp400 and Asn123 are shown in sticks with carbon in light grey, nitrogen in blue, oxygen atom 
in red and phosphorus in green. The CCP4MG program was used to generate the figure (Vanoni 
et al., 2012) 
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Figure 2.5. Comparison of the “flavin out” (MICAL-MOox) and “flavin in” (MICAL-MOred) conformations. Panel A: The stars indicate the positively charge residues (spheres) in the 
1-86 region (upper panels) and those in the putative NADPH binding site (lower panels). Panel B: detail of panel A. The arrow indicates the solvent exposed part of FAD, and the 
opening of the tunnel that leads to the putative active site in the reduced form. Panel C: FAD environment in the “flavin out” and “flavin in” conformations. The view is obtained by 
vertically flipping the models in Figure 2.2 with an approximately 45° rotation. The FAD ribityl side chain is cut at C1'. The conserved residues surrounding the FAD isoalloxazine 
ring (arrows) and comprising residues 121-130, 278-300 and 390-405 (red stars in Figure 2.1) are shown. Color code: light grey, Phe, Tyr, Trp; grey, Gly, Ala, Val,Leu, Ile; cyan, 
Ser, Thr, Gln, Asn; light yellow, Cys, Met; blue, Arg, Lys, His; red, Asp,Glu. The view is similar to that in Figure 2.2 to highlight the formation of the tunnel leading from the 
protein surface to the isoalloxazine ring in the “flavin in” (right) conformation (Vanoni et al., 2013).  
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The structures of the isolated CH domain of human MICAL1 (PDB ID 2DK9 Sun et al., 2006; PDB ID 
1WYL Jin et al., 2006), MICAL2 (PDB ID 2E9K, no accompanying publication) and MICAL3 (PDB ID 
2D88, no accompanying publication) have been solved by NMR, confirming its sequence-based 
identification.   
The CH domain is a protein interaction domain mainly found in actin- and microtubule-binding proteins. 
Invariant core residues define the CH domain, which are crucial for the stabilization of its three-
dimensional structure. Three types of CH domains have been identified (Gimona et al., 2002). One type 1 
and one type 2 CH domain form the F-actin binding region of several cytoskeleton proteins, (such as 
spectrin, α-actinin); the overall affinity for F-actin is in the low µM range (Gimona et al., 2002). Tandem 
CH domains can bind F-actin thanks to their conformational changes from an “open” (free state) to a 
“closed” conformation upon interaction with the actin filament (Galkin et al., 2012).  The single type 2 
CH domain is not sufficient to interact with F-actin. On the contrary type 1 CH domain alone is able to 
bind F-actin, but with a 10-fold lower affinity compared to the complete actin binding region composed 
by type 1 and type 2 CH domains. Thus, in the tandem type1-type2 CH domain, the type 2 CH region that 
has not an intrinsic ability to interact with F-actin, may function an initial docking site that contributes to 
the interaction with F-actin. This role has been also proposed for type 3 CH domains (Galkin et al., 2012).  
The architecture of the CH domain is conserved among the three types of domains. The three-dimensional 
structure of the CH domain of human MICAL1 consists of six α-helices and one 310 helix. The CH 
domain is composed by four long helices (A, B, D and F alpha-helix in Figure 2.6, panel A) and 
stabilized by hydrophobic interactions (Sun et al., 2006). Helix A forms the first hydrophobic region that 
makes contacts with residues in helix B, D and F. The presence of a crossing angle of 70° between the 
first and third helix is typical of the type 2 CH domain. The fold of the CH domains of human MICAL2 
(PDB ID 2E9K; Tomizawa 2007, no associated publication) and of human MICAL3 (PDB ID 2D88; 
Tomizawa 2006, no associated publication) is very similar to that of the CH domain of human MICAL1 
(not shown). The type 2 CH domain alone can not bind F-actin. Thus, it has been proposed that the CH 
domain of MICAL may assist or establish an initial interaction with F-actin (protein-substrate) favoring 
that with the N-terminal FAD-containing domain (Siebold et al., 2005; Sun et al., 2006).  
The LIM domain was named by its initial discovery in three homeodomain proteins Lin11, Isl-1 and Mec-
3 (Bach 1990); LIM domains are composed of ≈55 amino acids with the general sequence CX2CX16-
23HX2CX2CX16-23CX2C, where C is cysteine, H is histidine and X is any amino acid. LIM domains bind 
two  Zn++ ions through the conserved Cys and His residues. LIM domains are found in both nuclear and 
cytoplasmic proteins where they function in molecular recognition to assemble multiprotein complexes 
(Bach et al., 2000). The three-dimentional structure of the isolated LIM domain of human MICAL1 has 
been solved in 2005 (PDB ID 2CO8, Sato (2005), no associated publication; Figure 2.6, panel B), 
showing the typical structural features of the LIM domain. It is composed by two zinc fingers formed by 
2 antiparallel β-hairpins. The first zinc finger contains β-hairpin 1 and 2 and the second zinc finger 
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contains β-hairpin 3 and 4. The conserved Cys and His residues (Figure 2.1, panel B) of the tetrahedral 
zinc coordination establishes the secondary structure of the LIM domain (Kadrmas 2004) (Figure 2.6, 
panel B). The C- and N-terminal regions of the domain do not have a secondary structure (Figure 2.6, 
panel B). Overall, the LIM domain has an elongated conformation compared to that of the CH and N-
terminal domains of MICAL (Figures 2.6, panel B).  
Based on the sequence analysis several coiled-coil motifs have been predicted in the C-terminal region of 
MICAL. The isolated C-terminal region of MICAL has not been produced and purified yet so that the 
three-dimensional structure is not available. However, it is well known that the coiled-coil motifs form 
amphipathic α-helixes, which mediate protein-protein interactions by binding to the coiled-coil motif of 
the interactor (an example of coiled-coil motif formed by residues 860-960 of the heavy and light chain of 
myosin  (PDB ID 1I84, Wendt et al., 2001) is shown in Figure 2.6, panel C).  
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Figure 2.6. Three-dimensional structures of the CH, LIM domains and coiled-coil motif. Panel A: The secondary 
structures elements of the CH domains are indicated (upper panel) in the CH domain sequence of human MICAL1 
(upper panel). The three-dimensional structure of one chain (chainA) of the CH domain of human MICAL1 (PDB 
code 2KD9; Sun et al 2006) is shown. Color code: blue, helix A; light green, helix B; dark green, helix C; red, helix 
D; purple, helix E; yellow, helix F; dark red, 310, helix; unstructured region, grey. The N- and C-terminus are 
indicated. Panel B: The conserved Cys and His residues of the consensus sequence of the LIM domain are in bold 
and purple; residues forming the 4 β-hairpins and the 2 zinc finger are also indicated. In the three-dimentional 
structure of chain 1A of the LIM domain of human MICAL1 obtained by NMR (PDB code 2CO8) the Cys and Hys 
residues (in sticks) coordinating the binding of Zn++ (dark blue sphere) are shown. Color code: purple, β-sheet; β-3 
turn, coral; β-5 turn, dark red. Panel C: coiled-coil motif formed by residues 860-960 of the heavy (dark grey) and 
light (light grey) chains of myosin (PDB ID 1I84, Wendt et al., 2001). To draw the figures the program CCP4 has 
been used (McNicholas et al., 2011).   
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3. Engineering the DNA coding for human MICAL1 and the truncated forms containing the MO, 
CH and LIM domains (MOCHLIM) 
3.1. Introduction 
The DNA encoding human MICAL1 has been engineered for the production of the full-length protein 
(MICAL) and the form lacking the C-terminal region (MOCHLIM) in E.coli cells to study how the 
catalytic properties of the N-terminal MO domain can be modulated by the additional domains, namely 
the CH, LIM domains and the C-terminal region containing the Pro/Glu-rich regions and the coiled coil 
motifs that may mediate protein-protein interactions. The engineering of DNA to express the human 
MICAL1 form containing both the MO and CH domains was previously done (Vitali T 2012) and its 
characterization was extended during this work.  
The cloning strategy for MOCHLIM and MICAL was the same as that used for the production of the 
isolated MO domain (Zucchini et al., 2011) and MOCH. The pDON-MICAL1 plasmid was used as the 
template for the PCR amplification of fragments of interest. The PCR primers (Table 10.3) were designed 
to introduce at the 5’ end of the amplification product EcoRI and NdeI restriction sites and at the 3’ end a 
stop codon (TAG or TAA) between engineered BamHI and XhoI restriction sites. The presence of such 
restriction sites allowed us to clone the PCR product in a pET23b vector using NdeI and XhoI digestion 
for the expression of the C-terminally His6-tagged fusion protein. NdeI and BamHI restriction could be 
used for the production of the protein without tag. The PCR product could also be cloned into pET28b 
vector using the NdeI and BamHI restriction enzymes to obtain the protein form with a N-terminal His6-
tag (Figure 3.1and 3.2). For the amplification of the DNA encoding MOCHLIM, two reverse primers 
were synthetized (MOCHLIMRev2 and MOCHILMRev4, Table 10.3) for the production of two protein 
forms spanning residues 1-771 and 1-783, respectively.  
The isolated MO domain was produced “as is” and with the hexahistidinyl-tag at the C-terminus or at the 
N-terminus of the protein to determine (i) the effect of the His6-tag and of its position on the properties of 
the MO domain; (ii) the best protein form in terms of stability, activity and purification yield. The three 
MO forms showed similar properties (Zucchini et al., 2011), indicating that the presence of the His6-tag 
did not alter the stability and the activity of the MO domain. The form carrying the C-terminal His6-tag 
(MO-His) could be purified in larger quantities compared to the others and this form was used for 
MICAL-MO characterization (Zucchini et al., 2011). For these reasons MICAL, MOCHLIM and MOCH 
forms were first produced with the hexahistdinyl-tag at the C-terminus of the protein.  
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Figure 3.1. Scheme of the construction of plasmids for the production of MOCHLIM forms of human MICAL1 without or with a His6-tag at the C- or N-terminus of the protein. 
Color code is: MO domain, yellow; CH domain, cyan; LIM domain, purple; Pro rich region, orange; coiled-coil motif, dark grey; His6-tag, light grey. 
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Figure 3.2. Scheme of the construction of plasmids for the production of human MICAL1 without or with a His6-tag at the C- or N-terminus of the protein. Color code is as in Figure 
3.1.  
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3.2. PCR amplification and cloning of DNA encoding human MICAL1 and MOCHLIM forms in pJET1.2 
blunt-end vector     
pDON-MICAL1 plasmid encoding the full-length human MICAL1, received from Prof. Jeroen 
Pasterkamp (University Medical Center Utrecht, NL), was used as the template for the amplification of 
the DNA fragments of interest as described in Materials and Methods (Chapter 10). PCR products 
encoding MOCHLIM (1-771 and 1-783) and MICAL (1-1068) were purified from agarose gels to check 
their size and to determine their concentration by comparing the intensities of the sample bands with the 
signals of samples of linearized pUC18 vector loaded at known amounts on the same gel (Figure 3.3). 
The fragments had sizes similar to the expected ones: 2238 bp for MOCHLIM2, 2247 bp for 
MOCHLIM4 and 3200 bp for MICAL (Figure 3.3). All fragments were obtained in quantities sufficient 
for further work (Figure 3.3).  
The fragments were cloned into pJET1.2 blunt-end vector, as described in Materials and Methods, to 
obtain the corresponding pJET derivatives (pJET-MOCHLIM2, pJET-MOCHLIM4 and pJET-MICAL), 
which were transformed into E.coli DH5α cells for their propagation, purification and maintenance. 
Transformants were selected on LB-Amp plates and 10-20 of the resulting clones were analyzed by 
colony PCR using the pJETFw and pJETRev primers included in the pJET1.2 blunt-end cloning kit 
(Table 10.4). All the clones analyzed for pJET-MOCHLIM2 and pJET-MICAL and six clones for pJET-
MOCHLIM4 plasmids were positive. The plasmids from two of the positive clones for each construct 
were purified and analyzed by restriction enzymes digestion followed by agarose gel electrophoresis to 
verify the presence of the correct restriction sites introduced by PCR amplification and the size of the 
DNA fragments. The purified plasmids contained BamHI, NdeI, and XhoI restriction sites as expected 
(Figure 3.4). An exception was pJET-MOCHLIM4 plasmid from clone number 6 that lacked BamHI and 
one of the XhoI restriction site (Figure 3.4). The inserts of the samples (pJET-MICAL clone 1 and 2, 
pJET-MOCHLIM2 clone 1 and 2 and pJET-MOCHLIM4 clone 7, Figure 3.4) were sequenced to confirm 
the presence of the desired mutations and to rule out undesired ones. The pJETFw and pJETRev primers 
were used first, then sequencing was completed with ad hoc designed primers (Table 10.4). The sequence 
of each selected clone was correct. Thus, we continued the work with clone 1 for pJET-MOCHLIM2, 
clone 7 for pJET-MOCHLIM4 and clone 2 for pJET-MICAL.     
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Figure 3.3 Analysis of PCR products of the amplification of DNA fragments encoding MOCHLIM2, MOCHLIM4 
and MICAL. Agarose gel electrophoresis of the products of the amplification reaction reaction of the DNA 
fragments enconding MOCHLIM2 and MOCHLIM4 (panel A) and MICAL1 (panel B) after purification. Known 
amounts of linearized pUC18 plasmid were also loaded on the gel to allow quantification of the PCR products.  
 
 
 
 
Figure 3.4. Restriction analysis of pJET-MOCHLIM2, pJET-MOCHLIM4 and pJET-MICAL clones. Single 
digestion with NdeI (N), XhoI (X), BamHI (B); double digestion with NdeI and XhoI (NX) and triple digestion with 
NdeI, XhoI and PvuI of 300 ng of pJET-MOCHLIM2, pJET-MOCHLIM4 and pJET-MICAL plasmids.   
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3.3. Subcloning of MOCHLIM2, MOCHLIM4 and MICAL DNA fragments into the pET23b vector     
The pJET derivatives were used for the construction of the pET23b derivatives (pET-MOCHLIM2, pET-
MOCHLIM4 and pET-MICAL) for the production of the C-terminally His6-tagged fusion protein. The 
pJET plasmids and the pET23b vector were digested with NdeI and XhoI. For the construction of pET-
MICAL plasmid, the pJET derivative was also digested with PvuI to distinguish between the digested 
pJET vector (2900 bp) and the DNA fragment encoding the enzyme (3216 bp) that lack PvuI sites. The 
fragments of interest were purified from excised agarose gel bands and quantified following analytical 
electrophoresis. The procedure yielded the plasmids in quantities sufficient for further work.  
The DNA fragments encoding the MICAL forms were ligated with the digested pET23b vector using 
different vector/insert molar ratios (1:2 and 1:4) and 60 ng of vector. At the end of the ligation, aliquots 
(200 µl) of E.coli DH5α cells, previously made competent with the RbCl method, were transformed with 
4 µl of ligation mixture. The transformants were selected on LB-Amp plates. Analysis of the plates 
indicated that the ligation was successful. The number of colonies on the plates inoculated with cells 
transformed with the complete ligation mixture was much higher than that obtained for the negative 
control (ligation mixture without insert). To identify the clones containing the fragments of interest we 
carried out colony PCR on several (10-20) colonies using T7 promoter and T7 terminator primers that 
anneal onto the pET23b vector. We expected amplification products of 2316 bp for MOCHLIM2, 2342 
bp for MOCHLIM4 and 3202 bp for MICAL. We obtained 10 positive clones for both pET-MOCHLIM2 
and pET-MOCHLIM4 and 17 positive clones for pET-MICAL. Two for each one of the plasmids from 
the positive colonies were purified and subjected to restriction analysis that demonstrated the presence of 
the correct restriction sites and that the size of the fragments was similar to the expected one (Figure 3.5). 
Therefore, pET-MOCHLIM2 clone 2, pET-MOCHLIM4 clone 1 and pET-MICAL clone 14 were used 
for the expression of MOCHLIM (1-771 aa), MOCHLIM (1-786 aa) forms and full length MICAL (1-
1068 aa) of human MICAL1 (Figure 3.6).  
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Figure 3.5. Restriction analysis of pET-MOCHLIM2, pET -MOCHLIM4 and pET-MICALFL clones. 300 ng of 
plasmids pET-MOCHLIM2 (panel A), pET-MOCHLIM4 (panel B) and pET-MICALFL (panel C) plasmids were 
loaded as is (nd, not digested); after single digestion with NdeI (N), XhoI (X); double digestion with NdeI and XhoI 
(NX). 
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A  
Human MICAL1 protein sequence (code GenBank: BAB86289.1) 
MASPTSTNPAHAHFESFLQAQLCQDVLSSFQELCGALGLEPGGGLPQYHKIKDQLNYWSAKSLWTKLDKRAGQPVYQQGRACTSTK
CLVVGAGPCGLRVAVELALLGARVVLVEKRTKFSRHNVLHLWPFTIHDLRALGAKKFYGRFCTGTLDHISIRQLQLLLLKVALLLG
VEIHWGVTFTGLQPPPRKGSGWRAQLQPNPPAQLANYEFDVLISAAGGKFVPEGFKVREMRGKLAIGITANFVNGRTVEETQVPEI
SGVARIYNQSFFQSLLKATGIDLENIVYYKDDTHYFVMTAKKQCLLRLGVLRQDWPDTNRLLGSANVVPEALQRFTRAAADFATHG
KLGKLEFAQDAHGQPDVSAFDFTSMMRAESSARVQEKHGARLLLGLVGDCLVEPFWPLGTGVARGFLAAFDAAWMVKRWAEGAESL 
                                                         MO 
                                                         | 
EVLAERESLYQLLSQTSPENMHRNVAQYGLDPATRYPNLNLRAVTPNQVRDLYDVLAKEPVQRNNDKTDTGMPATGSAGTQEELLR
WCQEQTAGYPGVHVSDLSSSWADGLALCALVYRLQPGLLEPSELQGLGALEATAWALKVAENELGITPVVSAQAVVAGSDPLGLIA 
            CH 
            | 
YLSHFHSAFKSMAHSPGPVSQASPGTSSAVLFLSKLQRTLQRSRAKENAEDAGGKKLRLEMEAETPSTEVPPDPEPGVPLTPPSQH 
             LIM2 
             | 
QEAGAGDLCALCGEHLYVLERLCVNGHFFHRSCFRCHTCEATLWPGGYEQHPGDGHFYCLQHLPQTDHKKEGSDRGPESPELPTPS 
      LIM4 
      | 
ENSMPPGLSTPTASQEGAGPVPDPSQPTRRQIRLSSPERQRLSSLNLTPDPEMEPPPKPPRSCSALARHALESSFVGWGLPVQS 
PQALVAMEKEEKESPFSSEEEEEDVPLDSDVEQALQTFAKTSGTMNNYPTWRRTLLRRAKEEEMKRFCKAQTIQRRLNEIEAALRE
LEAEGVKLELALRRQSSSPEQQKKLWVGQLLQLVDKKNSLVAEEAELMITVQELNLEEKQWQLDQELRGYMNREENLKTAADRQAE 
        CC 
                              | 
DQVLRKLVDLVNQRDALIRFQEERRLSELALGTGAQG 
B 
MO        1MASPTSTN……………………………TPNQVRDLYDVLAK490 LEHHHHHH 
MOCH   1MASPTSTN……………………………AYLSHFHSAFKSMA616 LEHHHHHH 
MOCHLIM2 1MASPTSTN……………………………HKKEGSDRGPESPE771 LEHHHHHH 
MOCHLIM4 1MASPTSTN……………………………PELPTPSENSMPPG783 LEHHHHHH 
MICAL  1MASPTSTN……………………………RRLSELALGTGAQG1068LEHHHHHH 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Amino acid sequence of human MICAL1 and of the truncated MO, MOCH and MOCHLIM forms. Panel 
A: Sequence of human MICAL1 (code GenBank: BAB86289.1) with the domains highlighted as follows: MO, 
yellow; CH, cyan; LIM, purple. Panel B: The starting and ending sequence of the MO, MOCH, MOCHLIM and 
MICAL forms produced in this work are indicated. The sequence introduced by cloning into pET23b vector is in 
grey. Panel C:  The MO, CH and LIM domain, Pro- and Glu-rich and the coiled coil regions are indicated as in 
Figure 1.1. The grey bars indicate the His6-tag at the C-terminus of the protein. The isoelectric points of the isolated 
domains and region are indicated, as well as that of the MICAL forms calculated with Compute pI/Mw tool 
(http://web.expasy.org/compute_pi/). 
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4. Expression and purification of human MICAL1 and of the MO, MOCH and MOCHLIM 
truncated forms  
The isolated MO domain of human MICAL1 (MO) and the form containing both the MO and the CH 
domains (MOCH) can be produced in E.coli cells in a soluble form. The purified proteins contained FAD 
bound in stoichiometric amounts and were catalytically active (Zucchini et al., 2011; Vitali 2012; 
Chapters 5 and 6). For the overexpression of the MO form E.coli Rosetta(DE3) strain, which contains the 
pRARE plasmid encoding rare tRNA (AUA, AGG, AGA, CUA, CCC, and GGA for Ile, Arg, Leu, Pro 
and Gly tRNAs, respectively) and confers resistance to chloramphenicol (Chl), was used. The MOCH 
form was produced in E.coli BL21(DE3) strain containing the p18 plasmid (Castanié et al., 1997), which 
encodes the GroE chaperon and also confers resistance to Chl. In pilot experiments MOCHLIM2 
(residues 1-771), MOCHLIM4 (residues 1-783) and full-length MICAL1 were produced in both E.coli 
Rosetta(DE3) and BL21(DE3, p18) cells. MO and MOCH forms were used as positive controls in each 
expression experiment to compare the quantity and, more importantly, the quality of the produced 
recombinant proteins.  
 
4.1. Expression of human MICAL1 forms in E.coli cells 
The pET derivatives encoding the MO, MOCH, MOCHLIM2, MOCHLIM4 and MICAL (pET-MO, 
pET-MOCH, pET-MOCHLIM2, pET-MOCHLIM4 and pET-MICAL) forms of human MICAL1 
carrying the His6-tag at the C-terminus of the protein, were used to transform competent E.coli 
Rosetta(DE3) or BL21(DE3, p18) cells. For pilot experiments, 2-6 l of E.coli cultures were set-up. The 
transformants were selected on LB-Amp-Chl plates and used to inoculate 50-200 ml of LB medium 
supplemented with Amp (0.1 mg/ml) and Chl (0.025 mg/ml, see Materials and Methods, Chapter 10).  
Cultures were grown at 25°C, under stirring, until the OD600 value was ≈1. The cell cultures were 
transferred at 4°C and the day after the cells were harvested under sterile conditions by centrifugation, 
resuspended in LB medium and used to inoculate four-six 2 l flasks containing 500 ml selective LB 
medium each, to obtain an initial OD600 value of ≈0.05. The cultures were grown at 25°C, under stirring. 
When the OD600 value was ≈1, the expression of the MICAL forms (and of GroE for BL21(DE3, p18) 
cells) was induced by adding isopropyl-β-thiogalactoside (IPTG, 0.1 mM final concentration). The 
cultures were transferred at 15°C and harvested after 24 h. To maintain selective pressure Amp (0.1 
mg/ml) was added every 8-15 h after the IPTG addition. Immediately before and at different times after 
the induction of protein expression aliquots of the cell cultures were withdrawn and used to prepare total 
cell extracts for SDS-PAGE analysis. 
All MICAL forms were produced in E.coli cells after the addition of IPTG, as observed by comparing the 
total cell extracts before (0 h) and after ITPG addition (3, 16, 24 h, Figure 4.1). The level of protein 
expression was similar for all MICAL forms when expressed in E.coli Rosetta(DE3) or BL21(DE3, p18) 
cells. In both cases MOCHLIM forms showed the lowest expression levels. The protein bands 
corresponding to MO, MOCHLIM and full-length MICAL had a molecular mass similar to the expected 
one (Table 5.1) indicating that the proteins were produced in their full-length form. On the contrary, the 
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observed molecular mass of ≈62 kDa for MOCH was significantly lower than the theoretical value of 
68.5kDa, suggesting a possible degradation of the enzyme during its expression. As described in Chapter 
5, previous analyses had demonstrated that MOCH was produced in the full-length form, but had an 
anomalous electrophoretic migration under denaturing conditions.  
 
4.2. Small-scale purification of human MICAL1form 
Pilot small-scale purifications of MOCHLIM and full-length MICAL on Ni-NTA Sepharose affinity 
chromatography were carried out from 2-6 g of E.coli Rosetta(DE3) or BL21(DE3, p18) cells to compare 
the quality of MICAL produced in the two E.coli strains. MO and MOCH forms were also purified as 
positive controls for E.coli Rosetta(DE3) and BL21(DE3, p18) cells growth, respectively, and for the 
purification procedure.  
For MICAL, cells (2 g) were resuspended in homogenization buffer (buffer A, 50 mM Na-phosphate 
buffer, pH 7.5, 100 mM NaCl, 10% glycerol, supplemented with protease inhibitor cocktail (Sigma 
P8849; 50 μl/g cell), 1 mM 2-mercaptoethanol (2-ME), 1 mM PMSF and DNase) and disrupted by 
sonication. The crude extract obtained after centrifugation was incubated with Ni-NTA Sepharose resin (1 
ml) on a wheel for 1 h at 4°C. The suspension was poured into a column and the resin was allowed to 
settle. The unbound proteins were collected in the flow-through (FT). The weakly bound proteins were 
removed by flowing 5 volumes each of buffer A (fractions 1-5) and of buffer A + 20 mM imidazole 
(fractions 6-10). Bound proteins were eluted by flowing 5 volumes of buffer A + 100 mM imidazole 
(fractions 11-15), followed by 5 volumes of  buffer A + 500 mM imidazole (fractions 16-20; Figure 4.2). 
The fractions were analyzed by recording the absorption spectrum (Figure 4.2, panels A, C) and by SDS-
PAGE (Figure 4.2, panels B, D); the NADPH oxidase activity of the selected fractions was also measured 
in 20 mM Hepes/KOH buffer, pH 7 in the presence of 100 µM NADPH, at 25°C. 
MICAL eluted with 100 mM imidazole as demonstrated by the absorption spectra of the fractions that 
showed the presence of flavin (Figure 4.3, panels A and B). The peak fraction exhibited a NADPH 
oxidase activity with a specific activity, expressed as U/ml/A458, of 0.4 that was ≈5-fold lower than that 
measured for the MOCH form used as a control. The SDS-PAGE analysis of the fractions (Figure 4.2, 
panels B, D) confirmed that the flavin signal was associated with MICAL that migrates as a ≈120 kDa 
band, which represented ≈70% of the total protein content (Figure 4.2, panels C, D).   
These results indicated that MICAL was produced in a soluble form, with bound FAD, in both E.coli 
Rosetta(DE3) and in BL21(DE3) cells  in the presence of GroE. Moreover, the absorption spectrum of the 
full-length MICAL was very similar to that of the MO domain under similar conditions, with the 
characteristic long-wavelength absorbance band in the 500-600 nm region (Figure 4.3).  
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Figure 4.1. Production levels of human MICAL forms in E.coli cells. E. coli Rosetta(DE3) (panel A) or BL21(DE3, 
p18) (panel B) cells harboring the pET-derivatives for the production of human MICAL1 and MOCHLIM forms 
were grown in 0.5 l LB supplemented with 0.1 mg/ml ampicillin and 0.025 mg/ml choloramphenicol up to an OD600 
of ≈1. The temperature was lowered to 15°C and IPTG (0.1 mM final concentration) was added. Small aliquots of 
the culture were harvested before IPTG addition (0 h) and at the indicated times after induction.  For comparison, 
samples obtained by culturing E. coli Rosetta(DE3) and BL21(DE3, p18) cells harboring the pET-derivatives for the 
production of MO and MOCH, respectively, are shown. Aliquots of total cell extracts were analyzed by SDS-PAGE 
on 10% acrylamide+bis-acrylamide gels. The empty circles indicate the bands corresponding to the MICAL forms; 
the full circles indicate the bands corresponding to GroEL (59.7 kDa) encoded by p18. M, standard proteins of mass 
indicated in the figure in kDa.    
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Figure 4.2. Small-scale purification of human MICAL1 – Ni-NTA Sepharose affinity chromatography. The homogenate from 2 g of E.coli Rosetta(DE3) (panels A and B) and 
BL21(DE3, p18) (panels C and D) cells was incubated with 1 ml of Ni-NTA Sepharose at 4°C for 1 h. The resin was packed into a column. The bound MICAL was eluted by 
increasing imidazole concentration (0, 20, 100 and 500 mM). Panels A and C: elution profile showing absorbance values at 275 nm (empty symbols) and at 450 nm (full symbols). 
Panels B and D: SDS-PAGE analysis on 10% (AcA + bisAcA) gels of aliquots of: total cell extract (T24); crude extract (CE); pellet obtained after centrifugation of the homogenate 
(P); unbound proteins collected during sample loading (column flow-through, FT); aliquots of individual fractions numbered as in panels A and C; M, standard proteins of mass 
indicated in the figure in kDa. The quantity of MICAL loaded (μg) was calculated from the absorbance at 450 nm using the extinction coefficient of MO  (8.1 mM-1cm-1) and the 
theoretical mass of MICAL (119 kDa). 
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Figure 4.3. Absorption spectra of MICAL and of the isolated MO domain after affinity chromatography on Ni-NTA 
Sepharose. Absorption spectra of fraction 12 eluted with 100 mM imidazole during the chromatographies shown in 
Figure 4.2. For comparison, panel C shows the spectrum of the corresponding fraction obtained by 
chromatographying E.coli Rosetta(DE3) cells that had expressed MO under same conditions.  
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MOCHLIM2 (residues 1-771) and MOCHLIM4 (residues 1-783) were produced at levels lower than MO, 
MOCH and full-length MICAL (Figure 4.1) in both E.coli strains tested. To determine the quality of 
protein forms produced both in E.coli Rosetta(DE3) and in BL21(DE3) in the presence of GroE small 
scale purifications were carried out starting from 6 g of cells. 
For these experiments the procedure was that described for MICAL in the previous paragraph with minor 
modifications. The crude extracts (Table 4.1), were incubated with Ni-NTA Sepharose resin (2 ml) 
previously equilibrated in buffer A or, in subsequent experiments,  in buffer A + 20 mM imidazole to 
minimize the non-specific binding of proteins. From the elution profiles (Figure 4.4, panels A, C, E, G) 
and SDS-PAGE analyses of the collected fractions (not shown), we concluded that MOCHLIM eluted 
with 100-200 mM imidazole. The flavin signal was associated with both MOCHLIM2 and MOCHLIM4 
produced either in E.coli Rosetta(DE3) or in BL21(DE3, p18) cells (Figure 4.4, panels B, D, F, H). On 
the basis of the absorption spectra, fractions containing MOCHLIM were pooled, concentrated (Table 4.1 
and Figure 4.4, panels B, D, F, H) and stored overnight on ice at 4°C to verify the stability and solubility 
of the enzyme preparations.  
At this stage MOCHLIM preparations were stable after concentration and storage overnight on ice at 4°C 
independently from the protein form and from the E.coli background used for their production. The 
absorption spectra were similar to each other and to that of the MO domain at this stage of purification 
(Figure 4.4, panels B, D, F, H and Figure 4.3, panel C). The degree of purity of the enzyme preparations 
after affinity chromatography was also similar for MOCHLIM2 and MOCHLIM4 regardless of the E.coli 
strain used for their expression. MOCHLIM represented greater than 70% of the total protein present in 
the peak fractions. However, we observed several contaminating proteins with mass lower than that of 
MOCHLIM (≈87 kDa). In particular, the main contaminant had an apparent mass of ≈66 kDa (inserts of 
panels B, D, F, H in Figure 4.4). 
The concentrated fractions containing MOCHLIM were used to test additional chromatographic steps for 
further purification and to establish which construct yielded protein of higher quality for further work.  
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Figure 4.4. Small-scale purification of MOCHLIM forms – Ni-NTA affinity chromatography. Crude extracts from 6 
g of E.coli Rosetta(DE3) or BL21(DE3, p18) cells that had produced MOCHLIM2 or MOCHLIM4 were subjected 
to chromatography on Ni-NTA Sepharose resin as described in the legend of Figure 4.2. The host E.coli strain and 
the protein form under study are indicated. The insets of panels B, D, F and H show the SDS-PAGE analysis of the 
pooled fractions (P) from the corresponding chromatographies (panels A, C, E and G; shaded area) and the final 
sample after concentration (C). Other symbols are as in the legend of Figure 4.2. 
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4.3. Set-up of the purification protocol of MOCHLIM    
MOCHLIM samples after Ni-NTA chromatography were used for further protein purification by gel 
filtration and ion exchange chromatographies. Similar tests were made for MICAL.  
Size exclusion chromatography of MOCHLIM was carried out to evaluate its efficacy in the removal of 
contaminating proteins.   
Aliquots (500 µl, ≈2 mg) of the partially purified MOCHLIM2 and MOCHLIM4 forms were gel filtered 
in buffer B (50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM 
DTT) on a Superose12 column connected to an FPLC apparatus. The elution profile of the 
chromatography was similar for both MOCHLIM forms with a main peak containing the enzyme 
followed by a second peak corresponding to proteins with a lower mass, an example is shown in Figure 
4.5. The absorption spectrum in the visible region of the fractions containing MOCHLIM showed that the 
absorbance maximum was shifted from 455 nm observed after Ni-NTA Sepharose to 458 nm (Figure 4.6) 
that is characteristic of the homogeneous MO domain. On the basis of the value of the UV/Vis ratio 
(A275/A458), which is a measure of the degree of purity of flavoenzymes, fractions with the minimal values 
(≈22) were pooled and concentrated with a Centricon YM30 centrifugal filter device (Table 4.1).  
Gel filtration of MOCHLIM forms allowed to remove only part of the contaminating proteins, as 
demonstrated by the UV/Vis ratio of ≈22, which must be compared with the theoretical value of 16 for 
homogeneous holoenzyme, and by SDS-PAGE (insets in panels C, F and I of Figure 4.6). In fact, the 
main contaminating species of ≈66 kDa partially coeluted with MOCHLIM. The intensity of the band 
increased after protein concentration suggesting that it could be a product of proteolytic degradation of 
MOCHLIM (insets in panels C, F and I of Figure 4.6). Both MOCHLIM forms were able to catalyze a 
NADPH oxidase reaction with an initial velocity, expressed as v/[E], a measure of the apparent turnover 
assuming that all the protein present is MOCHLIM, of 0.7-0.8 s
-1
. This value is only ≈2-fold and ≈3-fold 
lower than that measured for MOCH (≈1.3 s-1)  and MO (≈2.5 s-1) under the same conditions (Table 4.1). 
The gel filtration allowed us to observe a difference in the proteins produced in E.coli Rosetta(DE3) cells 
compared to those expressed in BL21(DE3, p18) cells. In the latter case the absorption spectrum was 
better resolved in the 300-375 nm region (Figure 4.6, panels C, F and I). Moreover, the absorbance 
maxima in the UV region were at 275 and 265 nm for MOCHLIM forms produced in E.coli BL21(DE, 
p18) and Rosetta(DE3) cells, respectively (Figure 4.6, panels A, D and G). The absorbance maximum at 
265 nm of the enzyme obtained from E.coli Rosetta(DE3) cells could indicate the presence of cellular 
compounds that interact with the protein, such as non-specific interaction between DNA fragments and 
MOCHLIM through the LIM domain. Furthermore, the electrophoretic pattern of the proteins produced in 
E.coli BL21(DE3, p18) cells showed a higher degree of purity than that observed for the proteins 
expressed in Rosetta(DE3). In the latter case several faint protein bands below MOCHLIM suggested 
proteolytic degradation (insets in panels C, F and I of Figure 4.6). Thus, from these results coexpression 
of MOCHLIM with GroE in E.coli BL21(DE3, p18) seemed to give protein of higher quality.   
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Figure 4.5. Small-scale purification of MOCHLIM – Gel filtration. Panel A: Gel filtration of MOCHLIM2 
expressed in E.coli Rosetta(DE3) after Ni-NTA Sepharose affinity chromatography from 6 g of cells (Figure 4.4 
panels A-B) on a Superose12 column in buffer B. Fractions enriched in MOCHLIM were pooled (shaded area) and 
concentrated. Panel B: detail of the gel filtration profile obtained by recording the absorption spectrum of the 
individual fractions. Panel C: SDS-PAGE analysis of the sample loaded onto the column (L) and of the fractions 
collected during the gel filtration numbered as in panel B.       
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Figure 4.6. Comparison of the absorption spectra of the MOCHLIM forms after gel filtration on Superose12. MOCHLIM2 produced in E.coli Rosetta(DE3) and in BL21(DE3, p18)  
and MOCHLIM4 produced in BL21(DE3, p18) cells after Ni-NTA affinity chromatography (Figure 4.4) were gel filtered on a Superose12 column in buffer B as described in the 
legend of Figure 4.5. In panels A, B, D, E, G and H the absorption spectra of the fractions enriched in MOCHLIM are shown on two scales. Note that the elution profiles were in all 
cases similar to that shown in Figure 4.5 so that the different fractions numbers indicated do not correspond to different elution volumes. The absorbance spectra of the final samples 
are shown in panels C, F and I. The SDS-PAGE analyses of the pooled fractions (P) and of the same fractions after concentration (C) are shown in the insets.    
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Since gel filtration did not resolve MOCHLIM from contaminants, the efficacy of anion exchange 
chromatography was tested, taking also into account the isoeletric point of MOCHLIM (pI, 6.6).  
To verify if anion exchange chromatography could allow us to obtain homogeneous MOCHLIM 
preparation, MOCHLIM4 expressed in E.coli Rosetta (DE3) cells and purified by affinity 
chromatography (Figure 4.4, panels E, F) was further chromatographed on a MonoQ column equilibrated 
with buffer B without glycerol (50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM 
DTT).  
The enzyme solution was first dialyzed versus buffer B without glycerol with good recovery (Table 4.1). 
Then, it was loaded onto a MonoQ column, which was washed with 5 volumes of equilibration buffer 
followed by a linear 100-500 mM NaCl gradient in 60 column volumes. 0.5-1 ml fractions were collected 
(Figure 4.7, panels A, B).  
Under these conditions MOCHLIM did not bind to the resin, presumably due to the high ionic strength of 
the buffer and it coeluted with several contaminants (Figure 4.7, panels C and D). Protein bands of ≈22 
and 21.5 kDa, not present in the starting sample, bound to MonoQ and eluted at ≈130 mM NaCl. These 
observations indicated that proteolytic events were taking place. Thus, the fractions containing the 
enzyme (fractions 3-6) were pooled, concentrated (Figure 4.7, panels C; Table 4.1) and diluted 4-fold in 
buffer without NaCl to lower its concentration from 100 to 25 mM. The sample was loaded on to the 
MonoQ column equilibrated in 50 mM Na-phosphate buffer, pH 7.5, 25 mM NaCl, 1 mM EDTA, 1 mM 
DTT. Under these conditions MOCHLIM bound to the resin and eluted at ≈160 mM NaCl (Figure 4.7, 
panel E, F). Fractions 18-19 that contained the enzyme were pooled (Figure 4.7, panel G; Table 4.1). The 
electrophoretic analysis of the samples (Figure 4.7, panel H) indicated that the anion exchange 
chromatography removed most of the contaminants, but only part of the ≈66 kDa protein. Moreover, the 
electrophoretic pattern of the enzyme after concentration showed the appearance of novel protein bands 
with lower mass than that of MOCHLIM (Figure 4.7, panel H), strongly suggesting an ongoing 
proteolytic degradation of MOCHLIM.   
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Figure 4.7. Small-scale purification of MOCHLIM – Anion exchange chromatography. The MOCHLIM4  produced 
in E.coli Rosetta(DE3) cells and purified by Ni-NTA affinity chromatography (Figure 4.4, panels E, F) was loaded 
onto a MonoQ column equilibrated in buffer B without glycerol (50 mM Na-phosphate buffer, pH7.5, 100 mM 
NaCl, 1 mM EDTA, 1 mM DTT) and eluted by applying a linear NaCl gradient (panels A and B). Under these 
conditions MOCHLIM and most of the contaminants did not bind to the resin (panels C and D). Thus fractions 3-6 
were pooled (black line panel C, 0.38 mg/ml, 4.46 µM), concentrated (red line panel C, 0.69 mg/ml, 8.1 µM) and 
diluted 4-fold in 50 mM Na-phosphate buffer, pH 7.5, 1 mM EDTA, 1 mM DTT (black line panel C, 0.17 mg/ml, 2 
μM) to lower NaCl concentration to 25 mM. The sample was loaded onto MonoQ column equilibrated in 50 mM 
Na-phosphate buffer, pH 7.5, 25 mM NaCl, 1 mM EDTA, 1 mM DTT and developed by applying linear NaCl 
gradient (panels E and F). Peak fractions containing MOCHLIM (shaded area in panels E and F) were pooled. The 
absorption spectrum of the pooled fractions (18-19, 0.20 mg/ml, 2.35 µM)  is shown in panel G. Panel H shows the 
SDS-PAGE analysis of the fractions from the second MonoQ column, numbered as in panel F, the pooled peak 
fractions (P2) the sample loaded (C1) from the first chromatography (panels A-D).○, full-length MOCHLIM form 
(87 kDa); ●, ≈66 kDa protein species.     
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Table 4.1. Small-scale purification of MOCHLIM forms from E.coli Rosetta(DE3) and BL21(DE3, p18) cells. Summary of the quantitation of MOCHLIM forms obtained during 
the purifications shown in: Figure 4.4 (A-B), 4.5 and 4.6 (A-C) (MOCHLIM 2 expressed in Rosetta(DE3) cells), Figure 4.4 (C-D) and 4.6 (D-F) (MOCHLIM 2 expressed in 
BL21(DE3, p18) cells), Figure 4.4 (G-H)  and 4.6 (G-I) (MOCHLIM 4 expressed in BL21(DE3, p18) cells) and Figure 4.4 (E-F) and 4.7 (MOCHLIM 4 expressed in 
Rosetta(DE3) cells). The protein concentration was determine with the Bradford method (
a
) or from the absorbance at 458 nm, by using the extinction coefficient of 8.1 mM
-1
cm
-1
 
of MO (Zucchini et al., 2001) and the calculated mass of 85.6 and 86.4 kDa of MOCHLIM2 and MOCHLIM4, respectively (
b
). The NADPH oxidase activity was carried out in 
20 mM Hepes/KOH buffer, pH 7, 100 µM NADPH at 25°C.   
   
 
Bradford
a
   Absorbance
b
 Activity 
E.coli strain Protein form Sample ml mg/ml mg yield, % mg/ml mg yield, % µM UV/Vis U U/mg
a 
Rosetta(DE3) MOCHLIM2 Crude extract 27 12 324 100        
  Ni-NTA Sepharose 13 1.14 14.8 4.6 0.39 5.1 100 4.57    
  Concentration 2.10 5.82 12.2 3.8 1.84 3.9 76 21.6    
  Superose12 3.0 0.55 1.65 0.5 0.40 1.2 24 4.7 26.86 0.90 0.55 
  Concentration 0.48 2.58 1.23 0.4 2.0 0.95 19 23.3 23.30 0.66 0.54 
BL21(DE3, p18) MOCHLIM2  Crude extract 25 18 452.5 100        
  Ni-NTA Sepharose 7.0 3.9 27.2 6.0 0.8 5.60 100.00 9.41    
  Concentration 1.5 16 24.0 5.3 2.7 4.05 72.32 31.76    
  Superose12 2.5 1.3 3.33 0.73 0.66 1.66 29.62 7.78    
  Concentration 0.57 2.94 1.68 0.37 2.35 1.34 23.93 27.57 22.33 0.91 0.55 
BL21(DE3, p18) MOCHLIM4  Crude extract 25.00 9.53 238.25 100.00        
  Ni-NTA Sepharose 11.00 1.03 11.33 4.76 0.50 5.50 100.00 5.81    
  Concentration 2.00 4.91 9.82 4.12 2.21 4.42 80.36 25.70    
  Superose12 2.80 0.81 2.27 0.95 0.61 1.69 30.81 7.04 21.55   
  Concentration 0.44 3.86 1.70 0.71 3.05 1.34 24.37 35.42 19.70 0.98 0.58 
Rosetta(DE3) MOCHLIM4 Crude extract 25 10.29 257 100        
  Ni-NTA Sepharose 7.50 1.29 9.68 3.76 0.56 4.20 100 6.57    
  Concentration 2.00 4.00 8.00 3.11 1.76 3.52 84 20.64    
  Dialysis 2.00 3.95 7.90 3.07 1.60 3.20 76 18.76    
  MonoQ1 4.00 0.51 2.04 0.79 0.38 1.52 36 4.46    
  Concentration 1.10 0.77 0.85 0.33 0.69 0.76 18 8.09    
  MonoQ2 0.90 0.34 0.31 0.12 0.20 0.18 4.3 2.35    
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4.4. Large-scale production of MICAL and of the MO, MOCH and MOCHLIM forms 
To obtain the proteins forms in quantities sufficient to carry out their characterization, 12 l cell cultures were 
set up in a fermentor.  
On the basis of the results obtained during the previous experiments with MICAL and MOCHLIM forms we 
decided to coexpress the proteins in E.coli BL21(DE3) cells with GroE to favor protein folding. In the 
preliminary analyses MOCHLIM2 and MOCHLIM4 showed similar properties in terms of the quantity and 
quality (stability, activity). Thus, we focused on MOCHLIM4 form, which is 10 residues longer than 
MOCHLIM2, since the additional residues could promote the folding and stability of the LIM domain.  
The cells were cultured as described in Material and Methods (Chapter 10). After a series of preliminary 
experiments, cells were harvested 24 and 40 h after the addition of IPTG for MOCHLIM and MICAL, 
respectively. The analysis of the total cell extracts at different times (Figure 4.8) showed the appearance of 
protein bands expected for the MICAL forms after IPTG addition and their expression levels were similar to 
those obtained in cells cultured in 2 l flasks (Figure 4.1). MO and MOCH forms were produced in E.coli 
Rosetta(DE3) and in BL21(DE3, p18) cells, respectively.  
The cells were used for the purification of the four MICAL forms. For MO and MOCH, the available 
procedures were modified to improve purity of the final preparations. For MOCHLIM and MICAL several 
tests were made on the basis of preliminary experiments (Figures 4.2-4.6) to set-up novel purification 
procedures.   
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Figure 4.8. Large-scale production of MICAL forms in E.coli cells. E. coli Rosetta(DE3) or BL21(DE3, p18) cells harboring the pET-derivatives for the production of human 
MICAL1 forms were grown in a  fermentor in 12 l LB supplemented with 0.1 mg/ml ampicillin and 0.025 mg/ml choloramphenicol up to an OD600 of ≈ 1. The temperature was 
lowered to 15°C and IPTG (0.1 mM) was added. Small aliquots of the culture were harvested before IPTG addition (0 h) and at the indicated times after induction.  For 
comparison samples obtained from culturing, under the same conditions, E. coli Rosetta (DE3) and BL21(DE3, p18) cells harbouring the pET derivatives for the production of 
MICAL MO and MOCH, respectively, are shown. Aliquots of total cell extracts were analyzed by SDS-PAGE on 12% (AcA+bis-AcA) gels. The empty circles indicate the bands 
corresponding to the MICAL forms; the full circles indicate the bands corresponding to GroEL (59.7 kDa) encoded by p18.  
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4.5. Large-scale purification of MO  
30 g of E.coli Rosetta(DE3) cells that had produced MO were used for its purification. The crude extract 
(Table 4.2 A) in buffer A containing 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM 
PMSF, 1 mM 2-ME, 1% protease inhibitors cocktail was directly loaded on a Ni-NTA Sepharose column 
(30 ml) equilibrated in buffer A + 20 mM imidazole in the cold room. The weakly bound proteins were 
removed by flowing 1 volume of buffer A + 20 mM imidazole, 1 mM 2-ME (fractions 1-38, Figure 4.9, 
panel A) and 10 volumes of buffer A + 50 mM imidazole, 1 mM 2-ME (fractions 39-70, Figure 4.9, panel 
A). The column was connected to a FPLC apparatus with UV and conductivity detectors, thermostatted at 
4°C. The bound proteins were eluted by applying a linear 50-200 mM imidazole gradient in 10 column 
volumes (Figure 4.9, panel B). Fractions enriched in MO, as judged by the absorption spectrum (Figure 
4.9, panel C) and SDS-PAGE analysis (not shown), were pooled, concentrated and dialyzed against 
buffer B (Figure 4.9, panel D; Table 4.2 A). The NADPH oxidase activity of the pooled fractions and of 
the preparation after concentration and dialysis was measured (Table 4.2 A). After dialysis an aliquot of 
the enzyme was diluted to determine the value of the UV/Vis ratio (A275/A458) that was 11.5 (Figure 4.9, 
panel E) similar to the theoretical value of 11 expected for MO containing a stoichiometric amount of 
FAD (see Chapter 5).  The recovery of the protein after concentration and dialysis, and the quality of 
absorption spectrum with absorbance maxima at 375 and 458 nm (Figure 4.9, panel D) in the visible 
region were comparable to those obtained previously (Zucchini et al., 2011) and confirmed the enzyme 
stability. Moreover, the activity of the protein, expressed as v/[E], increased after concentration and 
dialysis, from 1 to 1.8 s
-1
 due to the combination of the removal of imidazole from the sample and the 
smaller amount of enzyme solution used to carry out the assay, leading to a decrease of the ionic strength 
of the reaction mixture. In fact, as better described in Chapter 6, the isolated MO domain is very sensitive 
to ionic strength and type of ions of the medium (Zucchini et al., 2011). MO preparation at the end of Ni-
NTA Sepharose chromatography was nearly homogeneous as demonstrated by the value of the UV/Vis 
ratio and the SDS-PAGE analysis. MO represented >90% of the total protein content and the main 
contaminating protein band with a mass of ≈68 kDa (Figure 4.9, panel F) could be removed by gel 
filtration, which was routinely carried out prior to each experiment to also exchange the buffer. 
The enzyme solution was divided in small aliquots and stored at -80° after flash-freezing in liquid 
nitrogen. MO was stable after long-term storage at -80°C (see Chapter 5).  
The contaminants present in trace amounts in the MO preparation from Ni-NTA Sepharose were removed 
by gel filtration on a Superose12 column in buffer B or “F-buffer no ATP” (9.5 mM Tris/HCl, pH 7.7, 45 
mM KCl, 0.18 mM CaCl2, 1.8 mM MgCl, 1.3 mM DTT) prior to each experiments to also transfer the 
protein in the appropriate buffer. The protein behavior during chromatography was independent from the 
buffer used. Thus, only the results obtained from the gel filtration of the enzyme in “F-buffer no ATP” 
will be shown.  
Aliquots up to 500 µl of protein solution (Table 4.2 B) were loaded on a Superose12 column and 0.5 ml 
fractions were collected. On the basis of the absorption spectrum (Figure 4.10, panels A-C) fractions 15-
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16 were pooled (Figure 4.10, panels D, E; Table 4.2 B) and concentrated (Figure 4.10, panel F; Table 4.2 
B).  
The resulting MO preparation showed absorbance maxima at 276, 375 and 458 nm and a A276/A458 ratio 
of 10.2. The contaminants were successfully removed as shown by the elution profile in which two peaks 
with a lower absorbance were observed before and after the main peak containing MO (Figure 4.10, panel 
A) and  by SDS-PAGE analysis of the individual fractions (Figure 4.10, panel C).  
The enzyme was used immediately for experiments or was stored at -80°C after flash-freezing of small 
aliquots in liquid nitrogen. Under these conditions the enzyme in buffer B or in F-buffer without ATP was 
stable.  
 
Table 4.2. Large-scale purification of MO. Quantitation of MO prepared from 30 g of E.coli Rosetta(DE3) cells as 
described in the text. A: Recovery after Ni-NTA Sepharose, concentration and dialysis as described in the legend of 
Figure 4.9. B: Example of final purification and buffer exchange by gel filtration on Superose12 column as 
described in the legend of Figure 4.10. The indicated quantities of MO are referred to two chromatographic runs. 
500 μl of sample were loaded in each run and the corresponding peak fractions were combined before concentration. 
The NADPH oxidase activity was carried out in 20 mM Hepes/KOH buffer, pH 7, 100 µM NADPH at 25°C
 a
Protein 
concentration was determined with the Bradford method. 
b
Protein concentration determined from the absorbance at 
458 nm, by using the extinction coefficient of 8.1 mM
-1
cm
-1
 of MO (Zucchini et al., 2001) and the calculated mass 
of  55.1 kDa of MO.   
A 
 
  Bradford
a
 Absorbance
b
 Activity   
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM U %U U/mg
a
 
Crude extract 140 16.29 2280 100 - - - - - - - 
Ni-NTA Sepharose 45 0.50 22.5 0.99 0.4 18 100 7.26 25 100 1.11 
Concentration 3.3 5.14 16.9 0.74 4 13 72 72.6 27 108 1.59 
Dialysis 3.1 5.03 15.6 0.68 3.76 12 67 68.2 28 112 1.8 
 
B 
  Bradford
a
 Absorbance
b
 
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM A276/A458 
Ni-NTA Sepharose 1 4 4 100 3 3.1 100 56 11.5 
Superose12 2.3 1.25 2.875 71.875 0.93 2.15 70 16.93 10.20 
Concentration 0.9 2.2 1.98 49.5 1.94 1.75 57 35.26 - 
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Figure 4.9. Large-scale purification of MO – Ni-NTA affinity chromatography. The crude extract from 30 g of 
E.coli Rosetta(DE3) cells that had expressed MO (Figure 4.8) was loaded onto 30 ml of Ni-NTA Sepharose column 
in buffer A + 20 mM imidazole. The column was rinsed with equilibration buffer and buffer A + 50 mM imidazole 
in the cold room (panel A). The column was connected to an FPLC apparatus and bound proteins were eluted by 
applying an imidazole gradient (panels B and C). Based on the elution profiles (panels B and C), quality of the 
absorbance spectra of the individual fractions and SDS-PAGE (not shown) the fractions in the shaded area were 
pooled, concentrated and dialyzed against buffer B. The absorption spectrum of the final protein preparation (panel 
D, 3.76 mg/ml, 68 µM) and of the sample after 6-fold dilution in buffer B (panel E, 0.63 mg/ml, 11 µM) are shown. 
Panel F shows the SDS-PAGE analysis of: crude extract (CE); fraction 22 eluted with buffer A + 20 mM imidazole 
(W1, panel A); fraction 45 eluted with buffer A + 50 mM imidazole (W2, panel A); the pooled MO containing 
fractions before (P) and after concentration (C) and dialysis (D). The indicated quantity of protein loaded was 
determined with the Bradford method for the crude extract and from the A458 of MO for the other samples.  
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Figure 4.10. Purification of MO – Gel filtration. An aliquot of MO preparation after affinity chromatography 
(Figure 4.9) was gel filtered on a Superose12 column in F-buffer no ATP to remove the ≈68 kDa contaminant and 
for buffer exchange. Panel A: elution profile obtained with on-line A280 detection. Panel B: detail of the elution 
profile shown in panel A, obtained by recording the absorption spectrum of individual fractions. Panel C: SDS-
PAGE analysis of MO after Ni-NTA chromatography loaded on Superose12 (L); fractions collected during gel 
filtration numbered as in panel B; fraction 15-16 pooled (P); different amounts of the MO preparation after 
concentration (Concentrate), calculated with the protein concentration determined by the A458 of the sample using 
the extinction coefficient of 8.1 mM
-1
cm
-1
 and a mass of 55.1 kDa calculated for MO. Panels D and E: absorption 
spectra of the pooled fractions 15-16 (0.93 mg/ml, 16.93 µM) on two different scales. Panel F: fractions 15-16 after 
concentration (1.94 mg/ml, 35 µM). 
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4.6. Large-scale purification of MOCH  
The crude extract (Table 4.3 A) was obtained by sonication of ≈30 g of E.coli BL21(DE3, p18) cells, 
which had overexpressed the protein (Figure 4.8), and centrifugation at 18000 rpm for 1 h at 4°C. It was 
directly loaded on to a column containing Ni-NTA Sepharose (25 ml) equilibrated in buffer A + 20 mM 
imidazole at 4°C. The column was washed overnight with 13 column volumes of buffer A+ 20 mM 
imidazole, 1 mM PMSF, 1 mM 2-ME to remove weakly bound proteins (Figure 4.11, panel A). The day 
after, the column was connected to an FPLC apparatus and to a water bath at 4°C. Protein elution was 
effected by applying a linear 20-200 mM imidazole gradient in buffer A. When the first protein peak 
emerged from the column, the concentration of imidazole was held constant at ≈70 mM for 2 column 
volumes (Figure 4.11, panel B). In this way, an increase of purity of MOCH, present in the second main 
peak, was obtained (Figure 4.11, panel C). From the absorption spectra (Figure 4.11, panel C) and SDS-
PAGE (not shown) of individual fractions, those enriched in MOCH were pooled (fractions 47-67; Table 
4.3 A). The protein solution (Pool 47-67; Table 4.3 A) was concentrated by ultrafiltration (Figure 4.11, 
panel D) and dialyzed against buffer B (Figure 4.11, panels E, F; Table 4.3 A). 
MOCH was stable as demonstrated by the greater than 85% of protein recovery after concentration and 
dialysis (Table 4.3 A), calculated from the enzyme concentration determined from the absorption 
spectrum and the extinction coefficient of 8.1 mM
-1
cm
-1
 (Zucchini et al., 2011), and by the quality of the 
absorption spectra (Figure 4.11, panel E). The final preparation showed a A276/A458 ratio value of 17.5 
(Figure 4.11, panel F) to be compared with the theoretical value of 14 and to the value of 19.3 for the 
enzyme solution obtained with the original protocol. At this stage MOCH preparation was still 
contaminated (inset of panel F in Figure 4.11) by protein species that were similar to those observed for 
MO after Ni-NTA Sepharose (Figure 4.9, panel F) and could be removed by gel filtration. As an 
alternative, MOCH could be further purified by anion exchange chromatography.  
Such additional purification steps, especially gel filtration, were often performed before certain 
experiments also for buffer exchange. In fact, MOCH after affinity chromatography and dialyzed in 
buffer B was stable at -80°C after flash-freezing of small aliquots in liquid nitrogen.    
As described above for MO, also the MOCH preparation after Ni-NTA Sepharose chromatography 
contained contaminants that could be removed by gel filtration on a Superose12 column in buffer B or in 
20 mM Hepes/KOH buffer, pH 7, 100 mM NaCl, with similar results. Thus, only an example of gel 
filtration of MOCH in buffer B is shown.  
Aliquots (up to 500 µl) of MOCH solution (≈5 mg/ml, Table 4.3 B) after Ni-NTA Sepharose affinity 
chromatography were loaded on a Superose12 column equilibrated and eluted with buffer B at 0.5 ml/min  
and 0.5 ml fractions were collected. The elution profile was similar to that observed for MO, with a main 
peak containing MOCH and two minor peaks corresponding to the contaminating proteins (Figure 4.12, 
panels A, B), as confirmed by the SDS-PAGE analysis (Figure 4.12, panel C). Fractions with an A276/A458 
value ≤16 were pooled (fractions 12-14, Figure 4.12, panels D, E; Table 4.3) and concentrated (Figure 
4.12, panel F; Table 4.3 B).  
 62 
The MOCH preparation at the end of gel filtration had a UV/Vis ratio of 15.7 (Figure 4.12, panel D) 
which was lower than the initial value of 17.5 in agreement with the removal of most of the contaminants 
(Figure 4.12, panel C). The yield was only 60% of MOCH (Table 4.3 B), also due to the fact that some 
side fractions were discarded. 
As an alternative to gel filtration, MOCH could be further purified after affinity chromatography by anion 
exchange on a MonoQ column. The column was equilibrated in 20 mM Na-phosphate buffer, pH 7.5, 40 
mM NaCl. At this pH the overall charge of MOCH is ≈0 (pI 7.67) so that it should not bind the resin as 
opposed to the contaminating proteins, according to pilot experiments.  
An aliquot of MOCH solution (black thick line in Figure 4.13, panel A; Table 4.3 C) in buffer B was 
dialyzed against 20 mM Na-phosphate buffer, pH 7.5, 40 mM NaCl (see Materials and Methods for the 
details). At the end of the dialysis the enzyme (red thin line in Figure 4.13, panel A; Table 4.3 C) was 
loaded on a MonoQ column equilibrated in the dialysis buffer. The column was developed by flowing 20 
volumes of the equilibration buffer, followed by a linear 40-500 mM NaCl gradient in 60 column 
volumes and 0.5 ml fractions were collected. Fractions enriched in MOCH (Figure 4.13, panels B, C) and 
with a UV/Vis value ≤ 16 were pooled (fractions 23-32; black thick line in Figure 4.13, panel D; Table 
4.3 C) and concentrated (red thin line in Figure 4.13, panel D; Table 4.3 C). Under these conditions 
MOCH bound very weakly to the resin and eluted with the equilibration buffer, while contaminating 
proteins bound to the resin and high concentrations of NaCl were required for their elution (Figure 4.13, 
panel A). 
At the end of chromatography, the UV/Vis ratio of the preparation was 14.8 close to the theoretical value 
of 14 (see Chapter 5). The electrophoretic pattern showed only traces of contaminants (Figure 4.13, panel 
F) that were similar in mass to those observed after gel filtration. However, the protein yield was only 
40% (Table 4.3 C) of the starting sample compared to 60% from size exclusion chromatography (Table 
4.3 B).   
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Table 4.3. Large-scale purification of MOCH.  Quantitation of MOCH prepared from 30 g of E.coli BL21(DE3, 
p18) cells as described in the text. A: Recovery after Ni-NTA Sepharose, concentration and dialysis as described in 
the legend of Figure 4.11. B: Example of final purification and buffer exchange by gel filtration on Superose12 
column as described in the legend of Figure 4.12. The indicated quantities of MOCH are referred to two 
chromatographic runs. 400 and 350 μl of sample were loaded onto Superose12 column and the corresponding peak 
fractions were combined before concentration. C: Example of final purification of MOCH by anion exchange 
chromatography on a MonoQ column as described in the legend in Figure 4.13. 
a
Protein concentration was 
determined with the Bradford method. 
b
Protein concentration was determined from the absorbance at 458 nm, by 
using the extinction coefficient of 8.1 mM
-1
cm
-1
 of MO (Zucchini et al., 2001) and the calculated mass of 68.5 kDa 
of MOCH.  
A 
  Bradford
a
 Absorbance
b
 
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM 
Crude extract 150 19 2850 100  - - - 
Ni-NTA Sepharose 38 0.95 36.1 1.3 0.54 20.4 100 6.3 
Concentration 5.8 - -  3.13 18.2 89 36 
Dialysis 5.6 5.25 29.4 1 3.13 17.6 86 36 
 
B 
  Bradford
a
 Absorbance
b
 
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM A276/A458 
Ni-NTA Sepharose 0.75 5.25 3.94 100 3.01 2.26 100 44 17.50 
Superose12 2.8 1.1 3.08 78 0.60 1.68 70 16 15.69 
Concentration 0.8 2.35 1.88 48 1.76 1.41 58 34 -  
 
C 
  Bradford
a
 Absorbance
b
 
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM A276/A458 
Ni-NTA Sepharose 0.8 9.5 7.6 100 6.7 5.36 100 98 - 
Dialysis 1.1 6.5 7.15 94 4.54 4.99 93 66 18.5 
MonoQ 4.5 0.66 2.97 39 0.57 2.57 48 8.3 14.5 
Concentration 1 2.4 2.4 32 2.07 2.07 37 30 - 
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Figure 4.11. Large-scale purification of MOCH – Ni-NTA affinity chromatography. A crude extract from ≈30g of 
E.coli BL21(DE3, p18) cells that had produced MOCH (Figure 4.8) was prepared and chromatographed on a Ni-
NTA Sepharose column as described in the legend of Figure 4.9.  Panel A: elution profile obtained by measuring the 
absorption spectrum of fractions during the initial rinsing of the column with buffer A + 20 mM imidazole. Panel B: 
elution profile obtained during the imidazole gradient and on-line detection of A280 of the eluate. Panel C: detail of 
the elution profile shown in panel B obtained by measuring the absorption spectra of the individual fractions. The 
absorption spectrum of pooled fractions 46-67 after concentration (panel D, 3.13 mg/ml, 36 µM) and  dialysis (panel 
E, 3.13 mg/ml, 36 µM) are shown. Panel F shows the spectrum of an aliquot of the final MOCH preparation after 
6.5-fold dilution in buffer B (0.48 mg/ml, 7 µM). The inset shows the SDS-PAGE analysis of the final MOCH 
sample.  
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Figure 4.12. Purification of MOCH – Gel filtration. An aliquot of MOCH preparation after affinity chromatography 
(Figure 4.11) was gel filtered on a Superose12 column in buffer  B in the FPLC to remove the ≈68 kDa contaminant 
and for buffer exchange. Panels A-F are as in Figure 4.10. MOCH concentration was: 0.6 mg/ml, 16 µM (pooled 
fractions 12-14, panels D and E) and 1.76 mg/ml, 34 µM (after concentration, panel F).  
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Figure 4.13. Purification of MOCH – Anion exchange chromatography. An aliquot of MOCH after Ni-NTA 
Sepharose chromatography (Figure 4.11) was dialyzed against 20 mM Na-phosphate buffer, pH 7.5, 40 mM NaCl 
and chromatographed in the FPLC onto a MonoQ column equilibrated with the dialysis buffer and eluted with a 
NaCl gradient. Panel A: absorption spetrum of MOCH after Ni-NTA Sepharose (black thick line, 6.7 mg/ml, 98 μM, 
0.8 ml, 5.36 mg) and after dialysis (red thin line; 4.54 mg/ml, 66 μM, 1.1 ml, 4.99 mg). Panel B: elution profile of 
the MonoQ column with on-line detection of A280. The NaCl gradient is indicated in red.  Panel C: detail of the 
elution profile of panel B obtained by recording the absorption spectrum of the individual fractions. Panel D: 
absorption spectrum of the pooled fractions 23-32 before (black thick line, 0.57 mg/ml, 8.3 µM) and after 
concentration (red thin line, 2.07 mg/ml, 30 μM). Panel E: comparison of the absorption spectrum of MOCH before 
(red thin line) and after (black thick line) anion exchange chromatography after dilution to determine the UV/Vis 
ratio. Panel F: SDS-PAGE analysis of: MOCH loaded onto the MonoQ column (L); pooled fractions 22-32 before 
(P) and after concentration (C). CON indicates a sample of the final concentrated enzymes (C) after overnight 
incubation on ice at 4°C. 
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4.7. Large-scale purification of MOCHLIM 
In order to set-up the purification procedure of MOCHLIM we needed to control its proteolytic 
degradation, that led to appearance of the ≈66 kDa , ≈62 kDa, ≈55 kDa and 22 and 21.5 kDa bands 
(Figure 4.7). The 62 kDa species clearly derived from that of 66 kDa, which was fully lost when the 
sample had to be treated over long period of time as during large scale purification. It derived from 
proteolytic cleavage of MOCHLIM in the region between the CH and the LIM domains as shown by the 
N-terminal sequencing (2ASTPN6) and by its mass of 71.2 kDa determined by MALDI-TOF. By checking 
the effect of incubating partially purified MOCHLIM from Ni-NTA affinity and anion exchange 
chromatographies, with 1 mM PMSF and 0.5% protease inhibitors cocktail (Sigma P8849), we found that 
the latter was sufficient to prevent MOCHLIM degradation (Figure 4.14).  
Due to the cost of the reagent we decided to add the protease inhibitors cocktail at 0.5% to pooled 
fractions after each chromatographic step and to the dialyzed samples. PMSF (1 mM final concentration) 
was included in all buffers to further inhibit serine proteases.  
 
 
 
 
Figure 4.14. Effect of the protease inhibitors on the proteolytic degradation of MOCHLIM form. Aliquots of 
MOCHLIM4 purified by Ni-NTA Sepharose and anion exchange chromatographies were diluted 2-fold in buffer in 
the absence and presence of 1 mM PMSF or 0.5% protease inhibitors cocktail (Sigma Aldrich P8849). After 0, 24 
and 44 h at 4°C aliquots of each sample were denatured by incubation at 100°C for 5 min. ○, full-length MOCHLIM 
form (87 kDa); ●, 62 kDa protein species; □, 55 kDa;■, 22 kDa; Δ, 21.5 kDa.  
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30 g of E.coli BL21(DE, p18) cells containing MOCHLIM4 forms, grown in fermentor and harvested 24 
h after the induction of protein expression (Figure 4.8), were homogenized by sonication in buffer A + 20 
mM imidazole. The crude extract obtained after centrifugation (Table 4.4 A) was loaded on a Ni-NTA 
Sepharose column (15 ml), preequilibrated in buffer A + 20 mM imidazole, in the cold room. The column 
was washed with ≈10 column volumes of buffer A + 20 mM imidazole, 1 mM PMSF, 1 mM 2-ME 
(Figure 4.15, panel A) and 5 column volumes of buffer A + 50 mM imidazole, 1 mM PMSF, 1 mM 2-ME 
to remove the unbound and weakly bound proteins (fractions 1-20, Figure 4.15, panel B). The bound 
proteins were eluted by applying a linear 50-200 mM imidazole gradient in 9 column volumes (Figure 
4.15, panel B). Fractions enriched in MOCHLIM were pooled, supplemented with 0.5% protease 
inhibitor cocktail (Table 4.4 A), concentrated by ultrafiltration (Table 4.4 A) and dialyzed against buffer 
B + 1 mM PMSF (Figure 4.15, panels D and E; Table 4.4 A). Protease inhibitors cocktail (0.5% v/v, final 
concentration) was added to the final MOCHLIM solution. The other half of the sample was further 
concentrated by ultrafiltration with 87% of protein recovery (Figure 4.15, panel F).  
The absorption spectrum of MOCHLIM showed absorbance maxima at 276, 375 and 458 nm (Figure 
4.15, panel E). The A274/A458 ratio of 19 to be compared with the theoretical value of 16 (see Chapter 5), 
indicated that the MOCHLIM preparation was not homogeneous at this stage. SDS-PAGE showed that 
the main contaminant species had mass of 22 and 21.5 kDa and only traces of the ≈66 kDa degradation 
products were also present (Figure 4.15, panel G), indicating that the addition of the protease inhibitors 
cocktail before concentration and after dialysis was sufficient to control proteolytic degradation of 
MOCHLIM.  
The final MOCHLIM preparation was divided in small aliquots and stored at -80°C after flash-freezing in 
liquid nitrogen. Under these conditions MOCHLIM was stable both after long-term storage at -80°C and 
after overnight incubation on ice at 4°C (see Chapter 5).  
The MOCHLIM preparation obtained by Ni-NTA Sepharose chromatography, which was stabilized by 
the addition of the protease inhibitors cocktail contained two main contaminanting species of 22 and 21.5 
kDa as well as trace amounts of other proteins, which were more likely residual E.coli proteins and 
degradation products of MOCHLIM. Such contaminants could be easily removed by gel filtration on a 
Superose12 column on a small scale or on a Superdex200 column on a large scale. Only results of the 
preparative Superdex200 column are shown here. An example of chromatography on a Superose12 
column is shown in Chapter 5.  
The MOCHLIM preparation after the Ni-NTA Sepharose affinity chromatography (Figure 4.15) was 
concentrated (Figure 4.16, panel A; Table 4.4 B) and gel filtered on a Superdex200 column (150 ml) 
equilibrated and eluted with buffer B + 1 mM PMSF at 4°C. 1.5 or 5 ml fractions were collected. The 
elution profile was qualitatively similar to that obtained during pilot purification experiments on a 
Superose12 column (Figure 4.16, panel B), with a main peak containing the enzyme and two peaks with 
low absorbance. SDS-PAGE analysis of the fractions showed that the proteins with mass just lower than 
that of intact MOCHLIM were in the first chromatographic peak (fractions 25-30, Figure 4.16, panels B, 
C) with some MOCHLIM. A peak containing the protein species of 22 and 21.5 kDa (fractions 60-70, 
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Figure 4.16, panels B, C) was well resolved from the main peak containing MOCHLIM (fractions 40-50, 
Figure 4.16, panels B, C). On the basis of the absorption spectrum, fractions were pooled (fractions 43-
48, Figure 4.16, panel D; Table 4.4 B) and concentrated (Figure 4.16, panel E; Table 4.4 B). The final 
MOCHLIM preparation was pure, stable and no degradation of the enzyme during this final purification 
step occured. MOCHLIM showed absorbance maxima at 278, 375 and 458 nm. The A278/A458 ratio value 
of 15.9 (Figure 4.16, panel F) was similar to the theoretical value of 16 indicating that MOCHLIM was 
homogeneous with the correct complement of FAD. Protein purity was confirmed by SDS-PAGE (Figure 
4.16, panel C). The NADPH oxidase activity of the final enzyme preparation was measured. The v/[E] 
value, which, assuming that all the protein present is MOCHLIM, would correspond to apparent turnover, 
was 1.1 s
-1
. This value was comparable with the values measured for the MOCHLIM preparations 
obtained by gel filtration on Superose12 column under same conditions.  
Similar results were obtained for gel filtration of MOCHLIM on a Superose12 column. Such 
chromatography was also used to exchange the buffer prior to several experiments.  
MOCHLIM was also stable upon storage at -80°C after flash-freezing in liquid nitrogen or if kept on ice 
up to 48 h (see Chapter 5).  
Table 4.4. Large-scale purification of MOCHLIM.  Quantitation of MOCHLIM prepared from 34 g of E.coli 
BL21(DE3, p18) cells as described in the text. A: Recovery after Ni-NTA Sepharose, concentration and dialysis as 
described in the legend of Figure 4.15. B: Half of the MOCHLIM preparation obtained by Ni-NTA chromatography 
was concentrated and gel filtered onto Superdex200 column as described in the legend of Figure 4.16. The NADPH 
oxidase activity was measured in 20 mM Hepes/KOH buffer, pH 7, in the presence of 100 μM NADPH at 25°C. 
a
Protein concentration was determined with the Bradford method. 
b
Protein concentration was determined from the 
absorbance at 458 nm, by using the extinction coefficient of 8.1 mM
-1
cm
-1
 of MO (Zucchini et al., 2001) and the 
calculated mass of 86.4 of MOCHLIM.  
A 
  Bradford
a
 Absorbance
b
 
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM 
Crude extract 200 20 4100 100  - - - 
Ni-NTA Sepharose 42 1.09 45.78 1.12 0.8 33.6 100 12.6 
Concentration 12 3.5 42 1.02 2.62 31.44 93 30 
Dialysis 12 3 37 0.91 2.48 29.76 88 29 
B 
  Bradford
a
 Absorbance
b
 Activity  
Sample ml mg/ml mg yield, % mg/ml mg yield, % µM A278/A458 U U/mg
a 
Ni-NTA Sepharose 6 3 18 100 2.57 15.57 100 31.25 19 - - 
Concentration 3.3    4.26 14 91 49    
Superdex200 8.7 1.5 13.05 43 1.2 10.4 64 13. 9 16.5 - - 
Concentration 2.2 5 11 37 4.33 9.5 59 50.1 15.9 8.8 0.77 
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Figure 4.15. Large-scale purification of MOCHLIM – Ni-NTA affinity chromatography. A crude extract from ≈30g 
of E.coli BL21(DE3, p18) cells that had produced MOCHLIM (Figure 4.8) was homogenized and used to purify 
MOCHLIM on a Ni-NTA Sepharose column as described in the legend of Figure 4.9.  Panel A: elution profile 
obtained by measuring the absorption spectrum of fractions during the initial rinsing of the column with buffer A + 
20 mM imidazole. Panel B: elution profile obtained during the imidazole gradient and on-line detection of A280 of 
the eluate. Panel C: detail of the elution profile shown in panel B obtained by measuring the absorption spectra of 
the individual fractions. The absorption spectra of the concentrated fractions 32-54 after dialysis against buffer B + 
1 mM PMSF (2.6 mg/ml, 30 μM; panel D) and after 5-fold dilution in dialysis buffer (0.52 mg/ml, 6 μM; panel E) 
are shown. Half of the MOCHLIM preparation was further concentrated (4.45 mg/ml, 51 μM; panel F). Panel G: 
SDS-PAGE analysis of: crude extract (CE); pellet obtained after centrifugation (P); unbound proteins eluted during 
rinsing of the column with buffer A + 20 mM imidazole (fraction 28 in panel A, FT); fractions numbered as in panel 
C; the pooled fractions 32-54 (P) after concentration (C) and after dialysis (D); the final sample was further 
concentrated ([D]) prior to storage at -80°C. Bands corresponding to full-length MOCHLIM (○, 87 kDa), and its 
presumed degradation products (●, 66 kDa; □, 62 kDa; ■, 22 kDa; Δ, 21.5 kDa) are indicated. 
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Figure 4.16. Large-scale purification of MOCHLIM – Gel filtration. To remove the contaminating proteins present 
in the MOCHLIM preparation obtained by Ni-NTA Sepharose affinity chromatography (Figure 4.15), half of the 
final sample was concentrated for its further purification on a Superdex200 column (150 ml) equilibrated and 
developed in buffer B + 1 mM PMSF in the cold room. The absorption spectrum of MOCHLIM solution from Ni-
NTA Sepharose after concentration (4.26 mg/ml, 49 μM) is shown in panel A. The elution profile obtained by 
recording the absorption spectra of the individual fractions is shown in panel B. Panel C shows the SDS-PAGE 
analysis of: MOCHLIM from Ni-NTA Sepharose after concentration loaded onto Superdex200 column (L); 
fractions numbered as in panel B; the pooled fractions 43-48 (shaded area in panel B) before (P) and after 
concentration (C); the other symbols are as in the legend of Figure 4.15. Panels D and E: the absorption spectra of 
the pooled fractions (1.2 mg/ml, 14 µM) and after concentration (4.3 mg/ml, 51 µM) are shown. An aliquot of the 
final MOCHLIM preparation was diluted 7-fold (0.62 mg/ml, 7 µM) in equilibration buffer to determine the UV/Vis 
ratio (panel F).     
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4.8. Large-scale purification of full-length MICAL 
The crude extract (Table 4.5) obtained by homogenization of 30 g of E.coli BL21(DE, p18) cells in buffer 
A + 5 mM imidazole, 1 mM PMSF, 1 mM 2-ME, 1% protease inhibitors cocktail  was loaded onto Ni-
NTA Sepharose column (15 ml) equilibrated in buffer A + 5 mM imidazole. The removal of the weakly 
bound proteins to the resin was carried out as described for the purification of the MOCH form. The 
bound proteins were eluted by applying a 20-200 mM imidazole linear gradient in buffer A in 10 column 
volumes (Figure 4.17, panel A). As done for MOCH, the concentration of imidazole was held constant at 
≈56 mM imidazole for 4 column volumes to resolve MICAL from some contaminants (Figure 4.17, panel 
A). MICAL started to elute at ≈80 mM imidazole. To try to separate it from the other E.coli proteins also 
bound to the resin, imidazole concentration was held constant to ≈115 mM for one column volume. After 
this step the gradient was resumed (Figure 4.17, panel A). To the pooled fractions (fractions 29-46, Table 
4.5) 0.5% (v/v) protease inhibitor cocktail was added as done for MOCHLIM to prevent proteolysis. The 
sample was concentrated by ultrafiltration (Figure 4.17, panel D; Table 4.5) and dialyzed against buffer B 
+ 1 mM PMSF.  
At this stage, the absorption spectrum of the MICAL preparation showed maxima at 278, 375 and 458 
nm, but the spectrum was less resolved in the 300-400 nm region compared to that of the other MICAL 
forms at the same purification step. Indeed, the calculated value of the UV/Vis ratio was 27 (Figure 4.17, 
panel E) to be compared with the theoretical value of 18, indicating that other proteins in addition to 
MICAL were present. The SDS-PAGE analysis confirmed the presence of contaminants. Among them, 
were protein species of ≈68 and 62 kDa (Figure 4.17, panel C). The first was present also in MO and 
MOCH preparation after Ni-NTA Sepharose, suggesting that it is an E.coli protein. The 62 kDa species 
may correspond to the MOCH form derived from proteolysis as found for MOCHLIM. However, no sign 
of proteolytic degradation was observed during concentration and dialysis indicating that the addition of 
the protease inhibitor cocktail to the enzyme before concentration and after dialysis was sufficient to 
prevent a possible degradation resulting in a stable MICAL preparation. MICAL form showed more 
contaminants compared to the other forms after Ni-NTA Sepharose chromatography. Thus one or more 
purification steps were required to obtain a homogeneous protein preparation.    
MICAL was further purified by anion exchange chromatography. In order to identify suitable conditions, 
several small-scale purifications on MonoQ column were carried out. The most satisfying protocol we 
designed is here described.  
The dialyzed MICAL from Ni-NTA Sepharose chromatography was loaded onto a Q-Sepharose column 
(10 ml) equilibrated with buffer B + 1 mM PMSF. The column was washed with equilibration buffer (4 
column volumes) and then connected to an FPLC apparatus for the elution of the bound proteins by 
applying a linear 100-500 mM NaCl in 60 column volumes. The interaction between MICAL and the 
resin was weak and the protein started to elute during the initial washing of the column with the 
equilibration buffer. Complete MICAL elution was obtained at the early stages of the applied NaCl 
gradient (Figure 4.18, panel A). Fractions enriched in MICAL, which had a A278/A458 value <21, were 
pooled (fractions 11-33, Figure 4.18, panel B; Table 4.5) and 0.5% of protease inhibitor cocktail was 
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added. The sample was concentrated (Figure 4.18, panel D; Table 4.5) and dialyzed against buffer B + 1 
mM PMSF (Figure 4.18, panel D; Table 4.5).  
The spectrum of the final enzyme preparation was well resolved in the 300-350 nm region suggesting that 
the protein was stable, with maxima at 278, 375 and 458 nm (Figure 4.18, panels D, E). The A278/A458 
ratio was 19 (Figure 4.18, panel E), a value similar to the theoretical one of 18 and much lower than that 
of 27 of the enzyme prior to anion exchange chromatography. SDS-PAGE confirmed that MICAL 
preparation was almost pure containing only traces of the of ≈68 kDa protein species (Figure 4.18, panel 
C). However, the yield of the procedure was low so that only 25% of MICAL was recovered in this step 
(Table 4.5). Such a low yield was in part due to the fact that we had to discard almost half of the fractions 
containing MICAL in order to remove the ≈68 kDa contaminant.  
The final MICAL preparation was stored at -80°C after flash-freezing in liquid nitrogen. 
 
 
Table 4.5. Large-scale purification of full-length MICAL. Quantitation of MICAL prepared from 30 g of E.coli 
BL21(DE3, p18) cells by Ni-NTA Sepharose and anion exchange chromatography onto Q-Sepharose resin as 
described in the legend of Figure 4.17.and 4.18, respectively. 
a
Protein concentration was determined with the 
Bradford method. 
b
Protein concentration was determined from the absorbance at 458 nm, by using the extinction 
coefficient of 8.1 mM
-1
cm
-1
 of MO (Zucchini et al., 2001) and the calculated mass of 119 of MICAL.  
 
  Bradford
a
 Absorbance
b
 
Sample ml mg/ml mg yield, % mg/ml mg yield, % A278/A458 µM 
Crude extract 160 19 3040 100 - - - -  
Ni-NTA Sepharose 35 1.18 41.3 1.36 0.78 27.3 100 - 6.55 
Concentration 7.5 4.48 33.6 1.11 3.24 24.3 89 - 27.2 
Dialysis 7.5 4.33 32.5 1.07 3.16 23.7 87 27 26.6 
Q-Sepharose 22 0.45 9.9 0.33 0.3 6.6 24 - 2.5 
Concentration 3.5 2.08 7.28 0.24 1.8 6.3 23 - 15.1 
Dialysis 3.5 2.03 7.11 0.23 1.7 5.95 22 19 14.3 
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Figure 4.17. Large-scale purification of MICAL – Ni-NTA affinity chromatography.  The crude extract of 30 g of 
E.coli BL21(DE3, p18) cells that had produced MICAL (Figure 4.8) form was loaded on Ni-NTA Sepharose 
column, the unbound and weakly bound proteins were removed with buffer A + 20 mM imidazole, 1 mM PMSF, 1 
mM 2-ME. Panel A: Elution profile of the bound proteins by applying a linear imidazole gradient in buffer A + 1 
mM PMSF (red line) with on-line detection at A280 (black line). Panel B: details of  panel A obtained by recording 
the absorption spectra of the individual fractions. Panel C: SDS-PAGE analysis of: pellet (P) obtained by 
centrifugation of the crude extract (CE); the weakly bound proteins were removed by flowing buffer A + 20 mM 
imidazole (W); fractions eluted during the development of imidazole gradient numbered as in panel B; the pooled 
fractions (29-49, shaded area in panels A and B) before (Pool) and after concentration (C) and dialysis (D); ○, full-
length MICAL (120 kDa); ●, protein species of ≈62 kDa; the quantity of protein loaded is calculated from the 
absorption spectrum. Panel D: the absorption spectra of MICAL after concentration (black thick line; 3.24 mg/ml, 
27 µM) and after dialysis against buffer B + 1mM PMSF (red thin line, 3.16 mg/ml, 26 µM) are shown. Panel E: 
absorption spectrum of an aliquot of the final MICAL preparation diluted 6-fold (0.53 mg/ml, 4.5 µM) in dialysis 
buffer + 1 mM PMSF is shown.  
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Figure 4.18. Large-scale purification of MICAL – Anion exchange chromatography. To remove the contaminating 
proteins from the MICAL preparation obtained by Ni-NTA affinity chromatography showed in Figure 4.17, the 
enzyme solution was further chromatographed onto a Q-Sepharose column (10 ml) equilibrated in buffer B + 1 mM 
PMSF and developed by applying NaCl gradient.   The protein solution was loaded onto the column and washed 
with the equilibration buffer in the cold room. The the column was connected to an FPLC apparatus to elute the 
proteins bound to resin with increasing NaCl in buffer B + 1 mM PMSF (panel A). The individual fractions were 
analyzed by recording the absorption spectrum (panel B). Panel C shows the SDS-PAGE analysis of: MICAL 
solution from Ni-NTA Sepharose loaded onto Q-Sepharose column (L); fractions numbered as in panel B; fractions 
11-30 were pooled (P, shaded area in panels A and B), concentrated (C) and dialyzed (D) against buffer B + 1 mM 
PMSF; the other symbols are as in the legend of Figure 4.17. The absorption spectra of MICAL preparation after 
concentration (black thick line; 1.8 mg/ml, 15 µM) and dialysis (red thin line, 1.7 mg/ml, 14 µM) are shown in panel 
D. An aliquot of the final preparation was diluted 3-fold (0.57 mg/ml, 4.76 µM) in dialysis buffer to determine the 
UV/Vis ratio (panel E).      
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5. Structural characterization of the purified MICAL forms.  
 
5.1. N-terminal sequence and mass of MICAL forms 
To verify the integrity of the MICAL forms we produced and purified (see Chapters 3 and 4), their N-
terminal sequence and mass were experimentally determined in the laboratory of Prof. Gabriella Tedeschi 
(Dipartimento di Scienze Veterinarie e Sanità Pubblica, Università degli Studi di Milano). 
The mass of MO observed in SDS-PAGE was similar to the calculated mass (Table 5.1). The N-terminal 
sequence of MO was that of MICAL (ASPTN) after post-traslational removal of Met1 and its mass 
determined by MALDI-TOF was similar to the theoretical one (Figure 5.1, panel A; Table 5.1). These 
results confirmed the integrity of the protein we prepared during this work .  
On the contrary, MOCH migrated as ≈62 kDa band on SDS-PAGE (Figure 4.1), leading to the hypothesis 
that degradation of the protein had occurred during its expression. However, the N-terminal sequence of 
the purified protein was that of MO and the mass obtained by MALDI-TOF was similar to the calculated 
one (Figure 5.1, panel A; Table 5.1) indicating that MOCH was expressed and purified in its full-length 
form. This result was also confirmed by the mass spectrometry analysis of peptides obtained after MOCH 
tryptic and chymotrypitic digestion (not shown). Thus, the isolated band of ≈62 kDa (Figure 4.11- 4.13) 
was intact MOCH, which showed an anomalous migration on SDS-PAGE.      
MOCHLIM was sensitive to proteolytic degradation (Figure 4.14) resulting in a truncated form of ≈62 
kDa on SDS-PAGE, which most likely corresponded to a form comprising the MO and CH regions. The 
analysis of purified MOCHLIM under conditions that blocked proteolysis showed that it was intact with 
only small traces of contaminants or degradation products (Figure 5.1, panel B). Indeed, the N-terminal 
sequence of MOCHLIM was ASPTN and its mass was consistent with the expected one (Figure 5.1, 
panel B; Table 5.1).  
 Also the full-length form of purified MICAL showed post-traslational modification with the removal of 
Met1 and a mass similar to the calculated one (Figure 5.1, panel C; Table 5.1) demonstrating its integrity. 
As observed for MOCHLIM, only small amounts of degradation products or E.coli contaminating 
proteins were present in the final enzyme preparation (Figure 5.1, panel C).  
All together these results demonstrated the integrity and purity of all the isolated MICAL forms.  
 
Table 5.1 Mass of MICAL forms. The theoretical mass of MICAL, MO, MOCH and MOCHLIM was calculated 
using the Compute pI/Mw tool at www.expasy.ch by taking into account the post-translational removal of the 
starting Met residue and is expressed in Da. The calculated values are compared with those obtained by SDS-PAGE 
and MALDI-TOF. 
Protein calculated SDS-PAGE  MALDI-TOF 
MO 55005 54500 ± 700 54915 
MOCH 68338 61700  ± 1500 68222 
MOCHLIM 86348 87900 ± 1300 87615 
MICAL 118920 121050 ± 600 119084 
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Figure 5.1. MALDI-TOF analysis of  MICAL forms. Aliquots of MICAL forms (10-20 mg/ml in 50 mM Na-
phosphate buffer, pH 7.5, 100 mM NaCl) were analyzed by MALDI-TOF. The mass spectrum of standard proteins, 
MO and MOCH is shown in panel A. In panels B and C the peaks at 87615 and at 119084 correspond to 
MOCHLIM and MICAL respectively; other peaks may be degradation products and/or E.coli contaminating 
proteins observed in trace in the SDS-PAGE of the sample (insets). The mass of MICAL forms determined by 
MALDI-TOF are also indicated in Table 5.1.   
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5.2. Determination of the FAD content and of the extinction coefficient in the visible region of MICAL 
forms.  
MICAL1 catalyzes a NADPH oxidation reaction thanks to its N-terminal monooxygenase-like domain. 
An important aspect was the determination of the stoichiometry of FAD bound to the purified MICAL 
forms. 
All MICAL forms were freshly transferred into 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl by 
gel filtration on a Superose12 column (for MO and MOCHLIM, as described in Chapter 4) or by anion 
exchange chromatography (for MOCH and MICAL, Chapter 4). The protein solutions were concentrated 
to a final concentration of ≈20 µM. The absorption spectrum was recorded (red line in Figure 5.2) and the 
protein concentration was determined with the Bradford method (Bradford). 
The sample was diluted 2-fold with a 10% trichloroacetic acid (TCA) solution and incubated 15 min at 
room temperature. The treatment caused immediate denaturation and release of FAD. The released FAD 
was recovered in the supernatant after centrifugation at 14900xg for 30 min at 4°C. From the absorption 
spectrum of the supernatant (black line in Figure 5.2) the FAD concentration, the stoichiometry and the 
extinction coefficient at 458 nm of MICAL forms were calculated (see Materials and Methods, Chapter 
10).  
For all MICAL forms greater than 0.8 mol of FAD per mol of protein was found (Table 5.2) with the 
protein concentration determined with the Bradford method. The calculated extinction coefficient at 458 
nm of bound FAD was similar for all MICAL forms (Table 5.2) and similar to the value determined for 
the isolated MO domain (8.1 mM
-1
cm
-1
 Zucchini et al., 2011).  
Protein denaturation with buffer containing guanidine is an alternative to TCA treatment as a method to 
determine the stoichiometry and the extinction coefficient of bound FAD. This method also allows 
determine the value of A280/A448 ratio of the denatured protein, which is a measure of the percentage of 
the holoprotein present, independently from the protein concentration determined with the Bradford 
method.   
As done for protein precipitation with TCA, MICAL, MOCH and MOCHLIM were gel filtered in 50 mM 
Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA and concentrated to ≈20 µM. 
The absorption spectra of the proteins were recorded before (red line in Figure 5.3) and after 2-fold 
dilution with 20 mM Tris/HCl buffer, pH 8, 500 mM NaCl, 6 M guanidine (black line in Figure 5.3).  
The absorption spectra of MOCH and MOCHLIM were stable up to ≈15 min after the addition of 
guanidine, while for MICAL formation of turbidity was observed after ≈10 min maybe due to an 
incomplete denaturation of the protein and formation of aggregates.  
For the calculation of the FAD content, the extinction coefficient and the value of A280/A448 ratio the 
average of the absorbance values recorded during the first 15 min was used for MOCH and MOCHLIM. 
For MICAL the absorbance values obtained immediately after the dilution in buffer containing guanidine 
were used.  
The amount of bound FAD (≈0.8 mol per mol of protein and the extinction coefficient at 458 nm, Table 
5.2) were similar to those determined by TCA denaturation. The values of the A280/A448 ratio were also 
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similar to the theoretical ones (Table 5.2) indicating that at least 90% of the MICAL proteins were present 
in the holoenzyme form. The lower percent of holoenzyme calculated with the protein concentration 
determined with the Bradford method may be due to a systematic overestimation of protein content with 
the method. 
 
 
Table 5.2. Flavin content of MICAL forms. The FAD content was determined on the supernatant obtained by TCA 
precipitation of the proteins and their removal by centrifugation or by denaturation in guanidine. The protein 
concentration was calculated with the Bradford method with bovine serum albumin as the standard protein using the 
theoretical protein mass (Table 5.1). Quantitation of FAD content was carried out on two different protein 
preparations for MOCHLIM and MICAL. For MO and MOCH the determination was done with 2-3 experiments 
using proteins from the same preparation. The theoretical A280/A448 was calculated as described in Materials and 
Methods (Chapter 10).   
  
 Denaturation method 
 5%TCA 3 M Guanidine 
Protein  FAD/protein  ɛ458
 FAD/protein  ɛ458  A280/A448  
A280/A448  
 mol/mol mM
-1
cm
-1
 mol/mol mM
-1
cm
-1
 experimental calculated 
MO 0.8 ± 0.03(2) 7.9 ± 0.054 (2)     
MOCH 0.84 ± 0.02(3) 7.92 ± 0.22 (3) 0.8 8.02 10.99 9.46 
MOCHLIM 0.81±0.017(2) 8.14 ± 0.07 (2) 0.79 ± 0.02(2) 8.42 ± 0.007 (2) 10.52 ± 0.17 (2) 10.38 
MICAL 0.83±0.005(2) 7.56 ± 0.56 (2) 0.76 8.48 13.56 12.49 
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Figure 5.2. Absorption spectra of MICAL forms before and after denaturation with 5% TCA. The spectra of MICAL 
forms were recorded before (red line) and after addition of an equal volume of 10% (w/v) TCA and centrifugation 
(black line). The spectra of the native enzymes are corrected to take into account the 2-fold dilution. Initial protein 
concentration was: MO, 26 μM; MOCH, 24 μM; MOCHLIM, 22 μM; MICAL, 22 μM. The amounts of FAD 
present and the extinction coefficients at 458 nm of MICAL forms are in Table 5.2.   
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Figure 5.3. Absorption spectra of MICAL forms before and after denaturation with 3 M guanidine. Left panels: The 
absorption spectra of MICAL forms were recorded before (red line, left panels, the spectra are corrected for 2-fold 
dilution) and after 2-fold dilution with buffer 20 mM Tris/HCl, pH 8, 500 mM NaCl, 6 M guanidine (black line). 
The initial protein concentration was: MOCH, 32 μM; MOCHLIM, 22 μM; MICAL, 14 μM. The FAD 
stoichiometry, protein extinction coefficients at 458 nm and the A280/A458 values of MICAL forms are indicated in 
Table 5.2.  
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5.3. Determination of the Zn
++
 content associated to LIM domain 
The LIM domain, as described in Chapter 2, is characterized by the presence of a consensus sequence 
(CX2CX16-23HX2CX2CX16-23CX2C), in which the Cys and His residues are responsible for the 
coordination of two zinc ions (Kadrmas et al., 2004). The three dimensional structure of the isolated LIM 
domain of human MICAL1 (Figure 2.5) demonstrated the presence of the expected 2 Zn
++
 ions (PDB ID 
2CO8) 
Since the presence of zinc ions in the LIM domain is essential for its secondary and ternary structures 
determining its stability and functionality, it was important to verify the stoichiometry of zinc bound to 
the purified MOCHLIM and MICAL forms. 
The zinc content of MICAL forms was determined using the colorimetric method developed by Bennie et 
al., (1985) to quantify the zinc content of serum samples. The method was modified by us to lower the 
quantity of sample required for the analysis, as described in Materials and Methods (Chapter 10). Several 
control experiments were also done to ensure that buffer composition did not interfere with the method 
and to identify the optimal concentration range of zinc ions (Chapter 10). 
Aliquots (0.025-0.2 ml, 0.2-3 µM) of the supernatants obtained by TCA denaturation of MICAL forms 
(see above) were added to 0.75 ml of 1 M Hepes/NaOH buffer, pH 8, 125 µM BrPAPS and the absorption 
spectrum was recorded for ≈10 min until no more changes in the spectrum were observed. The amount of 
zinc present was calculated using the extinction coefficient of 130 mM
-1
cm
-1
 at 550 nm for the Zn
++
-
BrPAPS complex. MO and MOCH forms were used as control samples to detect non-specifically 
associated zinc ions. For MOCHLIM and MICAL ≈1.5 mol of Zn++ per mol of protein was determined, 
when the protein concentration was calculated with the Bradford method (Table 5.3), which most likely 
systematically overestimates the protein content by 15-20%. In fact, by taking into account the FAD 
bound to the protein 1.9 mol of Zn
++
 per mol of FAD was calculated (Table 5.3).  
 
Table 5.3.  Zinc content of MICAL forms. The zinc content was determined on the supernatant obtained by TCA 
precipitation of the proteins and their removal by centrifugation (see Table 5.2). The protein concentration was 
calculated with the Bradford method with bovine serum albumin as the standard protein using the theoretical protein 
mass (Table 5.1). FAD quantitation is taken from the data in Table 5.2. 
 
Protein  Zn
++
/protein FAD/protein  Zn
++
/FAD  
 mol/mol mol/mol mol/mol 
MO  0.07 0.8 0.08 
MOCH  0.04 0.84 0.05 
MOCHLIM  1.5 ± 0.1 0.81 1.8 ± 0.1 
MICAL  1.6 ± 0.1 0.83 1.9 ± 0.1 
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5.4. Determination of the mass and oligomeric state of MICAL forms. 
The isolated MO domains of mouse MICAL1 and human MICAL are monomeric in solution (Nadella et 
al., 2005; Zucchini et al., 2011). To verify if the presence of the additional domains, which mediate 
protein-protein interactions, alters the quaternary structure of the proteins, we determine the mass of 
MICAL forms by gel filtration and by dynamic light scattering (DLS).  
Aliquots of (500 µl) of MOCH (3 mg/ml), MOCHLIM (2.8 mg/ml) and MICAL (2.25 mg/ml) solutions 
were gel filtered on a Superose12 column that had been calibrated with proteins of known mass (see 
Materials and Methods, Chapter 10). Under these conditions MOCH appeared to be monomeric in 
solution, while MOCHLIM and MICAL may form dimers (Figure 5.4; Table 5.4). 
 
Table 5.4. Mass determination of MICAL forms by gel filtration. Protein samples (2-3 mg/ml, 0.5 ml) were gel 
filtered on a calibrated Superose12 column in buffer B. The monomer mass was calculated as in Table 5.1. 
 
 
MICAL forms were also analyzed by DLS, which also yields information on the degree of polydispersion 
of the protein samples. MOCH form was confirmed to be monomeric as found by gel filtration, while 
MOCHLIM and MICAL appeared to oligomerize (Figure 5.5; Table 5.5). Aliquots of MOCHLIM and 
MICAL at varying concentrations obtained after centrifugation at 10000xg for 1 h at 4°C were analyzed 
in greater detail. For MOCHLIM formation of dimers, trimers and tetramers and higher order aggregates 
depending on protein concentration (Table 5.5). While for protein solutions <2 mg/ml the calculated 
values of the radius corresponded to an apparent trimer or dimer (Table 5.5). MICAL was found to be as a 
dimer for all the protein concentration tested (Table 5.5).   
Thus, either the LIM domain and the C-terminal region of MOCHLIM and of MICAL stabilize a dimer or 
these protein forms are monomeric but elongated. So that the globular species of 190 kDa would be 5.6 
nm and dimerization would lead to an increase of only 1.9 nm, which corresponds to a extended stretch of 
≈10 residues.  
Protein Elution volume,  Mass  Mass  Oligomeric state 
 ml observed calculated  
MOCH 12.75 78427 68338 1.15 
MOCHLIM 11.6 207107 86428 2.39 
MICAL 11.4  236775 118920 1.99 
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Table 5.5. Mass determination of MICAL forms by dynamic light scattering (DLS). Protein samples were analysed 
by DLS at 15°C. Instrument conditions: acquisition time, 15 s; sensitivity, 80-100%, solvent, glycerol 10%; pH, 7.5; 
concentrations are indicated in the table.R, 
a
 value of the sample radius;Rc,
 b
 the value of water shell radius  (0.2 nm) 
is subtracted to the value of sample radius (R);
 c
percentage of polydispersion;
  d
mass of the sample calculated using 
the Rc value; 
 e
mass calculated as in Table 5.1;
 f
 sample obtained after ultracentrifugation at 100000xg for 1 h at 4°C 
in rotor TLA100.3 a Beckmann TL100 centrifuge. Buffer B: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% 
glycerol, 1 mM EDTA, 1 mM DTT.    
Protein mg/ml μM R,  Rc,  Pd,  Mass mass Apparent 
   nm
a 
nm
b 
%
c 
experimental
d 
calculated
e
  Oligomeric state 
MOCH 0.5 7.3 4.1 3.9 6 81000 68330 1.18 
MOCHLIM
 
0.6 7.0 5.6 5.4 10 174000 86428 2.02 
MOCHLIM
f
 0.24 2.8 5.9 5.7 12 198000  2.3 
 0.65 7.5 7.2 7 34 320000  3.7 
 1 11.6 6.8 6.6 15 278000  3.2 
 2.1 24.3 9.7 9.5 46 653000  7.6 
 4 46.3 10.2 10 45 736000  8.5 
MICAL
 
0.5 4.2 6.1 5.9 13 214000 118920 1.8 
 2 16.8 6.7 6.5 20 269000  2.26 
 5 42.0 8.1 7.9 36 424000  3.56 
MICAL
f
 0.22 1.8 6.2 6 27 223000  1.87 
 0.6 5.0 6.3 6.1 28 232000  1.95 
 1.2 10.0 6.2 6 14 223000  1.87 
 2 16.8 6.1 5.9 30 214000  1.8 
 4 33.6 6.3 6.1 14 232000  1.95 
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Figure 5.4. Mass determination of MICAL forms by gel filtration. Aliquots (400 μl) of MOCH (3 mg/ml), 
MOCHLIM (2.8 mg/ml) and MICAL (2.25 mg/ml) were gel filtered in buffer B on a calibrated Superose12 column. 
Panel A:  Calibration curve obtained by gel filtration of standard proteins (○) from which thyroglobulin (667 kDa) is 
excluded and elution position of MICAL forms (♦). The calculated mass of MICAL forms is indicated in Table 5.4. 
Panel B: Elution profiles obtained by gel filtration of MICAL solutions.  The additional peaks correspond to small 
amounts of contaminating proteins (see Chapter 4). The elution volume of the standard proteins is indicated. 
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Figure 5.5. Determination of the apparent mass of MICAL forms by dynamic light scattering. Aliquots of MOCH 
(0.5 mg/ml, 7.3 μM), MOCHLIM (0.6 mg/ml, 6.95 μM) and MICAL (0.5 mg/ml, 4.2 μM) at the end of the 
purification were analyzed by DLS by recording signals for up to 30 min (left panels). The calculated radius (right 
panels) was corrected for the contribution of the water shell (0.2 nm) to determine the apparent mass of the proteins 
(Table 5.4). DLS conditions: acquisition time, 15 s; temperature, 15°C; sensitivity, 90%; solvent, 10% glycerol; pH, 
7.5; concentration, 0.5 mg/ml.    
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5.5. Stability of human MICAL1 forms 
A fundamental step prior to mechanistic and structural studies on a protein is the definition of the stability 
of the preparations upon storage and during the experiments. In particular for MOCHLIM and MICAL, 
which showed sensitivity to proteolysis, it was also important to establish the absence of proteolytic 
degradation. The absorption spectra, the NADPH oxidase activity and the electrophoretic pattern of 
samples were taken as a measure of  the quality and stability of the protein preparations.  
The absorption spectrum of protein-bound FAD is very sensitive to changes of protein environment.  
Shift of the absorbance maxima or changes at wavelength greater than 500 nm may reflect conformational 
changes, but also protein denaturation and formation of aggregates.   
MO, MOCH and MOCHLIM solutions that had been stored at -80°C showed absorption spectra (black 
line in Figure 5.6, panels A-C) similar to those recorded at the end of the purification (grey line in Figure 
5.6, panels A-C). No changes were observed for MOCH and MOCHLIM also after storage on ice at 4°C 
for 15 h (Figure 5.6, panels E-F). For MICAL, small changes were observed in its spectrum, in which the 
absorbance maximum shifted from 458 nm (grey line in Figure 5.6, panel D) to 456 nm (black line in 
Figure 5.6, panel D) with an increase of absorbance at 325 nm suggesting a tendency of the protein to 
aggregate. Such aggregates could be removed by centrifugation at 100000xg for 1 h at 4°C (not shown).  
Aliquots of the enzymes were also used for SDS-PAGE analysis, after thawing, during the experiments 
and up to 20 h incubation on ice at 4°C. In all cases, the different samples of MICAL forms showed a 
similar electrophoretic pattern (Figure 5.7) indicating their stability. 
The stability of the proteins, under various conditions, was also determined by monitoring the NADPH 
oxidase activity. As shown in Figure 5.8 there was no activity loss when the proteins were thawed after 
storage at -80°C. Furthermore, all MICAL forms were stable for up to 23 h in buffer B (for MO and 
MOCH) or in buffer B supplemented with 0.5% protease inhibitors cocktail (for MOCHLIM and 
MICAL) when kept on ice at concentrations greater than 1 mg/ml.  
The stability of MICAL forms was measured as a function of pH, also in the light of the planned studies 
of the pH dependence of their NADPH oxidase activity. Aliquots of MO and MOCH were diluted 10-fold 
to a final concentration of ≈0.2 mg/ml in mixed buffer A and MOCHLIM was diluted in mixed buffer B, 
at varying pH. The enzymes solutions were incubated at 25°C and their NADPH oxidase activity was 
measured at different incubation times under standard conditions. For MO and MOCH, the activity of the 
protein solutions at varying pH was similar to that measured for the stock enzyme (Figure 5.9). Only a 
small decrease of the activity (15%) was observed for MO when diluted in buffers at pH greater than 7.5 
(Figure 5.9), indicating that the enzyme is more stable in an acidic medium. On the contrary, MOCHLIM 
solutions showed a progressive loss of activity upon dilution in all buffer tested (Figure 5.9), suggesting 
that at this concentration MOCHLIM is not stable.  
Thus, the pH did not alter the stability of MO, MOCH and MOCHLIM. 
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Figure 5.6. Comparison of the absorption spectra of MICAL forms at the end of the purification and after storage. 
Panels A-D: grey, the absorption spectra recorded at the end of the purification; black, spectra recorded after 
thawing of the protein samples that had been stored at -80°C after flash-freezing in liquid nitrogen. Proteins were 
conserved in buffer B (for MO and MOCH) or buffer B supplemeted with 0.5% of protease inhibitors cocktail (for 
MOCHLIM and MICAL) and their concentration was: MO, 3.2 mg/ml, 58 μM; MOCH, 6.8 mg/ml, 99 μM; 
MOCHLIM, 4.6 mg/ml, 53 μM; MICAL, 1.7 mg/ml, 14 μM. Panels E-F: grey, absorption spectra of MOCH (2.4 
mg/ml, 35 μM) in 20 mM Hepes/KOH buffer, pH 7, 100 mM NaCl and of MOCHLIM (4.5 mg/ml, 52 μM) in buffer 
B at the end of the gel filtration; black, spectra recorded after storage on ice at 4°C for 15 h.   
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Figure 5.7. Check of the stability of MICAL forms by SDS-PAGE. The electrophoretic pattern of the protein 
preparations at the end of their purification (+) is compared to that of the proteins that had been stored at -80°C 
immediately after thawing (0 h) and at different subsequent times during which the proteins were kept on ice at 4°C. 
MO, 10 and 5 μg; MOCH, 10 and 15 μg; MOCHLIM, 15 μg; MICAL, 10 and 15 μg.    
 
 
 
Figure 5.8. Stability of MICAL forms. Aliquots of purified MO (1 mg/ml), MOCH (3 mg/ml), MOCHLIM (○, 1 
mg/ml; □, 5 mg/ml); MICAL (○, 5 mg/ml; □, 10 mg/ml) were thawed and kept on ice. Their NADPH oxidase 
activity was measured in 20 mM Hepes/KOH buffer, pH 7 in the presence of 100 μM NADPH at 25°C and 
indicated times. The residual activity is expressed as percentage with the respect of that of the sample at the end of 
the purification.   
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Figure 5.9. pH dependence of the stability of MO, MOCH and MOCHLIM. Aliquots of MO, MOCH and 
MOCHLIM were diluted 10-fold in mixed buffer A (MO and MOCH) or mixed buffer B (MOCHLIM) at varying 
pH or in 20 mM Hepes/KOH buffer pH 7 (H) to a final concentration of ≈0.2 mg/ml and incubated at 25°C. The 
NADPH oxidase activity was determined under standard conditions on aliquots withdrawn at different times: 
immediately after the dilution (white), after 10 min (light grey), 20 min (dark grey) and 30 min (black lines). The 
activity is expressed as percentage of that of the starting stock solution.   
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Aliquots of MOCH (2.35 mg/ml, 34 μM) in 20 mM Hepes/KOH buffer, pH 7 were diluted 2-fold in 
buffer at varying pH. At subsequent times and after incubation for 16-36 h of samples on ice at 4°C their 
absorption spectra were recorded and their activity was measured. The activity was similar to that 
measured for the protein stock solution (Figure 5.10, panel A) and their spectra were similar for all the 
samples (Figure 5.10, panel B). Only small changes were observed at pH > 8 that could be associated 
with partial denaturation of the enzyme.  
No evidence of a pH dependence of the intensity of the charge-transfer (CT) complex between FAD and 
Trp400 was obtained. Such pH dependence of CT complex was observed, for example for NikD 
flavoprotein (Venci et al., 2002). The long-wavelength absorption band of NikD is due to the formation of 
a CT complex between FAD and Cys42. Such band disappears as the pH decreased and it is coupled to an 
increase of absorbance at 455 nm (Figure 5.10, panel C). Analysis of nikD absorbance changes at 550 nm 
(or other wavelengths) as a function of pH yields a pKa value of 7.3 (Figure 5.10, panel C) suggesting 
that the CT interaction can occur only when an ionisable group in the donor is unprotonated (Venci et al., 
2005). 
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Figure 5.10. Stability of MOCH in mixed buffer at varying pH. The stability of  MOCH (1 mg/m, 17 μM) in 10 mM 
Hepes/KOH, 125 mM formic acid, 50 mM imidazole, 50 mM Tris, 50 mM NaCl buffer at varying pH was 
determined by measuring the NADPH oxidase activity and by recording the absorption spectra at different times. 
Panel A: The NADPH oxidase activity of MOCH solutions kept at 4°C were measured at different times (white, 15 
min; light grey, 15 h; dark grey, 30 h) is expressed as percentage of that of the protein stock solution in 20 mM 
Hepes/KOH buffer, pH 7, 100 mM NaCl (H). Panel B: The absorption spectra of MOCHLIM solutions after 2-fold 
dilution in 250 mM formic acid, 100 mM imidazole, 100 mM Tris varying pH recorded at 17°C. Panel C: Spectra 
were recorded at pH 8.55, 7.41 and 6.48 in 100 mM K-phosphate buffer at 25°C. The arrows indicate the direction 
of absorbance changes as the pH lowers. The insert shows the fit of the observed absorbance change at 550 nm to  
pH titration curve yielding a pKa value of 7.3 (Venci et al., 2002).  
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6. The NADPH oxidase activity of human MICAL1 and MO, MOCH, MOCHLIM forms 
 
6.1. Introduction 
Organisms have integrated flavin species in the form of flavin coenzymes during the long history of 
evolution (Miura, 2003). Flavin coenzymes are remarkably efficient in the sense that a single molecular 
entity, the isoalloxazine system, which is the reactive portion of the flavin can cope with a wide range of 
reactions. The versatility of flavins makes flavoproteins able to partecipate in a variety of important cell 
processes (Figure 6.1). In addition to flavoenzyme-catalyzed redox reactions, where flavins accept and 
donate electrons from and to substrates, they can also accept and emit photons. Enzyme-bound flavins can 
use received photons in catalysis, as in DNA photolyase, which repairs damaged DNA in a light-
dependent fashion (Miura, 2003; Sancar 2008). Flavin functions as a light emitter in bacterial luciferase, 
which emits photons during oxygenation of alkyl aldehydes (Massey, 2000). Apart from chemical 
attractiveness, flavin has aesthetic benefits. It has a yellow colour when it is in the oxidized state. It can 
assume other colours as well: red, pink, green, purple, blue, etc., depending on the redox, ionic, or 
electronic state. In fact, ionic states of flavins or reaction intermediates are often named after their 
characteristic colors, such as red flavosemiquinone, blue flavosemiquinone, purple intermediate, green 
complex, etc (Miura 2003).  
The isoalloxazine ring is a tricyclic system formed by the fusion of the hydrophobic dimethylbenzene 
moiety with the hydrophilic pyrimidine ring and a pteridine moiety (Figure 6.2). It can exist in the 
oxidized state, in the 2-electron fully reduced state and in the one-electron reduced state in the neutral 
(blue semiquinone) or the anionic form (red semiquinone) (Figure 6.3). The oxidation or reduction of the 
flavin cofactor may occur by two one-electron transfer steps or by one two-electrons transfer step. The 
side chain of the flavin cofactor is not directly involved in redox processes, but plays important roles in 
stabilizing the protein-coenzyme complex, in modulating coenzyme reactivity and assisting catalysis. The 
flavin coenzyme is often tightly but non-covalently bound to the apo-protein, although several enzymes 
containing covalently bound flavin exist, with consequences on the isoalloxazine reactivity.   
The three most common types of flavin cofactors are: riboflavin (vitamin B2) and its derivatives flavin 
mononucleotide (FMN) and flavin adenine dinucleotide (FAD). Riboflavin is converted to FMN by 
riboflavin kinase that catalyzes the phosphorylation of the ester linkage at the terminal hydroxyl group of 
the ribityl side chain. FAD synthetase catalyzes the adenylation of FMN to generate FAD (Figure 6.2; 
Barile et al., 2013).  
Under anaerobic conditions the free flavin can be present in solution in both the oxidized and the reduced 
states; the equilibrium between these forms is rapidly set up with only 5% of radical stabilized in an 
equimolar mixture of oxidized and reduced flavin (Massey 2000). On binding to the apo-protein this 
equilibrium can change dramatically resulting in no stabilization of semiquinone or in its complete 
stabilization. The flavin coenzymes can also form charge-transfer complexes (CT), which are novel 
electronic states that do not belong to any of the three redox states mentioned before, but are those in 
which partial charge is transferred to/from an acceptor/donor molecule of the three flavin redox states 
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(Miura 2003). They are formed upon interaction between the highest occupied molecular orbital (HOMO) 
of an electron donor and the lowest unoccupied molecular orbital (LUMO) of an electron acceptor 
(Miura, 2003).  Free flavins have typical absorption spectra in the visible and near UV region (300-700 
nm) that change when bound to the protein. In particular, the protein environment influences the 
absorption spectrum that becomes the identity signature of the specific enzyme.  Moreover, since the 
absorption spectrum depends on the oxidation state of the flavin, absorption spectroscopy allows 
monitoring the events that take place during the catalytic cycle. Figure 6.3 shows the absorption spectra in 
the visible region of FAD bound to D-amino acid oxidase in different redox, ionic, and charge-transfer 
states (Miura, 2003).  
Flavoprotein reactions often involve two separate half-reactions. The most common reaction is the 
reduction of the enzyme-bound flavin by the substrates that are dehydrogenated in a two-electron 
reduction step. To complete the catalytic cycle the resulting reduced flavin is re-oxidized by its oxidizing 
substrate in two- or one-electron transfer steps. For many other flavoenzymes the substrate or one of the 
substrates is molecular oxygen (Scheme 6.1). In this reaction, the reduced flavin (I) donates one-electron 
to O2 (a) to yield a radical pair (II). This radical pair (II) can collapse (b) into a flavin C4a-peroxide (IV) 
that (c) becomes electrophilic hydroperoxide (V). The peroxide species can eliminate hydrogen peroxide 
(e) to yield oxidized flavin (VI). As an alternative (j), a second electron transfer from the radical pair (II) 
gives the same products (VI). The radical pair (II) can also dissociate (k) into flavin radical (III) and 
superoxide (Massey, 2000).   
Several classifications of flavoproteins have been made on the basis of the type of the catalyzed reaction, 
the nature of the reducing and oxidizing substrates, physico-chemical properties and their structural 
features. Conventionally, flavoproteins are classified depending on their reactivity with oxygen 
distinguishing flavoproteins oxidases, monooxygenases and dioxygenases, electron-transferases and 
dehydrogenases (Table 6.1). The oxidases, such as for example D-amino acid oxidase, glucose oxidase or 
glycolate oxidase, react very rapidly with molecular oxygen with the production of hydrogen peroxide 
without the formation of any detectable intermediate. The monooxygenases can react with oxygen leading 
to the formation of the C4a-hydroperoxide intermediate after the reduction of flavin by NAD(P)H that is 
their physiological reductant. After the hydroxylation of the substrate, the flavin goes back to the oxidized 
state by dehydration. The prototype of this class of flavoproteins is p-hydroxybenzoate hydroxylase 
(PHBH) that has been extensively studied (see below). The electron-transferases, like flavodoxin, 
ferredoxin-NADP
+ 
reductase, NADPH-cytochrome P450 reducatse, catalyze a single-electron transfer 
reaction and interact very slowly with oxygen producing superoxide and flavin semiquinone. In this 
classification some important flavoproteins do not find an appropriate placement like flavoproteins that 
contain auxiliary redox center, such as metal- and heme-containing flavoproteins and flavoprotein 
disulfide reductases.   
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Figure 6.1. Biological processes involving flavoproteins function (Joosten and Van Berkel 2007). 
Figure 6.2. Structure of riboflavin, FMN and FAD in the oxidized (left), semiquinoid (middle) and reduced (right) 
state (Voet, D. and Voet, J. (2012), Biochemistry, 4th edn, Wiley, New York). 
 
Figure 6.3. Absorption spectra of D-amino acid oxidase. Top panel: neutral oxidized (dotted line), anionic 
semiquinoid (dashed line), and neutral semiquinoid (solid line) states of flavin bound to D-amino acid oxidase. 
Bottom panel: charge-transfer states of neutral oxidized bound-flavin (solid line), anionic semiquinoid flavin (dotted 
line), and anionic reduced flavin (dashed line). (Miura, 2003).  
riboflavin
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Scheme 6.1. Possible pathways in the reaction of reduced flavin with O2. (Massey 2000).  
 
Table 6.1 Classification of flavoproteins.  
Class Reaction 
Oxidases Sred + O2 ↔ Sox + H2O2 
Monooxygenases S + NAD(P)H + O2 ↔ SOH + NAD(P)
+
 + H2O 
Electron-transferases Sred + Aox ↔ Sox + Ared 
Dehydrogenases Sred + NADP
+
 ↔ Sox + NADPH 
 
 
 
Scheme 6.2. Reaction scheme of FAD-dependent monooxygenases. The flavin reduced by NAD(P)H interacts with 
O2 leading to the formation of C4a-hydroperoxy-FAD with (1) the hydroxylation of the bound substrate (S) or (2) 
H2O2 production when absent (Vanoni et al., 2012).    
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Flavin-dependent monooxygenases, to which MICAL N-terminal domain is structurally related (Chapter 
2), catalyze the incorporation of one atom of molecular oxygen into the oxidable substrate, while the 
other oxygen atom is reduced to water (Scheme 6.2). Typically, oxygen activation involves the formation 
of a flavin C4a-oxygen adduct. They catalyze hydroxylation, Baeyer-Villiger oxidation, sulfoxidation, 
epoxidation and halogenation reactions with high selectivity and constitute the largest family of 
flavoenzymes (Huijbers et al., 2013). On the basis of their structural and functional properties a division 
into six groups has been proposed (Huijbers et al., 2013). Groups A and B comprise single-component 
enzymes that have NAD(P)H as the reducing substrate. Groups C, D and F contain monooxygenases that 
need a reductase partner protein to be reduced. Internal flavoprotein monooxygenase that reduce the 
flavin coenzyme through substrate oxidation are included in groups G and H (Table 6.2 and Figure 6.4).  
Monooxygenases of group A are encoded by a single gene, contain a typical Rossman-fold for FAD 
binding and use NAD(P)H as electron donor. PHBH is the prototype of this group of monooxygenases. 
PHBH catalyzes the hydroxylation of p-hydroxybenzoate (pOHB) to form 3,4-dihydroxybenzoate in three 
steps: (i) reduction of the enzyme cofactor (FAD) by NADPH in response to binding of pOHB to the 
enzyme, followed by (ii) oxidation of reduced FAD by oxygen to form a 4a-hydroperoxide intermediate, 
which (iii) oxygenates pOHB to form 3,4-dihydroxybenzoate (Entsch et al., 2005; Scheme 6.3). The 
process has evolved to be carefully controlled to prevent the wasteful production of hydrogen peroxide 
(k10 in scheme 6.3), which would be the product of the reaction in the absence of pOHB. In the early work 
with the enzyme, it was found that the rate of reductive half-reaction increased by a factor of 2x10
5
 after 
the binding of pOHB, without significant changes in the dissociation constant for NADPH. Both the rate 
of dissociation and of association of pOHB with the enzyme is 10
4
-fold lower when the flavin is reduced. 
Thus, substrate stays on the enzyme so that it can be attacked by the flavin-C4a-hydroperoxide as soon as 
it is formed. Moreover, with pOHB bound to the active site, the reduced enzyme reacts 10
5
-fold faster 
with oxygen than the reduced flavin does in aqueous solution. Another important aspect of the catalytic 
cycle of PHBH is the presence of conformational changes that take place during the different steps of the 
catalytic cycle and that also represent another control mechanism of the reaction. On the basis of PHBH 
structures and kinetic data, a model of the reaction has been proposed. In the absence of the substrate, the 
enzyme is mainly in the “open” conformation with an open channel to facilitate substrate binding; binding 
of pOHB leads to a flavin shift from the “open” to the “flavin in” conformation; deprotonation of the 
substrate causes the conversion from the “flavin in” to  the “flavin out” conformation in which the 
isoalloxazine ring of the flavin is exposed to the solvent and can be reduced by NADPH; the positive 
electrostatic field of the active site pulls the reduced flavin back to the “in” conformation, where it can 
react with oxygen in a protected environment and it hydroxylates the substrate through the formation of 
the C4a-hydroperoxide (Figure 6.5; Brender et al., 2005).  
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Table 6.2 . Classification of FAD-dependent monooxygenases. (Van Berkel et al., 2013).  
 
 
Figure 6.4. Protein folds of FAD-dependent monooxygenases. A, hydroxybenzoate hydroxylase PHBH; B, 
phenylacetone monooxygenase; C, bacterial luciferase; D, hydroxylphenylacetate hydroxylase; E, styrene 
monooxygenase; F, tryptophan-halogenase; G, tryptophan monooxygenase; H, nitronate monooxygenase. Folds are 
indicated in Table 6.2. (Van Berkel et al., 2013).   
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Scheme 6.3 Catalytic cycle of PHBH.  In the figure, the numbered isoalloxazine ring represents the oxidized enzyme 
without ligands bound. Note that k1 to k10 represent the rate constants for the chemical reactions and ligand 
interactions in the forward reaction of the catalytic cycle. (Entsch et al., 2005).  
 
 
 
Figure 6.5. Conformational cycle of PHBH.  During the reaction cycle, the isoalloxazine ring of the flavin moves 
between conformations in which the flavin is exposed to solvent (designated “out” and “open”) and ones in which it 
is sequestered from solvent (“in”) as substrate (p-hydroxybenzoate, pOHB) is converted into product (3,4-
dihydroxybenzoate, diOHB). (Brender et al., 2005).  
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The three-dimensional structure of the isolated flavoprotein domain of mouse MICAL1 was solved in 
2005 (Nadella et al., 2005; Siebold et al., 2005), revealing its structural similarity to enzymes of PHBH 
the family (Chapter 2). However, the N-terminal domain of mouse MICAL1 was reported to catalyze a 
NADPH oxidase activity with a kcat of 77 s
-1
 and a Km for NADPH of 222 μM (Nadella et al., 2005) that is 
very high for a monooxygenase in the absence of the substrate to be oxidized.  
The MO domain of human MICAL1 was produced in our laboratory in E.coli cells in quantities sufficient 
to carry out its characterization (Zucchini et al., 2011; Chapter 4).  
The isolated MO domain of human MICAL1 was found to catalyze a NADPH oxidase activity with an 
apparent Km for NADPH of 20 µM and a kcat of 4 s
-1
 in 20 mM Hepes/KOH buffer, pH 7 (Table 6.3; 
Zucchini et al., 2011). These values are one order of magnitude lower than those reported for the mouse 
MO (Nadella et al., 2005). The discrepancies could be explained in various ways. The activity of the 
mouse enzyme was measured in presence of 0.1 M NaCl, which causes an increase of the Km for NADPH 
with a mild effect on the kcat (2.6 s
-1
) of the human MO domain (Table 6.3). Another important aspect is 
the activity assay used to monitor the NADPH oxidase reaction. For the mouse enzyme a coupled assay 
with horseradish peroxidase and amplex red was used to monitor the NADPH-dependent H2O2 production 
(Nadella et al., 2005). Instead, for the human protein the NADPH oxidation was directly monitored 
spectrophotometrically at 340 nm. Control experiments carried out in our laboratory demonstrated that 
NADPH consumption is stimulated in the presence of amplex red and HRP and H2O2. With this 
information it appears that the NADPH oxidase activity of mouse and human MO should be similar to 
each other, if measured under similar conditions.  
With human MO, the NADPH oxidase reaction was also carried out in the oxygen electrode (Table 6.4) 
showing an average of 0.87 mole of O2 consumed per NADPH. The rate of the reaction decreased 2-fold 
in the presence of catalase without affecting the NADPH consumption (Zucchini et al., 2011). End-point 
spectrophotometric methods were used to quantify the H2O2 produced and 1 mole of H2O2 was detected 
per mol of NADPH being oxidized (Table 6.4, Figure 6.5, Zucchini et al., 2011). These results are 
consistent with those expected for an authentic NADPH oxidase reaction producing H2O2.  
 
Table 6.3. Steady-state kinetic parameters of the NADPH oxidase activity of the MO domain human MICAL. Assays 
were carried out in 20 mM Hepes/KOH buffer, pH 7, in the presence of the indicated NADPH concentration ranges 
at 25°C. Apparent kcat and KNADPH values and their associated errors were determined by fitting the data to the 
Michaelis-Menten equation. (Zucchini et al., 2011).  
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Table 6.4. Comparison of the rates of oxygen consumption and NADPH oxidation in the NADPH oxidase reaction 
of MO. Parallel assays were setup in cuvettes and in the oxygen electrode chamber. Small aliquots (up to 10 µl) of 
MO solutions were added to start the assays that were monitored spectrophotometrically or with the oxygen 
electrode (Zucchini et al., 2011). 
The NADPH oxidase activity of MO was found to be very sensitive to ionic strength and specific anions. 
Increasing concentrations of neutral salts in the standard 20 mM Hepes/KOH buffer, pH 7 and buffer salts 
led to a decrease of kcat/KNADPH mainly due to an increase of Km for NADPH (Zucchini et al., 2011; Figure 
6.7). The stronger effect was exerted by phosphate, followed by chloride and acetate anions and no 
specific effect was observed as a function of their counter ions (Na
+
, K
+
, Ca
++
, Mg
++
) (Figure 6.7). The 
sensitivity to ionic strength of the affinity for NADPH is also a property of PHBH to which MICAL-MO 
is structurally related. In PHBH the interaction between NADPH and enzyme is controlled by 
electrostatic interactions, thus specific ions may compete with the phosphate group of NADPH for 
positively charged residues on the enzyme (Ortiz et al., 2004). 
 
In addition to the ionic strength, also solvent viscosity has been observed to have an effect on the kinetic 
parameters of the NADPH oxidase activity of the isolated MO domain of human MICAL1 (Zucchini et 
al., 2011).  
Enzymatic catalysis is a dynamic process where internal and external motions of protein and solvent 
molecules contribute to the sequence of catalytic steps. Critical protein dynamics must take place in the 
active site of the enzyme (Sitnitsky 2008). Therefore, solvent viscosity may have significant effects on the 
enzyme dynamics and activity by influencing the rate at which the substrate associates to the enzyme and 
the product is released and also on the rate at which conformational changes along the reaction path take 
place. (Sampson et al., 1992; Simpoulos et al., 1994; Eser et al., 2010). Varying solvent viscosity is a 
potential route to explore enzyme function and mechanism. The data (rate constants, equilibrium 
constants, kcat, kcat/Km etc) are plotted as the ratio of the relevant parameters in the absence of viscogen to 
that in its presence as a function of the relative solvent viscosity (Figure 6.8). A slope of 0 is expected 
when the parameter value is determined by the rate of chemical steps. A slope of 1 is expected when 
diffusional events (i.e.: access of the substrate or the release of product to/from the active site of the 
enzyme) fully determine the value of the parameter under study. A slope greater than 1 is expected when 
Enzyme NADPH, 
µM 
Catalase, µg v/E, s
-1
 Ratio 
   Oxygen NADPH O2/NADPH 
MICAL 200 0 3.0 3.3 0.91 
 400 0 3.0 3.6 0.83 
      
HisMICAL 187 0 3.7 4.4 0.84 
 94 0 3.2 3.6 0.89 
 47 0 2.6 2.9 0.89 
 28 0 2.1 2.4 0.88 
      
 187 10 1.7 3.8 0.44 
 94 10 1.7 3.3 0.51 
 47 10 1.3 2.6 0.50 
 28 10 1.1 2.2 0.50 
      
MICALHis 200 0 2.8 3.1 0.90 
 200 10 1.6 3.1 0.51 
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conformational changes that take place during the catalytic cycle contribute to the value of the parameter 
(Sampson et al., 1992; Simpoulos et al., 1994; Eser et al., 2010), (Figure 6.8).  
From the three dimensional structure of the MO domain of mouse MICAL1 conformational changes are 
predicted to take place during the catalytic cycle (Nadella et al., 2005; Siebold et al., 2005; Chapter 2). In 
a minimal scheme they would imply: (i) movement of Trp400 to allow hydride transfer from the NADPH 
nicotinamide ring to the flavin, (ii) the subsequent “flavin in”/”flavin out” transition (Scheme 6.3). With 
human MICAL-MO the slope of a plot of the the solvent viscosity effect on kcat/KNADPH was ≈3, which 
indicates that a conformational change contributes to determine the value of the parameter. The plot of the 
effect of solvent viscosity on kcat had a slope of 1. Stopped-flow studies of the reaction between MO and 
NADPH demonstrated that turnover is limited by the rate of flavin reduction by NADPH, which would 
have predicted no viscosity effect on kcat (Zucchini et al., 2011). Thus, the slope of 1 may reflect the fact 
that the conformational change seen in kcat/KNADPH partially contributes also to the value of kcat making the 
observed viscosity effect greater than 0.  
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Figure 6.6 End-point assays of H2O2 produced during the NADPH oxidase activity of MICAL. Left panel: His-MO 
was incubated with 51 µM NADPH (black line) in 20 mM Hepes/KOH buffer, pH 7.0, until all NADPH was 
consumed (purple line). o-dianisidine (0.4 mM, 50 µl) was added (blue line) followed by horseradish peroxidase 
(HRP, 1 µg). The spectrum at the end of the reaction is shown (red line) along with the calculated concentration of 
H2O2 formed. Right panel: MO-His was incubated with 100 µM NADPH in 20 mM Hepes/KOH buffer, pH 7.0 in 
the presence of 2.5 mM 2-oxoglutarate and 5 mM L-glutamine, and the reaction was monitored at 340 nm. At the 
indicated times an aliquot of glutamate synthase (GltS, 10 µl, 40 µg) was added to bring the reaction to completion. 
The spectrophotometer wavelength was switched to 436 nm and o-dianisidine (0.4 mM) and HRP (1 µg) were 
added. The reaction was allowed to reach completion before calculating the concentration of H2O2 formed. The 
black line shows an assay in which the reaction was allowed to reach completion in the absence of GltS (Zucchini et 
al., 2011).  
 
Figure 6.7. Effect of ionic strength and type of ions on MO NADPH oxidase reaction. Left and middle panels: the 
slopes of double reciprocal plots (KNADPH/kcat) obtained by measuring initial velocities in the presence of varying 
NADPH and different concentrations of salts or buffers are plotted as a function of the ionic strength (I) of the assay 
mixture. Left panel: the following salts were added to the standard assay buffer (20 mM Hepes/KOH, pH 7.0): ●, 
sodium acetate; Δ, magnesium acetate; □, NaCl; ■, KCl; ▲, calcium chloride; , sodium phosphate. Center panel: 
assays were carried out with different concentrations of Hepes/KOH buffer (○), Tris–chloride (Δ) or Tris–acetate 
(▲). The continuous line is the common fit of the data obtained with the chloride salts; the dotted line is the 
common fit obtained with the acetate salts; the dashed line is the fit to the data obtained with sodium phosphate. 
Right panel: assays were carried out with different concentrations of imidazole–chloride (○), imidazole–acetate (□) 
or Bis–Tris–acetate (●) (Zucchini et al., 2011).  
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Figure 6.8. Solvent viscosity effect on the kinetic parameters kcat and kcat/Km for a generic enzymatic reaction. Slope 
= 0, the value of parameter is determined by chemical steps (k3, k4); Slope = 1, diffusion-controlled events 
determine the value of the parameter (k1, k2, k5, k6); Slope >1, conformational changes determine the value of the 
parameter.  
 
 
 
Scheme 6.3 Reaction steps of the NADPH oxidase activity of MICAL and possible conformational changes 
occurring during the catalytic cycle. On the basis of the 3D-structure of the MO domain of mouse MICAL1 (PDB 
ID, 2C4C, 2BRY; Nadella et al., 2005; Siebold et al., 2005) conformational changes predicted to take place are the 
following: movement of Trp400 and transition between “flavin in” and “flavin out” conformations. White arrow, the 
reaction steps dependent on the chemistry of the reaction; Grey, diffusion limited steps and black, step in which 
conformational changes can occur.  
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6.2. Determination of the steady-state kinetic parameters kcat and Km, NADPH  of the NADPH oxidase activity 
of MICAL forms  
With the newly produced full-length MICAL and the truncated MOCH and MOCHLIM forms we 
characterized their NADPH oxidase reaction under steady-state kinetic conditions. These studies are 
important to determine if and to what extent some or all of the biological functions of MICAL are due to 
its H2O2-producing NADPH oxidase activity and to determine how the presence of the CH, LIM and C-
terminal domains affect the activity of the MO domain.  
To test the effect of the CH and LIM domains and of the C-terminal region on the NADPH oxidase 
activity of the MO domain, the apparent steady-state kinetic parameters kcat and Km for NADPH (KNADPH) 
of MICAL, MOCH and MOCHLIM forms were first determined in 20 mM Hepes/KOH buffer, pH 7, 
varying NADPH concentration. 
The measured v/[E] values, expressed in s
-1
, were fitted to the Michaelis-Menten equation (Eq 2) to 
determine the kinetic parameters of the reaction. The calculated kcat values of MOCH and MOCHLIM 
forms were similar to those of the isolated MO domain, while MICAL showed a 10-fold drop (Table 6.5, 
Figure 6.7). Instead, the value of KNADPH progressively increased from ~20 μM (MO), to ~130 μM 
(MOCH), ~230 μM (MOCHLIM) and ~370 μM (MICAL), (Table 6.5, Figure 6.9).  
The increase of Km for NADPH due to the presence of the CH, LIM and the C-terminal domains 
apparently correlates with the change of the overall charge of the protein starting from a positive value 
(MO pI 9, Figure 10.4) to progressively less positive and negative values at pH 7: 10.4, 2.6, -4.8 and -
12.7 for MO, MOCH (pI, 7.7), MOCHLIM (pI, 6.7) and MICAL (pI, 6.2), respectively (Figure 6.10) due 
to the addition of the acidic CH, LIM and C-terminal region (Figure 3.6). The effect exerted by the C-
terminal region on kcat, which is 10-fold lower than that of MO (0.28 s
-1
 vs 3 s
-1
) is in agreement with the 
proposal that the C-terminal region has an autoihnibitory function in MICAL and that MICAL activation 
takes place following the interaction between semaphorin and plexin (Schmidt et al., 2008; Giridharan et 
al., 2012; Figure 1.8). However, these data are not sufficient to clarify the effect of the CH and LIM 
domains and C-terminal region on the MO domain. The higher Km for NADPH and lower kcat of MICAL 
may depend on a different pH optimum of the reaction that might be linked to changes in the pKa of some 
key residues and/or to changes in the rate limiting steps of the reaction resulting from conformational 
changes induced by the CH, LIM and C-terminal domains. Thus the NADPH oxidase activity was studied 
as a function of pH and solvent viscosity. Prior to these experiments, we wished to test the sensitivity to 
ionic strength and type of ions on the NADPH oxidase activity of MOCH and MOCHLIM. Due to the 
high Km for NADPH (MOCHLIM and MICAL) and the low kcat (MICAL) only MOCH could be 
analyzed in detail. 
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Figure 6.9. Determination of the kinetic parameters kcat and Km for NADPH of the NADPH oxidase activity of 
MICAL forms. The initial velocity (v/[E], s
-1
) of the NADPH oxidation reaction catalyzed by MO (20 nM), MOCH 
(60 nM), MOCHLIM (60 nM) and MICAL (690 nM) was measured in 20 mM Hepes/KOH buffer, pH 7 varying 
NADPH concentrations at 25°C. The apparent kcat and KNADPH values and their associated errors were determined by 
fitting the data to the Michaelis-Menten equation (Eq.2) and are in Table 6.5.  
 
Table 6.5. Steady-state kinetic parameters of the NADPH oxidase activity of MICAL forms. Assays were carried out 
in 20 mM Hepes/KOH buffer, pH 7, in the presence of the indicated NADPH concentration ranges at 25°C. 
Apparent kcat and KNADPH values and their associated errors were determined by fitting the data to the Michaelis-
Menten equation.  
Protein,  nM NADPH, μM kcat, s
-1
 Km, μM kcat/Km,s
-1
mM
-1 
MO, 20 10-300 3.1 ± 0.1 19 ± 2 163 ± 18 
MOCH, 60 10-600 2.5 ± 0.1 134 ± 5 18.5 ± 1 
MOCHLIM, 60 30-1000 3.5 ± 0.1 230 ± 16 15.3 ± 1.2 
MICAL, 690 100-800 0.28 ± 0.01 375 ± 33  0.75 ± 0.07 
 
Figure 6.10. Calculated charge of MICAL forms as a function of pH. The total charge of each protein form as a 
function of pH was computed using the amino acyl composition of the proteins and the pKa values reported in Voet, 
D. and Voet, J. (2012), Biochemistry, 4th edn, Wiley, New York. 
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6.3. Effect of the ionic strength on the NADPH oxidase activity. 
The isolated MO domain of human MICAL was sensitive to ionic strength and anionic composition of the 
medium (Zucchini et al., 2011). As discussed previously this effect is mainly due to a competition 
between anions and NADPH for some of the positively charged residues of the NADPH binding site. 
However, with some anions the effect could be attributed to the overall charge of the protein. Since the 
CH, LIM and C-terminal domains of MICAL lower the total charge of the protein, the strong positive 
charge of MO may be attenuated. As a result also the sensitivity to ionic strength and anions could 
decrease. This properties would make it easier to carry out some experiments due to a less stringent need 
to maintain ionic strength at a low, and, especially, rigorously constant value.  
The kinetic parameters of the NADPH oxidase reaction catalyzed by MOCH were determined by varying 
the NADPH concentration in 20 mM Hepes/KOH buffer, pH 7 supplemented with NaCl (0-100 mM; I, 
4.4-104.4 mM) or Na-acetate (0-250 mM; I, 4.4-254.4 mM); in Tris-acetate buffer, pH 7 (50-250 mM; I, 
45-180 mM) or in imidazole-acetate buffer, pH 7 (50-150 mM; I, 24-72 mM).   
In all cases the plots of the reciprocal initial velocities as a function of the reciprocal of NADPH 
concentration were linear and converging on the Y axis, indicating that the various salts have an effect on 
kcat/KNADPH due to an increase of Km for NADPH. This effect is lower than that measured for MO (Figure 
6.11). The effect was exerted by NaCl was stronger than that of Na-acetate, imidazole-acetate buffer and 
Na-acetate (Figure 6.11).  kcat/KNADPH decreased linearly as the concentration of  NaCl, Na-acetate and 
Tris-acetate buffer increased (Figure 6.11, panels A and B). On the contrary, as observed for MO 
(Zucchini et al., 2011) the effect of imidazole-acetate buffer on kcat/KNADPH (expressed as  (kcat /KNADPH)/ 
(kcat /KNADPH)0) as a function of ionic strength was well fitted to the equation describing a limiting case of 
the Debye-Hückel equation (Norby et al., 1997; Eq 3), where the (kcat /KNADPH) is the parameter value 
obtained in the presence of a given value of ionic strength (I) and (kcat /KNADPH)0 is the value of the 
parameter calculated at zero ionic strength (Figure 6.11, panel C). The equation allows to calculate the 
ionic strength-independent value of the parameter and the charge of the NADPH binding site. Since at pH 
7 NADPH should carry 3-4 negative charges the active site of MOCH should have a charge of 0.031-
0.041 (Table 6.6), which is 3-fold lower than that calculated for MO (0.1-0.13; Table 6.6).  
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Figure 6.11. Comparison of the sensitivity to ionic strength and ions of the NADPH oxidase activity of MO and 
MOCH forms. The values of slopes ratio (KNADPH/kcat)/(KNADPH/kcat)0 are obtained by measuring initial velocities 
reaction of MO (empty symbols) and MOCH  (full symbols) in the presence of varying NADPH and different 
concentration of salts or buffers are plotted as a function of ionic strength (I) of the assay mixture. Panel A: Salts: 
NaCl (○, ●) and Na-acetate (□, ■) were added to the standard assay buffer (20 mM Hepes/KOH, pH 7); The 
continuous lines are the fit of the data obtained with NaCl, the dotted lines are the the fit of the data obtained with 
Na-acetate. Panel B: assays were carried out in the presence of different concentrations of Tris-acetate buffer (∆, 
▲). The continuous lines are the fit of the data obtained for MICAL-MO and MICAL-MOCH with different 
concentration of Tris-acetate buffer. Panel C: assays were carried out in the presence of different concentrations of 
Imidazole-acetate buffer (◊, ♦), the lines are the fit of data to Eq 3. The values of the slope and intercepts of the lines 
are in Table 6.6.  
 
 
Table 6.6. Determination of the charge (ze) of MO and MOCH forms. The slope of the lines show in Figure 6.14 
correspond to ze*zs, the intercept corresponds to –Log(kcat/Km)/ (kcat/Km)0 at zero ionic strength thus (kcat/Km)0 can be 
calculated. 
a
Data from Zucchini et al., 2011.  
Protein, nM buffer slope intercept ze*zs zNADPH, -3 zNADPH, -4 (kcat/Km)0 
MO, 20
a 
Imidazole-acetate 0.430±0.016 -1.004±0.061 - 0.43 0.143 0.107 3.38 
MOCH, 60 nM Imidazole-acetate 0.124±0.001 -0.645±0.0055 -0.124 0.041 0.031 0.041 
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The high Km for NADPH of MOCHLIM limited the analysis of the sensitivity of its reaction to ionic 
strength. Thus, the NADPH oxidase activity of MOCHLIM was studied only in selected buffers, namely: 
20 mM Hepes/KOH buffer, pH 6.5 (I, 1.35 mM); 12.5 mM formate, 5 mM imidazole, pH 7 (I, 12.5 mM); 
50 mM Na-phosphate buffer, pH 7.5 (I, 48 mM) and F-buffer (9.5 mM Tris/HCl, pH 7.7, 45 mM KCl, 
0.18 mM CaCl2, 1.18 mM MgCl2, 1.1 mM ATP, 1.33 mM DTT; I, 60 mM). 
The steady-state kinetic parameters obtained for MOCHLIM in such buffers are summarized in Table 6.7.  
By taking into account the differences in pH, which will be later analyzed in greater detail, it appears that 
with MOCHLIM kcat/KNADPH is little sensitive to the ionic strength of the buffer. The value of the 
parameter decreases only 4-fold when F-buffer substitutes the standard 20 mM Hepes/KOH buffer, pH 7. 
As observed for MO, phosphates appear to have a strong effect in lowering the affinity for NADPH.  
Also MICAL was sensitive to buffer composition. The low kcat and the high KNADPH prevented detailed 
analyses. An example is given in Table 6.7 (last two rows), in which it is clear that switching from Hepes 
buffer to F-buffer leads to an increase of KNADPH such that its value and, as a consequence, those that of 
kcat and kcat/KNADPH become undetermined.  
Overall, although MOCH and MOCHLIM seem to be less sensitive than MO to ionic strength and certain 
anions, these experiments clearly show that these parameters need to be carefully controlled in our 
experiments to avoid misleading results.  
The high sensitivity of the Km for NADPH of the NADPH oxidase activity of MICAL to ionic strength 
and anions, especially phosphate, which also influenced by the overall charge of the protein, may have 
consequences for the biological function of MICAL. In the cell, the H2O2-producing NADPH oxidase 
activity of its N-terminal flavoprotein domain may be low due to the predicted high ionic strength and the 
presence of phosphate anions that lead to a high KNADPH.  
However, local increases in NADPH concentration or interaction with specific proteins may increase the 
NADPH oxidase activity of MICAL. The changes of H2O2-production by MICAL may be responsible for 
some of its reported functions in cell.     
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Figure 6.12 Effect of the ionic strength and buffer composition on the kinetic parameters kcat and KNADPH of the 
NADPH oxidase activity of MOCHLIM form. The initial velocities of the NADPH oxidation reaction catalyzed by 
MOCHLIM form were measured by varying NADPH concentration in 20 mM Hepes/KOH buffer, pH 6.5 (panel 
A); 12.5 mM formate, 5 mM imidazole, pH 7 (panel B); in 50 mM Na-phosphate buffer, pH 7.5 (panel C); in F-
buffer (9.5 mM Tris/HCl, pH 7.7, 45 mM KCl, 0.18 mM CaCl2,, 1.18 mM MgCl2, 1.1 mM ATP, 1.33 mM DTT); 
the ionic strength of the buffers is indicated in the Figure. The values of the initial velocity were fitted to Eq 2 and 
the resulting kinetic parameters are reported in Table 6.7.  
 
Table 6.7. Effect of the ionic strength on the steady-state kinetic parameters of the NADPH oxidase reaction of 
MOCHLIM form and MICAL.  
Protein,     
nM 
Buffer pH 
I,  
mM 
NADPH, 
μM 
kcat,             
s
-1
 
KNADPH,   μM 
kcat/KNADPH,             
s
-1
 mM
-1
 
MOCHLIM, 
60 
20 mM Hepes/KOH 7 4.4 30-1000 3.5 ± 0.1 230 ± 16 15.3 ± 1.2 
MOCHLIM, 
60 
20 mM Hepes/KOH 6.5 1.35 30-1000 2.81 ± 0.17 202  ± 40 13.92 ± 2.9 
MOCHLIM, 
60 
12.5mM formate 5 mM imidazole 7 12.5 30-1000 2.87 ± 0.07 208 ± 15 13.78 ± 1.04 
MOCHLIM, 
300 
50 mM Na-phosphate 7.5 48 30-800 5.27 ± 0.65 2137 ± 350 2.47 ± 0.5 
MOCHLIM, 
125 
F buffer 7.7 60 30-800 4.3 ± 0.19 966 ± 69 4.45 ± 0.37 
MICAL, 690 20 mM Hepes/KOH 7 4.4  0.28 ± 0.01 375 ± 33  0.75 ± 0.07 
MICAL, 
1250 
F buffer 7.7 60  0.77 ± 0.47 4652 ±3202 0.17  ± 0.15 
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6.4. pH dependence of the kinetic parameters kcat, Km and kcat/Km of the NADPH oxidase activity of 
MICAL forms. 
The effect of pH on the kinetic parameters of the NADPH oxidase activity of MICAL forms was studied 
under carefully controlled buffer conditions. As done during the study of the pH dependence of the 
NADPH oxidase activity of MO, the ionic strength of the buffer needed to be kept low and constant 
throughout the explored pH range (Zucchini et al., 2011).  
In this present work, we used both mixed buffer A (10 mM acetate, 5 mM imidazole, 5 mM Tris) and 
mixed buffer B (12.5 mM formate, 5 mM imidazole, 5 mM Tris) at similar ionic strength (10 and 12.5 
mM for mixed buffer A and B, respectively). The pH dependence of the kinetic parameters of the 
NADPH oxidase reaction catalyzed by MO and MOCH was studied both in mixed buffer A and mixed 
buffer B, while for MOCHLIM and MICAL only mixed buffer B was used. The pH range investigated 
varied from 5 to 10 for MO and MOCH, but only from 5 to 9 for MOCHLIM and from 5 to 8 for 
MICAL, by taking into the account the stabilities of NADPH and of the enzymes, as well as the kcat and 
KNADPH values we measured.   
The initial velocity of the NADPH oxidase activity of the MICAL forms was measured in the mixed 
buffers at varying pH and varying the NADPH concentration. The standard NADPH oxidase activity of 
the enzymes was also measured every 1-1.5 h to check enzyme stability. Since values were constant 
during the experiment and similar to those measured at the end of the protein preparations, no correction 
of the v/[E] values was applied. Figure 6.13 shows that the pH profiles of kcat, kcat/KNADPH and 1/KNADPH of 
MICAL forms are complex. For MOCH no difference was observed depending on the mixed buffer used, 
while for MO differences were observed highlighting the sensitivity of MO to ionic strength and ionic 
composition of the medium (Figure 6.13). For MO and MOCH the kcat values increased from non-zero 
limits at low and high pH to a maximum around pH 7-8. The calculated pKa values (Table 6.8) were 
similar for MO and MOCH and may reflect changes of the overall charge of the protein, rather the 
ionization state of specific residues. The kcat of MOCHLIM was constant in the pH range 6-9 and similar 
to the maximum value of kcat measured for MO and MOCH. It decreases at lower pH to kcat values similar 
to those of MO and MOCH at the same pH (Figure 6.13, panel C). On the contrary, the kcat of MICAL 
increased from a non-zero value at pH 6-8 as pH lowered (Figure 6.13, panel D). This observation could 
be consistent with the hypothesis that the C-terminal region of MICAL inhibits the MO domain by 
forming a complex through electrostatic interactions. At pH < 6 the C-terminal domain (pI 5.2) would 
become less negatively charged, thus the interaction with the MO domain would weaken and the 
inhibition exerted by the C-terminal region on the MO domain would be (in part) decreased.    
The pH dependence of kcat/KNADPH and 1/KNADPH is similar in shape for all MICAL forms. It is also 
complex and similar to that previously reported for MO (Zucchini et al., 2011) and similar to the pH 
dependence of the Kd for NADPH observed with PHBH (Palfey et al., 1999). The pH profiles seem to 
reflect the fact that binding of NADPH is mainly determined by the overall charge of the protein. In 
support to this conclusion is the similarity of the shape of the kcat/KNADPH and 1/KNADPH profiles to that 
describing the protein charge as a function of pH (Figures 6.13 and 6.10).  
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Overall, these experiments also show that the differences in kcat and KNADPH among the various MICAL 
forms we initially determined at pH 7 (Table 6.5) are intrinsic properties of the proteins rather than 
caused by changes in the pH optimum of the reaction.  
 
 
 
 
 
Figure 6.13. pH dependence of kcat, kcat/KNADPH and 1/KNADPH of MICAL forms. The steady-state kinetic parameters 
kcat, kcat/KNADPH and KNADPH for the NADPH oxidase activity of the MO, MOCH, MOCHLIM truncated forms and 
the full-length protein (MICAL) were determined spectrophotometrically at 25°C by varying NADPH concentration 
in a mixed buffer composed of 10 mM acetate, 5 imidazole, 5 mM Tris, (○, mixed buffer A, ionic strength 10 mM , 
Zucchini et al., 2011) or of 12.5 mM formate, 5 mM imidazole, 5 mM Tris (●, mixed buffer B, ionic strength 12.5 
mM).The curves were drawn with the equations and parameters values reported in Table 6.7. 
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Table 6.8. pH dependence of the kinetic parameters kcat, kcat/KNADPH and 1/KNADPH of the NADPH oxidase activity of 
MICAL forms. Initial velocity measurements were carried out by varying NADPH concentration in the presence of 
10 mM acetic acid, 5 mM imidazole, 5 mM Tris (Ionic strength, 10 mM, mixed buffer A) or 12.5 mM formic acid, 5 
mM imidazole, 5 mM Tris (Ionic strength, 12.5 mM, mixed buffer B). The calculated parameters were used to draw 
the curves in Figure 6.13. 
a
Data obtained with mixed buffer A and B were fitted together; 
b
The parameters were 
poorly determined due to a combination of low kcat and high Km for NADPH. 
Protein Buffer Parameter Equation A1 A2 A3 pKa1 pKa2 
MO 1 kcat, s
-1
 2 2.2 ± 0.04 3.5 ± 0.1 2.5 ± 0.1 6.5 ± 0.1 9.0 ± 0.1 
kcat/Km, s
-1
mM
-1
 5 136 ± 25 68 ± 27  6.4 ± 0.3 8.2 ± 0.3 
1/Km, mM
-1
 5 69 ± 9 20 ± 10  6.4 ± 0.2 8.2 ± 0.6 
MO 2 
 
kcat, s
-1
 2 2.5 ± 0.2 3.5 ± 0.2 2.5 ± 0.1 6.1 ± 0.5 8.4 ± 0.4 
kcat/Km, s
-1
mM
-1
 5 114 ± 17 52 ± 16  5.9 ± 0.3 8.0 ± 0.4 
1/Km, mM
-1
 5 52 ± 6 14 ± 4  5.8 ± 0.2 8.1 ± 0.4 
MOCH 1+2
a 
kcat, s
-1
 2 1.8 ± 0.1 2.9 ± 0.1 1.4 ± 0.1 6.3 ± 0.2 8.5 ± 0.1 
kcat/Km, s
-1
mM
-1
 5 104 ± 3 7.3 ± 2.9  6.2 ± 0.1 9.1 ± 0.5 
1/Km, mM
-1
 5 60 ± 1 2.7 ± 0.7  6.0 ± 0.04 9.7 ± 0.6 
MOCHLIM 2 kcat, s
-1
 3 3.3 ± 0.1   4.4 ± 0.3  
kcat/Km, s
-1
mM
-1
 5 30 ± 3 13 ± 0.9  5.6 ± 0.2 8.8 ± 0.2 
1/Km, mM
-1
 5 21 ± 7 4.1 ± 0.4  5.0 ± 0.3 8.8 ± 0.3 
MICAL 2 kcat, s
-1
 4 0.5 ± 0.6
b 
0.2 ± 0.02  4.5 ± 1.8  
kcat/Km, s
-1
mM
-1
 5 10 ± 7
b 
0.3 ± 0.05  3.8 ± 0.4 8.6 ± 0.9 
1/Km, mM
-1
 5 33 ± 41
b 
1.3 ± 0.3  3.8 ± 0.6 8.3 ± 0.6 
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6.5. Effect of solvent viscosity on the NADPH oxidase activity of MICAL forms 
To obtain information on the effect of the CH, LIM and C-terminal domains on catalytically relevant 
conformational changes as well as possible changes of the rate determining steps of the reaction, the 
effect of solvent viscosity on the kinetic parameters kcat and Km for NADPH of the NADPH oxidase 
activity of MOCH, MOCHLIM and MICAL was studied in 20 mM Hepes/KOH buffer, pH 7, 
supplemented with fixed concentrations of glycerol and varying NADPH concentration (upper panels of 
Figure 6.14).  
Both kcat and kcat/KNADPH were lowered in the presence of glycerol. Data analysis ruled out that glycerol 
was an inhibitor of the NADPH oxidase reaction. Rather, the data were well fitted to Eq.8 that correlates 
the effect of viscosity on kcat/KNADPH (i.e.: (kcat/KNADPH)0/(kcat/KNADPH)η) and kcat (i.e.: kcat,0/kcat,η) to the 
relative viscosity of the solvent (Sampson et al., 1992; Simpoulos et al., 1994; Eser et al., 2010). The 
effect of solvent viscosity on kcat/KNADPH linearly increased with solvent viscosity with a slope of 2.7 ± 
0.4, 2.3 ± 0.3, 1.8 ± 0.2, and 1.7 ± 0.3 for MO, MOCH, MOCHLIM and MICAL, respectively (lower 
panels in Figure 6.14, Table 6.9). The slope calculated for the effect on kcat was ≈1 for all forms (namely: 
0.9 ± 0.1, 1.4 ± 0.1,  1.1 ± 0.1 and 0.9 ± 0.2 for MO, MOCH, MOCHLIM and MICAL respectively, 
lower panels in Figure 6.14, Table 6.9). The slope >1 of the dependence of the viscosity effect on 
kcat/KNADPH reveals the presence of conformational changes that contribute to the determination of the 
value of kcat/KNADPH (2011; McKay et al., 1996; Sampson et al., 1992; Eser et al., 2010). For the reaction, 
kcat/KNADPH includes steps from NADPH binding up to FAD reduction or NADP
+
 release (Zucchini et al., 
2011). The importance of such conformational change is maximal in MO and progressively decreases in 
MOCH, MOCHLIM and MICAL (Figure 6.14; Table 6.9). This observation can be explained by taking 
into account the increase of the Km for NADPH observed for the species (Figure 6.9; Table 6.5). As 
binding of NADPH becomes less efficient, the importance of the conformational change following 
NADPH binding in determining the value of kcat/KNADPH would decrease. Should the rate of binding of 
NADPH to the enzyme (a diffusion sensitive process) become fully rate limiting, the slope of the plot 
would become 1. By borrowing the terminology developed to describe kinetic isotope effect, we could 
say that the viscosity effect observed in kcat/KNADPH due to the conformational change is partially 
“suppressed” by less efficient binding of NADPH.  
The similarity of the solvent viscosity effect on kcat for all MICAL forms indicates that the CH, LIM and 
C-terminal domains do not alter the relative rates of the conformational change taking place after NADPH 
binding and of the chemical step of the reaction that contributes to the value of kcat.  
This observation is a further proof that the CH, LIM and C-terminal regions of MICAL have little effects 
on the mechanism of the reaction that takes place within the MO domain. Importantly, these results show 
that the low kcat of MICAL is unlikely to be due to a decrease of the rate of hydride transfer from NADPH 
to FAD or to slowing down other chemical steps. If such chemical step (or another chemical step beyond 
hydride transfer) had become fully determining, the kcat value would have become independent from 
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Figure 6.14. Viscosity effects on kcat and kcat/KNADPH of the NADPH oxidase activity of human MICAL1forms.  
NADPH oxidase reaction of MICAL forms were determined in the presence of varying NADPH concentrations in 
the presence of different glycerol concentrations expressed in % (w/w): ○, 0 %, ηrel, 1; ●: 2.5 %, ηrel, 1.04; □, 5%, 
ηrel, 1.13; ■, 10%, ηrel, 1.291, Δ, 15%, ηrel, 1.456; ▲, 20%, ηrel, 1.726; ◊, 25%, ηrel, 2.027. The curves correspond to 
the best fit of the entire datasets to Eq. 8, which provides the estimate of the slopes of the plots of the effect of 
viscosity on kcat (n value, kcat,0/kcat,η) and on kcat/KNADPH (m value, (kcat/KNADPH)0/(kcat/KNADPH)η) as a function of 
relative viscosity (ηrel, Table 6.8). For MOCH only the data up to 15% glycerol were fitted to Eq. 7 due to deviation 
from linearity of the kcat,0/kcat,η and (kcat/KNADPH)0/(kcat/KNADPH)η) values calculated by individually fitting the initial 
velocity data obtained at a given glycerol concentration to the Michaelis-Menten equation (Eq. 2, see lower panel). 
The dashed lines indicate the calculated curves at 20 and 25% glycerol using the parameters shown in Table 6.8. 
The lower panels compare the values of the effects of viscosity on kcat and on kcat/KNADPH calculated by fitting 
independently the individual series of data to the Michaelis-Menten equation (Eq.2) with the lines calculated by 
fitting the whole set of data to Eq. 8. For MO the data are taken from Zucchini et al., 2011 and reanalyzed.  
 
Table 6.9. Summary of the effects of viscosity on kcat and kcat/KNADPH of the NADPH oxidase activity of MICAL1 
forms. The initial velocity values  (v/E) obtained by varying NADPH in the presence of different glycerol 
concentrations in 20 mM Hepes/KOH buffer, pH 7.0 at 25°C (Figure 5)  were fitted to Eq. 8, in which the m and n 
values correspond to the slopes of the plots of  (kcat/Km)0/(kcat/Km)η and of  kcat,0/kcat,η  as a function of the relative 
viscosity of the solvent.  
    Slope 
Protein kcat, s
-1
 KNADPH, μM kcat/KNADPH , mM
-1
s
-1 
(kcat/Km)0/(kcat/Km)η kcat,0/kcat,η  
MO 2.8 ± 0.04 47 ± 3 59.5 ± 3.3 2.7 ± 0.4 0.9 ± 0.1 
MOCH 2.6 ± 0.05 111± 6 23.2 ± 1.3 2.3 ± 0.3 1.4 ± 0.1 
MOCHLIM 2.9 ± 0.07 178 ± 10 16.5 ± 1.0 1.8 ± 0.2 1.1 ± 0.1 
MICAL 0.3 ± 0.01 398 ± 31 0.73 ± 0.06 1.7 ± 0.3 0.9 ± 0.2 
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7. MICAL and F-actin 
 
7.1. Introduction  
The cytoskeleton of eukaryotic cells is composed of actin microfilaments, microtubules and intermediate 
filaments. The cytoskeleton is dynamic and strong, ever ready to adapt to the demands of the cells 
(Dominguez and Holmes 2011). Actin is the most abundant protein in eukaryotic cells and plays a critical 
role in fundamental cell processes ranging from cell motility and maintenance of cell shape, to polarity and 
regulation of transcription thanks to its ability to transition between monomeric (G-actin) and filamentous 
state (F-actin) under the control of nucleotide hydrolysis, ions and a large number of actin binding proteins 
(ABP) that control the organization of its polymerization and disassembly (Dominguez and Holmes 2011). 
Vertebrates express three main actin isoforms: α-actin of skeleton, cardiac and smooth muscles and β- and γ-
actin expressed in non-muscle and muscle cells, respectively, differing by few amino acids at their N-
terminus (Figure 7.1). Actin also undergoes various post-traslational modifications, such as, e.g., 
methylations and acetylations (Dominguez and Holmes 2011). The discovery of bacterial homologs of 
eukaryotic actin is relatively recent. MreB was first identified as a protein involved in cell shape regulation 
in E.coli in the late 1980s (Doi et al. 1988), but only in 2001 it was demonstrated that Bacillus subtilis MreB 
forms cytoskeletal filaments in vivo (Shaevitz and Gitai 2010). Actin and its bacterial homologs, with sugar 
kinases and Hsp90 proteins, belong to a structural superfamily. Common to these proteins is that the 
polypeptide folds into two major α/β-domains (Dominguez and Holmes 2011). Actin is formed by a small 
domain composed of subdomains 1 and 2, and a large domain composed of subdomains 3 and 4, leading to 
the formation of a cleft where ATP binds (Figure 7.2). G-actin can be found in “open” and “closed” 
conformations depending on the position of the D loop (Figure 7.2).  The latter probably oscillates in 
solution between the conformations in order to exchange the bound nucleotide (Figure 7.2; Aguda et al., 
2005).  
The phases of the process through which actin monomers self-assemble into filaments and higher order 
assemblies are: (1) a slow association of monomers to yield the actin dimer; (2) formation of a stable trimer, 
defined as the “nucleus of polymerization” and (3) the elongation phase. The polymerization of actin is 
promoted by high ionic strength (≈50 mM KCl) at neutral pH, high concentration of Mg++ rather than Ca++ 
and elevated temperatures. All these conditions are normally found within the cells, so that actin would all be 
present in the filamentous state. Polymerization is also coupled with the hydrolysis of ATP. Actin is 
endowed with an ATPase activity only in the polymeric state, so that along the filament there are 
ATP●Actin, ADP●Pi●Actin and ADP●Actin complexes (Figure 7.3; Bamburg et al., 2008). The ADP●Actin 
monomer is released from the filament that is in a continuous state of assembly and disassembly, defined as 
treadmilling (Figure 7.3). As a consequence, in the steady-state a small concentration of G-actin will be 
present in dynamic equilibrium with F-actin at the so called critical concentration (Cc). The elongation of 
actin filaments has a precise and distinguishable direction of growth due to the position of two monomers of 
actin leading to the formation of barbed- and pointed-ends of the filament (Figure 7.3). The barbed-end of 
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the filament has a lower Cc compared to that of the pointed-end. As a consequence at the barbed-end 
polymerization occurs faster than depolymerization.  
betaACTIN_mouse        --MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 58 
betaACTIN_rabbit       --MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 58 
betaACTIN_human        --MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 58 
gammaACTIN_mouse       --MEEEIAALVIDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 58 
gammaACTIN_human       --MEEEIAALVIDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 58 
alphaACTIN_rabbit      MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 60 
alphaACTIN_mouse       MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 60 
alphaACTIN_human       MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA 60 
                          ::: :*** *****: ***************************************** 
 
betaACTIN_mouse        QSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREK 118 
betaACTIN_rabbit       QSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEERPVLLTEAPLNPKANREK 118 
betaACTIN_human        QSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREK 118 
gammaACTIN_mouse       QSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREK 118 
gammaACTIN_human       QSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREK 118 
alphaACTIN_rabbit      QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK 120 
alphaACTIN_mouse       QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK 120 
alphaACTIN_human       QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK 120 
                       *****************:************************:*.*************** 
 
betaACTIN_mouse        MTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRL 178 
betaACTIN_rabbit       MTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRL 178 
betaACTIN_human        MTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRL 178 
gammaACTIN_mouse       MTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRL 178 
gammaACTIN_human       MTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRL 178 
alphaACTIN_rabbit      MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL 180 
alphaACTIN_mouse       MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL 180 
alphaACTIN_human       MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL 180 
                       **********.***********************:********.*************:** 
 
betaACTIN_mouse        DLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEK 238 
betaACTIN_rabbit       DLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEK 238 
betaACTIN_human        DLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEK 238 
gammaACTIN_mouse       DLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEK 238 
gammaACTIN_human       DLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEK 238 
alphaACTIN_rabbit      DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK 240 
alphaACTIN_mouse       DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK 240 
alphaACTIN_human       DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK 240 
                       **********************.***********************:************* 
 
betaACTIN_mouse        SYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTV 298 
betaACTIN_rabbit       SYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTV 298 
betaACTIN_human        SYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTV 298 
gammaACTIN_mouse       SYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTV 298 
gammaACTIN_human       SYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTV 298 
alphaACTIN_rabbit      SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV 300 
alphaACTIN_mouse       SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV 300 
alphaACTIN_human       SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV 300 
                       *********************:******:****.******:*******:*********.* 
 
betaACTIN_mouse        LSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIS 358 
betaACTIN_rabbit       LSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIS 358 
betaACTIN_human        LSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIS 358 
gammaACTIN_mouse       LSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIS 358 
gammaACTIN_human       LSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIS 358 
alphaACTIN_rabbit      MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT 360 
alphaACTIN_mouse       MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT 360 
alphaACTIN_human       MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT 360 
                       :**********************************************************: 
 
betaACTIN_mouse        KQEYDESGPSIVHRKCF 375 
betaACTIN_rabbit       KQEYDESGPSIVHRKCF 375 
betaACTIN_human        KQEYDESGPSIVHRKCF 375 
gammaACTIN_mouse       KQEYDESGPSIVHRKCF 375 
gammaACTIN_human       KQEYDESGPSIVHRKCF 375 
alphaACTIN_rabbit      KQEYDEAGPSIVHRKCF 377 
alphaACTIN_mouse       KQEYDEAGPSIVHRKCF 377 
alphaACTIN_human       KQEYDEAGPSIVHRKCF 377 
                       ******:********** 
 
Figure 7.1. Sequence comparison of human, rabbit and mouse  α-, β- and γ-actin. Highlighted in yellow are the residues 
that are responsible for longitudinal contacts in F-actin and stabilize the filament (Galkin et al., 2015). α-actin from 
mouse (Uniprot P68134), rabbit (P68135), human (P68133); β-actin from mouse (AAI38615.1), rabbit (P29751.1), 
human (P60709.1); γ-actin from rabbit (P63260.1), human (P63261).  
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Thus, it is the site of filament growth often indicated as + end of the filament. The Cc depends on solvent 
conditions and, particularly, on the presence of ABP, which play a major role in determining the structure 
and dynamics of filamentous actin (Bamburg et al., 2008).  
ABP proteins regulate actin dynamics primarily by varying the critical concentration of actin. There are three 
main classes of ABP: (1) monomer binding proteins, (2) severing, capping and uncapping proteins and (3) 
crosslinking proteins (Puius et al., 1998).  
The monomer binding proteins, among which profilin is the most studied, bind to free monomeric 
ADP●actin promoting the nucleotide exchange with ATP and polymerization of the ATP-actin monomer to 
the filament (Puius et al., 1998). Severing, capping and uncapping proteins are divided in two families 
represented by gelsolin and cofilin. These proteins are able to bind both G- and F-actin and to sever actin 
filaments. Members of the gelsolin family are activated in a Ca
++
-dependent manner. Ca
++
 binding fully 
exposes the actin binding site allowing the interaction with actin monomers of two different strands of the 
filament and leading to its severing. In addition they can also cap the barbed-end of the filament preventing 
its elongation. Cofilin and the homologous Actin Depolymerizing Factor (ADF) bind F-actin in a cooperative 
fashion causing partial depolymerization and weak severing of the filaments in a pH-dependent manner 
(Carlier et al., 1999; Bamburg et al., 2010).   
Crosslinking or bundling proteins are characterized by the presence of several actin binding regions, such as 
tandem CH and LIM domains, and are responsible for the assembly of complex structures like Y-junctions 
between actin filaments in lamellopodia (Borisy and Svitkina 2000).  
All ABP exert their activity by sequestering free monomers or by twisting and destabilizing the filaments for 
their depolymerization only through protein-protein interaction upon their activation and recruitment in 
response to cell demand. The main mechanism by which the ABP are regulated is represented by their 
phosphorylation/dephosphorylation state through kinase and phosphatase activities that determine the 
interactions and their specificity and thus their function (Bamburg 1999). 
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Figure 7.2. Three-dimensional structures of G-actin. 
The three dimensional structure of rabbit α-actin 
(PDB ID 3DAW) is shown. Colour code: green, 
subdomain 1 (residues 1-33, 96-145, 339-374); dark 
red, subdomain 2 (residues 34-95); yellow, 
subdomain 3 (residues 146-180, 270-338); blue, 
subdomain 4 (residues 181-269). ATP is shown in 
sticks with carbon in light grey, nitrogen in blue, 
oxygen atom in red and phosphorus group in red. The 
CCP4 program was used to generate the figure (left 
panel) (McNicholas et al., 2011). The open and 
closed conformations are also shown (Aguda et al., 
2005).    
 
 
 
Figure 7.3. Dynamic equlibrium of the actin filament.The 
polymerization of actin into filaments is coupled to ATP 
hydrolysis. As a result the actin filament is composed by 
ATP●Actin (light blue), ADP●Pi●Actin (green) and ADP●Actin 
(red) complexes. At the steady-state the ATP●Actin molecules 
are added to the barbed-end of the filament for its elongation and 
the ADP●Actin complexes dissociate (grey) from the pointed-
end of the filament. This process is defined as treadmilling 
(Bamburg et al., 2010).  
 
 
 
 
 
  Figure 7.4 Regulatory pathways controlling actin dynamics in cell. (Cell Signaling)  
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The interaction of semaphorins with their plexin receptors is one of the signaling pathways that leads to 
reorganization of the cytoskeleton (Figure 7.4). As discussed in the Introduction (Chapter 1), the activity 
of the N-terminal flavoprotein domain of MICAL is essential for the correct transduction of semaphorin 
signaling resulting in local F-actin depolymerization. Several hypotheses have been made about MICAL’s 
mechanism of action. The essentiality of the MO domain for MICAL’s function in actin depolymerization 
led to propose that it either acted by oxidizing a small molecule or a protein side chain through a NADPH 
oxidase (H2O2-producing) or NADPH-dependent hydroxylase activity as part of its signal transduction 
mechanism (Terman et al., 2002). Using genetic approches, Drosophila MICAL (D-MICAL) was shown 
to mediate growth and directionality of axons (Figure 7.5, panels a and b), but also that MICAL is 
required for pruning developing neuronal dendrites (Figure 7.5 panel c), muscle organization (Figure 7.5 
panel d), larval movements and flight (Figure 7.5 panels d-h) (Hung and Terman 2011). The MO and 
MOCH regions of D-MICAL were also expressed and purified (Hung et al., 2010, 2011). Although, no 
information on the quality of these preparations has been given, the proteins were found to catalyze 
irreversible F-actin depolymerization in a NADPH-dependent fashion indicating that the CH domain is 
not essential for MICAL function (Figure 7.6, panel A).  
The interaction between MICAL and F-actin appeared to take place along the filament rather than at one 
of the ends of the filament as demonstrated by the analysis of the site of cleavage of filament actin 
incubated with D-MICAL and NADPH using electron microscopy (Hung et al., 2011; Figure 7.6, panel 
B). Accordingly, the addition of latrunculin, a capping protein, had no effect on the depolymerizing 
activity of MICAL (Hung et al., 2011). Analysis of actin treated with the MOCH region of D-MICAL and 
NADPH revealed that Met44 and Met47 were converted to methionine sulfoxide. Actin Met44Leu and 
Met47Leu variants were both able to polymerize, but only the actin Met44Leu variant could not be 
depolymerized by MICAL (Hung et al., 2011; Figure 7.6, panel C). This result led to the proposal that 
actin Met44 is the substrate of the hydroxylase/monooxygenase activity of MICAL and that its oxidation 
causes the depolymerization  of the filament (Hung et al., 2011).  Further work led to identify a 
Drosophila-specific methionine sulfoxide reductase SelR, similar to mammalian MrsB, which opposes 
MICAL effect on actin by reverting the methionine-R-sulfoxide residue to methionine, so that G-actin is 
now able to repolymerize (Figure 7.6, panels D and E; Hung et al., 2013). Similar results were obtained 
with the MOCH form of mouse MICAL1 and MICAL2 (Lee et al., 2013).  
Recently, it has also been demonstrated that MICAL2 mediates serum response factor (SFR)/myocardin-
related transcription factor-A (MRTF-A)-dependent gene transcription through its depolymerizing redox 
activity on nuclear F-actin (Lundquist et al., 2014). Gene transcription is activated when nuclear MRTF-A 
levels increase leading to the formation of active SFR/MRTF-A complex. The level of nuclear MRTF-A 
is regulated by nuclear levels of G-actin, since the interaction between the proteins promotes MRTF-A 
nuclear export. MICAL2 activity would decrease nuclear G-actin and thus increase MRTF-A 
concentration in the nucleus, resulting in transcription of genes involved in diverse cellular processes such 
as cell migration, cancer cell metastasis, mammary myoepithelium development and neurite formation 
(Lundquist et al., 2014).  
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Figure 7.5.  In vivo organization of F-actin by MICAL from. Function of Drosophila MICAL during axon guidance 
(a and g), neuronal synapse formation (b), dendrite pruning (c), muscle formation (d and h), and bristle shape (e-f); -
/- mutant loss of function (G-to-W substitution in the FAD-binding region); +/+ mutant gain of function 
(overexpression of MICAL) (Hung et al., 2010).    
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Figure 7.6. Effect of Drosophila MICAL forms and NADPH on the actin polymerization state. Panel A: Pyrene-
labelled G-actin (1.1 μM final concentration) was incubated with Drosophila MICAL-MOCH (MicalredoxCH , 600 
nM) and/or NADPH (100 μM) in G buffer. Polymerization of actin was induced and fluorescence intensity was 
immediately monitored; Drosophila MICAL-MOCH, NADPH, and/or hydrogen peroxide were added to pre-
polymerized pyrene-labelled F-actin (1.1 μM) (Hung et al., 2010). Panel B: Electron microscopy analysis of F-actin 
filaments (left panel) and after incubation with Mical
redoxCH 
, 600 nM) and NADPH (100 μM) (right panel), the 
arrows indicate the cut due to MICAL activity along the filament. Panel C: cosedimentation assays of wild-type 
(WT) and M44L F-actin mutant incubated with MOCH form (Mical, 600 nM) in the absence and presence of  
NADPH (100 μM) (Hung et al., 2010, 2011). Panel D:Fluorescence increase was monitor for 1.1 µM Pyrenyl-actin 
alone (purple dots) and in the presence of 600 nM D-MOCH and 100 µM NADPH (black dots). Polymerization of 
MICAL-treated actin was followed after addition of  2.4 µM SelR (green dots) and buffer (blue dots).  Panel E: actin 
organization in muscles cells overexpressing MICAL (Muscle Mical) and co-expressing MICAL and SelR (Muscle 
Mical+Muscle SelR)   (Hung et al., 2013).    
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The human MICAL-MO was also found to exhibit an F-actin depolymerizing activity (Zucchini et al., 
2011). The reaction was monitored fluorimetrically, by exploiting the different fluorescence intensity of 
pyrene-labeled G- and F-actin (Figure 7.7 panels A and B), by sedimentation assays and by monitoring 
changes of the size of particles in solution by dynamic light scattering (Figure 7.7, panel C; Zucchini et 
al., 2011). Addition of human MICAL-MO to pre-polymerized pyrenyl-actin, in a buffer stabilizing F-
actin (F-buffer), after NADPH, led to a decrease of fluorescence, which was dependent on MICAL and 
NADPH concentration and much faster than that reported for D-MICAL. Moreover, catalytic amounts of 
human MO (10-30 nM) were sufficient to cause F-actin depolymerization compared to the stoichiometric 
amounts used in the experiments carried out with D-MICAL (Hung et al., 2010, 2011, 2013). Dynamic 
light scattering (DLS) was also used to monitor the decrease in size of actin filaments, which was partial, 
suggesting that MICAL caused fragmentation of filaments and/or aggregation (Figure 7.7, panel C; 
Zucchini et al., 2001). F-actin, but not G-actin, significantly stimulated NADPH oxidation (Figure 7.7 
panel D) by lowering the Km value for NADPH (50-fold) and increasing kcat (3- or 6-fold at 2.4 μM actin 
or extrapolated at infinite actin concentration, respectively) when compared to the values measured in the 
absence of actin (Table 7.1), resulting in a ~500-800-fold kcat/KNADPH increase (Zucchini et al., 2011). 
More importantly, assuming that MICAL-MO catalyzes the hydroxylation of one specific actin residue, 
with a 1:1 stoichiometry of NADPH being oxidized per actin monomer being modified, one would have 
predicted biphasic traces. Initially, MICAL would behave as expected for a monooxygenase in the 
presence of its substrate. The rate of NADPH consumption would be fast and the amount of NADPH 
consumed in this phase should be lower or equal to the total actin monomer concentration. A second 
slower phase of NADPH oxidation should follow due to the MICAL NADPH oxidase reaction with 
residual oxygen. On the contrary, although traces showed some biphasicity, which could not be clearly 
correlated with the total actin concentration present, the second phase was much faster than that measured 
in the NADPH oxidase activity under the same conditions and fast oxidation of all NADPH present was 
obtained (Figure 7.7 panel D; Zucchini et al., 2011). The observed extent and time-course of NADPH 
consumption are consistent with either a case of substrate recycling suggesting that the effect of MICAL 
(and NADPH) on F-actin may be reversible or with the fact that the depolymerization of F-actin is due to 
in situ H2O2 release. In this respect, that F-actin is sufficient to enhance the rate of FAD reduction by 
NADPH has been demonstrated in a stopped-flow experiment with the isolated MO domain of mouse 
MICAL2 (McDonald et al., 2013).   
Although the MO domain is sufficient to catalyze the NADPH-dependent F-actin depolymerization 
reaction, it was important to determine the effect of CH, LIM and C-terminal domains of MICAL on this 
activity. The CH and LIM domains are typical of cytoskeleton proteins and mediate protein-protein 
interactions and both can bind actin for its regulation in response to cell signaling (Puius et al., 1998). 
Thus, they may alter the affinity for actin and also modify the time-course and extent of NADPH 
oxidation observed with the isolated MO domain, which is in contrast with the specific Met hydroxylase 
activity proposed for Drosophila and mouse MICAL (Hung et al., 2013; Lee et al., 2013).   
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Figure 7.7. Effect of human MO domain on actin polymerization state and effect of F-actin on its NADPH oxidation 
reaction. Panel A: the polymerization state of pyrene-labelled G-actin (4.1 μM) in the presence or absence of 
NADPH (N, 100 μM) and human MICAL-MO (M, 660 nM) was monitored fluorimetrically in a Cary Eclipse 
(Varian) fluorimeter. The polymerization was induced by addition of 1/10 volume of polymerization buffer (P) to 
the solution in G-buffer; Panel B: Fluorescence-monitored polymerization and depolymerization of actin (2.3 μM) 
in the presence of NADPH (N, 100 μM) and human MICAL-MO (660 nM, M) added at the indicated times. In the 
panels the traces have been offset for graphical purposes. Panel C: polymerization of G-actin (5 μM) and the effect 
of the addition of MO (M, 30 and 300 nM) and NADPH (N, 100 μM) were monitored by dynamic light scattering. 
Solid lines: oxidation of NADPH (100 μM) monitored at 340 nm under identical conditions. The A340 traces are 
offset to match the time of enzyme addition to the solution containing F-actin and NADPH in the DLS experiment. 
Panel D: time-course and extent of NADPH oxidation catalyzed by MO (M, 20 nM) in the absence and presence of 
F-actin; the insert shows the same traces but on a different time-scale (Zucchini et al., 2011; Vanoni et al., 2012).  
 
 
Table 7.1. Effect of G- and F-actin on the steady-state kinetic parameters of the reaction of human MICAL-MO. The 
steady-state kinetic parameters of the reaction catalyzed by human MICAL-MO in the absence and presence of G- 
and F-actin were measured at 25 °C in 20 mM Hepes/KOH buffer, pH 7.0 (Hepes), G-buffer (5 mM Tris/HCl, pH 
8.0, 0.2 mM CaCl2, 0.2 mM ATP, 1 mM DTT) or and F-buffer (9.5 mM Tris/HCl, pH 7.7, 0.18 mM CaCl2, 1.1 mM 
ATP, 1.3 mM DTT, 45 mM KCl, 1.8 mM MgCl2). The substrates concentrations or concentration ranges are 
indicated. The KM is that calculated for the varied substrate. Data are from Zucchini et al., 2011.  
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7.2. NADPH dependent F-actin depolymerizing activity of MICAL forms  
The effect of MOCH, MOCHLIM and MICAL on the oligomeric state of F-actin was studied by 
monitoring fluorescence changes using pyrenyl-actin and by DLS.  
G-pyrenyl-actin solutions (0.12 mg/ml, 2.8 μM) were prepared as described in Materials and Methods 
(Chapter 10). The actin polymerization, after the addition of 1/10 volume of the polymerization buffer 
(P), was followed by monitoring the increase of emission fluorescence at 407 nm (λex 365 nm) (Figure 
7.8). The addition of NADPH (N, 50 μM) partially quenched the fluorescence intensity due to absorbance 
of the exciting light (Figure 7.8). The addition of MOCH (120 nM, Figure 7.8, panel A), MOCHLIM 
(120 nM, Figure 7.8, panel B) and MICAL (120 nM, Figure 7.8, panel C) caused a drop of the 
fluorescence intensity, indicating that they are all able to catalyzed the F-actin depolymerizing activity. 
Control experiments showed that this process is NADPH-dependent (Figure 7.8, panels D and E).   
As an alternative to fluorescence spectroscopy, the aggregation state of actin can be monitored by DLS 
that measures the mean radius of particles in solution as a function of time. In parallel experiments, the 
NADPH oxidation could be monitored spectrophotometrically at 340 nm. The polymerization of the G-
actin solution (0.19 mg/ml, 4.6 μM) was followed by measuring the increase of the mean radius in 
solution after the addition of 1/10 volume of the polymerization buffer (P). It should be noted that the 
starting G-actin solution showed a average radius of ≈ 20 nm (Figure 7.9, panel A), but data analysis 
demonstrated the presence of a protein species with a radius of 3.2 nm, 51 kDa (Figure 7.9, panel B) 
corresponding to G-actin, and a small fraction of aggregated protein (Figure 7.9, panel B) even after 
centrifugation at 100000xg for 1 h at 4°C.   After the addition of polymerization buffer the mean radius 
reached a maximum value within 20-25 min. Analysis of the data collected 50-60 min after the addition 
of the polymerization buffer (Figure 7.9, panel C) confirmed the complete conversion of G-actin to F-
actin (Figure 7.9, panel E) showing the presence of species with large molecular mass (R, 232 nm) along 
with smaller species (R ≈8.5 nm, 476 kDa; Figure 7.10, panel A). When NADPH (N, 100 μM) was added 
the average radius of particles in solution  did not change (Figure 7.9, panels C, D and E). Instead, after 
the addition of MOCH (130 nM or 30 nM) the average radius of particles in solution decreased from 110 
to 70 nm within 5 min, a time similar to that required for the consumption of all the NADPH present 
(Figure 7.9, panels C and D). The plateau value of the mean radius was higher than that observed for the 
starting G-actin indicating a partial depolymerization of F-actin and/or the presence of aggregates. In fact, 
by analyzing the data collected ≈ 30 min after MOCH addition two protein species were present with an 
apparent radius of 6.2 (252 kDa) and 177 nm (Figure 7.9, panel E), that were lower than those observed 
for F-actin incubated with NADPH (Figure 7.9, panel E). To remove large aggregates, which may be 
formed in solution, the sample was centrifuged at 14900xg for 15 min at 4°C. Now the average radius 
was 15 nm similar to that observed with the starting G-actin solution (Figure 7.9, panels A, C and D).  
The supernatant contained ≈75% of the total protein of the sample before centrifugation  and analysis of 
the DLS signals showed the presence of protein species with a radius of 3.3 or 3.5 nm (55 or 63 kDa) 
(Figure 7.9, panel E), similar to that measured for the starting G-actin solution. A second peak of ≈14 nm 
(156000 kDa; Figure 7.9, panel E) for the actin sample incubated with 130 nM MOCH and of 140 nm, 
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when 30 nM MOCH was added was observed. These species can correspond to shorter actin filaments 
and/or aggregates. Centrifugation was not sufficient to remove all the aggregates present (third peak in 
Figure 7.9, panel E). When MOCHLIM (120 nM or 47 nM) was added to F-actin (4.2 μM) in the 
presence of NADPH (100 μM) the mean radius decreased from 170 to 130 nm, but then increased 
suggesting the formation of aggregates (Figure 7.10, panel A). After centrifugation at 14900xg for 15 min 
at 4°C the mean radius of the supernatant, that contained ≈80% of the total protein content, was 90 nm 
(Figure 7.10, panel B) that was higher than that of G-actin solution. The higher value of the radius could 
be due to the presence of some aggregates that can not be removed at low speed or the presence of shorter 
actin filaments. In fact, in the supernatant protein species with a radius of 6.6 or 6.1 nm (280 or 232 kDa, 
Figure 7.10, panel B) and of 168 or 124 nm were detected (Figure 7.10, panel B), which can correspond 
to shortened actin filaments and/or aggregates.  
Interestingly, the addition of MICAL (1.57 μM) that has been proposed to be inactive with absence of 
plexin (Schmidt et al., 2008), in the presence of NADPH caused an instantaneous decrease of the average 
particles radius from 240 to 170 nm (Figure 7.10, panel C) and reached a final value of 70 nm in 10 min. 
The same time was required to the enzyme to completely oxidize all NADPH present (Figure 7.10, panel 
C). The supernatant of centrifugation at 14900xg for 15 min at 4°C showed an average radius of 40 nm 
indicating, also in this case, the removal of some aggregates (Figure 7.10, panels C and D). Species with a 
6.5 nm radius were observed as for MOCHLIM. To ensure that the drop of the mean radius was not due 
to the addition of the enzyme, F-actin was incubated with MICAL and the mean radius of the solution 
remained constant with a value similar to that of F-actin (Figure 7.10, panel E). The addition of NADPH 
(100 μM) to F-actin led to a decrease of the radius with a similar kinetic of the experiment just described 
(Figure 7.10, panel C) indicating that the depolymerization and or aggregation observed were dependent 
on the NADPH oxidation reaction catalyzed by the enzyme. The data obtained after centrifugation of the 
samples were similar to those observed for MOCHLIM (Figure 7.10, panels D and F). F-actin control 
sample indicated that the disappearance of the protein species with a radius >230 nm was not due to 
centrifugation and that F-actin solution was stable and no aggregates were detected in the supernatant 
(Figure 7.10, panels G and H).    
These experiments qualitatively show that all MICAL forms catalyze a NADPH-dependent reaction, in 
which F-actin filaments are disassembled to yield free monomers in the case of MO and MOCH, but 
larger fragments for MOCHLIM and full-length MICAL and aggregated forms are also present for all 
proteins . In order to obtain quantitative data on the kinetics of the process and on the affinity for NADPH 
and F-actin, the steady-state kinetic parameters of the reaction of MICAL forms with NADPH and F-actin 
were studied.  
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Figure 7.8. Time-course of F-actin 
depolymerization catalyzed by MICAL1 forms. 
Pyrenyl-actin (2.6 µM) in G-buffer was 
polymerized at room temperature upon 
addition of one tenth volume of polymerization 
buffer (P) NADPH (50 µM, N) and the 
indicated MICAL forms (120 nM, panles A-C) 
were added at times indicated by arrow. Panels 
D and E show that NADPH or MOCH alone 
are not sufficient to alter F-actin 
polymerization state. The reactions were 
monitored by measuring the fluorescence 
emission at 407 nm with excitation light at 360 
nm in a Cary Eclipse spectrophotofluorimeter. 
To avoid potential artifacts, irradiation was 
interrupted for several intervals of time 
(continuous lines).  
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Figure 7.9. Analysis of G- and F-actin solutions treated with NADPH and MOCH by DLS. The average radius of G-
actin solution (4.76 μM) was monitored by DLS for 10 min (panel A), which contains protein species corresponding 
to monomeric actin (3.4 nm) and aggregated forms (panel B). Panels C and D: Polymerization of G-actin was 
followed after addition of 1/10 volume of polymerization buffer (P). When G-actin was completely converted to F-
actin NADPH (100 μM, N) and MOCH (130 nM and 30 nM) were added. At ≈90 min the sample was centrifuged at 
14900xg for 15 min at 4°C and the supernatants (SN) were analyzed. Panel E: Determination of the protein species 
present in the F-actin, after the addition of NADPH, ≈30 min after the addition of MOCH and in the supernatants 
obtained by centrifugation.  
 
 
 
 
 
 
 
 
G-actin
3.4
0
10
20
30
0 2 4 6 8 10
Time, min
R
, 
n
m
G-actin, 4.76 μMA B
0
40
80
120
0 20 40 60 80 100 120
Time, min
R
, 
n
m
0
0.2
0.4
0.6
0.8
A
3
4
0
0
40
80
120
0 20 40 60 80 100 120
Time, min
R
, 
n
m
0
0.2
0.4
0.6
0.8
A
3
4
0
+MOCH, 130 nM
458 
C N M
SN
P
+MOCH, 30 nMD NM
P
SN
R
, 
n
m
A
3
4
0
R
, 
n
m
A
3
4
0
3.7
140
3.5
14
F-actin, 4.3 μM
232 +NADPH, 100 μM 242
8.5
6.4
179
E
+MOCH, 130 nM +MOCH 130 nM, SN +MOCH
30 nM, 
SN
 129 
 Figure 7.10. Analysis of G- and F-actin solutions treated with NADPH and MOCHLIM and MICAL by DLS Panels 
A, C, E,: Polymerization of G-actin was followed after addition of 1/10 volume of polymerization buffer (P). When 
G-actin was completely converted to F-actin NADPH (100 μM, N) and MOCHLIM (130 nM and 47 nM) and 
MICAL (1.7 μM) were added. At ≈90 min the sample was centrifuged at 14900xg for 15 min at 4°C and the 
supernatants (SN) were analyzed. Panel B, D, F: Determination of the protein species present in the F-actin, after the 
addition of NADPH, ≈30 min after the addition of MOCH and in the supernatants obtained by centrifugation. 
Analysis of F-actin control sample is shown in panels G and H.  
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7.3. Effect of F-actin on the NADPH oxidation reaction of  MICAL forms 
F-actin, but not G-actin, stimulates the rate of NADPH oxidation reaction catalyzed by the isolated MO 
domain of human MICAL1 (Zucchini et al., 2011). The effect of F-actin on the reaction catalyzed by 
MOCH, MOCHLIM and MICAL was studied.  
In preliminary experiments, F-actin solutions (0.2 mg/ml, 5 μM) were incubated with NADPH (100 μM) 
for 3 min at 25°C, then MOCH (150 nM), MOCHLIM (115 nM) or MICAL (1.57 μM) was added. The 
NADPH oxidation was monitored by recording the absorption spectrum every 10 s in a diode array 
spectrophotometer. In this way, we could detect the contribution of absorbance of F-actin and possible 
absorbance changes due to aggregation/denaturation. For comparison oxidation was measured in F-buffer 
in the absence of F-actin.  
For all MICAL forms F-actin enhanced the rate of NADPH consumption, so that the initial velocity, 
expressed as v/[E] to compensate for the different mass of the enzymes, increased ≈10-fold:  from 0.3 s-1 
in F-buffer to 2.9 s
-1
 for MOCH  (Figure 7.11, panel A), from 0.2 s
-1
 to 2.15 s
-1
  for MOCHLIM (Figure 
7.11, panel B) and from 0.02 s
-1
 to 0.2 s
-1
 for MICAL (Figure 7.11, panel C). 
As observed for MO, F-actin greatly stimulates NADPH consumption by MOCH, MOCHLIM and 
MICAL as expected for a monooxygenase in the presence of its substrate. However, in contrast with the 
hypothesis of a specific actin monooxygenase reaction, the amount of NADPH being oxidized always 
exceeded that of F-actin present. This result is in contrast with the specific modification of Met44 or 
Met47 of actin monomers that would have predicted fast oxidation of 2 molecules of NADPH per actin 
monomer present (Hung et al., 2014; Lee et al., 2014). Rather the observed time-course and extent of 
NADPH consumption could be explained, as done before, as due to: (i) a case of substrate recycling (i.e.: 
the effect of MICAL on F-actin is reversible); (ii) an enhanced rate of the NADPH oxidation upon 
interaction with F-actin leading to both Met hydroxylation (monooxygenase activity) and NADPH 
oxidase (H2O2-production) activity occurring at the same rate or (iii) enhanced NADPH oxidase activity. 
In the latter case, actin chemical modification would be due to in situ enhanced production of H2O2 rather 
than to a hydroxylation reaction.   
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Figure 7.11. Time-course of NADPH oxidation catalyzed by MICAL and the truncated MOCH and MOCHLIM 
forms in the absence (open circles) or in the presence of F-actin (5 µM, closed circles) in F-buffer. MOCH (150 
nM), MOCHLIM (115 nM), and full-length MICAL (1.5 µM) were incubated with NADPH (100 µM) in the 
absence (open circles) or in the presence of F-actin (5 µM, closed circles) in F-buffer at 25 °C. The time-course of 
NADPH oxidation was monitored by absorption spectroscopy at 340 nm. 
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7.4. Determination of the steady-state kinetic parameters of the NADPH oxidation reaction of MICAL 
forms  in the presence of F-actin 
The apparent steady-state kinetic parameters kcat, KNADPH and apparent Km for F-actin of MOCH, 
MOCHLIM and MICAL forms were determined by measuring the initial velocity of NADPH 
consumption monitored at 340 nm and 25°C.  
The kinetic parameters kcat and KNADPH were determined in the absence and in the presence of fixed F-
actin concentration (≈0.17 mg/ml, 4 μM) in F-buffer and varying the NADPH concentration (10 - 400 
μM).  
Double reciprocal plots were linear so that the kcat and KNADPH could be calculated by fitting the data to 
the Michaelis-Menten equation (Eq.2; Figure 7.12, upper and middle panels; Table 7.2). 
The kcat and apparent Km for F-actin parameters were determined in the presence of a fixed NADPH 
concentration (200 μM) and varying F-actin concentration (1-26 μM).  
Again, a hyperbolic dependence of v/[E] upon F-actin concentration was observed (Figure 7.12, lower 
panels; Table 7.2). The calculated kcat and Km for F-actin are in Table 7.2.  
F-actin stimulates the NADPH oxidation reaction by increasing kcat and lowering Km for NADPH leading 
to values that vary within a factor of 2 for MO, MOCH and MOCHLIM (Table 7.1 and 7.2). Also the 
apparent Km for F-actin of the three truncated MICAL forms was similar (≈4 μM). These results indicated 
that the presence of the CH and LIM domains, which are found in proteins that interact with actin do not 
apparentely alter the affinity of MICAL for filamentous actin and the flavoprotein domain seem to be the 
main site where the interaction with F-actin takes place. 
Full-length MICAL showed an apparent Km for F-actin 10-fold higher than that of the other forms (Table 
7.2) indicating that the C-terminal region of MICAL lowered the apparent affinity of the MO domain for 
F-actin. Instead, the apparent values of kcat and KNADPH (extrapolated at infinite actin concentration and at 
200 μM NADPH) were similar to those of the other forms (KNADPH) and only 2-3-fold lower (kcat) (Table 
7.2).  
Overall, contrary to early proposals, these results indicate that the CH and LIM domains do not alter the 
affinity for F-actin and have no effect on the rate at which the MO domain oxidizes NADPH in the 
presence of F-actin. Interaction between all MICAL forms and F-actin, presumably mainly through the 
MO domain, causes an increase of kcat to similar values, as well as a drop of KNADPH also to similar values 
for the four proteins forms. The C-terminal region of MICAL causes only a 10-fold increase of the 
apparent Km for F-actin, which makes this species able to bind to F-actin and depolymerize it also in the 
free form; i.e., in the absence of the activating interaction with plexin in response to semaphorins or other 
interactors.  
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Figure 7.12. Determination of the steady-state kinetic parameters of the NADPH oxidation reaction catalyzed by 
human MICAL1 forms in the absence and presence of F-actin. The initial velocity of the NADPH oxidation 
catalyzed by MOCH (panel A), MOCHLIM (panel B) and full-length MICAL (panel C) was measured in F-buffer 
in the absence (upper panels) and in the presence of 4 μM F-actin (middle panels) by varying NADPH 
concentration. The v/E values were also measured in the presence of 200 μM NADPH and by varying F-actin 
concentration (lower panels). The curves are the best fit of the data to the Michaelis-Menten equation (Eq 2). The 
calculated values of the kinetic parameters are indicated in Table 7.2.  
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Table 7.2. Steady-state kinetic parameters of the NADPH oxidative reaction in the presence of F-actin catalyzed by 
MICAL1 forms. Assays were carried out at 25°C in F-buffer in the absence or presence of the indicated 
concentrations or concentration ranges of F-actin and NADPH. The apparent kcat and Km values  for the varied 
substrate and their associated errors were determined by fitting the data to the Michaelis-Menten equation (Eq. 1). 
The error associated with the calculated kcat/Km values was calculated according to Bevington et al., 1969. 
 
Protein, nM NADPH, μM F-actin, μM kcat, s
-1
 Km, μM kcat/Km, s
-1
mM
-1 
MO, 120
a 
10-300 - 2.6 ± 0.4 555 ± 118 4.6 ± 1.2 
MO, 20
a 
10-300 2.4 12 ± 0.5 11.3 ± 2.7 1090 ± 260 
MO, 20
a 
300 7 - 35 20 ± 1.0 4.7 ± 1.0 4149 ± 908 
MOCH, 190 10-500 - 1.7 ± 0.1 459 ± 66 3.8 ± 0.6 
MOCH, 3 10-200 4.2 21 ± 1.2 50 ± 8  423 ± 72 
MOCH, 3 200 1 - 26 26 ± 1.2 2.7 ± 0.4 9487 ± 1468 
MOCHLIM, 125 25-1000 - 4.3 ± 0.2 966 ± 66 4.5 ± 0.4 
MOCHLIM, 12 20-200 4.4 6.4 ± 0.2 14 ± 1.6 448 ± 52 
MOCHLIM, 12 200 2-24 15 ± 0.6 4.4 ± 0.5 3390 ± 378 
MICAL, 1250 100-700 - 0.8 ± 0.5
b 
4652 ± 3202
b 
0.17 ± 0.15
b 
MICAL, 91 10-400 4.3 1.9 ± 0.1 29 ± 5 64.8 ± 12.2 
MICAL, 91 200 3.8-23 7.8 ±  1.2 29 ± 7 276 ± 87 
a
Data from Zucchini et al., 2011; 
b
the parameters are poorly defined due to the high Km value for NADPH. 
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7.5. Determination of the chemical modifications of actin introduced by the NADPH oxidation reaction 
catalyzed by human MICAL1 forms  
In the presence of F-actin all MICAL forms consumed all the NADPH present at a rate that was higher 
than that measured in the absence of F-actin. This result was in contrast with the proposal of a specific 
modification of Met44 and/or Met47 residue through hydroxylation (Hung et al., 2014; Lee et al., 2014); 
that predicted a fast consumption of 2 molecules of NADPH per mol of actin present. Thus, it was 
important to determine the extent of actin oxidation during this reaction with each one of the proteins. 
Toward this goal, actin samples treated with human MICAL forms were prepared to determine (i) the 
mass of the actin monomer and (ii) the modified residues, in comparison with control actin samples. The 
mass spectrometry analyses were carried out in the laboratory of Prof. Tedeschi (Dipartimento di Scienze 
Veterinarie e Sanità Publica, Università degli Studi di Milano).  
To prevent non-specific modifications of actin residues due to H2O2 production by the NADPH oxidase 
activity of free MICAL forms, catalase (0.83 μg/ml) was added in the reaction mixture in addition to DTT 
already present in F-buffer. Aliquots of F-actin solution that had been incubated with NADPH and 
MICAL forms at concentration suitable to bring the reaction to completion in less than 1 h were 
additionated with 10 volumes of cold acetone:methanol (8:1) to precipitate the proteins. The dried protein 
pellets were kept at -20°C until analyses. We also prepared several control samples of G- and F-actin that 
had been incubated on ice or at 25°C in the presence/absence of NADPH for times similar to those of the 
samples incubated with NADPH and MICAL forms.   
Actin samples and samples of actin treated with MICAL forms in the presence of NADPH, were analyzed 
by MALDI-TOF (at least two independent measurements per sample) to determine the mass of the 
protein.  
G-actin sample treated with MOCH (600 nM; Figure 7.13, panel A) showed an increase of mass (Δmass) 
of 16 Da with respect to the untreated sample  (Table 7.3, Figure 7.14 panel A) consistently with the 
introduction of one atom of oxygen in each actin monomer that, in this case, was due only to the NADPH 
oxidase H2O2-producing activity of MOCH. Instead, F-actin samples incubated with 100 or 200 μM 
NADPH and MO, MOCH, MOCHLIM and MICAL (Figure 7.13, panels B-H) until >90% of the 
NADPH had been oxidized, showed a similar Δmass of 30-48 Da compared to the control actin sample 
indicating the addition of 2-3 atoms of oxygen per actin monomer (Table 7.3, Figure 7.14, panels B-D). 
Interestingly, F-actin sample that had been incubated with NADPH and MOCH for a time corresponding 
to only 20-30 μM NADPH oxidation showed modification levels below detection. This observation 
would rule out that in the early reaction phase the enzyme acts as a Met monooxygenase and later as an 
oxidase. Analysis of peptides obtained by tryptic digestion follwed by mass spectrometry showed tha 
actin Met44 and Met47 were modified along several other Met and Trp residues (Table 7.4). Although 
aromatic residues could be substrates of a monooxygenase reaction of MICAL-MO, especially in the light 
of similarity with PHBH, it seems unlikely that the enzyme is equally able to modify Met and Trp 
residues. Rather, the modification of several residues would suggest that actin modification by MICAL is 
indirect and depends on in situ NADPH-dependent H2O2-production.  
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Figure 7.13. Time-course inspection of the NADPH oxidation of F-actin samples treated with human MICAL1 forms 
form their analysis by mass spectrometry. G-actin solution (23 μM) was incubated with NADPH (100 μM) and 
MOCH (panel A). F-actin (23 µM) was incubated with 100 µM NADPH and MO (30 nM, panel B), MOCH (30 nM 
or 10 nM, panels C, D), MOCHLIM (115 nM, panel E) and MICAL (115 nM, panel G) or with   200 µM NADPH 
and MOCHLIM (115 nM, panel F) and MICAL (115 nM, panel H). The arrow indicates the time at which the 
reaction was blocked by adding acetone-methanol. F-actin samples treated with MICAL forms were used to 
determine the whole mass of actin by MALDI-TOF to compare with that of control actin sample. The results are 
indicated in Table 7.3.    
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Figure 7.14. Mass spectra of G- and F-actin after incubation with NADPH and MOCH form of human MICAL1. 
Panel A: mass spectra of G-actin (red line) solution and that after incubation with MOCH (600 nM) and NADPH 
(100 μM; A340 changes are shown in Figure 7.13, panel A) are shown. The mass spectra of F-actin (20 μM) 
incubated with NADPH (100 μM) in the absence (panel B) and presence of MOCH (30 nM, panel C; 10 nM, panel 
D) are shown. The corresponding time-course of NADPH oxidation catalyzed by MOCH are shown in Figure 7.13, 
panels C and D. The observed mass of actin samples is indicated in Table 7.3.   
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Table 7.3. Summary of the mass of actin samples that had been treated with human MICAL1 forms, as determined 
by MALDI-TOF.  F-actin samples that has been incubated with MICAL forms and NADPH in F-buffer additioned 
with catalase (1 mg/ml) for the indicated amounts of time were precipitated with cold methanol/acetone and 
subjected to mass determination by MALDI-TOF (at least two independent measurement per sample). The mass 
change (ΔMass) was calculated with respect to the mass of F-actin samples that had been incubated in the absence 
of MICAL forms (in bold). Note that the actin batch used for Experiment 1 is different from that used for the other 
two experiments.  
Experiment Protein Actin NADPH Time Reaction Mass ΔMass Oxidations 
 nM µM µM min % Da Da  
1 - (G-) 23 100 - N/A 41879 -  
 MOCH, 600 (G-) 23 100 60 95 41894 15 1 
         
1 - (F-)23 100 20 N/A 42505 - - 
 MOCH, 30 (F-) 23 98 20 90 42553 48 3 
 MOCH, 10 (F-) 23 97 60 85 42548 43 3 
         
2 - (F-) 23 100 10 N/A 41847 - - 
 MO, 30 (F-) 23 100 20 96 41887 40 3 
 MOCHLIM,120 (F-) 23 100 10 96 41889 42 3 
 MICAL,120 (F-) 23 100 60 86 41887 40 3 
3 - (F-) 23 190 13 N/A 41847 - - 
 MOCHLIM, 120 (F-) 23 190 13 96 41879 32 2 
 MICAL,240 (F-) 23 190 60 96 41880 33 2 
 
 
 
Table 7.4. Identification of actin residues modified upon incubation with MICAL MO and MOCH forms. Aliquots of 
F-actin (25 µM) samples that had been incubated at 25°C with NADPH (85-200 µM) and MICAL MO (30 nM) or 
MOCH (10-20 nM) in F-buffer supplemented with catalase (1 mg/ml) for 10-60 min to reach 90-95% oxidation of 
NADPH were precipitated with methanol/acetone, digested with trypsin and analyzed by MALDI-TOF (at least two 
duplicates per sample).  The peptide maps were independent from the protein form, NADPH concentration and 
incubation time and led to identify the indicated residues. The numbering is that of rabbit skeletal α-actin (UniProt 
code P68135, ACTS_RABIT, see below), so that Met46 and Met49 correspond to Met44 and Met47 discussed in 
the main text and in (Hung et al., 2011, 2013; Galkin et al., 2015). 
Peptide sequence Residue Δ mass 
21AGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQK52 M46, M49 +32 (2ox) 
42HQGVMVGMGQK52 M46,M49 +32 (2ox) 
259CPETLFQPSFIGMESAGIHETTYNSIMK286 M271 or M285 +16 (1ox) 
331IIAPPERKYSVWIGGSILASLSTFQQMWITK361 M357 or W342 or W358 +16 (1ox) 
71YPIEHGIITNWDDMEKIWHHTFYNELR97 M84 or W81 orW88 +32 (2ox) 
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Inspection of the location of the modified residues on actin filaments reveals how their modification may 
take place through such in situ H2O2 production with some (stereo)specificity.     
F-actin consists of two interacting strands containing two-six subunits per turn. Thus it cannot be 
crystallized preventing its structural determination at the atomic level. Techniques such as cryo-electron 
microscopy (cryo-EM) and X-ray fiber diffraction have been the main tools available to study the 
structure of protein polymers like F-actin of which multiplicity of structural states and models have been 
proposed (Galkin et al., 2015). Recently, the development of direct electron detectors allows cryo-EM to 
reach near-atomic resolution (4.5 Ǻ); such technique has been used to study the details of intra- and inter-
molecular interactions of the actin filament (Galkin et al., 2015). In vitro polymorphism was observed in 
actin filaments, in agreement with the dynamic nature of the molecule and demonstrating that a unique 
model of its structure is not possible (Figure 7.15). Each actin strand in the filament is stabilized by 
longitudinal contacts between subdomains (SD) 3-4 and 2-1 of adjacent monomers; Asp241, Glu245, and 
Asp244 of the actin molecule interact with Thr324, Pro322, and Met325 of the monomer just above it, 
along the filament (Figure 7.16). The interface between SD2 of the lower subunit and SD1/3 of the upper 
subunit includes contacts between residues Met44:Tyr143, Met47:Phe352, Lys61:Ile167, Arg62:Asp288, 
and Ile64:Tyr166 (Figure 7.16).  Lateral contacts between the strands involve two pairs of interacting 
residues in SD1 and SD4, namely: residues Lys113:Asp195 and Arg111:Thr194 (Figure 7.16). Met44 
interacts with Tyr143 and the backbone of nitrogen of Met44 makes a hydrogen bond with Gly168 
indicating that this residue is crucial for the stabilization of the filament. In addition, Met47 interacts with 
Phe352 stabilizing the D loop that is a highly flexible region of actin and its position and stabilization is 
critical for the maintenance of the integrity of the filament. Met44 and Met47 are in the proximity of 
Lys61, Arg62, Ile64, Lys113 residues that stabilize lateral interactions in the filament.  The role and the 
position of Met44 and Met47 explain why F-actin depolymerization occurs upon their modification by 
MICAL. The other residues that have been found to be modified in F-actin treated with NADPH and MO 
and MOCH  (Table 7.4) are located close or at the interface between actin monomers. Met283 and 
Met269 are in the proximity of residues Glu241, Asp244, Asp288, Thr324, Met325, which are involved 
in the stabilization of dimer units of filament actin through interactions with upper-lower monomer; 
Trp356 and Met355 are in the proximity of Phe352 that stabilizes D-loop (Figures 7.17 and 7.18).   
The data are consistent with the work done with the Drosophila and mouse MICAL, for which the 
modification of Met44 and Met47 of actin that of several other residues was reported (Hung et al., Lee et 
al., 2013). We can speculate that MICAL may bind to F-actin with the MO domain at the interface 
between actin monomers. The interaction may activate the NADPH oxidase activity so that in situ release 
of H2O2 may lead to the modification of a limited number of residues. Met44 and Met47 may be located 
at a site that makes them especially vulnerable to H2O2 attack. The precise geometry of MICAL-MO/actin 
interaction may render the H2O2-mediated oxidation of these Met residues stereospecific to yield an 
enantiomeric excess of the R isomer. In this respect, experiments to test the interaction between MICAL 
forms and F-actin in the absence of NADPH are in progress to set the basis to determine precisely where 
the interaction between MICAL forms and F-actin takes place, e.g., by cryo-electron microscopy.    
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Figure 7.15. Comparison of Canonical F-Actin with T1-Actin and T2-Actin. Panels A-C: SD1–SD4 are labeled 1–4. 
The bottom are the same 3D reconstructions rotated by 90 degrees. Actin protomers are shown in different colors. 
All 3D reconstructions are filtered to 12 A ° resolution. Panel D: Transition from canonical actin (red) to T1-actin 
(cyan) involves a rotation of SD4/SD3 by 15° around the hinge region (black arrow). Panel E: Transition from T1-
actin (cyan) to T2-actin (blue) mainly involves transition of the 197–215 region of SD4 (magenta) toward SD2 (red 
arrow).Panel F) Alignment of T2-protomer (blue) with the crystal structure of actin in the open state (Galkin et al., 
2015).  
Figure 7.16. Interface between Actin Protomers in the Canonical Structural State of F-Actin .(A) Interface between 
SD3 and SD4. Residues in SD4 of the lower protomer are in red, while residues in SD3 of the upper protomer are in 
blue. Black arrow indicates a bridge of density between residues 241 and 324. Pro243 forms a kink in the top of the 
loop and is believed to position Asp241, and Asp244 is shown in orange. (B) Side chains of residues 205 (in red) 
and 286 (in blue) are seen in the map and are not involved in the SD3/SD4interactions. (C) Interface between SD2 
of the lower protomer (red residues) and SD1/3 of the upper protomer (blue residues). Red arrow indicates a contact 
between residues 44:143, while the red arrowhead marks a contact between residues 47:352. (D) Pro38 (red) makes 
a bridge of density with Tyr169 in blue (blue arrow), while Tyr53 (cyan) makes an interaction with Lys84, which is 
in magenta (magenta arrow). (E) Hydrophobic plug does not make any strong specific interactions with protomers in 
the opposite strand. There are hydrogen bonds between Val201/Thr202 (in red) and Ser271 (in magenta), along with 
a hydrophobic interaction between His173 (in cyan) and Ile267 (in blue). (F) Lateral contacts between the two 
strands contain two pairs of interacting residues in SD1 are in blue, while residues in SD4 are in red (Galkin et al., 
2015).    
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Figure 7.17. Sites of actin chemical modification upon 
incubation with human MICAL forms. The residues 
that were found to be oxidized in F-actin that had been 
treated with MICAL MO and MOCH (see Table 7.4) 
are shown in red in the sequence of rabbit skeleton 
muscle sequence (UniProt code P68135, 
ACTS_RABIT) and in spacefill in the 4.7 Å resolution 
structural model of F-actin (PDB ID 3J8I, Galkin et 
al., 2015) comprising 5 chains (D-H) using the 
numbering appearing in the PDB file that takes into 
account the fact that the chain starts at Asp, so that , 
e.g., M46 and M49 of table 7.4 and in the sequence 
become M44 and M47. The modified residues are 
identified in chain H and in the dimer of actin formed 
by chains F and D (lower panels). Colour code: carbon 
in light grey, nitrogen in blue, oxygen atom in red and 
phosphorus in green. The figure was drawn with CCP4 
(McNicholas et al., 2011). 
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Figure 7.18. Sites of actin chemical modification upon 
incubation with human MICAL forms. The residues that 
were found to be oxidized in F-actin that had been treated 
with MICAL MO and MOCH (see Table 7.4) are in ball 
and sticks (red labels in lower panel) and residues important 
to the stabilization of the actin filaments (black labels) 
according to Galkin et al., 2015 are in sticks in the 4.7 Å 
resolution structural model of F-actin (PDB ID 3J8I, Galkin 
et al., 2015) comprising chains A and E using the 
numbering appearing in the PDB file that takes into account 
the fact that the chain starts at Asp, so that , e.g., M46 and 
M49 of table 7.4 and in the sequence become M44 and 
M47. The modified residues are identified in chain H and in 
the dimer of actin formed by chains F and D (lower panels). 
Colour code: carbon in light grey, nitrogen in blue, oxygen 
atom in red and phosphorus in green. The figure was drawn 
with CCP4 (McNicholas et al., 2011). 
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8. MICAL and CRMP 
Collapsin Response Mediator Proteins (CRMP) form a family of cytoplasmic proteins, which participate 
in cytoskeleton dynamics by controlling the assembly of microtubules and actin filaments. It has been 
recently proposed that MICAL and CRMP proteins interact, and that such interactions link actin and 
microtubules dynamics in the cell (Schmidt et al., 2008).  
In this chapter an overview of CRMP properties and functions is followed by a summary of the 
experimental evidence of MICAL-CRMP interactions and how these interactions may link the actin and 
microtubules cytoskeleton components. Then, the results of a series of preliminary experiments aimed to 
study the interaction of CRMP1 with human MICAL1 MO and MOCH and its effect on the catalytic 
properties of MICAL, will be presented.   
 
8.1. Collapsin Response Mediator Proteins (CRMP) 
CRMPs form a family of cytosolic phosphoproteins that are expressed mainly in the central nervous 
system, with some isoforms also expressed in peripheral nervous system (Schimdt et al., 2007). Chick 
CRMP-62 protein was isolated as a factor required for collapsin1-mediated signaling leading to growth 
cone collapse in dorsal ganglion neurons (Wang et al., 1997). Independently, and at approximately the 
same time, a number of CRMP genes were indentified in different species and they were named 
according to their method of discovery. CRMP proteins are also known as TOAD-64 (turned on after 
division), DRP (dihydopyirimidinase related protein), Ulip (unc33 like protein) and TUC 
(TOAD64/Ulip/CRMP) (Schimdt et al., 2007). In vertebrates 4 genes encode CRMP1, 2, 4 and 5 
proteins, with CRMP4 sometimes called CRMP3 and CRMP5 also named “CRMP3-associated molecule” 
(Table 8.1). Drosophila has only one gene coding for CRMP. CRMP1-5 proteins show high protein 
sequence identity with each other (Figure 8.1, Table 8.1)  and some isoforms of  CRMP1, 2 and 4 have 
been found to derive from alternative splicing (Leung et al., 2002; Quinn et al., 2003). CRMP1-5 proteins 
show high sequence homology and structural similarity to dihydropyrimidinase (DHPase), which belongs 
to the family of metal-dependent aminohydrolases (Wang et al., 1997; Deo et al., 2004). However, 
CRMPs have no enzymatic activity, likely due to the absence of the crucial catalytic His residues of 
DHPase that coordinate the zinc ion in the active site (Deo et al., 2004).  
A form of mouse CRMP1 lacking the first 7 residues was produced in E.coli cells and purified in order to 
subject it to crystallization experiments. During purification the protein underwent proteolytic removal of 
the last 60 residues so that crystals of CRMP1 8-490 form were obtained (Deo et al., 2004). In the crystal, 
each polypeptide chain folds in two domains and oligomerizes to yield a tetramer. The three-dimensional 
structure of full-length human CRMP2 and CRMP5 showed the same fold (Stenmark et al., 2007; 
Ponnusamy et al., 2013) as that of mouse CRMP1 (Figure 8.2). The asymmetric crystallographic unit of 
CRMP2 consisted of a homotetramer. However, the protein eluted from gel filtration with a mass of 150 
kDa that corresponds to a trimer of 55 kDa monomers, indicating the presence of various oligomeric 
states (Stenmark et al., 2007). In both CRMP 2 and CRMP5 structures the C-terminal region was not 
visible, in the structure of CRMP5 10 extra residues were observed compared to CRMP1 and 2. Their 
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location indicated that the C-terminal region of CRMP does not have a secondary structure and is far 
away from the core of the protein supporting its role in stabilizing interactions among monomeric units 
rather than intramolecular interactions (Figure 8.2; Ponnusamy et al., 2013).  
CRMP proteins are able to interact with each other to form heterotetramers when purified from brain 
(Wang et al., 1996). It has been proposed that the specificity of the hetero-oligomerization is driven by 
the different tendency of CRMP proteins to interact with each other, but in vivo, also by the spatio-
temporal expression of CRMP1-5 protein. The formation of heterotetramers was also confirmed by co-
immunoprecipitation of lysate of HEK293T cells expressing CRMP2 and CRMP3 (actually CRMP4) 
(Wang et al., 1997). CRMPs are most highly expressed during the neurogenic period of brain 
development and expression levels increased during axon cone growth. CRMP proteins are mainly found 
in the cytoplasm, but a significant fraction has been found associated with the cell membrane at the 
leading edge of the growth cone, in lamellipodia and filopodia, supporting a role in axon outgrowth and 
guidance, as well as cell migration and cell-cell contacts. Moreover, CRMP expression is induced after 
injury in both the central and peripheral nervous system (Schimdt et al., 2007). In this respect, it has been 
demonstrated that also CRMPs are involved in the control of cytoskeleton dynamics in response to the 
semaphorins signaling (Deo et al., 2004). COS7 cells expressing PlexA1 and NP1 (neuropilin 1) alone or 
in the presence of CRMP1-5 were incubated with Sema3A. The cells area of COS7 cells co-expressing 
PlexA1-NP1 and CRMPs decreased 10 min after of the addition of Sema3A, while 60 min were required 
when only PlexA1-NP1 were expressed (Deo et al., 2004). An interaction between PlexA1 and CRMP1-5 
was observed in co-immunoprecipitation experiments, but direct complex formation between the purified 
proteins expressed in E.coli cells was not detected (Deo et al., 2004). Mutation of residues 49-56, which 
form the “activation loop” (shown in red in Figure 8.1 and 8.2) of the mouse CRMP1 resulted in a 
constitutively active protein that leads to cell contraction also in the absence of PlexA and/or Sema3A 
(Deo et al., 2004).  
The activation of CRMP is also regulated by their phosphorylation state. It has been demonstrated that the 
phosphorylation of Ser522 by Cdk5 allows for the subsequent phosphorylation of CRMP2 and CRMP4 at 
Ser518, Thr509 and Thr514 by the serine/threonine kinase GSK3β (Glycogen sintase kinase 3-beta) 
(Zhang et al., 2008; Figure 8.1). The contractile effect exerted by CRMP in cells indicates that also 
CRMP has a functional role in the control of cytoskeleton dynamics in the semaphorin signaling pathway. 
In fact, CRMP2 induces microtubule assembly by binding to α- and β-tubulin heterodimers through 
residues 500-570 (double underlined sequence in Figure 8.1; Figure 8.3; Gu et al., 2000; Lin et al., 2008). 
However, this activity is abolished when Thr514 is phosphorylated by GSK3β kinase and also by Rho 
kinase suggesting that also other guidance cues may converge on this pathway (Lin et al., 2008). Other 
studies have shown that a pool of CRMP proteins colocalize with actin in growth cones (Khazaei et al., 
2014). It is therefore possible that CRMP modulates changes in actin dynamics as well. However, CRMP 
may be linked to actin cytoskeleton by other proteins, like MICAL. 
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Table 8.1. Summary of CRMP sequences retrieved from databanks. The identification was done by taking into 
account annotations and direct sequence comparison. When several isoforms were present the putative full-length 
protein was selected. The comparison of the following sequences is shown in Figure 8.1 and was done using 
ClustalW (Goujon et al., 2010). 
 
Protein Chromosome 
location 
Organism Protein synonym Accession number 
CRMP1 4p16.1 Homo sapiens dihydropyrimidinase-related protein 1 
dihydropyrimidinase-like 1 
unc-33-like phosphoprotein 3 
NP_001304.1 
CRMP1 5 B3; 5 19.96 cM Mus musculus  NP_031791.3 
CRMP1 14 Rattus norvegicus  Q62950.1 
CRMP1 1 Danio rerio  NP_001018561.1 
CRMP1 5 Macaca mulatta  NP_001253004.1 
CRMP2 8p22-p21 Homo sapiens dihydropyrimidinase-related protein 2 
unc-33-like phosphoprotein 2 
NP_001377.1 
CRMP2 14 D1; 14 34.6 cM Mus musculus DRP-2 
ULIP-2 
NP_034085.2 
CRMP2 15p12 Rattus norvegicus  NP_001099187.1 
CRMP2 10 Danio rerio  NP_001018353.1 
CRMP2 8 Macaca mulatta  EHH28366.1 
CRMP4 10q26 Homo sapiens dihydropyrimidinase-related protein 4 
unc-33-like phosphoprotein 4 
CRMP3 
DRP-4 
ULIP-4 
NP_006417.2 
CRMP4 7 (F4) Mus musculus  NP_036123.3 
CRMP4 1q41 Rattus norvegicus  NP_037065.1 
CRMP4 21 Danio rerio  NP_001018348.1 
CRMP5 2p23.3 Homo sapiens dihydropyrimidinase-related protein 5 
unc-33-like phosphoprotein 6 
DRP-5 
ULIP-6 
CRMP3-associated molecule 
NP_001240653.1 
CRMP5 5 (B5) Mus musculus  NP_075534.1 
CRMP5 6q14 Rattus norvegicus  NP_075412.1 
CRMP5 4 Danio rerio  AAX86822.1 
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      Activation loop  
humanCRMP1           -MS---YQGKKSIPHITSDRLLIKGGRIINDDQSLYADVYLEDGLIKQIGENLIVPGGVK 56 
macaqueCRMP1         -MS---YQGKKSIPHITSDRLLIKGGRIINDDQSLYADVYLEDGLIKQIGENLIVPGGVK 56 
mouseCRMP1           -MS---HQGKKSIPHITSDRLLIRGGRIINDDQSFYADVYLEDGLIKQIGENLIVPGGVK 56 
ratCRMP1             -MS---HQGKKSIPHITSDRLLIRGGRIINDDQSFYADVYLEDGLIKQIGENLIVPGGVK 56 
zebrafishCRMP1       -MSGTGYQGKKNIPHLTSERLLIKGGRVVNDDQSLYADVYVEDGIIKQVGENLIVPGGVK 59 
mouseCRMP2           -MS---YQGKKNIPRITSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVK 56 
ratCRMP2             -MS---YQGKKNIPRITSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVK 56 
humanCRMP2           -MS---YQGKKNIPRITSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVK 56 
macaqueCRMP2         -MS---YQGKKNIPRITSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVK 56 
zebrafishCRMP2       -MSG--YQGKKNIPRITSDRLLIKGAKIVNDDQSFCADIYMEDGLIKQIGENLIVPGGVK 57 
mouseCRMP4           -MS---FQGKKSIPRITSDRLLIKGGKIVNDDQSFHADLYVEDGLIKQIGENLIVPGGIK 56 
ratCRMP4             -MS---FQGKKSIPRITSDRLLIKGGKIVNDDQSFHADLYVEDGLIKQIGENLIVPGGIK 56 
humanCRMP4           -MS---FQGKKSIPRITSDRLLIRGGRIVNDDQSFYADVHVEDGLIKQIGENLIVPGGIK 56 
zebrafishCRMP4       -MS---YQGKKNIPKITSERLLIKGGRIVNDDQSFYADIYMEDGVIKQIGDNLIVPGGVK 56 
mouseCRMP5           -ML----------ANSASVRILIKGGKVVNDDCTHEADVYIESGIIQQVGRELMIPGGAK 49 
ratCRPM5             -ML----------ANSASVRILIKGGKVVNDDCTHEADVYIENGIIQQVGRELMIPGGAK 49 
humanCRMP5           -ML----------ANSASVRILIKGGKVVNDDCTHEADVYIENGIIQQVGRELMIPGGAK 49 
zebrafishCRMP5       MMS----------GGGSSMRILIKGGRVVNDDVTEEADVYLENGRIQQVGRDLMIPGGAK 50 
                      *               * *:**:*::::*** :  **: :* * *:*:*  *::*** * 
humanCRMP1           TIEANGRMVIPGGIDVNTYLQKPSQGMTAADDFFQGTRAALVGGTTMIIDHVVPEPGSSL 116 
macaqueCRMP1         TIEANGRMVIPGGIDVNTYLQKPSQGMTAADDFFQGTRAALVGGTTMIIDHVVPEPGSSL 116 
mouseCRMP1           TIEANGRMVIPGGIDVNTYLQKPSQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGSSL 116 
ratCRMP1             TIEANGRMVIPGGIDVNTYLQKPSQGMTSADDFFQGTRAALAGGTTMIIDHVVPEPGSSL 116 
zebrafishCRMP1       VIEANGCMVIPGGIDVNTCLHKPYLGTPPVDDFYQGTKAALAGGTTMIIDHVTPQPGDGL 119 
mouseCRMP2           TIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSL 116 
ratCRMP2             TIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSL 116 
humanCRMP2           TIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSL 116 
macaqueCRMP2         TIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSL 116 
zebrafishCRMP2       TIDAHGRMVMPGGIDVHTRFQMPDRGMTAADDFYQGTRAALAGGTTIIVDHVVPEPGTSL 117 
mouseCRMP4           TIDAHGLMVLPGGVDVHTRLQMPVMGMTPADDFCQGTKAALAGGTTMILDHVFPDAGVSL 116 
ratCRMP4             TIDAHGLMVLPGGVDVHTRLQMPVLGMTPADDFCQGTKAALAGGTTMILDHVFPDAGVSL 116 
humanCRMP4           TIDAHGLMVLPGGVDVHTRLQMPVLGMTPADDFCQGTKAALAGGTTMILDHVFPDTGVSL 116 
zebrafishCRMP4       TIEANGKMVIPGGIDIHTHLQMPFRGTTTADDFTQGTKAALAGGTTMIVDHVIPEPGCSL 116 
mouseCRMP5           VIDATGKLVIPGGIDTSTHFHQTFMNATCVDDFYHGTKAALVGGTTMIIGHVLPDKETSL 109 
ratCRPM5             VIDATGKLVIPGGIDTSTHFHQTFMNATCVDDFYHGTKAALVGGTTMIIGHVLPDKETSL 109 
humanCRMP5           VIDATGKLVIPGGIDTSTHFHQTFMNATCVDDFYHGTKAALVGGTTMIIGHVLPDKETSL 109 
zebrafishCRMP5       VIDATGKLVIPGGIDSSVHLHQTFMNAHTQDDFYSGTKAALLGGSTMLISHVLPDRGASL 110 
                      *:*   :*:***:*               ***  **:*** ** *::: ** *     * 
humanCRMP1           LTSFEKWHEAADTKSCCDYSLHVDITSWYDGVREELEVLVQDKGVNSFQVYMAYKDVYQM 176 
macaqueCRMP1         LTSFEKWHEAADTKSCCDYSLHVDITSWYDGVREELDVLVQDKGVNSFQVYMAYKDLYQM 176 
mouseCRMP1           LTSFEKWHEAADTKSCCDYSLHVDITSWYDGVREELEVLVQDKGVNSFQVYMAYKDLYQM 176 
ratCRMP1             LTSFEKWHEAADTKSCCDYSLHVDITSWYDGVREELEVLVQDKGVNSFQVYMAYKDLYQM 176 
zebrafishCRMP1       LEAFEKWQEAADKKSCCDYSLHVDIPHWHEGVKEELEQLVQEKGINSFQVYMAYKGLYQM 179 
mouseCRMP2           LAAFDQWREWADSKSCCDYSLHVDITEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQL 176 
ratCRMP2             LAAFDQWREWADSKSCCDYSLHVDITEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQL 176 
humanCRMP2           LAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQL 176 
macaqueCRMP2         LAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQL 176 
zebrafishCRMP2       ISAFNQWREWADSKACCDYSLHVDITEWHKGVQEEMEALVKDHGVNSFLVYLAYKDFFQL 177 
mouseCRMP4           LAAYEQWRERADSAACCDYSLHVDIPRWHESTKEELEALVRDKGVNSFLVFMAYKDRCQC 176 
ratCRMP4             LAAYEQWRERADSAACCDYSLHVDIPRWHESTKEELEALVRDKGVNSFLVFMAYKDRCQC 176 
humanCRMP4           LAAYEQWRERADSAACCDYSLHVDITRWHESIKEELEALVKEKGVNSFLVFMAYKDRCQC 176 
zebrafishCRMP4       LEAFDRWSKWADEKACCDYSLHVDITHWNDSVKQEVETLIKEKGVNSFQVYMAFKDLYQM 176 
mouseCRMP5           VEAYEKCRALADPKVCCDYALHVGITWWAPKVKAEMETLVREKGVNSFQMFMTYKDLYML 169 
ratCRPM5             VEAYEKCRALADPKVCCDYALHVGITWWAPKVKAEMETLVREKGVNSFQMFMTYKDLYML 169 
humanCRMP5           VDAYEKCRGLADPKVCCDYALHVGITWWAPKVKAEMETLVREKGVNSFQMFMTYKDLYML 169 
zebrafishCRMP5       LDAFEQMRAHADAKACCDYALHVGVTWWGPKVEREMEVLVGERGVNSFQMFMAYKDAMML 170 
                     :         **   **** *** :  *      *:: *: ::*:*** ::: :*     
 
humanCRMP1           SDSQLYEAFTFLKGLGAVILVHAENGDLIAQEQKRILEMGITGPEGHALSRPEELEAEAV 236 
macaqueCRMP1         SDSQLYEAFTFLKGLGAVILVHAENGDLIAQEQKRILDMGITGPEGHALSRPEELEAEAV 236 
mouseCRMP1           SDSQLYEAFTFLKGLGAVILVHAENGDLIAQEQKRILEMGITGPEGHALSRPEELEAEAV 236 
ratCRMP1             SDSQLYEAFTFLKGLGAVILVHAENGDLIAQEQKRILEMGITGPEGHALSRPEELEAEAV 236 
zebrafishCRMP1       PDSQLYEAFSFLKELGAVVLVHAENGDLIAQEQSKILGMGIIGPEGHPLSRPEELEAEAV 239 
mouseCRMP2           TDSQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAV 236 
ratCRMP2             TDSQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAV 236 
humanCRMP2           TDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAV 236 
macaqueCRMP2         TDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAV 236 
zebrafishCRMP2       TDSQIYEVFSVIRDLGAIAQVHAENGDIIAEEQRRILDLGITGPEGHVLSRPEEVEAEAV 237 
mouseCRMP4           TDGQIYEIFSLIRDLGAVAQVHAENGDIVEEEQKRLLEQGITGPEGHVLSHPEEVEAEAV 236 
ratCRMP4             TDGQIYEIFSLIRDLGAVAQVHAENGDIVEEEQKRLLEQGITGPEGHVLSHPEEVEAEAV 236 
humanCRMP4           SDSQMYEIFSIIRDLGALAQVHAENGDIVEEEQKRLLELGITGPEGHVLSHPEEVEAEAV 236 
zebrafishCRMP4       SNTELYEVFTFLGEHGGIAQVHAENGEIIAEEQARMLEMGITGPEGHVLSRPEELEAEAV 236 
mouseCRMP5           RDSELYQVFHACRDIGAIPRVHAENGELVAEGAKEALDLGITGPEGIEISHPEELEAEAT 229 
ratCRPM5             RDSELYQVFHACRDFGAIPRVHAENGELVAEGAKEALDLGITGPEGIEISHPEELEAEAT 229 
humanCRMP5           RDSELYQVLHACKDIGAIARVHAENGELVAEGAKEALDLGITGPEGIEISRPEELEAEAT 229 
zebrafishCRMP5       KDSELYQALNTCKNIGAIARIHAENGELVLEGAKEALDLGISGPEGMEISRPEELEAEAT 230 
                         :*         *::  :*****::: :     *  ** ****  :*:***:**** 
            CaM binding site1 
humanCRMP1           FRAITIAGRINCPVYITKVMSKSAADIIALARKKGPLVFGEPIAASLGTDGTHYWSKNWA 296 
macaqueCRMP1         FRAITIAGRINCPVYITKVMSKSAADIIALARKKGPLVFGEPIAASLGTDGTHYWSKNWA 296 
mouseCRMP1           FRAIAIAGRINCPVYITKVMSKSAADIIALARKKGPLVFGEPIAASLGTDGTHYWSKNWA 296 
ratCRMP1             FRAIAIAGRINCPVYITKVMSKSAADIIALARKKGPLVFGEPIAASLGTDGTHYWSKNWA 296 
zebrafishCRMP1       FRAITIGNRVNCPVYITKVMSKSAAETVAIARKKGSVVFGEPITASLATDGSHYWSKNWA 299 
mouseCRMP2           NRSITIANQTNCPLYVTKVMSKSAAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWA 296 
ratCRMP2             NRSITIANQTNCPLYVTKVMSKSAAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWA 296 
humanCRMP2           NRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWA 296 
macaqueCRMP2         NRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSTNWA 296 
zebrafishCRMP2       NRSVTVANQTNCPLYITKVMSKSAADVIAQARKKGTVVYGEPITASIGTDGSHYWSKNWA 297 
mouseCRMP4           YRAVTIAKQANCPLYVTKVMSKGAADMVAQAKRRGVVVFGEPITASLGTDGSHYWSKNWA 296 
ratCRMP4             YRAVTIAKQANCPLYITKVMSKGAADMVAQAKRRGVVVFGEPITASLGTDGSHYWSKNWA 296 
humanCRMP4           YRAVTIAKQANCPLYVTKVMSKGAADAIAQAKRRGVVVFGEPITASLGTDGSHYWSKNWA 296 
zebrafishCRMP4       FRAVTIASQTNCPLYVTRVMSKSAADIISQARKKGNVVFGEPITASLGTDGTHYWSKNWA 296 
mouseCRMP5           HRVITIANRTHCPIYLVNVSSISAGDVIAAAKMQGKVVLAETTNAHATLTGLHYYHQDWS 289 
ratCRPM5             HRVITIANRTHCPIYLVNVSSISAGDVIAAAKMQGKVVLAETTNAHATLTGLHYYHQDWS 289 
humanCRMP5           HRVITIANRTHCPIYLVNVSSISAGDVIAAAKMQGKVVLAETTTAHATLTGLHYYHQDWS 289 
zebrafishCRMP5       HRAITIGNRAHCPVYLVNVSSMSAADVIGAARMQGKVVQAETTVAHAVLSGMHYYHQDWA 290 
                      * : :     **:*:  * *   :: :: *:  * :*  *   *     * **:   *  
humanCRMP1           KAAAFVTSPPLSPDPTTPDYLTSLLACGDLQVTGSGHCPYSTAQKAVGKDNFTLIPEGVN 356 
macaqueCRMP1         KAAAFVTSPPLSPDPTTPDYLTSLLACGDLQVTGSGHCPYSTAQKAVGKDNFTLIPEGVN 356 
mouseCRMP1           KAAAFVTSPPLSPDPTTPDYLTSLLACGDLQVTGSGHCPYSTAQKAVGKDNFTLIPEGVN 356 
ratCRMP1             KAAAFVTSPPLSPDPTTPDYLTSLLACGDLQVTGSGHCPYSTAQKAVGKDNFTLIPEGVN 356 
zebrafishCRMP1       KAAPYVTSPPLNPDPTTPEHLHSLLACGDLQVVGSGHCAYSTSQKAIGKDNFTLIPEGTN 359 
mouseCRMP2           KAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTN 356 
ratCRMP2             KAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTN 356 
humanCRMP2           KAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTN 356 
macaqueCRMP2         KAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTN 356 
zebrafishCRMP2       KAAAYVTSPPLSPDPTTPDYLNSLLSCGDLQVTGSAHCTFNTSQRAVGKDDFTLIPEGTN 357 
mouseCRMP4           KAAAFVTSPPINPDPTTADHLTSLLSSGDLQVTGSAHCTFTTAQKAVGKDNFTLIPEGVN 356 
ratCRMP4             KAAAFVTSPPINPDPTTADHLTSLLSSGDLQVTGSAHCTFTTAQKAVGKDNFTLIPEGIN 356 
humanCRMP4           KAAAFVTSPPVNPDPTTADHLTCLLSSGDLQVTGSAHCTFTTAQKAVGKDNFALIPEGTN 356 
zebrafishCRMP4       KAASFVTSPPLSPDPTTPDYLNTLLASGDLSVVGSAHCTFSVAQKAIGKDDFTQIPEGVN 356 
mouseCRMP5           HAAAYVTVPPLRLDTNTSTYLMSLLANDTLNIVASDHRPFTTKQKAMGKEDFTKIPHGVS 349 
ratCRPM5             HAAAYVTVPPLRLDTNTSTYLMSLLANDTLNIVASDHRPFTTKQKAMGKEDFTKIPHGVS 349 
humanCRMP5           HAAAYVTVPPLRLDTNTSTYLMSLLANDTLNIVASDHRPFTTKQKAMGKEDFTKIPHGVS 349 
zebrafishCRMP5       HAAAHVIAPPLRLDPNTPDHLIGLLGNDIINVVASDHRAFSTKQKAMGKEDFTKIPHGAP 350 
                     :**  *  **:  * *    *  **    : :  * *  :   *:*:**::*: ** *   
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humanCRMP1           GIEERMTVVWDKAVATGKMDENQFVAVTSTNAAKIFNLYPRKGRIAVGSDADVVIWDPDK 416 
macaqueCRMP1         GIEERMTVVWDKAVATGKMDENQFVAVTSTNAAKIFNLYPRKGRIAVGSDADVVIWDPDK 416 
mouseCRMP1           GIEERMTVVWDKAVATGKMDENQFVAVTSTNAAKIFNLYPRKGRIAVGSDADVVIWDPDK 416 
ratCRMP1             GIEERMTVVWDKAVATGKMDENQFVAVTSTNAAKIFNLYPRKGRIAVGSDADVVIWDPDK 416 
zebrafishCRMP1       GVEERMGFVWDKAVAMGKMDDYFFVAVTSTNAAKIFNLYPRKGRIAVGSDADIVIWDPDK 419 
mouseCRMP2           GTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRISVGSDADLVIWDPDS 416 
ratCRMP2             GTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRISVGSDADLVIWDPDS 416 
humanCRMP2           GTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDS 416 
macaqueCRMP2         GTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDS 416 
zebrafishCRMP2       GTEERMSIIWDKCVVTGKMDENQFVAVTSTNAAKIFNLYPRKGRIAVGSDADLVLWDPDV 417 
mouseCRMP4           GIEERMSVVWEKCVASGKMDENEFVAVTSTNAAKIFNFYPRKGRVAVGSDADLVIWNPRA 416 
ratCRMP4             GIEERMSVVWEKCVASGKMDENEFVAVTSTNAAKIFNFYPRKGRVAVGSDADLVIWNPRA 416 
humanCRMP4           GIEERMSMVWEKCVASGKMDENEFVAVTSTNAAKIFNFYPRKGRVAVGSDADLVIWNPKA 416 
zebrafishCRMP4       GAEERMSIIWDKAVVTGKMDENMFVAVTSTNAAKILNLYPRKGRIAVGSDSDLVIWDTDA 416 
mouseCRMP5           GVQDRMSVVWERGVVGGKMDENRFVAVTSSNAAKILNLYPRKGRIIPGADADVVVWDPEA 409 
ratCRPM5             GVQDRMSVVWERGVVGGKMDENRFVAVTSSNAAKILNLYPRKGRIIPGADADVVVWDPEA 409 
humanCRMP5           GVQDRMSVIWERGVVGGKMDENRFVAVTSSNAAKLLNLYPRKGRIIPGADADVVVWDPEA 409 
zebrafishCRMP5       GVEDRMSVIWERGVVSGKMDENRFVAVTSSNAAKIYNLYPRKGRIMPGADADVVVWDPDA 410 
                     * ::** ::*:: *: ****:  ******:****: *:******:  *:*:*:*:*:                                                                                  
humanCRMP1           LKTITAKSHKSAVEYNIFEGMECHGSPLVVISQGKIVFEDGNINVNKGMGRFIPRKAFPE 476 
macaqueCRMP1         VKTITAKSHKSAVEYNIFEGMECHGSPLVVISQGKIVFEDGNINVNKGMGRFIPRKPFPE 476 
mouseCRMP1           MKTITAKSHKSTVEYNIFEGMECHGSPLVVISQGKIVFEDGNISVSKGMGRFIPRKPFPE 476 
ratCRMP1             MKTLTAKSHKSTVEYNIFEGMECHGSPLVVISQGKIVFEDGNISVSKGMGRFIPRKPFPE 476 
zebrafishCRMP1       IKTITAKSQQSALEYNIFEGMDCRGGPLHVVSQGRVVFEEGKLQVQQGTGRFISRKPFPD 479 
mouseCRMP2           VKTISAKTHNSALEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPD 476 
ratCRMP2             VKTISAKTHNSALEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPD 476 
humanCRMP2           VKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPD 476 
macaqueCRMP2         VKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPD 476 
zebrafishCRMP2       TKIISAKSHNLAVEYNIFEGMEVRGVPLVVISQGKIVLEEGTLHTTEGSGRFISRKPFPD 477 
mouseCRMP4           TKVISAKSHNLNVEYNIFEGVECRGVPTVVISQGRVVLEDGNLLVTPGAGRFIPRKTFPD 476 
ratCRMP4             TKVISAKSHNLNVEYNIFEGVECRGMPTVVISQGRVVLEDGNLLVTPGAGRFIPRKTFPD 476 
humanCRMP4           TKIISAKTHNLNVEYNIFEGVECRGAPAVVISQGRVALEDGKMFVTPGAGRFVPRKTFPD 476 
zebrafishCRMP4       VRTITAKTHHSAAEYNVFEGMELRGAPMLVVCQGKIVLEDGNLHATSGTGRFIPCSPFPD 476 
mouseCRMP5           TKTISASTQVQGGDFNLYENMRCHGVPLVTISRGRVVYENGVFMCAEGTGKFCPLRSFPD 469 
ratCRPM5             TKTISASTQVQGGDFNLYENMRCHGVPLVTISRGRVVYENGVFMCAEGTGKFCPLRSFPD 469 
humanCRMP5           TKTISASTQVQGGDFNLYENMRCHGVPLVTISRGRVVYENGVFMCAEGTGKFCPLRSFPD 469 
zebrafishCRMP5       TRTISASTQAQGGDFNLFEGQRCHGVPLVTISRGRLVCENGVFMCAQGSGKFYPMRAFPD 470 
                      : ::* ::    ::*::*    :* *   : :*::: *:* :    * *::    **: 
                                            __________________________Microtubule 
                                                     ____GSK3β ____  cdk5 
                     CaM binding site2               p    p       p   p 
humanCRMP1           HLYQRVKIRNKVFGLQGVSRGMYDGPVYEVPATPKYATPAP----SAKSSPSKHQPPPIR 532 
macaqueCRMP1         HLYQRVKIRNKVFGLQGVSRGMYDGPVYEVPATPKYATPAP----SAKSSPSKHQPPPIR 532 
mouseCRMP1           HLYQRVRIRSKVFGLHSVSRGMYDGPVYEVPATPKHAAPAP----SAKSSPSKHQPPPIR 532 
ratCRMP1             HLYQRVRIRSKVFGLHSVSRGMYDGPVYEVPATPKHAAPAP----SAKSSPSKHQPPPIR 532 
zeebrafishCRMP1      FAYQRIKYRNKIMNMQGVSRGMYDGPVYDVPATPKYITPAP----SAKTSPTTHQPPPIR 535 
mouseCRMP2           FVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPAS----SAKTSPAKQQAPPVR 532 
ratCRMP2             FVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPAS----SAKTSPAKQQAPPVR 532 
humanCRMP2           FVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPAS----SAKTSPAKQQAPPVR 532 
macaqueCRMP2         FVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPAS----SAKTSPAKQQAPPVR 532 
zeebrafishCRMP2      YVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKAVTPAS----SAKTSPAKQPGQPVR 533 
mouseCRMP4           FVYKRIKARNRLAEIHGVPRGLYDGPVHEVMLPAKPGSGTQ----ARASCSGKISVPPVR 532 
ratCRMP4             FVYKRIKARNRLAEIHGVPRGLYDGPVHEVMLPAKPGSGTQ----ARASCPGKISVPPVR 532 
humanCRMP4           FVYKRIKARNRLAEIHGVPRGLYDGPVHEVMVPAKPGSGAP----ARASCPGKISVPPVR 532 
zeebrafishCRMP4      FAYKRVKARKQLAILKAVPRGMYDGPVSEFSPMSRGGTPSA----STRTSPTK---VPVR 529 
mouseCRMP5           IVYKKLVQREKTLKVRGVDRTPYLGDVAIVVHPGKKEMGTPLADTPTR---PVTRHGGMR 526 
ratCRPM5             IVYKKLVQREKTLKVRGVDRTPYLGDVAVVVNPGKKEMGTPLADTPTR---PVTRHGGMR 526 
humanCRMP5           TVYKKLVQREKTLKVRGVDRTPYLGDVAVVVHPGKKEMGTPLADTPTR---PVTRHGGMR 526 
zeebrafishCRMP5      FLYKKLIQREKTLAVRGVDRAPYSGDVASVMSSIRKESGSPEGDVPMRTAATAARHTGIR 530 
                       *:::  * :   :: * *  * * *       :    :                  :* 
                     binding site   _________________________ 
                                          ROCK 
                                           p 
humanCRMP1           NLHQSNFSLSGAQIDDNNPRRTGHRIVAPPGGRSNITSLG* 572 
macaqueCRMP1         NLHQSNFSLSGAQIDDNNPRRTGHRIVAPPGGRSNITSLG* 572 
mouseCRMP1           NLHQSNFSLSGAQIDDNNPRRTGHRIVAPPGGRSNITSLG* 572 
ratCRMP1             NLHQSNFSLSGAQIDDNNPRRTGHRIVAPPGGRSNITSLG* 572 
zebrafishCRMP1       NLHQSNFSLSGSQIDDNIPRRSGHRIVAPPGGRSNITSLG* 575 
mouseCRMP2           NLHQSGFSLSGAQIDDNIPRRTTQRIVAPPGGRANITSLG* 572 
ratCRMP2             NLHQSGFSLSGAQIDDNIPRRTTQRIVAPPGGRANITSLG* 572 
humanCRMP2           NLHQSGFSLSGAQIDDNIPRRTTQRIVAPPGGRANITSLG* 572 
macaqueCRMP2         NLHQSGFSLSGAQIDDNIPRRTTQRIVAPPGGRANITSLG* 572 
zebrafishCRMP2       NLHQSGFSLSGAQVDDNIPRRNTQRIVAPPGGRANITSLG* 573 
mouseCRMP4           NLHQSGFSLSGSQADDHIARRTAQKIMAPPGGRSNITSLS* 572 
ratCRMP4             NLHQSGFSLSGSQADDHIARRTAQKIMAPPGGRSNITSLS* 572 
humanCRMP4           NLHQSGFSLSGSQADDHIARRTAQKIMAPPGGRSNITSLS* 572 
zebrafishCRMP4       NLHQSGFTLSGP—EEAPIRPAGRRIVVPPGGRSNITSLS*  567 
mouseCRMP5           DLHESSFSLSGSQIDDHVPKRASARILAPPGGRSSGIW*   564 
ratCRPM5             DLHESSFSLSGSQIDDHVPKRASARILAPPGGRSSGIW*   564 
humanCRMP5           DLHESSFSLSGSQIDDHVPKRASARILAPPGGRSSGIW*   564 
zebrafishCRMP5       DLHESSFSLSGAQVDDHIPKRSSARILAPPGGRSSGIW*   568 
                      **:* * ***   :         *::*****      
 
 
Figure 8.1 Sequence comparison of CRMP1-5 forms.The output reflects the degree of 
sequence similarity among the proteins. Sequence in red: activation loop (49-56 aa, 
Strittmatter et al., 2007); underlined sequence: putative CaM binding site: region rich in 
basic, (highlighted blue) and hydrophobic residues, (highlighted grey; 475-493 aa, 
Zhang et al., 2008); in bold and italic: residues undergoing phosphorylation (p, Thr509, 
514, 555; Ser518, 522) with the specific GSK3ß,Cdk5 and ROCK kinases indicated 
(Zhang et al., 2008 and Lin et al.; 2011); double underlined sequence: Microtubule 
interaction domain (500-570 aa, Lin et al.,2011); in bold and grey are regions important 
to stabilize the tetramer (Deo et al., 2004); in bold and dark blue are Cys 132 and 133 
exposed to solvent, in bold and blue are Cys 248, 323 and 439 at the interface region 
involved in tetramer stabilisation, in bold and light blue are Cys 334 and 439 not 
accessible to solvent; highlighted yellow Cys 504 in CRMP2, the putative Cys involved 
in thioredoxin interaction (Morinaka et al., 2011) that is absent in all the other CRMP 
isoforms. *, identical residues; :, conserved residues.  
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Figure 8.2. Comparison of the three dimensional structures of 
mouse CRMP1, human CRMP2 and human CRMP5 proteins. 
Left panel: The structure of mouse CRMP1 (PBD ID 1KCX; Deo 
et al., 2004), human CRMP2 (PDB ID 2V8M; Stenmark et al., 
2007) and CRMP5 (PDB ID 4CNT; Ponnusamy et al., 2013) are 
shown. The colour scheme of secondary structure is the following: 
green, α-helix; blue, β-sheet; α3-turn, magenta; α5-turn, orange; 
unstructured region, grey; the activation loop (residues 49-56) is 
shown in red. To generate the figures the CCP4 program has been 
used. Right panel: (a) homotetramer of human CRMP5 protein; 
(b) dimer formed by subunits A (yellow) and B (orange) and (c) 
interface of the dimer between subunit C (purple) and D (blue) 
(Ponnusamy et al., 2013).  
 
 
 
 
 
 
 
 
mouse CRMP1
human CRMP2
human CRMP5
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Figure 8.3 Distribution of CRMP-2 and cytoskeleton in N2a cells. Colocalization of CRMP-2 with microtubule 
bundles in the spindle at the metaphase (upper panel) and in the midbody at the late telophase (lower panel) in 
mitotic cells. Double labeling was performed with a monoclonal antibody to α-tubulin and a polyclonal antibody to 
CRMP-2, A667; the primary antibodies were detected with FITC-conjugated goat anti-mouse IgG (green) or 
rhodamine-conjugated donkey anti-rabbit IgG (red), respectively. Yellow indicates colocalization of CRMP-2 with 
α-tubulin (Gu et al., 2000). 
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As mentioned before, interaction between mouse MICAL1 and mouse CRMP1-5 was detected in 
HEK293T cell lysates coexpressing V5-CRMP and Myc-tagged MICAL1 (Schimdt et al., 2008; Figure 
8.4, panel A). Lysates of HEK293T cells transfected with truncated forms of mouse MICAL1 were used 
to try to identify the region of MICAL responsible for the interaction with mouse CRMP1. In these 
experiments CRMP1 was found to interact only with the full-length MICAL and with the form 
comprising the MO, CH and LIM domain (MOCHLIM), although to a lesser extent (Figure 8.4, panel B; 
Schmidt et al., 2008). However, MICAL forms were expressed at different levels in COS7 cells either in 
the absence or presence of CRMP, as shown in Figure 8.4 (panel B). In particular, no production of the 
isolated MO domain was observed. These observations may explain the reason why the interaction with 
CRMP was observed only in lysates of cells expressing full-length MICAL and MOCHLIM form.  
COS7 cells transfected with mouse CRMP1 and mouse MICAL1 showed a decrease of H2O2 production 
compared to the cells transfected only with MICAL1 (Figure 8.4, panel C). An increase of cell 
contraction was observed in COS7 cells containing MO, MOCH and MOCHLIM forms of MICAL1 and 
CRMP1/8-525 form compared to that of cells expressing only MICAL forms or CRMP1 (Figure 8.4, 
panel D and Figure 8.5, panels A and B; Schmidt et al., 2008). These results suggested that the 
coexpression of MICAL1 and CRMP1 leads to local cytoskeleton disassembly even in the absence of 
semaphorin-plexin interaction. Two mechanisms were proposed: (i) CRMP positively modulates the 
enzymatic activity of MICAL1 mimicking Sema/PlexA-dependent activation of MICAL1 or (ii) MICAL 
modifies CRMP through its activity promoting its phosphorylation and, therefore, microtubules 
disassembly (Schmidt et al., 2008). To distinguish between these hypotheses the H2O2 produced by the 
NADPH-dependent activity of MICAL was measured in lysates of cells that had expressed MICAL and 
or CRMP. Coexpression of mouse CRMP1 (residues 8-525) did not alter the activity of the mouse full-
length MICAL1, while it decreased the activity of the MICAL form lacking the C-terminal region 
(MOCHLIM) (Figure 8.5, panel C). To independently verify these results, wild-type GST-CRMP (8-525) 
and the constitutively active form (mutated in the activation loop, CA CRMP) were added to lysates of 
cell expressing MICAL or MOCHLIM. A reduction of H2O2 production was observed for MOCHLIM in 
the presence of both wild-type and mutant forms of GST-CRMP (8-525) (Figure 8.5, panels D and E). 
These data would rule out that CRMP activates the NADPH oxidase activity of MICAL by producing 
H2O2 as a second messenger. The experimental observations could be explained by assuming that CRMP 
is a substrate of the monooxygenase reaction of MICAL1. In this case, the reaction would be the 
hydroxylation of CRMP and H2O production rather than H2O2 production (Scheme 6.2).  
These experiments also revealed a possible autoihnibitory function of the C-terminal region of MICAL 
(Schimdt et al., 2008). H2O2 was not detected in the lysates of HEK293T cells expressing full-length 
MICAL and MICAL form lacking the MO domain. On the contrary, MOCH and MOCHLIM forms 
incubated with NADPH were active (Schmidt et al., 2008), leading to the proposal that the C-terminal 
region inhibits the N-terminal MO domain of MICAL. To test this hypothesis, purified GST-fusion 
MICAL1 form comprising residues 761-1048 was added to lysates of cells expressing MOCH and 
MOCHLIM. The addition of the C-terminal region (1 µM) led to up to 75% decrease of the activity 
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(Schmidt et al., 2008) (Figure 8.6). The autoihnibitory function of the C-terminal region of MICAL1 was 
later confirmed also for the human protein (Giridharan et al., 2012; Chapter 1).   
 
 
 
Figure 8.4. Interaction between human MICAL1 forms and CRMP proteins in HEK293T and COS7 cells. Panel A: 
HEK293T cells were co-transfected with plasmids encoding mouse Myc-MICAL1 and V5-CRMP1-4 proteins. Cell 
lysates were immunoprecipitated (IP) with anti-Myc antibodies, and Western blots were probed for Myc or V5 
immunoreactivity. Panel B: Scheme of MICAL1 truncation mutants (tMICALs) with domains indicated. Lysates of 
HEK293T cells transfected with V5-CRMP1 and Myc-tagged full-length or truncated MICAL1 were 
immunoprecipitated (IP) with anti-V5 and after western blotting they were tested for anti-V5 or anti-Myc 
immunoreactivity. Panel C: H2O2  production from lysates of HEK293T cells cotransfected with indicated FL-
MICAL, tMICAL 1–760, and CRMP1 expression vectors in the presence of 200 μM NADPH. Panel D: 
Quantification of contraction of COS7 cells transfected with the indicated truncated MICAL forms and 
constitutively active PlexA (ΔECT) (Schmidt et al., 2008).  
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Figure 8.5. Effect of CRMP1-MICAL1 
interaction. Panel A: COS7 cells 
cotransfected with V5-CRMP1 (green) and 
Myc-MICAL1 (red). Cells expressing either 
MICAL1 alone or CRMP1 alone appeared 
spread (arrowheads), whereas many of the 
cells expressing both proteins were 
contracted (arrows). Panel B: Quantification 
of contraction of cells from panel A. Sixty-
one percent of the cells expressing both 
proteins were contracted. Panel C: H2O2 
production from lysates of HEK293T cells 
cotransfected with the indicated FL-MICAL, 
tMICAL 1–760, and CRMP1 expression 
vectors in the presence of 200 μM NADPH 
(data are from 3 experiments; comparing 
with and without CRMP1). Panel D: 
Quantitation of the rate of H2O2 production 
by full-length and truncated 1-760 forms of 
MICAL in HEK293T lysates after the 
addition of purified wilde-type CRMP (WT 
CRMP1) or of the form mutated in the 
activation loop (CA CRMP1), which were 
added as GST-fusion proteins. Panel E: 
MICAL activity was measured in the 
presence of 1 μM GST or 1μ M mouse GST-
WT CRMP1 at various NADPH 
concentrations (Schmidt et al., 2008).  
 
 
 
 
 
Figure 8.6. Activity of  MICAL1 forms expressed in 
HEK293T cells. Panel A: flow chart depicting the 
assay used by Schmidt et al., (2008). H2O2 
production is measured by the Amplex Red 
Peroxidase assay (Nadella et al., 2005). Panel B: 
Measurement of H2O2 production from lysates of 
HEK293T cells untransfected (NT) or transfected 
with the indicated MICAL constructs in the presence 
of 200 μM NADPH. H2O2 (1 μM) in reaction buffer 
was used to show the sensitivity of the assay. Panel 
C: Quantitation of the NADPH oxidase activity in 
cell lysates that had expressed  tMICAL 1– 630 and 
1–760 when increasing concentrations of GST-761–
1048 form of MICAL1 were added. The addition of 
the MICAL C-terminal domain decreased the 
constitutive activity and shifted the concentration 
dependence for NADPH (insets) (Schmidt et al., 
2008). 
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Independent experiments confirm a modulatory role of MICAL-CRMP interaction, linked to the H2O2-
producing NADPH oxidase activity of MICAL1 (Morinaka et al., 2011). Morinaka and coworkers 
isolated a covalent CRMP2-TRX (thioredoxin) adduct due to the formation of a disulfide bond between 
TRX-Cys32 and CRMP-Cys504.  
Starting from the observation that silencing CRMP2 in dorsal root ganglion neurons abolished growth 
cone collapse induced by Sema3A (Goshima et al., 1995), Morinaka et al. compared the effect of 
overexpressing the wilde-type and the C504S mutant of CRMP2 in COS7 cells. They concluded that 
Cys504 is required for the transduction of the signal upon semaphorin/plexin interaction, because the 
overexpression of CRMP2 C504S form suppressed the Sema3A-induced cone growth collapse (Morinaka 
et al., 2011). Cys504 is conserved in CRMP2 proteins, which is absent in the other CRMP forms (Figure 
8.1). This is responsible for the stabilization of a disulfide-linked homodimer of CRMP2 and for the 
interaction with TRX. In fact, incubation of COS7 cells expressing CRMP2 with H2O2 led to the 
formation and stabilization of dimeric CRMP2. From the same cells CRMP2 was isolated by 
immunopurification and its incubation with TRX led to the disappearance of dimeric CRMP2 with the 
stabilization of the monomer (Morinaka et al., 2011). The homodimeric CRMP2 is the form that can be 
phosphorylated by serine/threonine kinase GSK3β preventing the interaction of CRMP2 with tubulin 
dimers and, thus, leading to microtubules disassembly. Morever, CRMP2 did not form the disulfide-
linked homodimer in MICAL knockdown neurons in response to Sema3A stimulation (Morinaka et al., 
2012). These observations led to the proposal that CRMP2 can be regulated by the H2O2-producing 
activity of MICAL stimulated by Sema3A leading to the activation of CRMP by phoshorylation (Figure 
8.7; Morinaka et al., 2011). As a result CRMP2 would not longer promote microtubules assembly and 
thus, axon cone growth collapse would occur (Morinaka et al., 2011).  
In a recent review that discusses the redox regulation of cytoskeleton dynamics (Gellert et al., 2014)  the 
authors state that the proposed mechanism of control of the oxidation state of CRMP2 by the 
MICAL/TRX system is unlikely since they demonstrated that the transient mixed disulfide of TRX is not 
stable enough to serve as a signal due to the different pKa values of Cys in the active site of the proteins 
(Gellert et al., 2013). Rather, they identified Grx2c (Glutaredoxin 2c) protein, which is necessary for axon 
outgrowth and embryonic development, as a CRMP2 partner.  
Glutaredoxins are glutathione-dependent reductases, which reduce protein disulfides and can form 
reversible protein-GSH mixed disulfide. Neuroblastoma cells overexpressing Grx2c during differentiation 
showed 2-fold longer axons (Gellert et al., 2013). This observation indicated that Grx2c is essential for 
neuronal differentiation by controlling axonal outgrowth. In this process the dithiol reaction mechanism is 
required, in which at last one specific protein disulfide is reduced (Bräutigam et al., 2011). It has been 
also demonstrated that Grx2c controls axonal outgrowth via thiol redox regulation of CRMP2. In fact, 
knockdown of Grx2 in zebrafish led to a phenotype similar to that observed for a knockdown of CRMP2.  
However, a stable complex between Grx2c and CRMP2 was not detected leading to the proposal that 
redox regulation of CRMP2 could induce conformational changes with the consequent exposure of 
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phosphorylation sites of CRMP2 for its activation in response to semaphorins (Figure 8.8; Gellert et al., 
2013).  
All together these studies indicated that MICAL-CRMP interaction is important for the transduction of 
the signal initiated by the interaction between semaphorins and plexins to the control of cytoskeleton 
dynamics. However, the molecular mechanism that leads to the re-organization of cytoskeleton by 
MICAL-CRMP complex remains unclear. 
Cellular studies carried out with CRMP1 demonstrated that MICAL1 and CRMP interacted and such 
interaction led to a decrease of the H2O2 produced by MICAL1 coupled to an increase of cell contraction 
(Schmidt et al., 2008). These observations led the proposal that CRMP could be the substrate of the 
monooxygenase activity of MICAL1 and this interaction mutually modulates the activity of MICAL1 and 
CRMP1.  Thus, in this case MICAL1 exerts its function through a monooxygenase activity (Schmidt et 
al., 2008).  
On the other hand, for CRMP2 it has been proposed that MICAL1 stabilizes the formation of disulfide-
dimeric CRMP2, which can be phosphorylated preventing the assembly of microtubules (Morinaka et al., 
2011). In this case it is the H2O2 produced by MICAL1 in response to semaphorin that modulates the 
CRMP2 activity. Thus, here MICAL1 would function as a NADPH oxidase (Morinaka et al., 2011).  
It is evident that it was not clear if MICAL1 functions as a monooxygenase or as a oxidase to modulate 
the activity of CRMP proteins or if CRMP modulates MICAL1 activity in response to semaphorin/plexin 
interaction. Thus, in the effort to clarify and better understand the relation between MICAL and CRMP, 
we initiated a series of in vitro experiments with purified mouse CRMP1 and MO and MOCH forms of 
human MICAL1. In these experiments we first investigated the interaction between MO and CRMP1/8-
525 form by Ni-NTA affinity chromatography. Then we studied the effect of CRMP on the rate of 
NADPH oxidation reaction catalyzed by MO and MOCH under several conditions. Finally, we also tested 
the effect of CRMP on the activity of MOCH when F-actin was present.     
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Figure 8.7 Model of thioredoxin(TRX)-mediated CRMP2 phosphorylation. After Sema3A stimulation, MICAL 
generates H2O2 at growth cones and oxidizes CRMP2 to form a disulfide-linked homodimer through Cys504. In 
turn, oxidized CRMP2 forms a disulfide complex with thioredoxin (capturing by TRX) and becomes preferentially 
phosphorylated by GSK-3, resulting in growth cone collapse (Morinaka et al., 2012) 
 
 
 
 
 
 
Figure 8.8 Redox switches in semaphorin signaling, cofilin, and actin dynamics. Sema3A binding to NP1 activates 
PlexA and the semaphorin signaling cascade. Activated PlexA interacts with MICAL1/2 that then leads to direct 
actin depolymerization or through cofilin activation. CRMP2 is another mediator of the Sema3A signalling cascade 
that induces growth cone collapse and axon repulsion (left side: ‘oxidation’).Without Sema3A binding, MICALs are 
not activated by the NP1/PlexA receptor. The reduction of CRMP2 by cytosolic Grx2 leads to a conformational 
change of the homo-tetramer. This conformational change causes (directly or indirectly) the polymerisation of actin 
and tubulin. MsrB1 is able to reduce the sulfoxides of methionyl residues of β-actin, allowing polymerisation. The 
WAVE complex is activated close to the membrane by active Rac1 and binds Arp2/3which leads to actin 
polymerisation and branching. Activated Rac1 also leads to the phosphorylation and therefore inactivation of cofilin. 
The absence of Sema3A and the resulting changes of the cytoskeletal dynamics lead to axon outgrowth and 
branching as well as enabling active migration (right side: ‘reduction’) (Gellert et al., 2014). 
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8.2. Expression and small- scale purification of mouse CRMP1 forms 
The plasmids encoding various mouse CRMP1 forms have been received from Prof. S.M Strittmatter 
(Yale University, CN, USA); the constructs have been designed to generate mouse CRMP1 forms that 
differed for the presence or absence of the C-terminal 50 residues (disordered) region and the presence or 
absence of mutations in the “activation loop” at position 49-56 introducing the AAGAAGAA sequence 
leading to a constitutively active CRMP (CA-CRMP; Table 8.2). The plasmids were pGEX-derivatives 
for the expression of CRMP forms as GST-fusion proteins, with a prescission protease site to release 
CRMP from GST. The plasmids we received from Yale were transformed in E.coli DH5α cells, purified, 
analyzed by restriction digestion (not shown) and sequenced.  
Table 8.2 . Summary of plasmid for the expression of mouse CRMP1 forms. The theoretical mass and pI values of 
the proteins was calculated with Mw/pI at www.expasy.ch  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
They were used to transform E.coli BL21(DE3) cells for protein production by following the protocol 
received from Prof. Strittmatter with some modifications (see Materials and Methods, Chapter 10).  
The SDS-PAGE analysis of extracts of cells harvested at different times after the addition of IPTG 
showed the expression of the proteins (Figure 8.9, panel A), but their apparent mass were lower than 
those expected for the different GST-fusion proteins (Table 8.2). The wild-type form lacking the C-
terminal region (CRMP1/8-525) was produced at higher levels compared to the other forms (Figure 8.9, 
panel A).  
To determine the integrity and quality of the expressed CRMP forms, their purification by affinity 
chromatography on a glutathione(GSH)-Sepharose resin was done on a small-scale from ≈2 g of these 
cells (Figure 8.9, panel B; Table 8.3) was set-up.   
The protein bands that accumulated after IPTG induction (Figure 8.9, panel A), probably the GST-CRMP 
fusion proteins, bound to the resin and were found in the fractions eluted with 15 mM GSH (E1-3, Figure 
8.9, panel B). However, their amounts and quality varied for the different CRMP forms. SDS-PAGE 
analysis of the fractions derived from cells that had expressed the longer wild-type form (8-575) showed 
the presence of two main bands of ≈75 kDa and ≈72 kDa (Figure 8.9, panel B) both lower than the 
expected value of 88.9 kDa (Table 8.2). Also the corresponding constitutively active mutant forms of 
Plasmid Protein, residues Theoretical mass, Da pI 
EFS10 GST-mCRMP1 8-572 wt 
mCRMP1 8-572 wt 
88580 
62167 
6.09 
6.27 
EFS11 GST-mCRMP1 8-572 mut 49-56 (CA-CRMP) 
mCRMP1 8-572 mut 49-56 (CA-CRMP) 
88357 
61944 
6.03 
6.17 
EFS12 GST-mCRMP1 8-525 wt 
mCRMP1 8-525 wt 
84193 
57780 
5.87 
5.95 
EFS13 GST-mCRMP1 8-525 mut 49-56 (CA-CRMP) 
mCRMP1 8-525 mut 49-56 (CA-CRMP) 
83281 
56868 
5.76 
5.77 
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CRMP showed two bands with a mass lower than that expected for the intact fusion protein (Figure 8.9, 
panel B), suggesting a proteolytic degradation of the proteins that probably occurred at their C-terminal. 
Instead, the wild-type form lacking the C-terminal region (8-525) did not seem to be proteolitically 
degraded, although its mass was lower than the expected one (≈74 vs 84 kDa; Table 8.2). However, this 
form of CRMP was present in the highest amounts in the starting cells (Figure 8.9, panel B). The 
corresponding mutant form also seemed to be proteolytically degraded after purification and it was the 
form that could be purified at the lowest levels (Figure 8.9, panel B).  
The fractions containing the full-length (8-575) and truncated wild-type CRMP (8-525) forms were 
pooled (fractions E1-3, Table 8.3), dialyzed overnight against 20 mM Hepes/NaOH buffer, pH 7.5, 100 
mM NaCl (Schimdt et al., 2008) to remove GSH, and concentrated. At this stage, the full-length (8-575) 
form of CRMP was very sensitive to proteolysis as shown by SDS-PAGE of the sample after 
concentration, in which the bands of ≈75 kDa and ≈72 kDa had disappeared with the formation of species 
of ≈54 kDa and ≈26 kDa. On the contrary, the form comprising residues 8-525 was stable both during 
dialysis and concentration (Figure 8.9, panel C).  
Thus, these preliminary results indicated that the C-terminal region of CRMP is sensitive to proteolysis 
leading to destabilization of the whole protein that undergoes further degradation. However, the removal 
of the last 50 residues is sufficient to obtain a stable form of CRMP fused with GST protein. The 
mutations leading to the constitutively active forms seem to make the protein very sensitive to proteolysis 
regardless of the presence of the C-terminal fragment. On the basis of these results we decided to focus on 
the most abundant 8-525 CRMP1 form, which is the form used to show quenching of H2O2 production by 
MOCH and MOCHLIM forms of mouse MICAL1 in cell extracts (Schmidt et al., 2008).  An aliquot of 
the wild-type CRMP1/8-525 after GSH-Sepharose chromatography was incubated with prescission 
protease, which specifically cleaved the protein in the linker region between the protein of interest and 
GST, to release CRMP. In a preliminary experiment aliquots of the reaction mixture were withdrawn at 
different incubation times with the proteases, to monitor the extent of GST release by SDS-PAGE. As 
shown in Figure 8.10 the ≈75 kDa band of progressively disappeared with the accumulation of protein 
bands of ≈55 kDa and ≈27 kDa. Now the observed mass matched those expected for CRMP and GST. In 
particular, no bands with a lower mass were observed indicating the stability of the released GST and 
CRMP proteins (Figure 8.10). Interestingly, the calculated mass of CRMP (55.3 kDa) and GST (27.26 
kDa) were now similar to the expected ones (57.7 and 26.4 kDa, respectively) (Figure 8.10).  The sum of 
the molecular mass of the two proteins is 82.56 kDa, greater than the 75 kDa observed for the GST-
CRMP before the cleavage of GST but similar to the expected mass of 84.19 kDa for GST-CRMP1/8-525 
protein. Therefore the GST-CRMP1/8-525 protein had an anomalous electrophoretic behavior and the 
same may apply to the other CRMP forms.  
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Figure 8.9. SDS-PAGE analysis of mouse CRMP1 forms expressed in E.coli BL21(DE3) cells and purified by glutathione-affinity chromatography. Panel A: Total cell extracts 
before (0 h) and after the addition of 1 mM IPTG (2, 16 h) to E.coli BL21(DE3) cells transformed with pGEX derivatives for the expression of GST-CRMP proteins. Panel B: GST-
CRMP proteins were purified on GSH-Sepharose resin and eluted with 15 mM GSH; CE, crude extract; FT, unbound proteins; W1-3, weakly bound proteins removed by flowing 
lysis buffer; E1-3; fractions eluted with 15 mM GSH. Panel C: Fractions enriched in wild-type GST-CRMP (8-575 and 8-525) were pooled (P) and concentrated (C). ○, full-length 
GST-CRMP proteins; ●, truncated GST-CRMP proteins.   
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Table 8.3. Purification of the different mCRMP1 forms from 2 g of BL21(DE3) E.coli cells containing the different 
protein forms on Glutathione Sepharose4B affinity chromatography. Protein concentration was determined with the 
Bradford method.   
 
Protein Sample mg/ml ml mg yield, % 
mCRMP1, 8-575 aa Crude Extract 11.58 7.00 81.06 100.00 
 E1 0.65 1.00 0.65 0.80 
 E2 0.67 1.00 0.67 0.83 
 E3 0.36 1.00 0.36 0.44 
 Pool E1-E3 0.49 2.50 1.23 1.51 
 After concentration 1.17 0.40 0.47 0.58 
mCRMP1, 8-575 aa  mut 49-56 Crude Extract 11.02 7.00 77.14 100.00 
 E1 0.73 1.00 0.73 0.95 
 E2 0.55 1.00 0.55 0.71 
 E3 0.27 1.00 0.27 0.35 
mCRMP1, 8-525 aa  Crude Extract 10.38 7.00 72.66 100.00 
 E1 2.22 1.00 2.22 3.06 
 E2 1.11 1.00 1.11 1.53 
 E3 0.40 1.00 0.40 0.55 
 Pool E1-E3 1.24 2.60 3.22 4.44 
 After concentration 3.06 0.46 1.41 1.94 
mCRMP1, 8-525 aa mut 49-56 Crude Extract 11.32 7.00 79.24 100.00 
 E1 0.18 1.00 0.18 0.23 
 E2 0.09 1.00 0.09 0.11 
 E3 0.10 1.00 0.10 0.13 
 
 
 
Figure 8.10. SDS-PAGE analysis of proteolytic cleavage of the GST-tag from the GST-CRMP1/8-525 protein. The 
GST-CRMP (8-525, ○, Figure 8.9, panel C) form was incubated with prescission protease at 4°C to separate GST 
(●) from  CRMP (○); the reaction was monitored by SDS-PAGE of aliquots withdrawn at different times (0.5, 1, 2, 
8 and 24 h).      
 
 
180
100
75
63
135
245
48
35
25
20
17
0 0.5 1M 2 8 24 M+ h
66
45
36
29
24
20.1
Reaction Mix
GST
 160 
8.3. Large-scale purification of the mouse CRMP1/8-525 form 
In order to obtain amounts of CRMP1/8-525 sufficient for our planned experiments, 4 l cell cultures were 
set up.  
The crude extract from 20-30 g of E.coli BL21(DE3) cells that had produced the GST-CRMP1/8-525 
fusion protein was subjected to GSH-Sepharose affinity chromatography (Table 8.4) (Materials and 
Methods, Chapter 10).   
The fractions were analyzed by SDS-PAGE (Figure 8.11, panel A) and determining the protein 
concentration with the Bradford method (Table 8.4). Fractions containing most of GST-CRMP (E1-E5) 
were pooled (Table 8.4) and dialyzed against Cleavage buffer (50 mM Tris/HCl, pH 7, 150 mM NaCl, 1 
mM EDTA, 1 mM DTT) for 16-18 h at 4°C. At the end of the dialysis the sample (Table 8.4; Figure 8.11) 
was incubated overnight at 4°C with prescission protease (2 U/µl; 10 µl/mg of protein) to remove the 
GST protein. The reaction mixture was incubated with GSH-Sepharose to allow the binding to the resin 
of the released GST and residual uncleaved GST-CRMP. The cleavage and removal of GST from CRMP 
was complete (Figure 8.11, panel B). The fractions containing most of CRMP (fractions 1-2) were 
pooled, concentrated (Table 8.4) and dialyzed against 20 mM Hepes/KOH, pH 7.5, 300 mM NaCl, 10 % 
glycerol, 1 mM DTT (Stenmark et al., 2007). This buffer was used instead of 20 mM Hepes/NaOH, pH 
7.5, 100 mM NaCl as indicated in Deo et al., 2004 because we observed that it leads to protein 
aggregation after dialysis and instability of CRMP preparations after freezing and thawing. The final 
CRMP solution (≈10 mg/ml) was stored in 0.25-0.5 ml aliquots at -80°C after flash freezing in liquid 
nitrogen. At this stage the CRMP preparation showed small amounts of contaminants as well as a fraction 
of aggregated protein that could be both removed by gel filtration on a Superose12 column.  
 
Table 8.4.  Large-scale  purification of CRMP 8-525 form (CRMP) by glutathione affinity chromatography from 20 
g of E.coli BL21(DE3) cells that had overexpressed the GST-CRMP fusion protein. The protein concentration was 
determined with the Bradford method.  
 
Sample mg/ml ml mg yield, % 
Crude extract 15.5 100 1550 100 
E1 1.38 10.00 13.78 0.89 
E2 1.16 10.00 11.63 0.75 
E3 0.63 10.00 6.27 0.40 
E4 0.66 1.00 0.66 0.04 
E5 0.63 1.00 0.63 0.04 
Pool E1-E5 1.15 30.00 34.38 2.22 
After dialysis 1.02 30.00 30.69 1.98 
After incubation with Prescission Protease     
Fractions 1-2 from GSH-Sepharose 0.51 40 20.5 1.32 
After concentration 13.59 1.23 16.71 1.08 
After dialysis 12.21 1.30 15.87 1.02 
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Figure 8.11. SDS-PAGE analysis of the large-scale purification of CRMP1/8-525 form by glutathione affinity 
chromatography. The crude extract from 20 g of E.coli BL21(DE3) cells containing GST-CRMP1/8-525 (GST-
CRMP) was incubated with  GSH-Sepharose resin and GST-CRMP was eluted 15 mM GSH. Panel A: CE, crude 
extract; FT, unbound proteins; P, pellet; W1-W3, proteins removed by flowing lysis buffer; E1-4, proteins eluted 
with 15 mM GSH; Pool, fractions E1-4 were pooled. Panel B: analysis of the proteolytic cleavage of the purified 
GST-CRMP before (0 h) and after incubation with prescission protease for 15 h (ON) at 4°C. At the end of the 
reaction, the sample was loaded on a GSH-Sepharose column. CRMP (○) was found in the initial wash (fractions 1-
3), while GST (●) remained bound to the resin (GS4B). Fractions 1-2 were pooled (Pool), concentrated (C) and 
dialyzed (D).   
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Aliquots of CRMP were gel filtered in 20 mM Hepes/KOH buffer, pH 7, 25-100 mM NaCl or in F-buffer, 
prior each experiment to remove contaminating proteins and aggregates, but also for buffer exchange. An 
example of gel filtration of CRMP in 20 mM Hepes/KOH buffer, pH 7, 25 mM NaCl is shown (Figure 
8.12; Table 8.5).  
The fractions (0.5 ml) were analyzed by SDS-PAGE (Figure 8.12, panel B) and by dynamic light 
scattering (DLS). The protein concentration was determined with the Bradford method (Table 8.5). The 
elution profile showed the presence of a first peak with a low absorbance that eluted in the column void 
volume. This peak, containing aggregated CRMP (Figures 8.12, panel A), was followed by the main peak 
containing most of the protein (Figure 8.12, panel A). The final protein peak contained residual CRMP, 
but also contaminants and was discarded. Fractions 21-24 were pooled and concentrated (Figures 8.12, 
panel B; Table 8.5). The CRMP preparation was used for the experiments after storage for 15-18 h on ice 
at 4°C or was flash-frozen in liquid nitrogen and transferred at -80°C for later use.  
DLS analysis of individual fractions from the Superose12 column and of the sample after concentration 
showed that CRMP is not monomeric (Figure 8.12, panel C; Table 8.5). The calculated radius of CRMP 
in solution was 5.1-5.6 nm, corresponding to a mass of 150-193 kDa, assuming a spherical particle. This 
calculated mass could correspond to that of a compact tetramer or of a non-spherical dimer. The latter 
conclusion would be consistent with the fact that CRMP forms an elongated dimer in the crystals (Figure 
8.2).   
A similar behavior was observed for CRMP gel filtered in 20 mM Hepes/KOH buffer, pH 7, 50 or 100 
mM NaCl or in F-buffer no ATP.  
 
Table 8.5. Size exclusion chromatography of CRMP on Superose12 column and determination of the apparent mass 
by DLS. CRMP1 was gel filtered on Superose12 column in 20 mM Hepes/KOH buffer, pH 7, 25 mM NaCl; protein 
concentration was determined with the Bradford method; DLS conditions; temperature, 15°C; sensitivity, 80%; 
solvent, NaCl 0.2%, pH, 7; concentration, 0.1-2.4 mg/ml. The mass of 57.78 for monomeric CRMP (8-525) was 
calculated as in Table 8.2.  
 
Sample mg/ml ml mg yield, % R, nm Calculated mass, kDa Oligomeric state 
CRMP1/8-525 9.62 0.4 3.84 100.00 7.5 371 6.42 
17 0.12 0.5 0.06 1.56 24 6154 106.50 
21 0.2 0.5 0.1 2.60    
22 1.14 0.5 0.57 14.81 5.6 193 3.34 
23 2.37 0.5 1.18 30.80 5.4 173 2.99 
24 1.74 0.5 0.87 22.61 5.5 183 3.17 
25 0.45 0.5 0.23 5.85 5.3 168 2.9 
26 0.28 0.5 0.14 3.64 5 147 2.54 
27 0.22 0.5 0.11 2.86 5.1 151 2.61 
28 0.08 0.5 0.04 1.04    
Pool 21-24 1.28 1.6 2.04 53.22 5.5 185 3.20 
after concentration 2.82 0.65 1.83 47.64 5.7 196 3.39 
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Figure 8.12. Size exclusion chromatography of CRMP1/8-525. An aliquot of CRMP solution (10 mg/ml) purified by 
GSH-Sepharose affinity chromatography was gel filtered on a Superose12 column connected to an FPLC apparatus 
in 20 mM Hepes/KOH buffer, pH 7, 25 mM NaCl. Panel A: elution profile of the chromatography obtained by 
monitoring A280; fractions pooled are in the shaded area. Panel B: SDS-PAGE analysis of the sample loaded (L), of 
individual fractions (numbered as in panel A); fractions 21-24 were pooled (P) and concentrated (C). The amount of 
protein loaded in each lane, as calculated from the protein concentration determined with the Bradford method, is 
indicated. Panel C: DLS analysis of individual fractions from the Superose12 column, of the pooled fractions and 
after concentration. DLS conditions: temperature, 15°C; acquisition time, 15 s; sensitivity, 80%; solvent, NaCl 1%; 
pH, 7; concentration, 0.1-2.5 mg/ml. The calculated radius of the individual fractions and that of the pooled fractions 
before and after concentration and the corresponding mass is indicated in Table 8.5.  
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8.4. Study of the interaction between the isolated MO domain and CRMP 8-525 form by Ni-NTA affinity 
chromatography 
Schimdt et al. (2008) demonstrated that CRMP1-5 interact with MICAL by co-immunoprecipitation 
experiments (Figure 8.4, panel A). Furthermore, it was shown that addition of CRMP/8-525 (as GST-
fusion protein) to cell lysates expressing MOCHLIM form of mouse MICAL1 led to a rdecrease of H2O2 
produced by MICAL NADPH-dependent activity, leading to the proposal that CRMP could be the 
substrate of the monooxygenase/hydroxylating activity of MICAL (Schmidt et al., 2008).  
The absorption spectrum of flavoenzymes is very sensitive to changes in the FAD environment (Chapter 
6), which may induced by bound ligand. Thus, we tested the effect of CRMP on the absorption spectrum 
of the MO form of human MICAL1.  
Prior the addition of CRMP to MO solution, the absorption spectrum of the individual proteins was 
recorded (Figure 8.13, panels A and B). When a stoichiometric amount of CRMP was added to MO (18 
μM) in 20 mM Hepes/KOH buffer, pH 7, the solution immediately became opalescent, indicating that the 
interaction between MO and CRMP caused protein aggregation. The addition of 100 mM NaCl to the 
sample was sufficient to remove the turbidity, suggesting that the interaction between MO and CRMP 
was probably due to their opposite charges at neutral pH (MO, pI 9; CRMP, pI 5), rather than to a specific 
interaction. The absorption spectra of MO before and after the addition of CRMP were similar to each 
other indicating that the interaction at this ionic strength is weak or that, MICAL-CRMP complex 
formation does not alter the FAD enviroment (Figure 8.13, panel C).  
Next we tested the effect of CRMP on the absorption spectrum of MOCH that has a lower pI than MO 
(MOCH, pI 7.67) in 20 mM Hepes/KOH, buffer, pH 7, 100 mM NaCl. The lower positive charge of 
MOCH than MO at this pH should decrease non specific interactions.   
CRMP was added at different final concentrations (1-20 μM) to a MOCH solution (17 μM). The 
absorption spectrum of MOCH did not significantly change during the titration (Figure 8.13, panel D). 
Only a small increase of absorbance was observed when CRMP was added to a final concentration >10 
μM, maybe due to the formation of turbidity.  Thus, specific and strong interaction between MO or 
MOCH and CRMP could not be readily detected with this approach.    
CRMP-MICAL interaction was also tested by Ni-NTA Sepharose affinity chromatography by taking 
advantage of the presence of His6-tag at the C-terminus of MO. A solution containing equimolar amounts 
of MO and CRMP was incubated with Ni-NTA Sepharose in 20 mM Hepes/KOH buffer, pH 7, 100 mM 
NaCl and proteins were eluted with increasing concentrations of imidazole (0-500 mM). Control samples 
using MO or CRMP alone were also carried through the same procedure.  
CRMP was found to interact with the resin and started to elute by applying 40 mM imidazole both in the 
absence and presence of MO (Figure 8.14). MO eluted when imidazole concentration was increased from 
80 to 500 mM. Thus, under these conditions we could not detect any interaction between MO and CRMP, 
probably due to the high ionic strength of the medium selected to prevent the non specific interaction 
observed in 20 mM Hepes/KOH buffer, pH 7 (see above).  
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Subsequently, the experimental set-up was modified to prevent the non specific binding of CRMP to Ni-
NTA Sepharose by adding 20 mM imidazole and to promote the interaction between MO and CRMP. In 
this case, prior the addition of CRMP, the MO solution was incubated in batch with Ni-NTA Sepharose 
resin (1 ml) in 20 mM Hepes/KOH buffer, pH 7 to allow its binding to the resin in a random fashion, 
which should have prevented aggregation with CRMP at low ionic strength allowing for complex 
formation. As done for the previous experiment, control samples were set-up. The proteins were eluted by 
increasing NaCl concentration with addition of buffer containing 500 mM imidazole as final step.  
As expected MO eluted by applying 500 mM imidazole (Figure 8.15). Most of CRMP was now present in 
the unbound fractions (Figure 8.15) and only a small amount of CRMP eluted with 500 mM NaCl and 
imidazole when MO was present (Figure 8.15).  
These results suggested that the interaction between MO and CRMP is weak. However, it is possible that 
the CH, LIM and C-terminal regions of MICAL are required for formation of CRMP-MICAL complex. 
In this respect, experiments are in progress to test the interaction between CRMP and MOCH, 
MOCHLIM and full-length forms of MICAL.  
The fact that MICAL-MO and CRMP do not form a tight complex does not rule out that they may 
transiently interact, as expected if CRMP is a MICAL substrate.  
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Figure 8.13. Studies of the CRMP1/8-525 interaction with MO and MOCH forms. The absorption spectra of MO (1 mg/ml, 18 μM, panel A) and CRMP (1 mg/ml, 17 μM, panel B) 
in 20 mM Hepes/KOH buffer, pH 7, 100 mM NaCl were recorded. In panel C the comparison of absorption spectrum of MO before (black line) and after the addition of CRMP (red 
line) is shown. The absorption spectrum of MOCH alone (red line, 17 μM) and after incubation with varying concentrations of CRMP (1, 3, 20, 5, 10 and 20 μM) in 20 mM 
Hepes/KOH buffer, pH 7, 100 mM NaCl  at 17°C are shown in panel D.  
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Figure 8.14. Study of the interaction between MO and CRMP1/8-525 by Ni-NTA affinity chromatography. SDS-
PAGE analysis of the samples collected during the interaction assay between MO and CRMP on Ni-NTA Sepharose 
resin in 20 mM Hepes/KOH buffer, pH 7, 100 mM NaCl. L, sample incubated with the resin; FT, unbound proteins; 
the imidazole concentrations used for proteins elution are indicated; ○, MO-His; ●, CRMP.   
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Figure 8.15. Study of the interaction between MO and CRMP1/8-525 by Ni-NTA affinity chromatography. SDS-
PAGE analysis of the samples collected during the interaction assay between MO and CRMP on Ni-NTA Sepharose 
resin in 20 mM Hepes/KOH buffer, pH 7. L, sample incubated with the resin; FT, unbound proteins; the NaCl 
concentrations and that of imidazole used for proteins elution are indicated; ○, MO-His; ●, CRMP. 
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8.5. Study the interaction between MO, MOCH forms and CRMP1/8-525 form by measuring the NADPH 
oxidase activity 
We tested the effect of CRMP (8-525) on the NADPH oxidase activity of MO and MOCH. The oxidation 
of NADPH by MO and MOCH was measured as a function of CRMP under various conditions.  
Prior to each experiment, CRMP solution was gel filtered on a Superose12 column both to remove the 
aggregates and residual contaminants and to transfer CRMP in 20 mM Hepes/KOH buffer, pH 7 with 
varying NaCl concentrations (25, 50 and 100 mM) and in F-buffer (without ATP). MO and MOCH 
solutions stored in buffer B, in which they were stable, were diluted in 40 mM Hepes/KOH buffer pH 7 to 
lower the ionic strength and yield a buffer composition similar to that of CRMP. Full buffer exchange of 
MO and MOCH in the same buffer as that of CRMP was not required due to the addition of a very small 
volume of MICAL solution to each assay (1-2 μl to 120 μl). The v/[E] values of the NADPH oxidase 
activity of MO and MOCH were measured in the presence of 100 μM NADPH and varying CRMP 
concentrations (from 0 to 50 μM) in 20 mM Hepes/KOH buffer, pH 7 supplemented with 25, 50, 100 or 
200 mM NaCl and in F-buffer by recording the entire absorption spectrum was recorded every 10 s at 
25°C to detect artifacts (e.g. formation of turbidity). The changes of A340 values were used to calculate the 
initial reaction velocity. Standard NADPH oxidase activity assays of MO and MOCH were carried out in 
20 mM Hepes/KOH buffer, pH 7 (no CRMP) every 1-1.5 h to check the stability of the enzyme dilutions.   
For MO, we observed up to 90% inhibition of the NADPH oxidase activity with increasing CRMP 
concentrations in 20 mM Hepes/KOH buffer, pH 7 (I, 4.4 mM). The inhibitory effect of CRMP 
progressively decreased as the ionic strength of the medium increased (Figure 8.16, panel A). 
Interestingly, the activity of MO was weakly stimulated (up to 35%) by CRMP when its concentration 
was <15 μM in 20 mM Hepes/KOH buffer, pH 7, 200 mM NaCl (I, 204.4 mM) and in F-buffer (I, 60 
mM) (Figure 8.16, panel A). However, at higher CRMP concentrations the inhibitory effect seemed to 
prevail (Figure 8.16, panel A). To try to quantify the strength of the interaction between CRMP and MO 
in the ionic strength regime that leads inhibition, the v/E calculated in the presence of CRMP (v/Ec) was 
subtracted from that calculated in the absence of CRMP (v/Eo). The resulting values showed reasonable 
hyperbolic dependence on CRMP concentration (Figure 8.16, panel B). The data were fitted to Eq.9 that 
describes ligand binding to determine the apparent dissociation constant (Kd) of the MO-CRMP complex. 
The calculated Kd values were 0.13 ± 0.01 μM in the absence of NaCl, 8.88 ± 1 μM with 25 mM NaCl 
and 17.68 ± 2.6 μM with 50 mM NaCl (Figure 8.16, panel B). For the conditions that led to activity 
increase the v/Ec-v/Eo values were fitted to Eq.9 and the calculated Kd were 4.34 ± 0.18 μM with 200 mM 
NaCl and 8.20 ± 1.5 μM in F-buffer (Figure 8.16, panels C and D).  
A qualitatively similar behavior was observed for MOCH, but the stimulatory effect exerted by CRMP 
was observed at lower ionic strength (20 mM Hepes/KOH buffer, pH 7, 50 mM NaCl; I, 54.4)  (Figure 
8.16, panel E). The calculated Kd for MOCH-CRMP complex were 0.76 ± 0.1 µM with 10 mM NaCl and 
21.94 ± 1.73 µM with 25 mM NaCl (Figure 8.16, panel F). CRMP stimulated (≈20%) the NADPH 
oxidase activity of MOCH in 20 mM Hepes/KOH buffer, pH 7 supplemented with 50 (I, 54.4 mM) and 
100 mM NaCl (I, 104.4 mM) and in F-buffer (I, 60 mM) (Figure 8.16, panel E) and the calculated Kd for 
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MOCH-CRMP complex in the presence of 100 mM NaCl and in F-buffer were 19.6 ± 3 μM and 5.9 ± 1 
μM, respectively (Figure 8.16, panels G and H).  
The data indicated that CRMP interacts with MO and MOCH leading to inhibition of the NADPH 
oxidase  activity at low ionic strength and to a weak stimulation at higher ionic strength. These results 
suggested that the interaction between the proteins leading to inhibition is electrostatic in nature. In fact 
the inhibitory effect exerted by CRMP switched to a weak activation of MOCH at ionic strength lower 
than that required for MO that correlates with the total charge of the proteins at neutral pH (MO, pI 9; 
MOCH, pI 7.67).  
The inhibitory effect of CRMP on MO and MOCH due to non specific interactions at the lower ionic 
strength would explain the decrease of H2O2 observed by Schmidt et al., (2008) when CRMP was added 
to cell extracts containing MOCHLIM. The observed increase of activity was too small to be consistent 
with the hypothesis that CRMP is the substrate of a monooxygenase activity of MICAL or a strong 
activator.   
The activation of MICAL by CRMP was very weak. However, the kinetic parameters kcat and KNADPH of 
the NADPH oxidase activity of MOCH in the presence of CRMP in F-buffer were determined to obtain 
further information on how the activity of MOCH was increased by CRMP. The calculated parameters 
kcat and KNADPH in the presence of CRMP (15 μM) were 1.73 ± 0.05 s
-1
 and 349 ± 23 μM to be compared 
with 1.73 ± 0.14 s
-1
 and 459 ± 66 μM in its absence (Figure 8.17) . These results indicated that the 
increase (≈25%) of the NADPH oxidase activity of MOCH observed previously (Figure 8.16, panel E) 
was due to a very small decrease of the Km value for NADPH due to MICAL-CRMP interaction.  
If CRMP was the substrate of the postulated monooxygenase activity of MICAL, we would have 
expected to a significant decrease of the Km for NADPH and a dramatic increase of the kcat value (Chapter 
6), as observed for enzymes of PHBH class and also with MICAL in the presence of F-actin (Chapeter 7). 
As part of the preliminary survey of MICAL-CRMP interaction, we also tested the effect of CRMP on the 
rate of NADPH consumption in the presence of F-actin in F buffer.  
When F-actin (4 μM) was present, the calculated v/[E] values decreased by increasing CRMP 
concentration up to 20 μM (25% of inhibition); with higher concentration of CRMP the velocity of the 
NADPH oxidation increased to the values of the measured in its absence (Figure 8.18). Thus, with actin, 
the stimulatory effect of CRMP was reverted to an inhibition of the NADPH oxidation reaction catalyzed 
by MOCH in a CRMP concentration dependent manner (Figure 8.18). However, the NADPH was rapidly 
oxidized at a rate (≈15 s-1) similar to that measured in the presence of F-actin (Chapter 8) compared to 
that measured in F-buffer in the absence or presence of CRMP (Figures 8.17 and 8.18). This observation 
indicate that the interaction between MOCH and F-actin is favored, and only a small fraction of MOCH 
binds to CRMP preventing its interaction with F-actin and thus, leading to a decrease (up to 25%) of its 
activity (Figure 8.18).  
Overall, the data obtained by studying the effect of CRMP1/8-525 on the NADPH oxidase activity of MO 
and MOCH forms of MICAL indicated that an interaction between MO and MOCH with CRMP takes 
place. Such interaction leads to an inhibition of the NADPH oxidase activity at low ionic strength due to 
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the opposite charge of the proteins. Thus, the decrease of H2O2 production in lysates of cells expressing 
MICAL forms and CRMP1/8-525 observed by Schmidt et al., (2008) was probably due an inhibition of 
the NADPH consumption rather than a moonoxygenase/hydroxylase activity of MICAL in which CRMP 
would be the substrate. At higher ionic strength, the activity of MO and MOCH is inhibited when CRMP 
is present at high concentration (Scheme 8.1), but stimulation up to 25% occurs with lower CRMP 
concentrations (Scheme 8.1). Interestingly, in the presence of F-actin the enhanced NADPH consumption 
by MOCH is decrease up to 25% by CRMP. This suggests a competition between F-actin and CRMP to 
interact with MICAL, in which the interaction with F-actin is favored resulting in its depolymerization 
and enhancement of the NADPH oxidase (H2O2-producing) activity of MICAL (Scheme 8.1).  However, 
it is possible that the presence of the LIM domain and C-terminal region of MICAL are required for the 
stabilization the MICAL-CRMP complex having a different (stronger) effect on MICAL activity.  
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Figure 8.16. Effect of CRMP1/8-525 on the NADPH oxidase activity of MO and MOCH forms at varying ionic strength and ionic composition of the buffer. The initial velocity of the 
NADPH oxidase activity of MO and MOCH was measured in the presence of a fixed concentration of NADPH (100 μM) and varying CRMP concentration in 20 mM Hepes/KOH 
buffer, pH 7 (○), supplemented with 10 mM NaCl (●), 25 mM (□), 50 mM (■), 100 mM (Δ) and 200 mM (▲) and in F-buffer (◊). The activity measured in the absence of CRMP is 
taken as 100% of the activity (panels A and D). The Kd values of the MO- or MOCH-CRMP complex are calculated as described in the text (panels B-D and F-H).   
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Figure 8.17. Effect of CRMP1/8-525 on the steady-state kinetic parameters kcat and  KNADPH of the NADPH oxidase 
activity of MOCH. The calculated v/[E] values of the NADPH oxidation reaction in the absence (○) and in the 
presence of 15 μM CRMP (●) at varying NADPH concentration in F-buffer were fitted to Eq2 and the calculated 
kinetic parameters are indicated in the text.  
 
Figure 8.18. Effect of CRMP1/8-525 on the NADPH oxidation reaction catalyzed by MOCH in the presence of F-
actin. The initial velocity of the NADPH oxidation reaction were measured in F-buffer in absence (○) and presence 
of F-actin (4 μM, ●) with fixed concentration of NADPH (100 μM) and by varying CRMP concentration.  
 
 
 
 
Scheme 8.1. Schematic representation of possible mechanisms of action of MICAL and CRMP for the control of 
cytoskeleton dynamics in response to semaphoring signaling pathway. 
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9. Discussion and conclusions 
 
The aim of this work was to produce and purify the full-length human MICAL1 protein and its truncated 
forms (MO, the isolated MO domain; MOCH, comprising the MO and CH domains; MOCHLIM, lacking 
the C-terminal region) to determine for the first time: (i) the catalytic properties of human MICAL 1; (ii) 
the effect of the CH and LIM domains and the C-terminal region on the catalytic properties of the N-
terminal monooxygenase-like domain and (iii) to open the way to study how MICAL interacting proteins  
can modulate its activities.  
We engineered the DNA coding human MICAL1 for the expression of the full-length protein and the 
form lacking the C-terminal region carrying the His6-tag at their C-terminus, as previously done for the 
production of the isolated MO domain (Zucchini et al., 2011) and of the form comprising the MO and CH 
domains (Vitali 2012). Two forms of MOCHLIM were constructed, MOCHLIM2 and MOCHLIM4, 
spanning residues 1-771 and 1-783, respectively.  
On the basis of the results of pilot experiments, MOCH, MOCHLIM comprising 1-783 residues and the 
full-length MICAL1 were produced in E.coli BL21(DE3) cells in the presence of GroE to favor protein 
folding.  
The proteins were purified by affinity chromatography on Ni-NTA Sepharose resin followed by gel 
filtration on a Superose12 column (on a small scale; for MO, MOCH and MOCHLIM) or on a 
Superdex200 column (on a large scale, for MOCHLIM) or by anion exchange chromatography (for 
MICAL) to obtain homogeneous protein preparations. MOCHLIM form and to a lesser extent the full-
length form were sensitive to proteolytic degradation. The addition of 0.5% of a protease inhibitors 
cocktail to the enzyme preparation after each chromatographic and dialysis step and the presence of 1 
mM PMSF in buffer solutions allowed us to obtained stable protein preparations to carry out their 
characterization. All MICAL forms were stable after concentration up to ≈5 mg/ml by ultrafiltration and 
after dialysis against 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 
mM DTT, 1 mM PMSF. Mass spectrometry analysis of the purified MICAL forms confirmed their 
integrity with the N-terminal sequence corresponding to that of MICAL1 after post-traslational removal 
of Met1.The absorption spectrum of all MICAL forms showed the characteristic long-wavelength 
absorption band due to the formation of the charge-transfer complex (CT) between FAD and Trp400 
(Nadella et al. 2005; Siebold et al., 2005) and absorbance maxima at 375 and 458 nm in the visible 
region. Small differences were observed in the absorbance maxima in the UV region, which is influenced 
by the amino acidic composition of the proteins so that the maxima were at 273, 276, 278 and 280 nm for 
MO, MOCH, MOCHLIM and MICAL, respectively. The fact that the absorption spectra in the visible 
region of the final MICAL forms were very similar to that of the isolated MO domain indicated that the 
presence of the CH, LIM domains and of the C-terminal region did not perturb the FAD environment of 
the N-terminal domain of MICAL. For the isolated MO domain it has been previously demonstrated that 
1 mol of FAD was bound per mol of the purified protein. The calculated extinction coefficient was 8.1 
mM
-1
cm
-1
 at 458 nm (Zucchini et al., 2011). These results were confirmed with MO preparations 
produced during the present work. More importantly, also the MOCH, MOCHLIM and the full-length 
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MICAL showed a stoichiometry of ≈0.8 mol of FAD per mol of protein with the protein concentration 
determined with the Bradford method, which likely overestimates the protein content by 15-25%. Similar 
values of the extinction coefficient at 458 nm were determined for MICAL forms (7.9 ± 0.22 mM
-1 
cm
-1
, 
8.1 ± 0.07 mM
-1 
cm
-1
  and  7.6 ± 0.56 mM
-1 
cm
-1
 for MOCH, MOCHLIM and MICAL, respectively, with 
the protein denatured with TCA to release the FAD  and 8.02 mM
-1
cm
-1 
(MOCH), 8.4 mM
-1
cm
-1
  
(MOCHLIM) and  8.4  mM
-1
cm
-1
 (MICAL) when the proteins were denatured in buffer containing 
guanidine). The MOCHLIM and full-length proteins contained also zinc ions with a stoichiometry 
consistent with the expected 2 zinc ions bound to the LIM domain.  
The purified proteins were stable after long-term storage at -80°C or after incubation up to 24 h on ice at 
4°C, as demonstrated by their absorption spectra, activity and by SDS-PAGE analysis.  
MO and MOCH forms were monomeric in solution as demonstrated by gel filtration and by DLS 
experiments. MOCHLIM and MICAL were found to be dimeric by gel filtration. For full-length MICAL 
the result was confirmed by DLS. Instead, DLS showed that the presence of the LIM domain causes 
MOCHLIM to oligomerize yielding dimers, trimers, tetramers and higher order aggregates. This 
observation is in agreement with the the tendency of such domain to aggregate as well as to stabilize 
various oligomeric states depending on the protein concentration (Mathews et al., 2013).  
All MICAL forms were able to catalyze a NADPH oxidase activity. The catalytic efficiency (kcat/KNADPH) 
of the NADPH oxidase activity catalyzed by MICAL forms progressively decreased (from ≈163 s-1mM-1 
to ≈18.5 s-1mM-1, ≈15.3 s-1mM-1  and ≈0.75 s-1mM-1 for MO, MOCH, MOCHLIM and MICAL, 
respectively) mainly due to an increase of the Km for the NADPH (MO, ≈20 μM; MOCH ≈134 μM; 
MOCHLIM, ≈230 μM; MICAL, ≈375 μM). MO, MOCH and MOCHLIM forms showed similar kcat 
values (≈3 s-1). Instead, a 10-fold drop of the kcat was observed for the full-length protein (≈0.3 s
-1
).The 
pH profiles of 1/KNADPH and kcat/KNADPH that were similar in shape for MICAL forms and they appeared to 
reflect the overall charge of the protein, which plays a major role for NADPH bnding to enzymes of the 
PHBH family. MO and MOCH showed a similar pH profile of the kcat with similar pKa values and 
revealed a greater sensitivity of the MO domain to the ionic strength and ionic composition of the 
medium compared to that of the other forms. The kcat of MOCHLIM was little sensitive to pH between pH 
6 and 9, with values similar to the maxima values observed for MO and MOCH. At pH lower than 6 also 
the kcat decreased as observed for the other truncated forms. These result suggests that at this pH value 
LIM, which becomes less negatively charged, may lose  its interaction with the rest of the protein, leading 
to that the decrease of kcat observed with MO and MOCH at acidic pH.  Instead, the kcat of the full-length 
MICAL remained lower compared to the values measured with the truncated forms in the entire pH range 
we could explore, and it increased from a low value at pH 6-8 as the pH decreased. It is possible, that as 
the pH lowers the C-terminal region becomes less negatively charged so that its interaction with the 
positively changed MO could be weakened leading to the observed increase of kcat.  
Studies of the effect of solvent viscosity on the kinetic parameters of the NADPH oxidase activity of the 
MO domain suggested the presence of conformational changes that take place during the catalytic cycle 
between substrate binding and NADP release, which contribute to determine the value of the parameter 
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(Zucchini et al., 2011).  On the basis of the known properties of PHBH and the structures of MICAL-MO 
in the oxidized and reduced state (Nadella et al., 2005; Siebold et al., 2005), in  a minimal scheme,  the 
predicted conformational changes may be: (i) movement of Trp400 to allow hydride transfer from the 
NADPH nicotinamide ring to the flavin and (ii) the subsequent “flavin in”/”flavin out” transition. The 
effect of the solvent viscosity on the kinetic parameters of the NADPH oxidase reaction catalyzed by 
MOCH, MOCHLIM and MICAL confirmed that the NADPH oxidase reaction catalyzed by the MO 
domain of MICAL1 is solvent sensitive. The CH and LIM domains and the C-terminal region of MICAL 
partially suppressed the viscosity effect on kcat/KNADPH in a fashion that may be explained by their 
progressively lower affinity for NADPH. Interestingly, the effect of solvent viscosity on the kcat was 
similar for all MICAL forms demonstrating that it is unlikely that the drop of kcat of full-length MICAL 
is due to a decrease of the chemical steps of the reaction. 
The study of the pH and solvent viscosity dependence of the NADPH oxidase reaction catalyzed by 
MICAL forms led us to conclude that the observed changes in the values of the kinetic parameters are not 
due to changes of the optimal pH and/or in the rate determining steps of the reaction taking place in the 
MO domain. The increase of the Km for NADPH correlates with a decrease of the positive charge of the 
protein due to the presence of the acidic CH, LIM and C-terminal domain. The 10-fold decrease of the 
NADPH oxidase activity observed for the full-length MICAL is in agreement with the proposal that the 
C-terminal region has an inhibitory function on the activity of the MO domain (Schmidt et al., 2008; 
Giridharan et al., 2012). Our experiments indicate that the observed lowering of kcat is likely due to the 
presence of a conformational equilibrium between an inactive/close (a) and active/open (b) conformation 
of MICAL in the free state (Scheme 9.1), which is shifted 9:1 toward the inactive conformation in 
solution so that only a 10% of MICAL would be present in the catalytically active state (Scheme 9.1). In 
fact the value of kcat reflects the actual concentration of the active enzyme present in solution. These 
conformations, which are expected to be in rapid equilibrium with each other so that their relative 
cncentrations would remain constant in solution, depend on the position of the C-terminal region. 
In spite of the fact that the MICAL MO domain is structurally related to PHBH, the prototype of FAD-
containing aromatic monooxygenases and that it share with it the high sensitivity of NADPH binding to 
ionic composition and ionic strength and catalytically relevant conformational changes, all MICAL forms 
have an unusually high NADPH oxidase activity for a monooxygenase in the absence of the substrate to 
hydroxylate suggesting that they function as true oxidases. The differences between monooxygenases and 
oxidases may be very subtle and depend on the ability of being reduced by NADPH even in the absence 
of the hydroxylating substrate and the abitity to stabilize the Flavin 4a-hydorperoxide intermediate, which 
are linked to the fine details of the active site architecture. It should be noted that the overall structure of 
MICAL MO is similar to that of PHBH, but the active sites of the two enzymes are different as well as 
the details of their topologies (Figure 2.3 in Chapter 2), which suggest a greater degree of flexibility of 
MO compared to PHBH (Nadella et al., 20155, Siebold et al., 2005). Thus, a PHBH-like module could 
have been recruited in MICAL to generate a NADPH oxidase that can be finely regulated by modulating 
 177 
NADPH binding and catalysis through electrostatics and by modulating the catalytically relevant 
conformational changes as in PHBH.  
A unique feature of MICAL proteins is their ability to catalyze a NADPH-dependent F-actin 
depolymerizing activity. We have demonstrated that all MICAL forms were able to catalyze a NADPH-
dependent depolymerization of actin filaments. F-actin greatly stimulated the rate of NADPH 
consumption by all MICAL forms, leading to a (≈10-fold) increase the kcat and to a decrease of the Km for 
NADPH (10-50 μM vs 400-900 μM in the absence of F-actin). As a result, MO, MOCH and MOCHLIM 
forms are similar to each other with respect to the KNADPH measured in the presence of F-actin (4 μM), 
and kcat values vary within a factor of 2-3 (20 s
-1
, 26 s
-1
 15 s
-1
 and 8 s
-1
 for MO, MOCH , MOCHLIM and 
full-length MICAL,, respectively). The apparent Km for actin was also similar for MO, MOCH and 
MOCHLIM (≈4 μM) indicating that the main site of MICAL interaction with F-actin is its MO domain. 
Thus,the presence of the CH and LIM domains, which mediate the interaction with F-actin in actin-
binding proteins, did not alter the affinity of MICAL for F-actin and the N-terminal monooxygenase-like 
domain is sufficient for the interaction. This is in contrast with the proposal that the CH and LIM domains 
are required to present the physiological substrate to the catalytic domain (Siebold et al., 2005), but it is in 
agreement with the fact that single CH or LIM domains are not able to bind F-actin. In fact, cytoskeleton 
proteins that interact with F-actin or with actin binding proteins (ABP) contain tandem CH and LIM 
domains (Bamburg et al., 2000). Thus, the presence of single CH and LIM domains in MICAL proteins is 
another unusual feature of MICAL proteins. 
For the full-length MICAL F-actin stimulates the rate of the NADPH oxidation reaction catalyzed by 
MICAL by lowering the Km for NADPH to a value of ≈30 µM, which is similar to those calculated for 
the truncated forms. The apparent kcat was ≈8 s
-1
 that is only 2-3-fold lower than those of the other forms. 
Interestingly, assuming that the Km value reflects the Kd, the affinity for F-actin was 10-fold lower (≈30 
µM) than that measured for MO, MOCH and MOCHLIM. Also this effect could be explained by the 
conformational equilibrium between an inactive and active conformation of the full-length MICAL in the 
free state (Scheme 9.1 and Figure 1.8 in Chapter 1). The higher Km for actin of MICAL could reflect the 
coupled equilibria between the inactive(a)/active(b) conformations and between the formation of F-
actin/MICALactive (c) complex and MICAL in the active conformation (b) (Scheme 9.2). Only in the 
active (b) conformation of MICAL the actin binding site of the MO domain would be physically 
accessible. This time binding of F-actin would shift the equilibrium towards the active species, justifying 
the fact that kcat of MICAL is only 3-fold lower than that measured with the other forms.   
Interestingly, actin depolymerization catalyzed by MO and MOCH led to the release of actin monomer 
(G-actin), while the incubation of F-actin with MOCHLIM and the full-length protein in the presence of 
NADPH led to the formation of actin fragments of approximately 240 kDa suggesting that they function 
as severing proteins.. We can speculate that part of the actin filament is physically protected by the 
presence of the LIM domain and the C-terminal region of MICAL reducing the number of site on the 
actin filament that can interact with the MO domain. As a result several actin monomers could not be 
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modified by the NADPH oxidation reaction catalyzed by the MO domain bound to actin and, thus, they 
remain associated to yield the observed fragments.  
In all cases, the amount of NADPH rapidly oxidized by MICAL forms exceeded that of the actin present. 
This result can be explained as due to: (i) a case of substrate recycling; (ii) enhanced NADPH oxidation 
leading to both the hydroxylation (monooxygenase activity) of F-actin residues and the H2O2 production 
(NADPH oxidase activity) at a similar rate or (iii) enhanced NADPH oxidase activity. If F-actin Met 44 
(and Met 47) were the substrate of the monooxygenase/hydroxylating activity of the N-terminal domain 
of MICAL, as proposed for the Drosophila and mouse proteins (Hung et al., 2013; Lee et al., 2013), we 
would have expected rapid oxidation of a molar amount of NADPH corresponding to that of actin (or 
twice its concentration), followed by a slow oxidation of NADPH at the same rate as that observed in the 
absence of F-actin. The mass spectrometry analyses of actin samples treated with MICAL forms and 
NADPH revealed that a maximum of two residues are oxidized per actin molecule. Actin Met44 and 
Met47 are modified but that also several other Met and Trp residues are oxidized with similar probability. 
The oxidation of several residues, which are all in proximity of the interface between actin monomers 
(Figures 7.17 and 7.18 in Chapter 7), would suggest that their modification depends on in situ H2O2 
production through the NADPH oxidase activity of MICAL. This is in contrast with the proposal of the 
specific conversion of Met44 (and Met 47) to methionine sulfoxide (Scheme 9.3) by a hydroxylase 
activity for the Drosophila and mouse MOCH forms, in which the resulting R-methionine sulfoxide 
residue is reverted to methionine through R-specific methione sulfoxide reducatase (Hung et al., 2013; 
Lee et al., 2013) (Scheme 9.3; Figure 8.8 in Chapter 8). However, it is possible that MICAL binds to F-
actin in such a way that the first residue being hit by released H2O2 could be Met44 (or Met 47), which 
belong(s) to loop D, at the interface between actin monomers in the filament. As a result of preferential 
modification of Met 44 (and/or Met47), disassembly of the filament would locally take place, causing 
MICAL-MO release and inhibition of its NADPH oxidase activity. This process would further limit 
uncontrolled actin oxidation. The precise geometry of MICAL/F-actin interaction would control the 
stereochemistry of Met oxidation to yield methionine sulfoxide with excess of the R enantiomer, which 
could be repaired by R-specific methionine sulfoxide reductase. 
Overall it appears that, in the cell, MICAL can catalyze a basal NADPH oxidase activity in the free state. 
This activity is enhanced by the binding of MICAL to F-actin, which catalyzes depolymerization of actin 
filaments, even in the absence of activating proteins. The removal of the interaction between the C-
terminus and the N-terminal catalytic domain of MICAL by interactor proteins, like the cytoplasmic 
portion of plexin, in response to semaphorin signaling would shift the inactive/active equilibrium toward 
the active form favoring its interaction with F-actin and thus, promoting its local depolymerization.  
Several proteins have been identified as MICAL interactors (CasL, GTPases, NDR, CRMP), which could 
modulate its activity. With purified MICAL forms now available, it will be possible to identify specific 
interactors and to study in detail their effect on the activities catalyzed by the MO domain. In this respect, 
preliminary experiments were carried out to start to study the interaction between MICAL and CRMP. 
Experiments in COS7 cells  demonstrated that the interaction between MICAL1 interact with CRMP1-5 
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proteins and that such interaction leads to reorganization of the cytoskeleton also in the absence of 
semaphorin stimulation (Schmidt et al., 2008). For CRMP2 it has been proposed that the H2O2 produced 
by the NADPH oxidase activity of MICAL modulates the activity of CRMP2 by oxidizing a Cys residue, 
which would stimulate its phosphorylation and, as a consequence, promote microtubules disassembly 
(Morinaka et al., 2011). Instead, CRMP1 has been proposed to be possible substrate of the 
monooxygenase/hydroxylase activity of MICAL due to a decrease of H2O2 produced in the presence of 
NADPH in lysates of COS7 cells expressing MICAL1 and CRMP1 compared to that measured in cells 
expressing only MICAL1 or CRMP (Schmidt et al., 2008). Thus, it was proposed that hydroxylation of 
CRMP1 by MICAL1 would be responsible for the observed synergistic action of MICAL and CRMP in 
cells collapse.  We produced and purified  the mouse CRMP1 form comprising residues 8-525 used by 
Schmidt et al. (2008) to show the quenching of H2O2 production by MICAL. Our experiments 
demonstrated that CRMP1 and MICAL1 MO and MOCH interact, but in a complex way. At low ionic 
strength, CRMP1 caused an inhibition of the NADPH oxidase activity due to non specific interactions 
depending on the opposite charge of the proteins. At higher ionic strength, the non specific interactions 
were removed and CRMP (up to 15 μM) led to a weak stimulation (≈25%) of the NADPH oxidase 
activity of MO and MOCH, which was followed by an inhibition at higher CRMP concentrations. The 
stimulatory effect of CRMP on the activity of MO and MOCH was due to a small decrease of the Km for 
NADPH.  If CRMP were the hydroxylatable substrate of the monooxygenase activity of the N-terminal 
monooxygenase-like domain of MICAL we would have expected a significant increase of kcat and a 
significant decrease of the Km for the NADPH.  Interestingly, when F-actin was present, the stimulatory 
effect of CRMP was reverted to an inhibition of NADPH oxidation. From this observation we can 
speculate that CRMP and F-actin compete for binding to MICAL and that the formation of MICAL/F-
actin complex is favored. 
In general these results suggested that CRMP1/8-525 is not the substrate of a hydroxylase activity of the 
MO domain of MICAL1 and the observed inhibitory effect on the NADPH consumption by MO and 
MOCH could explain the decrease of the H2O2 production detected in cell lysates. The interaction  
between CRMP and  MO or MOCH seems weak (estimated of Kd are in the microM range (Figure 8.16 in 
Chapter 8), but it may be explained  by the absence of the LIM domain and C-terminal region of MICAL, 
which could be the protein region at which the interaction between MICAL and CRMP takes place. It is 
possible that CRMP can interact with the C-terminal regions of MICAL removing the autoinhibitory 
effect exerted on the N-terminal catalytic domain, leading to activation of the NADPH oxidase activity of 
MICAL also in the absence of semaphor-plexin interaction or maintaining MICAL in a conformation to 
that would promote its binding to plexin to potentiate the signal transduction.  
The H2O2 produced by MICAL could modulate the ability of CRMP to promote microtubules assembly 
indirectly by inhibiting phosphatase activity though oxidation (Figure 8.8 in Chapter 8). In this respect, 
the NADPH oxidase H2O2-producing activity of MICAL that should be enhanced when bound to the 
cytoplasmic side of plexin thorugh its C-terminal region could also maintain CRMP in the 
phosphorylation state (by inhibiting phosphatases) and thus destabilize the microtubules. In such way 
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actin and microtubules cytoskeleton component could be linked and controlled by MICAL activity in 
response to semaphoring-plexin signaling.  
Our studies revealed that MICAL may be an authentic NADPH oxidase rather than a monooxygenase and 
that it exhibits such activity even in the free state. 
In order to evaluate the relevance of MICAL NADPH oxidase activity in the absence/presence of F-actin 
in the cell, we searched the literature for estimates of the cellular concentrations of NADPH and F-actin.  
For both species the published values vary over several orders of magnitude. For F-actin, concentrations 
varying from μM to mM were reported depending on cell type and cell localization (Koelster et al., 
2009). Also the reported NADPH concentrations varied from 30 μM in brain (Klaidman et al., 1995) to 
300 μM in liver (Slater 1967) and 900 μM in suprachiasmatic nucleolus cell lines (SCN2.2) (Wise et al., 
2004). NADPH concentrations also depend on the metabolic conditions, which influence the activity of 
NADPH generating or consuming enzymes (Ying et al., 2008). By considering the highest NADPH 
concentration of 900 μM, the free full-length MICAL would exhibit a low, but not neglible, NADPH 
oxidase (H2O2-producing) activity, which would be controlled by local NADPH levels. Such activity 
would remain low even after the removal of  C-terminal interaction upon its interaction with plexin 
activated by semaphorin, which would probably corresponds to the activity of the MOCHLIM form. The 
NADPH concentration could also control the activity of MICAL upon F-actin binding, if local NADPH 
concentration were < 100 μM. Thus, NADPH levels in the cell can control H2O2 produced by the 
NADPH oxidase activity of free MICAL and also cytoskeleton dynamics by regulating the F-actin 
depolymerizing activity of MICAL.   
With purified MICAL forms it will be possible to better understand the reaction mechanism of F-actin 
depolymerization, to identify MICAL interactors and to determine their mutual effects. In this respect, it 
will be interesting to clarify the catalytic properties of full length MICAL in complex with CRMP1 (or 2) 
and MICAL and of MICAL with other proteins such as CasL, NDR which are involved in the integrin 
pathway and apoptosis, respectively.  
Inhibition of MICAL has been proposed to be beneficial to prevent neurodegenerations associated with, 
e.g., spinal cord injury or even Amyotrophic lateral sclerosis (Kaneko et al., 2006; Schmidt et al., 2009) 
and even some cancer forms (Ashida et al., 2006; Lundquist et al., 2014). Recently, a compound named 
CCG1423 that had been shown to inhibit cancer cells proliferation (Lundquist et al., 2014)  has been 
proposed to be a potent inhibitor (Ki, 1.57 μM) of MICAL2 activity (Lundquist et al., 2014). In these 
experiments, the inhibition studies had to be carried out in the presence of F-actin to enhance the rate of 
NADPH oxidation catalyzed by the MO domain of MICAL2 to measurable levels.  This set-up certainly 
complicates the interpretation of the data. The higher kcat and lower KNADPH of human MICAL1 forms, 
even in the absence of F-actin, compared to those of the still poorly characterized MICAL2 and 3, makes 
MICAL1 better suited than other MICAL isoforms for detailed structure-function studies aiming to 
dissect the catalytic mechanism of the reaction that is associated with its monooxygenase-like domains 
and to, e.g., search for inhibitors of potential medical interest.  For example, we tested the effect of 
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CC1423 on the NADPH oxidase activity of human MICAL MO and MOCH forms in the absence of F-
actin and we could not confirm the results of Lundquist et al. with MICAL2. The similarity between the 
catalytic domains of MICAL isoforms would suggest that the the effect observed on MICAL2 could be an 
artifact due to the intrinsic low activity of MICAL2 MO domain even in the presence of F-actin or to the 
presence of F-actin itself. 
Finally, with homogeneous preparations of the various MIAL1 forms available it will be possible to 
initiate structural studies of the proteins in the free state, in complex with its interactors and F-actin by 
using the potent techniques now available (e.g.: small-angle X-ray scattering or cryo-electron 
microscopy)  for structure determination even in the case of proteins that resist cystallyzation such as 
conformationally heterogeneous proteins,  weak protein-protein complexes and complexes with F-actin. 
 
 
Scheme 9.1.  Conformational equilibrium between the inactive (a) and active (b) conformation of MICAL in the free 
state. Only the active form would react with NADPH and molecular oxygen, but at the end of the catalytic cycle 
active MICAL would rapidly equilibratewith the inactive form so that the relative concentrations of active/inactive 
conformations would be independent from NADPH concentration.  
 
Scheme 9.2.  Conformational equilibrium between the inactive (a), active (b) conformation of MICAL in the free 
state and in complex with interacting protein (c). F-actin (P) would be able to shift the equilibrium between the 
inactive and active form of full-length MICAL increasing the concentration of the active species. 
 
 
Scheme 9.3. Mechanism of the reaction for the oxidation if methionine to methionine sulfoxide in a monooxygenase 
(R-OOH, FAD 4a hydroperoxide) or by H2O2 (ROOH, hydrogen peroxide). 
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10. Materials and Methods 
 
10.1. Microbiology and Molecular biology techniques  
 
For microbiology and molecular biology methods protocols reported in Sambrook, J et al., (1988) and 
Ausubel, F.M., et al., (2005) were used. 
 
Ultrapure water produced with a MilliQ Reagent water system (Millipore, Billirica, MA, USA) was used 
to prepare all solutions, while growth media were prepared with deionized water produced with a Elix 5 
(Millipore) apparatus. 
 
Growth medium  
LB medium (Luria Bertani) 
Tryptone 10g/l, NaCl 10g/l and Yeast extract 5g/l. 
 
Antibiotic solutions 
Ampicillin (Amp) 100 mg/ml in ultrapure H2O; the solution is sterilized with a 0.22 μm filter (sterile 
syringe filter with cellulose-acetate membrane, VWR); 
Chloramphenicol (Chl) 25 mg/ml in ethanol.  
Antibiotic solutions are divided in aliquots and stored at -20°C.  
 
Preparation of E.coli Rosetta (DE3) and BL21(DE3) competent cells with the CaCl2 method 
Solutions 
- 0.1 M CaCl2 sterile solution, stored at -20°C;  
- DMSO (Sigma, D-8418, St. Louis, MI, USA).  
Procedure 
The night before the experiment: 
- remove an aliquot of E.coli Rosetta(DE3) or BL21(DE3) cells stored at -80°C as glycerol stocks; 
- inoculate the cells on a LB (for BL21(DE3)) or LB-Amp (for Rosetta(DE3)) plate and incubate 
overnight at 37°C; 
- inoculate 100 ml of LB or selective LB medium with a single colony from the plate; 
- incubate at 37°C under stirring (220 rpm); 
- monitor cell growth by measuring the optical density at 600 nm (OD600) at different times; 
When the culture reaches a OD600 value of 0.4-0.5: 
- transfer the culture into 250 ml bottle for Sorvall rotor SLA1500 and centrifuge at 4000 rpm for 10 min 
at 4°C (Sorvall RC6 Plus); 
- discard the supernatant and resuspend the pellet in 0.1 M CaCl2 (20 ml);  
- transfer the suspension into a 50 ml sterile centrifuge tube and centrifuge at 4500 rpm for 10 min at 4°C 
(rotor SS34); 
- discard the supernatant and resuspend the pellet in 0.1 M CaCl2 (4 ml); 
The cells are ready to be transformed with the plasmid.   
 
For a later use of the competent cells: 
- add 35 μl of DMSO per ml of competent cells suspension; 
- incubate 15 min on ice; 
- add 35 μl of DMSO per ml of competent cells; 
- distribute 600 μl aliquots in cryotubes; 
- flash-freeze in liquid nitrogen and store at -80°C.  
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E.coli Rosetta(DE3) and BL21(DE3) competent cells trasformation 
Solutions  
- TE buffer: 10 mM Tris/HCl, pH 8, 1 mM EDTA sterilized in autoclave; 
- plasmid solution (0.2-0.6 μg/μl); 
- E.coli competent cells; 
- LB medium; 
- selective LB plates.  
 
Procedure  
- thaw an aliquot of E.coli competent cells or use freshly prepared competent cells; 
- thaw the desiderate plasmid solutions and, if needed, dilute it in TE buffer to have 1-50 ng of DNA in 1-
50 μl;  
  - set-up the transformation mixture:  
      Negative control           sample 
Plasmid        -   1-50 μl 
Competent cells           200 μl                  200   μl 
- mix gently and incubate for 30 min on ice; 
- carry out the thermal shock at 42°C for 90 s; 
- incubate for 2 min on ice; 
- add 800 µl of LB medium; 
- incubate for 45 min at 37°C; 
- centrifuge at 13000 rpm for 2 min at 4°C in a microfuge (Heraeus Biofuge Pico, Chandler, AZ, USA) ; 
- discard the supernatant and resuspend the pellet in 200 µl of LB medium; 
- spread on selective LB plates; 
- incubate overnight at 37°C.  
 
Preparation of E.coli DH5α competent cells with the RbCl method 
E.coli DH5α strain is used for the maintenance and propagation of the plasmids. The strain is mutated in 
the gene coding RecA protein involved in the recombination process and in the gene coding EndA 
endonuclease. This method is used to transform E.coli cells when high transformation efficiency is 
required, e.g. during cloning.  
Solutions   
- Solution A: 10 mM MOPS, pH 6.5, 10 mM RbCl (sterilized in autoclave); 
- Solution B: 10 mM MOPS, pH 6.5, 10 mM RbCl, 50 mM CaCl2 (sterilized in autoclave); 
- Solution B + glycerol: 7 ml of Solution B + 1 ml of 80% glycerol (freshly prepare for use and 
maintained on ice).  
Procedure 
The night before the experiment: 
- remove an aliquot of E.coli DH5α cells stored at -80°C as glycerol stocks; 
- inoculate the cells on a LB plate and incubate overnight at 37°C; 
- inoculate 80 ml of LB or selective LB medium with a single colony from the plate; 
- incubate at 37°C under stirring (220 rpm); 
- monitor cell growth by measuring the optical density OD600 at different times; 
When the culture reaches a OD600 value of 0.3-0.5; 
- transfer and split the culture in 50 ml sterile centrifuge tube and centrifuge at 6500 rpm for 10 min at 
4°C (Sorvall RC6 Plus, rotor SS34); 
- discard the supernatant and resuspend the pellet in 20 ml of Solution A;  
- centrifuge at 6500 rpm for 10 min at 4°C (rotor SS34); 
- discard the supernatant and resuspend the pellet in 20 ml of Solution B; 
- incubate 30 min on ice; 
- centrifuge at 6500 rpm for 10 min at 4°C (rotor SS34); 
- discard the supernatant and resuspend the pellet in 4 ml of Solution B + glycerol; 
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- split in aliquots of 200 µl in eppendorf tubes and store at -80°C 
The cells are ready to be transformed with the plasmid.   
 
E.coli DH5α competent cells trasformation 
The procedure is similar to that described for E.coli Rosetta(DE3) and BL21(DE3) cells with the 
following modifications:  
- carry out the thermal shock at 37°C for 1 min; 
- add 1 ml of LB medium; 
- incubate for 1 h at 37°C; 
- spread 120 µl (1/10) of sample on selective LB plate; 
- centrifuge the remaining sample at 13000 rpm for 3 min at 4°C; 
- discard the supernatant; 
- resuspend the pellet in 200 µl of LB medium (9/10);    
- spread on selective LB plates; 
- incubate at 37°C overnight.  
 
Table 10.1 E.coli strains. 
E.coli strains Genotype Marker 
DH5α recA– endA– - 
BL21 (DE3)
a 
F 
–
 ompT hsdSB (rB
–
 mB
–
) gal dcm (DE3) - 
Rosetta (DE3)
a 
F
–
 ompT hsdSB(rB
–
 mB
–
) gal dcm lacY1 (DE3) pRARE6 (CmR) Chl 
a
Studier et al., 1986 
 
Table 10.2 Properties of the plasmids used.  
Plasmid Vector Marker Dimensions, bp Encoding proteins 
pJET-MICAL 
pJET1.2 
(Thermo 
scientific) 
Amp 6205 
Full length human MICAL1, 1-1068 aa 
pET-MICAL 
pET23b 
(Novagen) 
Amp 6791 
pJET-MOCHLIM2 pJET1.2 Amp 5311 MO, CH and LIM domain of human MICAL1, 
1-771 aa pET-MOCHLIM2 pET23b Amp 5933 
pJET-MOCHLIM4 pJET1.2 Amp 5347 MO, CH and LIM domain of human MICAL1, 
1-783 aa pET-MOCHLIM4 pET23b Amp 5897 
pET-MOCH pET23b Amp 5434 MO and CH domains of human MICAL1 
pET-MO pET23b Amp 5054 MO domain of humanMICAL1 
EFS10 
pGEX-6P (GE 
Healthcare) 
Amp 6673 Mouse CRMP1 8-875 aa 
EFS11 pGEX-6P Amp 6673 Mouse CRMP1 8-875 aa, mut 49-56 
EFS12 pGEX-6P Amp 6535 Mouse CRMP1 8-825 aa 
EFS13 pGEX-6P Amp 6535 Mouse CRMP1 8-825 aa, mut 49-56 
p18 pBR22 Chl 3773 GroES-GroEL of E.coli 
pRARE pRIG Chl 4629 tRNA per Ile, Gly, Arg, Leu e Pro 
 
 
Table 10.3 Primers used for the amplification of the cDNA of human MICAL1 coding MICAL-MOCHLIM and the 
full length protein forms. Restriction sites are indicated: EcoRI (bold), NdeI (italic), BamHI (underlined) and XhoI 
(double underlined). The start and the stop codons are highlighted in grey. The lower case types indicate the 
mismatch with respect to the DNA template. The melting temperature (Tm) is calculated with the formula indicated 
in the text.     
primer sequence Tm 
MICAL Fw new 5’ccgaattccatATGGCTTCACCTACCTCCACCAACCCAGCGCATGCCC 3’ 70.5 
MICALMOCHLIMRev1 5’ GCTGgaTcCCTacTcGaGGTCTGTCTGGGGCAGGTGC 3’ 71.5 
MICALMOCHLIMRev2 5’ TCTCggaTccTtactcGAGCTCCGGACTCTCAGGGCCTCTATCGCTGC 3’ 71.3 
MICALMOCHLIMRev4 5’AGGCgGatccctactcGAGGCCTGGTGGCATGCTATTCTCACTTGGTG 3’ 68.5 
MICALFLRev 5’ GGTACAgGATcCTtacTCGagCTGGGCCCCTGTCCCCAAGGC 3’ 70.3 
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Table 10.4. Primers used for sequencing of pDON-hMICAL1, pUC-MOCH, pJET-MOCHLIM and pJET-MICAL. 
 
Primer Sequence plasmid 
MICCt Fw 5’-CGGTGCAGGAATTGAATCTG-3’ pDON-hMICAL1 
M13 (-21) Fw 5’- TGTAAAACGACGGCCAGT -3’ 
pUC-MOCH 
M13 Rev  5’- CAGGAAACAGCTATGACC -3’ 
pUCFw1 5’- CGCAATTAATGTGAGTTAGCTC -3’ 
pUCFw2 5’- GTGGTAGCAGGGAGTGAC -3’ 
MOCH rev 5’- CTTCACCATCCAGGCTGCATC -3’ pUC-MOCH and pJET derivatives 
pJET Fw 5’-CGACTCACTATAGGGAGAGCGGC -3’ 
pJET derivatives pJET Rev 5’-AAGAACATCGATTTTCCATGGCAG -3’ 
MOCH Fw 5’- TCGTGTGCAAGAGAAGCATG -3’ 
MICFL Rev 5’- AGCTTGAGGGCTCTGGAC -3’ pJET-MICAL 
 
 
10.2. Engineering of the DNA coding MICAL and preparation of the plasmids for the production of 
MICAL-MOCHLIM and MICAL-FL forms  
Plasmids purification by midi prep 
E.coli DH5α cells are transformed with the plasmids of interest for their purification using the Midi-Prep 
Kit (Qiagen, Milano, Italy). Aliquots of competent E.coli DH5α cells are transformed with ≈60 ng of 
plasmid DNA. The trasformants clones are selected on LB plates containing suitable antibiotics (Table 
10.2).  
Solutions   
- RNAse 100 µg/ml; 
- Buffer P1 (Resuspension Buffer): 50 mM Tris/HCl, pH 8.0, 10 mM EDTA; 
- Buffer P2 (Lysis Buffer): 200 mM NaOH, 1% (w/v) SDS; 
- Buffer P3 (Neutralization Buffer): 3 M K-acetate, pH 5.5; 
- Buffer QBT (Equilibration Buffer): 50 mM MOPS, pH 7, 750 mM NaCl, 0.15% (v/v) isopropanol, 
0.15% Triton X-100; 
- Buffer QC (Wash Buffer): 50 mM MOPS, pH 7, 1 M NaCl, 0.15% (v/v) isopropanol; 
- Buffer QF (Elution Buffer): 50 mM Tris/HCl, pH 8.5, 1.25 M NaCl, 15% (v/v) isopropanol; 
- TE buffer: 10 mM Tris/HCl, pH 8, 1 mM EDTA (sterile); 
- Na-acetate: 3 M Na-acetate, pH 5.3 (sterile); 
- 70% EtOH: ethanol 70% (v/v), stored at -20°C; 
- 100%EtOH: absolute ethanol, stored at -20°C.   
Procedure 
The night before plasmid DNA preparation a single colony of trasformant E.coli DH5α cells is used to 
inoculate 100 ml of selective LB medium and cells are grown overnight at 37°C under stirring (220 rpm).  
For plasmid purification proceed as follows: 
- transfer the culture in a 250 ml sterile centrifuge bottle and centrifuge at 5000 rmp for 15 min at 4°C 
(rotor SLA1500); 
- discard the supernatant and resuspend the pellet in 4 ml buffer P1 containing RNAse conserved on ice 
(e.g., 4 ml buffer P1 + 4 µl of RNAse 100 µg/ml); 
- transfer the suspension in a 50 ml centrifuge sterile tube (rotor SS34);  
- add 4 ml buffer P2, mix gently and incubate for 5 min at RT; 
- add 4 ml buffer P3 (stored on ice), mix gently and incubate for 15 min on ice; 
- centrifuge at 13000 rpm for 30 min at 4°C; 
- equilibrate the Qiagen-tip 100 column with 4 ml buffer QBT;  
- transfer the supernatant in a 50 ml sterile tube; 
- centrifuge at 13000 rpm for 15 min at 4°C; 
- add the supernatant on the Qiagen-tip 100 column;  
- wash with 20 ml buffer QC (2 washes of 10 ml); 
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- elute the DNA with 5 ml  buffer QF in a 50 ml sterile tube for Sorvall centrifuge;  
- add 3.5 ml of isopropanol for plasmid DNA precipitation;  
- centrifuge at 13000 rpm for 30 min at 4°C; 
- discard the supernatant and wash the pellet with 4 ml 70% EtOH; 
- centrifuge at 13000 rpm for 10 min at 4°C; 
- discard the supernatant and air-dry the pellet near the bunsen flame;  
- resuspend the pellet in 500 µl TE buffer; 
- centrifuge at 3000 rpm for 3 min at 4°C; 
- transfer the sample in a 2 ml sterile eppendorf tube and measure the volume; 
- add 1/10 of volume of Na-acetate and 2 volumes of 100% EtOH (stored at -20°C); 
- incubate the sample for 1 h at least at -20°C; 
- centrifuge at 13000 rpm for 15 min at 4°C in a microfuge; 
- discard the supernatant and wash the pellet with 1 ml of EtOH 70% (stored at -20°C); 
 - centrifuge at 13000 rpm for 15 min at 4°C in microfuge; 
- remove the supernatant and air-dry the pellet near the bunsen flame;  
- resuspend the pellet in 100 µl TE buffer; 
- determine the plasmid concentration spectrophotometrically; 
- split up in 2-3 aliquots and stored at -20°C. 
DNA quantitation  
DNA concentration is determined by measuring the absorbance value at 260 nm taking into account that 
50 ng/µl DNA solution absorbs 1 at 260 nm. An aliquot (8 µl) of the sample is diluted 100-fold in TE 
buffer (792 µl) and the absorption spectrum is recorded with HP8453 diodearray spectrophotometer 
(Hewlett Packard, Agilent, La Jolla, CA, USA). The quality of the DNA plasmid preparation is verified 
by calculating the A260/A280 ratio, which must be ≥ 1.8 for pure DNA, and by restriction analysis.  
Restriction analysis  
Restriction enzymes and their corresponding buffers used for the analysis of plasmids and their 
derivatives are indicated in the following table: 
Restriction enzyme U/µl Manufacturer Working temperature, °C 
BamHI 15 Amersham Pharmacia 30 
NdeI 20 New England BioLabs 37 
PvuI 10 New England BioLabs 37 
ScaI 10 Fermantas 37 
SphI 10 Fermentas 37 
XhoI 10 Fermantas 37 
Solutions 
- Buffer K (Amersham Pharmacia, now GE Healthcare, Little Chalfont,UK ) for BamHI: 200 mM 
Tris/HCl, pH 8.5, 100 mM MgCl2, 10 mM DTT, 1000 mM KCl; 
- Buffer NEB3 (New England BioLabs, Ipswich,USA) for PvuI: 50 mM Tris/HCl, pH 7.9, 100 mM NaCl, 
10 mM MgCl2, 1 mM DTT; 
- Buffer NEB4 (New England BioLabs) for  NdeI: 200 mM Tris-acetate, pH 7, 500 mM K-acetate, 
100 mM Mg-acetate, 10 mM DTT; 
- Buffer R (Fermentas, Vilnius, Lithuania) for XhoI: 10 mM Tris/HCl ,pH 8.5, 10 mM MgCl2, 100 mM 
KCl e 0.1 mg/ml BSA; 
- Buffer H (Fermentas) for ScaI and SphI: 500 mM Tris/HCl, pH 8.5, 1000 mM  KCl, 100 mM MgCl, 10 
mM DTT; 
- Loading Dye 10X (LD10X): 0.25% (w/v) blu di bromofenolo, 30% (v/v) glycerol in H2O. 
- GeneRuler 1 Kb DNA ladder (Fermentas): mixture of DNA fragments with a size ranging from 250 to 
10000 bp; 
- TE Buffer: 10 mM Tris/HCl, pH 8.0 (25°C), 1 mM EDTA, sterile. 
Procedure  
- thaw aliquots of the solutions of the plasmid of interest; 
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- If needed, prepare a dilution of the sample in H2O to obtain a final concentration between 30 and 100 
ng/µl; 
- prepare the samples as follows, by adding the enzyme last: 
 Plasmid            1-4 µl 
 Buffer 10x        1    µl 
 Restriction enzyme   1    µl 
 H2O to a final volume of   10  µl  
- incubate for 1 h at the working temperature for the enzyme (see table above) in a thermomixer 
(Eppendorf, Cambridge, UK) or a thermostatted bath; 
- add 1 µl of LD10x at the end of the single digestion to block the reaction, to load the sample and to add 
dye that will allow monitoring the electrophoretic migration of the samples.  
For the double digestion proceed as follows:  
At the end of the single digestion add: 
 Buffer 10x               2    µl 
 Restriction enzyme               1    µl 
 H2O to a final volume of   20 µl  
- incubate for 1 h at optima temperature for the enzyme; 
- add 2 µl of LD10x. 
At the end of the double digestion for the triple add: 
Buffer 10x               3    µl 
 Restriction enzyme               1    µl 
 H2O to a final volume of   30 µl  
- incubate for 1 h at the working temperature for the enzyme; 
- add 3 µl of LD10x. 
 
Analytical electrophoresis on 1% agarose gel  
The analysis of DNA fragments obtained by PCR or plasmid digestion is done by agarose gel 
electrophoresis.  
Materials 
- Electrophoresis apparatus: Submarine Mini Horizontal HE33B (Hoefer-Amersham). 
Solutions  
- Buffer TAE 50X: 200 mM Tris-acetate, pH 8.5, 1 mM EDTA, made up by mixing 242 g Tris, 57.1 ml 
acetic acid, 100 ml 500 mM EDTA, pH 8 to a final volume of 1 l with H2O. The solution is sterilized in 
the autoclave  
- Ethidium bromide (EtBr): ethidium bromide 0.5 mg/ml in H2O.  
Procedure  
- prepare TAE 1X buffer: 8 ml TAE50X buffer + 392 ml ultrapure H2O; 
- add 0.5 g of agarose (Sigma A9539) to 50 ml of TAE1X buffer; 
- melt under stirring on a hot plate; 
- allow cooling under stirring by transferring to another plate;  
- add 50 µl of EtBr when the temperature is ≈ 40°C; 
- pour into the gel casting mold and allow solidifying; 
- load samples and apply 80 V for 1.5 h until the band of the dye reaches the end of the gel; 
- visualize the bands on a transilluminator (Vilber Lourmat, Marne-la-Vallée, France) and record the 
photograph of gel (Kodak Digital Science 1D; Rochester, New York, USA).  
 
Polymerase Chain Reaction   
Materials 
- thermocycler (Gene Amp PCR 2400, Applied Biosystem, Foster City, CA, USA);  
Solutions 
- Pfu Ultra DNase (Agilent, La Jolla, CA, USA), DNA polymerase from Pyrococcus furiosus, 40 U/µl. 
- Pfu Buffer 10X (Agilent). 
- dNTPs, (Takara, Madison, WI, USA), 2.5 mM each; 
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- pDON201-MICAL1 13 ng/µl TE buffer; 
- oligonucleotide  primers, 100 µM each (see Table 10.3). 
 
Primers are designed using the program OligoCalc, (www.basic.northwestern.edu/biotools/ 
OligoCalc.html) that calculates the percentage of G+C and the presence of potential hairpin formation. 
The melting temperature Tm is calculated using the following formula, which take into account the 
presence of mismatches, the percentage of GC (%GC) and the number of nucleotides of the oligo (N):  
  mismatch
N
GCTm %
675%41.05.81   
Procedure  
- prepare the reaction mixture as follows: 
 Product 
 MOCHLIM2 MOCHLIM4 MICAL 
pDON201-MICAL (13 ng/ µl), µl 2.5 5 2.5 5 10 
Oligo MICAL Fw new (10 µM), µl 2 2 2 2 8 
Oligo MICALLIM Rev2 (10 µM), µl 2 2 - - - 
Oligo MICALLIM Rev4 (10 µM), µl - - 2 - - 
Oligo MICALFL Rev(10 µM), µl - - - - 8 
dNTPs (2.5 mM each), µl 4 4 4 4 16 
Pfu Ultra Buffer 10X, µl 5 5 5 5 20 
Pfu DNA Polymerase (2.5 U/µl), µl 1 1 1 1 4 
H2O 33.5 31 33.5 31 134 
Total volume, µl 50 50 50 50 200 
 
The solutions are added in the following order using Gilson pipettes equipped with sterile filter tips and a 
different set of pipettes aside for PCR for the addition of primers:  
- sterile H2O, Pfu ultra buffer, dNTPs, primers, template DNA, Pfu Polymerase; 
When the reaction mixture is >50 µl: 
- aliquot 50 µl of the sample in PCR tubes.  
For the amplification:  
- transfer the sample into thermocycler;  
- set-up the following conditions: initial denaturation, 1 min at 95°C; cycle 1-30, 30 s at 95°C, 30 s at 
60°C and 6 min at 68°C; final extension 10 min at 68°C. 
At the end of the PCR reaction the DNA fragments are purified by agarose gel electrophoresis  followed 
by extraction and purification with Illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare, Little Chalfont, UK). 
Preparative agarose gel electrophoresis   
The procedure is the same as that described for analytical agarose gel electrophoresis but with the 
following modifications: 
- use TAE1X buffer that has been sterilized in autoclave to prepare the gel and the running buffer; 
- add 10 µl of EtBr 0.5 mg/ml to the agarose solution rather than 50 µl to limit the photodegradation of 
DNA fragments; 
-  carry out the electrophoresis at 60 V rather than 80 V; 
To check if sufficient separation of DNA fragments has been obtained during the electrophoresis run, 
switch off the power and examine the gel with a hand held UV lamp (λ 254 nm ). If DNA fragments are 
sufficiently separated:  
- excise the bands containing the DNA fragments of interest with a blade previously cleaned with 100% 
EtOH; 
- transfer the bands into sterile eppendorf tubes, previously weighted to determine the amount (in mg) of 
gel.  
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Purification of DNA fragments  
Illustra GFX PCR DNA and Gel Band Purification kit (GE Healthcare) is used to purify the DNA 
fragments of interest. The kit is designed for the purification and concentration of DNA fragments from 
PCR or enzymatic digestion and from agarose gels. It is important to control the solution pH, which must 
be ≤7.5 for an efficient binding of the DNA to the silica membrane and the successive elution in H2O or 
in a buffer at pH 8.   
Materials 
- GFX Illustra spin column.  
Solutions (stored at RT) 
- Capture buffer type 3 containing pH indicator; 
- Wash Buffer: 10 ml 100% EtOH + 2.5 ml of wash buffer; 
- Elution Buffer type 4: 10 mM Tris/HCl, pH 8; 
- Elution Buffer type 6: nuclease free H2O; 
- Na-acetate: 3 M Na-acetate pH 5.3 (sterilized in autoclave); 
Procedure  
- add the calculated volume of capture buffer to each sample (i.e.: 10 µl/10 mg of gel); 
- incubate at 60°C in a thermomixer until the agarose gel is dissolved (≈20 min) mixing every 3 min. 
Check the color of the solution that must be yellow; if the color of solution is pink adjust the pH by 
adding Na-acetate.  
- centrifuge at 13000 rpm for 1 min in microfuge at RT; 
- load each sample onto a spin column placed in a 2 ml eppendorf tube; 
- centrifuge at 13000 rpm for 1 min at RT; 
- discard the flow through; 
- load 500 µl of wash buffer; 
- centrifuge at 13000 rpm for 1 min at RT; 
- discard the eluate; 
- place the column in a new eppendorf tube; 
- load 10-50 µl of elution buffer type 4 or 6 and incubate for 1 min at RT; 
- centrifuge at 13000 rpm for 2 min at RT; 
- prepare samples for the electrophoresis analysis: 
 DNA solution     2 µl 
 TE buffer     7 µl 
 LD10x      1 µl  
- store DNA solution at -20°C.  
 
Quantitation of DNA obtain from the purification  
To determine the concentration of the DNA fragments after the purification step, aliquots of a pUC18 
vector solution (50 ng/µl) linearized with EcoRI  are loaded on  the analytical agarose gel (1%) to have a 
range between 25 and 200 ng of DNA.  
The samples are prepared as follows:  MOCHLIM2 MOCHLIM4 MICAL pUC18EcoRI 
pUC18/EcoRI (50 ng/µl), µl - - - - - - 0.5 1 2 4 
MOCHLIM2 3 5 - - - -     
MOCHLIM4 - - 3 5 - -     
MICAL - - - - 3 5     
TE, µl 6 4 6 4 6 4 8.5 8 7 6 
LD 10X, µl 1 1 1 1 1 1 1 1 1 1 
Total volume, µl 10 10 10 10 10 10 10 10 10 10 
pUC18, ng       25 50 100 200 
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Cloning of the cDNA coding for MOCHLIM and MICAL in pJET1.2 blunt-end vector  
The DNA fragments encoding MOCHLIM and full-length MICAL obtained from PCR and purified were 
cloned in pJET1.2/blunt-end cloning vector (CloneJET PCR cloning kit, Thermo Scientific Fermentas, 
Waltham, MA, USA).  The CloneJET PCR Cloning kit presents a series of advantages such us: (i) a 
positive selection system, in that the vector contains a lethal gene that is disrupted by ligation of the DNA 
insert into the cloning site; (ii) blunt-end PCR products generated by proofreading DNA polymerase (e.g., 
Pfu Polymerase) can be directly ligated in just 5 min with the pJET1.2 blunt linearized vector included in 
the kit. The kit also contains a “PCR product” to be used as positive control to verify the efficiency of the 
blunting and ligation steps.  
Sticky-end cloning protocol for positive control 
- Set up the “blunting reaction mixture” on ice:  
 
 Positive  control 
Reaction Buffer 2x, µl 10 
Control “PCR product” (24ng/ µl) µl 2 (48 ng) 
pJET1.2/blunt cloning vector (50 ng/ µl), µl 1 (0.05 pmol ends) 
Water, nuclease free, µl 5 
DNA Blunting enzyme , µl 1 
Total volume, µl 18 
 
- centrifuge at 13000 rpm in microfuge for 3 min at 4°C; 
- incubate the mixture at 70°C for 5 min; 
- chill on ice; 
- set-up the ligation reaction mixture on ice by adding the following to the blunting reaction mixture: 
  
pJET1.2/blunt cloning vector (50 ng/ µl), µl 1 (0.05 pmol ends) 
T4 DNA Ligase (5 U/ µl), µl 1 
Total volume, µl 20 
 
- centrifuge the mixture at 13000 rpm in for 1 min at 4°C;  
- incubate the ligation mixture at 22°C in a thermomixer for 15 min; 
- transform E.coli DH5α competent cells with 5 µl of the ligation mixture (as described previously); 
- select transformants on LB-Amp (100 µg/ml) plates.  
Blund-end cloning protocol for MOCHLIM and MICAL 
- Set up the “ligation reaction mixture” on ice using the solutions including in the kit  
 MOCHLIM2 MOCHLIM4 MICAL 
Reaction Buffer 2x, µl 10 10 10 
MOCHLIM2 (2338 bp, 25 ng/µl) 4 (100 ng) - - 
MOCHLIM4 (2437 bp, 17 ng/µl) - 6 (102 ng) - 
MICAL (3200 bp, 65 ng/ µl), µl - - 3 (195 ng) 
pJET1.2/blunt cloning vector (50 ng/ µl), µl 1 1 1 (0.05 pmol ends) 
Water, nuclease free, µl 4 2 5 
T4 DNA Ligase (5 U/ µl), µl 1 1 1 
Total volume, µl 20 20 20 
 
- centrifuge the mixture at 13000 rpm for 1 min at 4°C in microfuge;  
- incubate the ligation mix at 22°C in a thermomixer for 15 min; 
- transform E.coli DH5α competent cells with 5 µl of the ligation mix and the transformants are selected 
on LB-Amp (100 µg/ml) plates.  
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Analysis of the transformants by colony PCR 
To check the presence of the correct plasmid in the E.coli cells transformed with the ligation mix, the 
trasformants are analysed by colony PCR. The same method is used to verify the cloning of cDNA 
fragments encoding MOCHLIM and MICAL in pET23b vector.  
Solutions  
- Go Taq Polymerase: DNA Polymerase from Thermus aquaticus (Promega, Madison, WI, USA) 5 U/ µl; 
- Go Taq buffer 5x (Promega); 
- dNTPs (Takara) 2.5 mM each; 
- pJETFw primer (included in CloneJET PCR cloning kit, Table 10.4), 10 µM; 
- pJETRev primer (included in CloneJET PCR cloning kit, Table 10.4), 10 µM; 
- T7 fw (Amersham Pharmacia) primer, 5’-TAATACGACTCACTATAGGG-3’, 10 µM; 
- T7 terminator (Amersham Pharmacia) primer, 5’-GCTAGTTATTGCTCAGCGG-3’, 20µM.  
Procedure  
- set up the following Master Mix:  
 Master Mix 
GoTaq Buffer, µl 100 
H2O, µl 327 
dNTPs, µl 40 
pJETFw, µl 10 
pJETRev, µl 10 
GoTaq , µl 3 
Total volume, µl 500 
 
- distribute 20 µl aliquots of the Master Mix into PCR tubes;  
- inoculate a colony of E.coli DH5α into one of the PCR tubes (negative control); 
- add 60 ng of a well characterized plasmid derivative that has the same vector, but that contains a 
different insert into another PCR tube (positive control);  
For each construct, 10 transformants are analyzed.  
- pick up the colony and replicate it on a selective LB plate and then dissolve the rest of the cells in a PCR 
tube containing the Master Mix; 
Amplify the desired DNA fragments using the same PCR conditions as those used for their initial 
production. At the end:  
- add 2 µl of LD10X to each PCR tube; 
- analyze by agarose gel electrophoresis; 
- choose the clones containing the correct insert for the subsequent storage in glycerol at -80°C, midi prep 
and restriction analysis.  
Two positive clones for each plasmid will be sequenced. The pJET derivatives containing the DNA 
coding for MOCHLIM and the full-length MICAL were sequenced by Primm srl (Milano, Italy) using the 
Sanger method with ddNTPs labeled with fluorophores and separated by capillary electrophoresis. The 
plasmid solution (50 µl) to provide must have a concentration of 150 ng/µl in H2O. An aliquot (3 µl) of 
such plasmid solution is diluted in TE buffer up to 10 µl and 1 µl of LD10X is added for (1%) agarose gel 
electrophoresis. The image of the gel must be sent to Primm with the sample to be sequenced.  pJETFw 
and pJETRev (1 µM, 30 μl) primers were also sent to Primm for sequencing of the samples. For each 
sequencing reaction 10 µl of primer solution is used. To complete sequencing, three specific primers 
(Table 10.4) have been designed.  
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Subcloning of fragments encoding MOCHLIM (1-771 aa), MOCHLIM (1-786 aa) and the full-length 
MICAL in pET23b vector 
pJET derivates containing the correct DNA fragment coding for MOCHLIM2, MOCHLIM4 and full-
length MICAL were used for subcloning into a pET23b vector, in order to express the eterologous 
proteins with a C-terminal His-tag in E.coli cells.   
Aliquots of pET23b , pJET-MOCHLIM2, pJET-MOCHLIM4 and pJET-MICAL plasmid are digested 
with NdeI restriction enzyme, followed by XhoI. For pJET-MICAL, at the end of the double digestion, the 
sample was precipitated, resuspended in H2O and incubated with PvuI to discriminate between the pJET 
vector (2990 bp) and the DNA fragments encoding MICAL (3200 bp).  
For the first digestion with NdeI the following samples were prepared:  
 pET23b MOCHLIM2 MOCHLIM4 MICAL 
pET23b (20 µg/µl), µl 20 - - - 
pJET-MOCHLIM2 (1.1 µg/µl), µl - 9 - - 
pJET-MOCHLIM4 (0.6 µg/µl), µl - - 16 - 
pJET-MICAL (1.08 µg/µl) - - - 10 
NEB4 buffer 12 12 12 12 
NdeI (20 U/µl) 1 1 1 1 
H2O 87 98 91 97 
Total volume, µl 120 120 120 120 
 
- incubate 1h and 30 min at 37°C; 
- withdraw an aliquot (3 µl) of each sample, add TE buffer (6 µl) and LD10X (1 µl); 
- load the samples on agarose gel and start the electrophoresis; 
In the mean time: 
- add 1 µl of NdeI to the remaining reaction mixture and incubate for 1 h at 37°C; 
If the digestion with NdeI was successful after 1 h (as judged by analytical electrophoresis):  
- inactivate NdeI by incubating the reaction mixture at 60°C for 20 min; 
- prepare the second digestion by adding to the samples:  
 
 pET23b MOCHLIM2 MOCHLIM4 MICAL 
pET23b NdeI, µl 120 - - - 
pJET-MOCHLIM2/NdeI - 120 - - 
pJET-MOCHLIM4/NdeI - - 120 - 
pJET-MICAL/NdeI, µl - - - 120 
Buffer R 14 14 14 14 
XhoI (10 U/µl) 1 1 1 1 
H2O 5 5 5 5 
Total volume, µl 140 140 140 140 
 
- incubate for 1 h and 30 min at 37°C; 
- withdraw 3 µl from each sample, add TE buffer (6 µl) and LD10X (1µl) and analyze electrophoretically; 
In the mean time: 
- add 1 µl of XhoI to the remaining reaction mixture and incubate for 1 h at 37°C; 
If the second digestion was successful: 
- inactivate XhoI by incubating the reaction mixture at 80°C for 20 min. 
After the double digestion, for pET23b, pJET-MOCHLIM2 and pJET-MOCHLIM4 samples, proceed as 
follows: 
- add LD10x (10 µl) to each sample; 
- load each sample on preparative agarose gel and purify the fragments of interest with the Illustra GFX 
PCR DNA and Gel Band Purification kit.    
pJET-MICALFL was further digested with PvuI: 
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- divide the reaction mixture in two aliquots; 
- add 10 µl of Na-acetate, H2O to a volume of 100 µl and 1 ml of cold 100% EtOH to each sample; 
- incubate for 1 h at least at -20°C; 
- centrifuge at 13000 rpm for 15 min at 4°C; 
- discard the supernatant and add 1 ml of 70% EtOH;  
- centrifuge at 13000 rpm for 15 min at 4°C; 
- discard the supernatant and dry on air the pellet; 
- resuspend the pellet in 30 µl TE buffer; 
- set up the digestion reaction with PvuI: 
 
 
- incubate for 1 h and 30 min at 37°C; 
- withdraw an aliquot (3 μl) for the analytical agarose gel electrophoresis; 
- add 1 µl of PvuI to the remaining reaction mixture and incubate for 1 h at 37°; 
If the digestion with PvuI after 1 h was successful: 
- add LD10x (7 μl) to the sample, load on preparative agarose gel and purify the fragment of interest.  
 
The purified DNA fragments were ligated using 60 ng of pET23b vector and two different molar 
vector:insert ratios (1:2 and 1:4) for each plasmid.   
Materials  
T4 Ligase: DNA Ligase of T4 phage (5 U/µl, Fermentas); 
T4 Ligase Buffer 10X: 400 mM Tris/HCl , pH 8, 100 mM MgCl2, 100 mM DTT, 5 mM ATP. 
Procedure 
- set up the following reaction mixtures in eppendorf tubes:  
 pET23b MOCHLIM2 MOCHLIM4 MICAL 
pET23b NdeI/XhoI/PvuI (30ng/µl), µl 2 2 2 2 2 2 2 
pJET-MOCHLIM2 NdeI/XhoI (80 ng/µl), µl - 1.5 3 - - - - 
pJET-MOCHLIM4 NdeI/XhoI (60 ng/µl), µl - - - 1.5 3 - - 
pJET-MICAL/NdeI/XhoI (40ng/µl), µl - - -   3 6 
T4 ligase buffer 3 3 3 3 3 3 3 
T4 ligase (5 U/µl) 1 1 1 1 1 1 1 
H2O 24 22.5 21 22.5 21 21 18 
Total volume, µl 30 30 30 30 30 30 30 
- incubate over-night at 16°C. 
For each sample an aliquot (4 µl) of the reaction mixture is used to transform E.coli DH5α cells made 
competent with the RbCl method. The trasformants are selected on LB-Amp (100 µg/ml) plates, and then 
analyzed by colony PCR using T7 promoter and T7 terminator primers to identify clones containing the 
correct insert. Among the positive clones, two are used to purify the plasmid by midi prep, followed by 
restriction analysis. The plasmid preparations will be used for the expression of MICAL forms proteins in 
E.coli cells.   
 
 
 
 
 MICAL 
pJET-MICAL/NdeI/XhoI, µl 48 
NEB3 buffer, µl 7 
BSA (1 mg/ml), µl 7 
PvuI (10 U/µl), µl 1 
H2O, µl 7 
Total volume, µl 70 
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10.3. Production of human MICAL1 forms in Escherichia coli cells 
E.coli Rosetta (DE3) and BL21(DE3) cells are used for the production of the truncated MO, MOCH and 
MOCHLIM  forms and the full-length human MICAL1 for the production of the proteins with the His6-
tag at their C-terminus.   
 
Preparation of cell culture for the expression of MICAL forms in 2.5 l flasks  
E.coli Rosetta(DE3) cells that have been made competent with CaCl2 method are transformed with pET 
derivatives encoding MICAL forms. BL21(DE3) competent cells are transformed with p18 plasmid 
encoding GroE (Castanié et al., 1997) first, then transformed with pET23b derivatives coding for MICAL 
forms (Table 10.2).  
Procedure 
- transfer ≈30 colonies of transformants in 50 ml of LB medium supplemented with Amp (0.1 mg/ml) and 
Chl (0.25 mg/ml);   
- incubate the flask in an incubator at 25°C under stirring (220 rpm) and monitor the cells growth by 
measuring the OD600; 
When OD600 is ≈1: 
- add 50 μl of ampicillin solution (100 mg/ml) and transfer the flask at 4°C. 
The day after:  
- harvest the cell cultures under sterile conditions; 
- resuspend the pellet in 10 ml of LB medium; 
- inoculate 500 ml of selective LB with 5 ml of cell suspension to have an initial OD600 of ≈0.05; 
- incubate at 25°C under stirring (220 rpm); 
When the OD600 is ≈1:  
- add 500 μl of Amp stock solution (100 mg/ml) and 500 μl of 1 mM IPTG (0.1 mM final concentration);  
- transfer the cell culture at 15°C; 
- add 500 μl of Amp every 8-15 h; 
- monitor the cell growth by measuring OD600; 
- harvest the cells 24 after IPTG addition.  
 
Preparation of cell culture for the expression of MICAL forms in 12 l fermentor  
Preparation of the preculture 
- transfer ≈30 colonies of E.coli Rosetta (DE3) or BL21(DE3, p18) cells freshly transformed with pET23b 
derivatives encoding MICAL forms (Table 10.2) in two 2 l flask containing 300 ml of selective LB 
medium; 
- incubate the flask in an incubator at 25°C under shaking (220 rpm) and monitor the cells growth by 
measuring the OD600; 
When OD600 is ≈1: 
- add 300 μl of ampicillin solution (100 mg/ml) and transfer the flask at 4°C. 
 
Preparation of fermentor and cells growth  
- position the fermentor vase containing 12 l of sterile LB medium in the MF100 fermentor (New 
Brunswick Scientific, Enfield, CT, USA);  
- connect the aeration system and the bath thermostatted at 25°C; 
- equilibrate at 25°C under stirring (140 rpm); 
- harvest the cells from the preculture under sterile conditions (centrifugation at 6000 rpm for 10 min at 
4°C, rotor SLA1500);  
- remove the supernatant and resuspend the pellet in 30 ml LB medium; 
- add the antibiotics and the suspension under sterile conditions to the fermentor; 
- set-up stirring at 140 rpm and the airflow 5-6 l/min; 
When OD600 is ≈1: 
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- lower the temperature to 15°C; 
- add 12 ml of IPTG solution (100 mM) and 12 ml of ampicillin solution (100 mg/ml); 
- add 12 ml of ampicillin solution every 12 h; 
- follow the cells growth by measuring OD600; 
40 h after the addition of IPTG solution: 
- harvest the culture using 1 l  bottles  for Beckamn Avanti J-20 (Beckman, Brea, CA, USA) centrifuge 
equipped with JLA 8.1 rotor at 6000 rpm for 10 min at 4°C; 
- remove the supernatant and resuspend the pellet with saline solution (200-250 ml) and transfer the 
suspension in centrifuge tube and centrifuge at 6000 rpm for 15 min at 4°C (rotor SLA1500); 
- remove the supernatant, weight out the pellet and store the cells at -20°C.  
 
Total cell extracts preparation 
The aliquots of culture used to measure the OD600 before and after the addition of IPTG solution are used 
for the preparation of total cell extracts for the analysis of the time-course of protein production by SDS-
PAGE. The samples are prepared as follows: 
- transfer the sample (1-1.4 ml) in an eppendorf tube; 
- centrifuge at 13000 rpm for 3 min at 4°C; 
- discard the supernatant and resuspend the pellet in a volume of SB1x calculated as follows: 
 OD600 x 100 x sample volume (ml) 
- mix with vortex; 
- incubate at 100°C for 10 min; 
- centrifuge at 13000 rpm for 30s; 
- store at -20°C for SDS-PAGE.  
 
10.4 Small and large-scale purification of MICAL forms 
 
Small-scale purification of MICAL forms  
 
Small-scale homogenization of E.coli cells (2-6 g) by sonication 
Materials 
- Branson Ultrasonic Sonifier250 (Branson, Darbury, CA, USA) equipped with a microtip; 
- DNase: Deoxyribonuclease from bovine pancreas type II-S (Sigma D4513); 
 
Solutions 
- Protease inhibitor cocktail, EDTA free (Sigma P8849).  
- buffer A: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol; 
- homogenization buffer: buffer A + DNase (few crystals), protease inhibitors cocktail (50 μl/g of cells), 1 
mM PMSF, 1 mM 2-ME, 5 or 20 mM imidazole; 
Procedure 
- resuspend the cells in 2.5 ml homogenization buffer/g cells;  
- transfer the suspension into a glass tube and place on an ice-salt mixture; 
- sonicate for 4 min (eight 30 s cycles); instrument setting: power, 60 W; output, 60%; duty cycle, 
constant; the temperature is maintained below 5°C by waiting between sonication cycles. 
At the end of sonication: 
-  add 2.5 ml homogenization buffer/g cells; 
- mix gently and transfer to 50 ml centrifuge tubes uge and centrifuge at 18000 rpm for 1 h at 4°C (rotor 
SS34); 
- recover the supernatant (crude extract), measure the volume and check the pH; 
- transfer 1 ml of supernatant in an eppendorf tube for the determination of protein concentration by the 
Bradford method and for the analysis by SDS-PAGE. 
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Small-scale purification of MICAL forms - Ni-NTA affinity chromatography  
Materials 
- Ni-NTA Sepharose resin (HisPur Ni-NTA Resin, Thermo Fisher Scientific); 
- column for chromatography (2x9 cm); 
- HP8354 diodearray spectrophotometer connected to a thermostatted bath at 17°C.  
Solutions 
- buffer A: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol; 
- buffer A + 20, 100, 200 and 500 mM imidazole;  
Procedure 
This procedure is used to check the productivity of the cells expressing MICAL forms and in preliminary 
experiments during the set-up of the purification procedure.   
- add Ni-NTA Sepharose resin (1 or 2 ml) equilibrated in buffer A + 5 or 20 mM imidazole to the crude 
extract obtained by sonication (see above); 
- incubate on a wheel (6 rpm) for 1 h at 4°C; 
- transfer the resin into the column and let it pack; 
- collect the flow-through (FT); 
- elute the proteins by applying 5 volumes of:  
 Buffer A+ 5 or 20 mM imidazole  
 Buffer A + 20 mM imidazole 
 Buffer A + 100 mM imidazole 
 Buffer A + 200 mM imidazole 
 Buffer A + 500 mM imidazole 
1 or 2 ml fractions are collected and analyzed by (1) recording the absorption spectrum with a hp8453 
diodearray spectrophotometer at 17°C, (2) SDS-PAGE and (3) measuring the NADPH oxidase activity 
(see below).  
For MOCHLIM:  
- pool the fractions containing most of the protein based on their absorption spectrum; 
- concentrate the sample to a final volume of 1-2 ml with a CentriconYM30 filter device by 
centrifugations at 3500xg in a swing-out rotor (Labfuge, Heraeus) for 10 min at 4°C each;  
- analyze the sample before and after concentration as described for the individual fractions and by 
determining the protein concentration with the Bradford method;  
- store the sample overnight on ice at 4°C.  
MOCHLIM preparations obtained by Ni-NTA affinity chromatography (see above) were further purified 
by gel filtration on a Superose12 column or by anion exchange chromatography on a MonoQ column. 
  
Small-scale final purification of MOCHLIM - Gel filtration 
Materials 
-  Superose12 column for FPLC, cutoff 10000-30000, stationary phase 24ml: dextran and agarose 
(microsphere diameter 8-12 μm) (Amersham Pharmacia); 
- FPLC Akta apparatus (GE Healthcare); 
- HP8453 diodearray spectrophotometer and Cary100 spectrophotometer (Varian, Mulgrave, Australia); 
Solutions  
- buffer B: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT 
Procedure 
- load the sample (200-500 µl) on a Superose12 column equilibrated in buffer B; 
- inject the sample and elute at a flow rate of 0.5 ml/min collecting 0.5 ml fractions; 
- analyze the fractions by recording the absorption spectrum at 17°C and by SDS-PAGE; 
- pool the fractions containing most of MOCHLIM; 
- centrifuge at 18000 rpm for 10 min at 4°C (SS34); 
- concentrate the sample to a final concentration >2 mg/ml with a Centricon YM30 device; 
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- analyze the sample before and after concentration by (1) recording the absorption spectrum, (2) 
measuring the standard NADPH oxidase activity, (3) determining protein concentration with the Bradford 
method and (4) by SDS-PAGE;  
- slip the sample in 0.2 ml aliquots; 
- flash-freeze in liquid nitrogen; 
- store at -80°C.  
 
Small-scale final purification of MOCHLIM - Anion exchange chromatography  
Materials 
- MonoQ anion exchanger column (Amersham Pharmacia);  
- FPLC Akta apparatus (GE Healthcare); 
- HP8354 diodearray spectrophotometer and Cary100 spectrophotometer; 
Solutions  
- buffer A: 50 mM Na-phosphate, pH 7.5, 10% glycerol, 1 mM EDTA, 1 mM DTT 
- buffer A + 1 M NaCl; 
Procedure 
The MonoQ column is equilibrated with buffer in which the protein is conserved. 
- load the sample (0.5-2 ml) in the loading loop; 
- injetct the sample; 
- flow 5 ml of buffer A + 25 or 100 mM NaCl at a flow rate of 0.5 ml/min; 
- apply a linear gradient form 25 or 100 to 500 mM NaCl in 60 column volume; 
- collect 0.5-1 ml fractions; 
Then proceed as described for the gel filtration on Superose12 column.  
   
Large-scale purification of MICAL forms - Ni-NTA Sepharose affinity chromatography 
 
Homogenization of E.coli cells (20-40g) by sonication 
Materials 
- Rosette cooling cell (250 ml) (Branson); 
- Branson Ultrasonic Sonifier250; 
- DNase: Deoxyribonuclease from bovine pancreas type II-S (Sigma D4513); 
Solutions 
- Protease inhibitor cocktail, EDTA free (Sigma P8849).  
- buffer A: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol; 
- homogenization buffer: buffer A + DNase (few crystals), protease inhibitors cocktail (50 μl/g of cells), 1 
mM PMSF, 1 mM 2-ME, 5 or 20 mM imidazole; 
Procedure 
The procedure is the same as that described for the homogenization of 2-6 g cells with the following 
modifications:  
- transfer the cell suspension in a rosette cooling cell that allows a good efficiency of mixing and cooling 
of the sample during sonication; 
- place the rosette cell on ice and layer salt only on the top of bulk ice; 
- sonicate for 8.5 min (seventeen 30 s cycles).  
  
Large-scale purification of MOCH - Ni-NTA affinity chromatography  
The purification of the MO form was carried out as described in Zucchini et al., 2011.  
Materials 
- Ni-NTA Sepharose resin (Ni Sepharose 6 Fast Flow, GE Healthcare); 
- dialysis membranes (Spectra/Por MWCO 12-14000, Spectrum Laboratories, Inc. Rancho Dominguez, 
CA, USA) previously washed in ultrapure water; 
- XK16 column (1.6x19 cm; Amersham Pharmacia); 
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- peristaltic pump Pump P-1 (Amersham Pharmacia); 
- fraction collector Bromma 2111 Multirac (LBK, Uppsala); 
- FPLC Akta apparatus (GE Healthcare); 
- HP8354 diodearray and Cary100 spectrophotometers connected to thermostated bath set at 17°C. 
Solutions  
- Buffer A: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol; 
- Buffer A + 20 mM imidazole; 
- Buffer A + 500 mM imidazole; 
- Buffer B (dialysis buffer): 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 
mM DTT; 
 
Procedure  
- load the crude extract on  the Ni-NTA Sepharose column with a peristaltic pump at a flow rate of ≈42 
ml/h at 4°C, in the cold room; 
- wash with 1 column volume of  buffer A + 5 mM imidazole, 1 mM 2-ME (flow rate: 40 ml/h) collecting 
5-7 ml fractions; 
- wash with 10 column volumes of buffer A + 20 mM imidazole at 4°C (overnight, flow rate: 9 ml/h) 
collecting 5-7 ml fractions; 
- connect the column to the Akta apparatus for FPLC and to a thermostatted bath (5°C); 
- load pump A with buffer A + 1 mM 2-ME and pump B with buffer A + 500 mM imidazole, 1 mM 2-
ME;  
- flow 1 column volume of buffer A + 20 imidazole (5 % buffer B); 
- apply a linear imidazole gradient: from 20 to 200 mM imidazole in buffer A in 10 column volumes with 
a flow rate of 1 ml/min and collecting 2 ml fractions; 
- analyze the collected fractions by: (1) recording the absorption spectrum and (2) by SDS-PAGE; 
- pool the purest MOCH containing fractions on basis of absorption spectrum; 
- centrifuge at 18000 rpm for 10 min at 4°C (rotor SS34); 
- concentrate to 4-6 mg/ml by ultrafiltration in an Amicon apparatus equipped with YM30 membrane, the 
sample is kept on ice and under gently stirring (60 rpm). 
At the end of concentration: 
- centrifuge at 18000 rpm for 10 min at 4°C (rotor SS34); 
- dialyze overnight against 2 l of buffer B at 4°C; 
- centrifuge at 18000 rpm for 15 min at 4°C (rotor SS34); 
- split sample in 0.2-0.5 ml aliquots; 
- flash-freeze in liquid nitrogen;  
- store at -80°C.   
At this stage only trace amounts of contaminating proteins are present, which can be removed by gel 
filtration on a Superose12 column or by anion exchange chromatography.  
Final MOCH purification - Gel filtration 
Aliquots up to 500 μl of MOCH preparation obtained by Ni-NTA affinity chromatography are gel filtered 
on a Superose12 column in buffer B as described previously for small-scale purification of MOCHLIM.   
Individual fractions and the final sample are analyzed by (1) recording the absorption spectrum, (2) SDS-
PAGE, (3) measuring the standard NADPH oxidase activity and (4) by dynamic light scattering (DLS).  
Analysis of samples by dynamic light scattering (DLS)  
Dynamic light scattering measures the dimensions of particles in solution based on the analysis of the 
brownian motions that determine the movement of the particles. When light pass through moving 
particles it is “scattered”. This scattering and its decay depends on the dimension of the particles in 
solution (fast small molecules will lead to a wider scattering than slowly moving larger molecules) and on 
the composition of solvent. DLS allow to determine the radius of the particle, from which calculates its 
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mass assuming a globular particle. In addition DLS can also be used to monitor the stability and the 
tendency of the sample to aggregates under various conditions, such as sample concentration, buffer 
composition and pH.  
Materials  
- 50 µl quartz cuvette;  
- Dynapro MS/X apparatus (Protein Solutions, Lakewook, NJ, USA);  
 
Solutions 
- buffer; 
- protein solution: 0.1-5 mg/ml.  
Procedure  
Data acqusition 
- set up the instruments parameters for the acquisition of data through the Dynamic V5 interface that 
controls the:  
 Acquisition time  15 s 
 Sensitivity    80%  
 Temperature    15°C  
 Solvent    10% glycerol (for protein stored in buffer B) 
     Water (for protein stored in 20 mM Hepes/KOH buffer, pH 7 ) 
 pH    7 
- centrifuge 100 µl of buffer at 13000 rpm for 10 min at 4°C; 
- transfer 60 µl of the supernatant into the cuvette; 
- start the acquisitions of the signal and stop after the acquisition of at least 20 measures validated by the 
instrument;  
 
This measurement is carried out to check the presence of particles and the stability of the instrument. For 
the proteins samples the procedure is the same of that described for the buffer. At the end of the data 
acquisition the software can calculate number of particle in solution and their radius, along with the 
degree of polydispersity of each species. To calculate the mass of each particle the thickness of the water 
shell (0.2 nm) is subtracted from the radius calculated by the software.  
Final MOCH purification - Anion exchange chromatography  
MOCH preparation after Ni-NTA chromatography can be further purified by anion exchange 
chromatography on a MonoQ column.  
Materials  
- dialysis membrane (Spectra/Por MWCO 12-14000, Spectrum Laboratories) previously washed in 
ultrapure water; 
- MonoQ anion exchanger column (Amersham Pharmacia);  
- FPLC Akta apparatus (GE Healthcare); 
- HP 8354 diodearray spectrophotometer connected to a thermostatted bath at 17°C. 
Solutions  
- buffer A: 20 mM Na-phosphate, pH 7.5; 
- buffer A + 40 mM NaCl (dialysis buffer); 
- bufferA + 1 M NaCl. 
Procedure 
- thaw an aliquot of 0.8 ml MOCH solution obtained by Ni-NTA affinity chromatography; 
- centrifuge at 18000 rpm for 10 min at 4°C (SS34 rotor, Sorvall RC6 Plus); 
- recover the sample and analyze it by (1) recording the absorption spectrum, (2) determining the protein 
concentration with the Bradford method and (3) SDS-PAGE;  
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- transfer the sample into dialysis membrane; 
- dialyze against 500 ml of buffer A + 40 mM NaCl for 4 h at 4°C; 
- repeat the previous step; 
- dialyze against 1.5 l of buffer A + 40 mM NaCl for 16 h at 4°C;  
- centrifuge at 18000 rpm for 10 min at 4°C (rotor SS34).  
For the chromatography of sample proceed as describe previously for final small-scale purification of 
MOCHLIM.  
 
Large-scale purification of MOCHLIM - Ni-NTA affinity chromatography  
The details of the protein purification by Ni-NTA Sepharose resin are discussed in Chapter 4.  
The MOCHLIM4 form (1-783, which will be indicated as MOCHLIM) is purified as indicated for 
MOCH, with the following modifications: 
- add 1 mM PMSF to buffer A and buffer A + 20, 50 and 500 mM imidazole; 
- elute MOCHLIM by applying a linear gradient of imidazole from 50 to 200 mM in 9 column volumes;  
- add 0.5% protease inhibitors cocktail to the pooled fractions and at the end of the dialysis.     
At this stage MOCHLIM preparation shows the presence of contaminating proteins with a mass of ≈22 
kDa that can be removed by gel filtration on a small-scale on a Superose12 column and on a large-scale 
on a Superdex200 column.  
Final MOCHLIM purification - Small-scale gel filtration 
Aliquots up to 500 μl of MOCHLIM preparation obtained by Ni-NTA affinity chromatography are gel 
filtered on a Superose12 column in buffer B as described previously for small-scale purification, with the 
following modifications: 
- add 0.5% of protease inhibitors cocktail to the polled fractions; 
- concentrate in a Amicon apparatus (3 ml) by ultrafiltration rather than in a CentriconYM30 filter device.  
Final MOCHLIM purification - Large-scale gel filtration 
Materials 
- Superdex 200 prep grade resin (GE Healthcare);  
- XK16column, height 100 cm, diameter 1.6 cm (Amersham Pharmacia);   
- peristaltic pump Pump P-1 (Amersham Pharmacia); 
- fraction collector Bromma 2111 Multirac (LBK, Uppsala); 
- HP 8354 diodearray spectrophotometer.  
Solutions  
- buffer B + 1 mM PMSF: 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM 
EDTA, 1 mM DTT, 1 mM PMSF;  
Procedure 
- load the sample 2-3 ml onto the column containing 150ml of Superdex200 resin equilibrated in buffer B 
+ 1 mM PMSF; 
- flow buffer B + 1 mM PMSF with a flow rate of 0.5 ml/min; 
- collect 1.5-3 ml fractions; 
- analyze the fraction by (1) recording the absorption spectrum and (2) SDS-PAGE; 
- pool the fractions containing most of MOCHLIM as judge by the absorption spectrum of the individual 
fractions; 
- add 0.5% of protease inhibitors cocktail; 
- centrifuge at 18000 rpm for 10 min at 4°C;  
- concentrate the sample to 3-5 mg/ml in Amicon apparatus equipped with YM30 membrane;   
- analyze the sample befor and after concentration as for the fractions and determine the protein 
concentration with the Bradford method;  
- split the sample in 0.2-0.5 ml aliquots; 
- flash-freeze in liquid nitrogen and stored at -80°C.  
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Large-scale purification of MICAL - Ni-NTA affinity chromatography  
The details of the protein purification by Ni-NTA Sepharose resin are discussed in Chapter 4.  
The full-length form of MICAL is purified as indicated for MOCH, with the following modifications: 
- add 1 mM PMSF to buffer A and buffer A + 20 and 500 mM imidazole; 
- elute MOCHLIM by applying a linear gradient of imidazole from 20 to 200 mM in 10 column volumes;  
- add 0.5% protease inhibitors cocktail to the pooled fractions and at the end of the dialysis.   
At this stage MICAL preparation shows the presence of contaminating proteins and it is further purified 
by anion exchange chromatography on a MonoQ column as described previously for MOCH or on a 
large-scale on a Q-Sepharose resin.  
Final MICAL purification - Large-scale anion exchange chromatography 
Materials 
- XK16 column (1.6x19 cm, GE Healthcare) containing Q-Sepharose Fast flow resin (GE, Healthcare); 
- Akta  apparatus for FPLC (GE Healthcare);  
- HP8453 diodearray spectrophotometer connected to a thermostatted bath at 17°C. 
Solutions 
- buffer A: 50 mM Na-phosphate, pH 7.5, 1 mM PMSF; 
- buffer A + 100 mM NaCl; 
- buffer A + 1 M NaCl.  
Procedure 
- load the sample onto the column containing Q-sepharose resin (10 ml) equilibrated with buffer A+ 100 
mM NaCl in cold room; 
- flow 2 volumes of buffer A + 100 mM NaCl by gravity and collect 5 ml fractions; 
- connect the column to FPLC apparatus, of which pump A was washed with buffer A and pump B with 
buffer A + 1 M NaCl, and to a thermostatted bath at 10°C; 
- flow 5 volumes of buffer A + 100 mM NaCl with a flow rate of 1 ml/min and collect 2 ml fractions; 
- elute proteins by applying a first linear gradient from 100 to 500 mM NaCl in 60 column volumes and a 
second gradient from 500 to 1000 mM NaCl in 5 column volumes and collect 2 ml fractions;  
- analyze the individual fractions by (1) recording the absorption spectrum and (2) by SDS-PAGE;  
- pool the fractions enriched in MICAL; 
- add 0.5% of protease inhibitors cocktail to the pooled fractions; 
- centrifuge the sample at 18000 rpm for 10 min at 4°C; 
- concentrate the sample up to 5 mg/ml in Amicon apparatus equipped with YM30 membrane; 
- centrifuge the sample at 18000 rpm for 10 min at 4°; 
- dialyze the sample against 2 l of buffer B overnight at 4°C; 
- split the sample in 0.2-0.5 ml aliquots; 
- flash-freeze in liquid nitrogen and store at -80°C.  
Before and after concentration and dialysis analyze the sample as done for the individual fractions and 
determine the protein concentration with the Bradford method.  
 
10.5. N-terminal sequencing and mass determination of MICAL forms 
The N-terminal sequence and the mass of MICAL forms are determined by mass spectrometry in the 
laboratory of Prof. Gabriella Tedeschi (Università degli Studi di Milano, Dipartimento di Scienze 
Veterinarie e Sanità Pubblica). For the determination of the N-terminal sequence of protein in solution 
and of the mass of the intact protein 100 and 10 pmole of sample are required, respectively. For the 
analysis, the samples had to be stored in a buffer with low ionic strength and devoid of components such 
as glycerol and DMSO for technical reasons. In our case, buffer with high ionic strength was required to 
maintain the stability of MICAL forms, thus for their analysis proteins were concentrated to ≈150 µM 
 202 
(≈10-20 mg/ml) in 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, in a way that samples can be 
dilute at low ionic strength for their analysis by mass spectrometry.   
Protein preparation - Gel filtration on Sepharose G25(medium) column   
Materials 
- PD10, Sepharose G25 column (1.9x11 cm, 9 ml; GE Healthcare); 
- HP 8453 diodearray spectrophotometer; 
- Microcon centrifugal filter YM30 (Millipore). 
Solutions 
- equilibration buffer: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl.  
Procedure 
- equilibrate PD10 column with 50 ml (5 volumes) of equilibration buffer; 
- load ≤ 500 µl volume of sample (0.75-1.5 mg); 
- elute with 0.5 ml aliquots of equilibration buffer; 
- collect 1.5 ml in the first fraction; 
- collect 0.5 ml in the next fractions; 
- record the absorption spectrum of the individual proteins; 
- pool the fractions containing the protein;  
- concentrate the sample in a microcon filter device by centrifugation at 12000xg at 4°C in microfuge to 
reach a final concentration of 50-150 μM (10-20 mg/ml, 0.05 ml, 0.5-1 mg); 
- flash-freeze the sample and store at -80°C until analysis.  
Before and after concentration the sample is analyzed by (1) recording the absorption spectrum, (2) 
determining the protein concentration with the Bradford method and (3) SDS-PAGE.  
Mass spectrometry analysis 
The N-terminal sequence of MICAL forms was determined with a pulsed-liquid sequencer equipped with 
a PTH analyser (Procise model 491, Applied Biosystems, Foster City, CA, USA) either after SDS-PAGE 
and electrotransfer on polyvinyldifluoride membranes (ImmobilonP, Merck-Millipore, see below) or on 
50-150 µM protein samples that had been gel filtered in 50 mM sodium phosphate buffer, pH 7.5, 100 
mM NaCl and concentrated. Concentrated MICAL solutions were also used for mass determination of the 
intact protein by an AUTOFLEX III MALDI-TOF instrument (Bruker Daltonics, Milano, Italy). After 
dilution, each sample was loaded onto a MALDI plate with a matrix of sinapinic acid in 0.1% 
trifluoroacetic acid: acetonitrile (2:1). Mass spectrometry analysis was carried out on a Bruker Daltonics 
Reflex IV instrument (Bruker Daltonics,) equipped with a nitrogen laser, operating in positive mode. 
Each spectrum was accumulated for at least 200 laser shots and Bruker peptide calibration standards were 
used for calibration.   
10.6. Quantitation of FAD content and the extinction coefficient at 458 nm of human MICAL1 forms 
Among essentials steps for the characterization of flavin-containing enzymes are (i) the determination of 
the stoichiometry of the bound flavin cofactor and (ii) their extinction coefficient in the visible region.    
Several methods are available in the literature in order to achieve such goals (Aliverti et al., 1999), which 
mainly differ for the method of protein denaturation for the release of flavin-bound cofactor. Moreover, 
the flavin stoichiometry and the degree of purity of protein preparation can be determined from the 
UV/Vis ratio of the absorption spectrum under native and denaturating conditions.  
Determination of the theoretical UV/Vis ratio for MICAL forms 
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We use the expasy tool Peptide Property Calculator (www.expasy.org/tools/protparam) to calculate the 
extinction coefficient at 280 nm of the apo-protein forms. The program calculates the extinction 
coefficient at 280 nm of the protein under denaturing conditions using the following formula: 
EMapo = aEM, Tyr + bEM, Trp + cEM, Cys 
Where a, b and c are the number of tyrosine, tryptophan and cystein residues per mol of protein and ETyr, 
Trp, Cys are the molar extinction coefficient of the residues at 280 nm.  
The ε280 of holoproteins is calculated by adding the ε280 of 22.7 mM
-1
cm
-1
 of free FAD in 3 M guanidine 
(obtained from 5 experimental determinations by 2-fold dilution of 20 μM FAD solution in 20 mM 
Tris/HCl, pH 8, 500 mM NaCl, 6 M guanidine).  
FADapoMICALholoMICAL
280280280    
To determine the theoretical UV/Vis ratio in denaturing conditions the ε280 of the holoprotein is divided 
by the ε448 of 11.9 mM
-1
cm
-1
 of the free FAD in 3 M guanidine. The calculated UV/Vis ratio expected for 
MICAL forms are indicated in Table 10.5  
Table10.5. Theoretical values of the UV/Vis (A280/A448) ratio expected for human MICAL1 and MO, MOCH and 
MOCHLIM forms when different percentage of apoprotein is present. The extinction coefficient at 280 nm 
(
holoMICAL
280 ) was calculated with ProtParam tool at www.expasy.ch and the extinction coefficient at 280 and 448 nm 
of free FAD in 3 M guanidine was experimentally determined (5 determinations).  
   
f holo f apo 
FAD
280  
FAD
448  
holoMO
280  A280/A448 
holoMOCH
280  A280/A448 
MholoMOCHLI
280  A280/A448 
holoMICAL
280  A280/A448 
1 0 22.7 11.9 68.87 7.69 89.84 9.46 100.81 10.38 125.91 12.49 
0.95 0.05 21.57 11.31  8.00  9.85  10.82  13.05 
0.9 0.1 20.43 10.71  8.34  10.30  11.32  13.66 
0.85 0.15 19.30 10.12  8.72  10.79  11.87  14.36 
0.8 0.2 18.16 9.52  9.14  11.34  12.50  15.13 
0.75 0.25 17.02 8.93  9.62  11.97  13.20  16.02 
0.7 0.3 15.89 8.33  10.18  12.69  14.01  17.02 
0.65 0.35 14.76 7.74  10.81  13.52  14.94  18.19 
0.6 0.4 13.62 7.14  11.55  14.49  16.03  19.54 
0.55 0.45 12.49 6.55  12.43  15.63  17.31  21.15 
0.5 0.5 11.35 5.95  13.48  17.01  18.85  23.07 
 
Determination of the theoretical UV/Vis ratio for native MICAL forms 
We assume that the extinction coefficient at 280 nm calculated under denaturing conditions is the same as 
that of native protein. The molar extinction coefficient for the holoprotein forms is calculated by adding 
the extinction coefficient of free FAD at 280 nm (ε280 = 21 mM
-1
cm
-1
) to the extinction coefficient 
calculated for the apoprotein:  
FADapoMICALholoMICAL
280280280    
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The UV/Vis ratio (A280/A458) is calculated by dividing the extinction coefficient of holoprotein at 280 nm 
(Table 10.5) by the extinction coefficient at 458 nm of 8.1 mM
-1
cm
-1
 determined for the MO form 
(Zucchini et al., 2011) 
holoMICALholoMICALVisUV 459280   
 
Protein A280/A458 
MO 10.5 
MOCH 14 
MOCHLIM 16 
MICAL 18 
 
Protein denaturation with 5% TCA 
Solutions  
- TCA10%; 
- protein solution ≈ 20 μM in 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl.  
Materials 
- HP 8453 diodearray  or Cary 100 spectrophotometers connected to a thermostatted bath at 25°C. 
Procedure  
Protein solutions are freshly gel filtered in 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl on a 
Superose12 column as described previously. 
- record the absorption spectrum of MICAL solution (≈20 μM); 
- transfer 120-400 μl of protein solution into an eppendorf tube; 
- add 1 volume 10% (w/v) TCA solution; 
- incubate for 15 min at RT; 
- centrifuge at 13000 rpm for 15 min at 4°C; 
- transfer the supernatant in a clean eppendorf tube; 
- centrifuge at 13000 rpm for 15 min at 4°C; 
- transfer directly the supernatant in a quartz cuvette; 
- record the absortion spectrum of the supernatant;  
- calculate the concentration of FAD:  
%5,
448448,
TCAFADAmMFAD  ; where
%5,
448
TCAFAD  is the extinction coefficient of  9.7 mM-1cm-1 of free FAD in 5% 
TCA calculated from 5 experimental determinations by 2-fold dilution of FAD (20 μM) in 10%TCA;   
- calculate the stoichiometry of FAD bound to the enzyme by dividing the concentration of FAD by that 
of the starting enzyme determined with the Bradford method by taking into account the protein mass and 
the 2-fold dilution factor: )5.0*,(),(/ MICALmMFADmMMICALFAD  ; 
- calculate the extinction coefficient of bound FAD by dividing the A458 of the starting MICAL solution 
by FAD concentration by taking into account the 2-fold dilution factor:  
FADmMA LnativeMICAMICAL ,5.0*458458  . 
 
Protein denaturation in buffer containing 3 M guanidine 
Solutions  
- guanidine buffer: 20 mM Tris/HCl, pH 8, 500 mM NaCl, 6 M guanidine; 
- protein solution ≈ 20 μM in 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM 
EDTA.  
Materials 
- Spectrophotometer HP 8453 (Hewlett Packard) or Cary 100 (Varian). 
Procedure  
Protein solutions are freshly transferred in 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% 
glycerol, 1 mM EDTA by gel filtration on a Superose12 column or on a SephadexG25 column as 
described previously.  
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- record the absorption spectrum of MICAL solutions (150-400μl; ≈20 μM); 
- add 1 volume of guanidine buffer and mix well; 
- record the absorption spectra for ≈60 min every 1-10 min;  
- calculate the concentration of FAD:  
MguanidineFAD
AmMFAD
3,
448448,  ;
MguanidineFAD 3,
448  is the extinction coefficient 11.9 mM
-1
cm
-1
 of free FAD in 
guanidine buffer determined experimentally; 
- calculate the stoichiometry of FAD bound to the enzyme by dividing the concentration of FAD by that 
of the starting enzyme determined with the Bradford method by taking into account the 2-fold dilution 
factor: )5.0*,(),(/ MICALmMFADmMMICALFAD  ; 
- calculate the extinction coefficient of bound FAD by dividing the A458 of the starting MICAL solution 
by FAD concentration by taking into account the 2-fold dilution factor: 
FADmMA LnativeMICAMICAL ,5.0*458458   
 
10.7. Quantitation of zinc ions content of MICAL forms  
The determination of Zn
2+ 
content of the samples was carried out following the procedure reported in 
Homsher., R. and Bennie., Z. (1985, Spectrophotometric investigation of sensitive complexing agents for 
the determination of zinc in serum. Clin. Chem. 31, 1310-1313) modified to reduce the final volume of 
the assays.  
Solutions  
- 1 M Hepes/KOH buffer pH 8; 
- TCA10%; 
- 5BrPAPS 86 mM (1 mg/ml, dissolved in water);  
- Zn
++
 stock solution: 1g/l (standard zinc solution for atomic absorption spectroscopy, Sigma 18827); 
- Zn
++
 working solution: 50 mg/l, prepared by dilution of 20-fold of Zn
++
 stock solution in water; 
- Buffer: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl;  
- buffer +TCA: 25 mM Na-phosphate buffer, 50 mM NaCl, 5% TCA;  
- MICAL form solution ≈ 20 μM.  
Materials 
- HP 8453 and Cary100 spectrophotometer thermostatted at 25°C.  
Preparation of Zn
++
 standard solutions and calibration 
- prepare the standard zinc solutions at different concentration in NaPi buffer as described in the table:  
 
Sample Zn
++
 working solution Buffer Total volume Zn
++
 
 ml ml ml mg/ml μM 
Buffer 0 5 5 - - 
1 0.15 5 5.15 1.456 22.13 
2 0.1 5 5.1 0.98 14.19 
3 0.05 5 5.05 0.495 7.52 
4 0.03 5 5.03 0.28 4.53 
5 0.02 5 5.02 0.199 3.03 
6 0.01 5 5.01 0.099 1.516 
 
- dilute 2-fold the sample with 10% TCA:  
 
Zn++ standard solution sample 10%TCA Zn
++
 
 ml ml mg/ml µM 
blank Buffer, 0.5 0.5 - - 
1 1, 0.5 0.5 0.73 11.1 
2 2, 0,5 0.5 0.49 7.10 
3 3, 0.5 0.5 0.25 3.76 
4 4, 0.5 0.5 0.14 2.26 
5 5, 0.5 0.5 0.1 1.52 
6 6, 0.5 0.5 0.05 0.76 
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For the blank sample:  
In a plastic cuvette:  
- add 0.7 ml of 1 M Hepes/NaOH buffer, pH 8 and 0.05 ml of 5 BrPAPS (125 μM final concentration);  
- record the absorption spectrum and the A550 value (A550 1); 
- add 0.2 ml of buffer diluted 2-fold in 10%TCA;  
- record the absorption spectrum and the A550 value (A550 2);  
- calculate the value of the blank: A550 blank= A550 2- A550 1(0.75/0.9);  
Each sample:  
- add 0.7 ml of 1 M Hepes/NaOH buffer, pH 8 and 0.05 ml of 5 BrPAPS (125 μM final concentration);  
- record the absorption spectrum and the A550 value (A550 1); 
- add 0.2 ml of Zn
++ 
standard solution; 
- record the absorption spectrum and the A550 value (A550 2); 
- calculate the final A550 (A550X) value by taking into the account the dilution and the A550 of the blank:  
A550X= [A550 2- A550 1(0.75/0.9)]- A550 blank;  
- divide the resulting A550 value by the extinction coefficient of the zinc-PAPS complex of 130 mM
-1
cm
-1
 
to determine the concentration of zinc present in the sample.  
This procedure is used for all zinc standard solutions and the blank sample is repeated after two zinc 
standard solutions to ensure that the blank A550 value is similar for all the samples analyzed.  
 
The following figure shows an example of the calibration curve obtained with zinc standard solutions.  
 
Procedure for the determination of the zinc content of MICAL forms 
- denature the protein with TCA5% as described previously;  
For zinc quantitation:  
- determine the blank A550 value as described for the calibration curve;  
To quantify the zinc content of the sample, in a 1 ml cuvette:  
- add 0.7 ml of 1 M Hepes/NaOH buffer pH 8 in 1 ml plastic cuvette;  
- add 0.05 ml of PAPS;  
- record the absorption spectrum and sign the A550 value (A550 1);  
- set-up the following samples individually: 
 
Sample Buffer +TCA SN, ml 
1 - 0.2 
2 0.05 0.15 
3 0.1 0.1 
4 0.150 0.05 
 
- determine the A550 value (A550 2); 
- calculate the zinc content as described previously.  
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As a part of the method set-up we quantified the amount of zinc in sample obtained by denaturation of 
MO and MOCH forms, which lack the LIM domain and thus, the associated zinc ions. To ensure that zinc 
does not precipitate with 5%TCA, control sample was carried out with MO form in which a known 
amount of zinc was added to the protein solution prior protein denaturation:  
 
 Volume, μl  μM 
MO, 28 μM 300 13 
Zn working solution, 765 μM 20 5 
10% TCA 320  
Total volume 640  
 
The supernatant obtained after incubation for 15 min at RT and centrifugation and the zinc content is 
determined as described previously.  
  
Control samples were also set-up during each experiment by adding a known amount of zinc standard 
solution to the supernatant obtained after protein denaturation. Here, an example of the sample set-up is 
shown: 
 “SN only” “SN+Zn++” “Zn++ only” 
SN , 28 μM 75 75 - 
Buffer +TCA 75 - 75 
Zn
++
 standard solution 19 μM  - 75 75 
Total volume 150 150 150 
 
The zinc content was determined using 0.1 ml of each sample.  
 
10.8. Production of mouse CRMP1 forms in Escherichia coli cells 
E.coli BL21(DE3) cells made competent with CaCl2 method are freshly transformed with pGEX 
derivatives (Table 10.2) encoding mouse CRMP1 forms.  
Preparation of the preculture  
- transfer ≈30 colonies of transformants in a 500 ml flask containing 50 ml of selective LB; 
- incubate the flask under stirring (220 rpm) at 25 °C and monitor cell growth by measuring the optical 
density at 600 nm (OD600);  
When the cell culture reaches an OD600 value of 1: 
- add 50 μl of ampicillin solution (100 mg/ml) and transfer the flask in the cold room overnight. 
Preparation of the culture 
- transfer the preculture in a falcon tube and centrifuge in a swing-out rotor at 3500xg for 10 min at 4°C 
(Labofuge 400 Heraeus, Chandler, AZ, USA);  
- remove the supernatant and resuspend the pellet in 10 ml of LB; 
- transfer, under sterile conditions, 5 ml of suspension in a  500 ml of selective LB broth in a 2.5 l flask to 
have an initial OD600 value of ≈0.05;  
- transfer the flask in the incubator under stirring (220 rpm) at 25°C; 
When the OD600 value is ≈1: 
- add 500 μl IPTG solution (1 mM final concentration) and 500 μl Amp solution; 
16 h after the addition of the IPTG solution: 
- transfer the culture in 500 ml centrifuge bottles and centrifuge at 6000 rpm for 15 min at 4°C (rotor SLA 
3000); 
- discard the supernatant, resuspend the cells with saline solution (0.9% NaCl, 30-40 ml) and pool in a 
centrifuge tube; 
- centrifuge at 6000 rpm for 15 min at 4°C; 
- discard the supernatant and weight the cells; 
- store at -20°C. 
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10.9. Purification of mouse CRMP1 forms 
Small-scale purification of CRMP forms - Glutathione-Sepharose affinity chromatography  
The crude extract is obtained by homogenization of 2 g of E.coli BL21(DE3) cells expressing CRMP 
forms as described for the small-scale purification of MICAL forms.  
Materials 
- Glutathione Sepharose 4B resin (GE Healthcare) equilibrated in lysis buffer; 
Solutions 
- Lysis Buffer: 50 mM Hepes/KOH, pH 7.5, 150 mM KCl; 
- Elution Buffer: 50 mM Tris/HCl, pH 8.5, 15 mM reduced glutathione (GSH); 
- Protease inhibitor cocktail (EDTA free), 50 µl/g cells.  
Procedure 
- resuspend the resin (0.5 ml/g of cells) in 1 volume of lysis buffer and transfer to a falcon tube; 
- add the crude extract (CE); 
- incubate for 1 h on a wheel at 6 rpm and 4°C; 
- centrifuge in the swing-out rotor at 500xg for 5 min at 4°C; 
- remove the supernatant containing unbound proteins (flow-through); 
- add 5 ml of lysis buffer and gently mix for 3 min at RT; 
- centrifuge in swing-out rotor at 500xg for 5 min at 4°C; 
- remove the supernatant (wash 1, W1); 
- repeat the last three steps twice for a total of three wash steps (W1 above, W2, W3); 
- add 1 ml of elution buffer; 
- incubate for 1 h on a wheel at 6 rpm and 4°C; 
- centrifuge in the swing-out rotor at 500xg for 5 min at 4°C; 
- recover the supernatant (elution 1, E1); 
- repeat the last four steps twice for a total of three elution steps (E1 above, E2 and E3).  
 
Fractions collected during the chromatography are analysed by (1) recording the absorption spectrum, (2) 
SDS-PAGE and (3) determining protein concentration with Bradford method.   
 
Large-scale purification of CRMP (8-525) form 
The crude extract is obtained by sonication of 20-30 g of E.coli BL21(DE3) cells that had produced the 
mouse CRMP1 (8-525) form following the same procedure indicated for the homogenization of E.coli 
cells containing MICAL forms (see above).  
Materials 
- column  (14 x 1.7 cm; BioRad, Hercules, CA, USA); 
- Glutathione Sepharose 4B resin (GE Healthcare) equilibrated in lysis buffer. 
Solutions 
- Lysis Buffer: 50 mM Hepes/KOH, pH 7.5, 150 mM KCl; 
- Elution Buffer: 50 mM Tris/HCl, pH 8.5, 15 mM glutathione reduce (GSH). 
- Cleavage Buffer: 50 mM Tris/HCl, pH 7, 150 mM NaCl, 1 mM EDTA, 1 mM DTT; 
- Prescission Protease (2 U/µl, GE Healthcare, stored at -20°C), which is a GST-fusion protein to allow 
its binding to GSH-Sepharose resin and its separation from the cleaved GST-fusion protein;  
- Equilibration buffer: 50 mM Tris/HCl, pH 7; 
- Dialysis Buffer: 20 mM Hepes/KOH, pH 7.5, 300 mM NaCl, 10 % glycerol, 1 mM DTT (Stenmark et 
al., 2007).  
Procedure 
- resuspend the resin (0.5 ml/g cells) in 1 volume of lysis buffer; 
- incubate for 1 h on a wheel at 6 rpm at 4°C; 
- centrifuge in a swing-out at 500xg for 5 min at 4°C; 
- remove the supernatant containing unbound proteins (flow-through, FT); 
- add 50 ml of lysis buffer to the resin and gently mix for 3 min at RT; 
- centrifuge in swing-out rotor at 500xg for 5 min at 4°C; 
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- remove the supernatant (wash 1, W1); 
- add 50 ml of lysis buffer to the resin and gently mix for 3 min at RT; 
- centrifuge in swing-out rotor at 500xg for 5 min at 4°C; 
- remove the supernatant (wash 2, W2); 
- add 50 ml of lysis buffer to the resin and gently mix for 3 min at RT; 
- pour the suspension into the column, let it pack under flow to fully remove the unbound proteins (W3); 
- resuspend the resin in 10 ml of elution buffer; 
- transfer the suspension in a falcon-type tube; 
- incubate for 15 min on a wheel at 4°C; 
- pour the suspension into the column, let it pack under flow and collect bound proteins (E1); 
- repeat the last four steps two more times (E2 and E3); 
- add 5 ml of elution buffer and collect eluate 4 (E4); 
- add 3 ml of elution buffer and collect eluate 5 (E5).  
 
The collected fractions are analyzed by (1) recording the absorption spectrum, (2) SDS-PAGE and (3) 
determining protein concentration with Bradford method. Fractions containing CRMP (8-525) are pooled 
and dialyzed against 2 l of cleavage buffer for 20-22 h at 4°C.  
To separate CRMP from GST protein at the end of the dialysis:  
-  remove aggregated proteins by centrifugation at 18000 rpm for 10 min at 4°C (rotor SS34); 
- determine the protein concentration with the Bradford method;  
- set-up the reaction mixture with prescission protease by adding 10 µl of the protease per mg of GST-
fusion protein;  
- incubate for 16 h at 4°C in cold room.  
To the reaction mixture:  
- add 10 ml of GSH-Sepharose equilibrated in equilibration buffer; 
- incubate on a wheel for 1 h at 4°C;  
- pour the suspension into the column, let it pack under flow and collect the unbound proteins, flow-
through (FT); 
- flow 40 ml of equilibration buffer and collect 5 ml fractions;  
- analyze the FT and individual fractions as described previously; 
- add fractions enriched in CRMP to the flow-through; 
- centrifuge at 18000 rpm for 10 min at 4°C; 
- concentrate the sample to ≈10 mg/ml in an Amicon ultrafiltration apparatus equipped with YM10 
membrane; 
- centrifuge at 18000 rpm for 10 min at 4°C; 
- dialyze against 2 l of dialysis buffer for 16 h at 4; 
- recover the sample by centrifugation; 
- split the sample in 0.5 ml aliquots; 
- flash-freeze in liquid nitrogen and store at -80°C.  
The pooled fractions and the sample after concentration and dialysis are analyzed as described for the 
individual fractions.  
At this stage CRMP preparation showed small traces of contaminating proteins and aggregates. Aliquots 
of CRMP solution obtained by GSH-Sepharose affinity chromatography were further purified by gel 
filtration on a Superose12 column.  
Final CRMP (8-525) purification - Gel filtration 
Prior each experiments aliquots up to 500 μl of CRMP (8-525) preparation obtained by affinity 
chromatography are gel filtered on a Superose12 column in 20 mM Hepes/KOH buffer, pH 7 + 25-100 
mM NaCl or in F-buffer no ATP (9.5 mM Tris/HCl buffer, pH 7.7, 45 mM KCl, 0.18 mM CaCl2, 1.18 
mM MgCl2, 1.3 mM DTT) as described for MOCHLIM.  
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The individual fractions and the final sample are analyzed (1) by recording the absorption spectrum, (2) 
DLS, (3) SDS-PAGE and (4) determining the protein concentration with the Bradford method. 
The final CRMP preparation is flash-frozen in liquid nitrogen in 0.5 ml aliquots and stored -80°C or 
stored overnight on ice at 4°C to if it will be used the day after for experiments.  
 
10.10. Preparation of G- or F-actin solution  
Solutions 
G-, F- and polymerization buffers are prepared from the following stock solutions:  
- 10 mM Tris/HCl buffer, pH 8;  
- 100 mM Tris/HCl buffer, pH 7.5; 
- 2 M KCl; 
- 10 mM CaCl2; 
- 20 mM MgCl2; 
- 85 mM ATP pH 7 (concentration spectrophotometrically determined; stored at -20°C); 
- 100 mM DTT in 50 mM Na-acetate buffer (stored at -20°C); 
- G-buffer: 5 mM tris/HCl, pH 8, 0.2 mM CaCl2, 0.2 mM ATP, 1 mM DTT; 
- Polymerisation buffer 10X: 50 mM Tris/HCl, pH 7.5, 500 mM KCl, 20 mM MgCl2, 10 mM ATP, 5 mM 
DTT; 
- F-buffer: 0.9 ml G buffer + 0.1 ml F buffer, 9 mM Tris/HCl, pH 8.0, 0.18 mM CaCl2, 45 mM KCl, 1.8 
mM MgCl2, 1.3 mM DTT, 1.1 mM ATP; 
- G-actin (AKL99, Cytoskeleton, Acoma St. Denver, CO, USA), 1 mg in 5 mM Tris/HCl, pH 8.0, 0.2 
mM CaCl2, 0.2 mM ATP, 5% (w/w) sucrose, 1% (w/w) dextran; 
-  G-pyrenyl-actin solution (AP05-A, Cytoskeleton) 20 mg/ml in 5 mM Tris/HCl, pH 8.0, 0.2 mM CaCl2, 
0.2 mM ATP, 5% (w/w) sucrose, 1% (w/w) dextran was diluted to desiderate final concentration in G 
buffer. 
Equipment  
- Beckman TL100 ultracentrifuge (Beckman, Brea, CA, USA), equipped with a TLA 100.3 rotor; 
- fluorimeter Cary Eclipse (Varian); 
- Dynapro MS/X. 
Procedure 
- resuspend 1 mg of lyophilized G-actin in 100 µl of cold ultrapure water (freshly drawn from MilliQ 
Reagent water system apparatus, Millipore) to have a G-actin 10 mg/ml stock solution; if pyrenyl-actin is 
used dissolve 1 mg of lyophilized protein in 50 µl of cold water to have a 20 mg/ml stock solution;  
- centrifuge at 13000 rpm for 3 min at 4°C; 
- dilute G-actin or G-pyrenyl-actin stock solution to desired final concentration in G buffer (0.2-2 mg/ml) 
in an eppendorf type for ultracentrifugation (357448, Beckman); 
- incubate 1 h on ice;  
- centrifuge at 100000 x g (55000 rpm) for 1 h at 4°C in Beckman TL100 ultracentrifuge equipped with a 
TLA 100.3 rotor; 
- transfer the supernatant into a clean eppendorf tube; 
- determine the protein concentration with the Bradford method; 
- add 1/10 of volume of polymerisation buffer to the G-actin solution; 
- incubate 1 h at 25°C in a Thermomixer.  
 Polymerization can be monitored by dynamic light scattering; for G-pyrenyl-actin polymerization is 
monitored in a Cary Eclipse fluorimeter (λex= 365 nm; λem= 407 nm).  
At the end of the polymerization F-actin solution is maintained on ice or at 25°C. 
Monitoring the aggregation state of actin   
DLS is used to monitor the polymerization of actin and the effect of MICAL forms on the oligomeric 
state of actin in a kinetic mode. 
Procedure  
- set-up the instruments parameters:  
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 Acquisition time    15 s 
 Sensitivity     50% 
 Temperature    25°C 
 Solvent     H2O or PBS buffer  
 pH     8 
- measure the DLS signal (intensity and average radius of the particles in solution) of G-buffer solution 
(20 valid acquisitions); 
- transfer 120 µl of G-actin solution (0.1-0.18 mg/ml, 2-4.5 µM; after ultracentrifugation) in the cuvette; 
- measure the DLS signal for 10 min; 
- add 12 µl of polymerization buffer  and mix gently with a Gilson P200 pipette equipped with a cut tip; 
- follow the increase of DLS signal of the solution until it reaches a maximum and constant value. 
If the effect of MICAL forms on the aggregation state of actin is under study: 
- add 1.2 µl of 10 mM NADPH solution (100 µM); 
- monitor DLS signal for at least 5 min; 
- add 1-5 µl of enzyme solution; 
- monitor the DLS signal every 15 s for ≈30 min.  
At the end: 
- transfer the sample into a eppendorf tube; 
- centrifuge at 13000 rpm for 15 min at 4°C; 
- recover the supernatant and monitor the DLS signal.  
Preparation of actin samples for mass spectrometry analysis 
To determine the residues of actin that are modified upon incubation with MICAL forms, actin samples 
are precipitated with cold acetone:methanol to block the reaction at a specific time. The actin samples 
were prepared at a concentration of ≈1 mg/ml (23 µM), which was the concentration required for their 
analysis by mass spectrometry carried out in the laboratory of Prof. Gabriella Tedeschi (Dipartimento di 
Scienze veterinarie e Sanità Pubblica, Università degli Studi di Milano). 
Materials 
- spectrophometer hp 8453 thermostatted at 25°C.  
Solutions  
- G- or F-actin solution ≈ 1 mg/ml (23 µM); 
- 10 mM NADPH in 20 mM TrisOH (100-200 µM final concentration); 
- Catalase 1 mg/ml stock solution in 20 mM Hepes/KOH buffer pH 7 stored at -20°C; 
- Catalase working solution 0.1 mg/ml obtained by 10-fold dilution of the stock solution G- or F-buffer;  
- MICAL forms stored in buffer B (50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol, 1mM 
EDTA, 1 mM DTT); Protein solutions was diluted to appropriate concentration in buffer B to add 1 μl of 
enzyme to 120 μl of actin sample; the final concentrations of MICAL proteins are indicated in the figures 
legends (Chapter 7); 
- Acetone:Methanol: 8 ml acetone (100%) + 1 ml methanol (100%) conserved at -20°C.  
Procedure  
In a 0.2 ml cuvette:  
- transfer 120 μl of G- or F-actin solution;  
- record the absorption spectrum and incubate for 2 min;  
- add 1-2 μl of 10 mM NADPH (100-200 μM final concentration) and gently mix; 
- record the absorption spectrum and incubate for 3 min and check that no changes occur in the absorption 
spectrum; 
- add 1 μl of 0.1 mg/ml catalase (0.83 μg/ml) and mix gently; 
- record the absorption spectrum and incubate for 2 min;  
- add 1 μl of enzyme solution and record the absorption spectrum to check the formation of turbidity 
and/or aggregates and record spectra every 20 s to limit the radiation damage of sample;  
At the desired time, to block the reaction: 
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- transfer the sample into a eppendorf tube containing 10 volumes of cold acetone:methanol (e.g., 120 µl 
sample + 1200 µl acetone:methanol);  
- incubate the sample at -20°C for 15-20 h;  
- centrifuge at 13000 rpm for 30 min at 4°C (15 min + 15 min);  
- discard the supernatant;  
- resuspend the pellet in 500 µl of cold acetone:methanol; 
- incubate at -20°C for 2 h;  
- centrifuge at 13000 rpm for 30 min at 4°C (15 min + 15 min); 
- discard the supernatant; 
- dry the pellet on air under a hood near a Bunsen burner; 
- store the samples at -20°C. 
Analysis of actin by mass spectrometry.  
This part of the experiments were carried out in laboratory of Prof. G. Tedeschi  
For mass determination of the intact protein mass, each actin sample was diluted 10-fold in water and 
loaded onto a MALDI plate with a matrix of sinapinic acid in 0.1% trifluoroacetic acid: acetonitrile (2:1). 
Mass spectrometry analysis was carried out on a Bruker Daltonics Reflex IV instrument (Bruker 
Daltonics,) equipped with a nitrogen laser, operating in positive mode. Each spectrum was accumulated 
for at least 200 laser shots and Bruker peptide calibration standards were used for calibration. For analysis 
and identification of the actin modification sites, precipitated protein samples were resuspended in 50 mM 
ammonium bicarbonate, reduced, alkylated and digested overnight with trypsin (sequence grade), at 37 
°C, using a protease: protein ratio (1:10). Tryptic digests were extracted with 50% acetonitrile in 0.1% 
trifluoroacetic acid, desalted/concentrated on a μZipTipC18 (Millipore) and mass spectrometry analysis 
was carried out on a Bruker Daltonics Reflex IV instrument (Bruker Daltonics,) equipped with a nitrogen 
laser, operating in positive mode. Each spectrum was accumulated for at least 200 laser shots and Bruker 
peptide calibration standards were used for calibration. The identification of the corresponding peptides 
was carried out using the theoretical fingerprint of actin digested with trypsin with Expasy tools 
(www.expasy.org, Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D. & 
Bairoch A. (2005) Protein Identification and Analysis Tools on the ExPASy Server in The Proteomics 
Protocols Handbook (Walker, J. M., ed) pp. 571-607 Humana Press). 
 
10.11.  NADPH oxidase activity of MICAL forms 
MOCHLIM and MICAL preparations (3-5 mg/ml) stored in buffer B (50 mM Na-phosphate buffer, pH 
7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT) are diluted to 1 mg/ml in the same buffer to 
measure the NADPH oxidase activity. Instead, MO and MOCH solutions are gel filtered on a 
SepharoseG25 column to transfer the proteins transfer the protein in 20 mM Hepes/KOH, pH 7, 10% 
glycerol, 1 mM EDTA, 1 mM DTT.  
Standard NADPH oxidase activity 
Materials 
- HP 8453 diodearray  and Cary100 spectrophotometers connected to circulating bath set at 25°C.  
Solutions 
- Assay buffer: 40 mM Hepes/KOH, pH 7; 
- NADPH stock solution: 10 mM NADPH in 20 mM TrisOH; 
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Procedure  
The initial velocity of NADPH oxidation is continuously monitored at 340 nm (ε340 = 6.23 mM
-1
cm
-1
) 
when the Cary100 spectrophotometer is used, when HP 8453 diodearray spectrophotometer is used the 
entire absorption spectrum of the reaction is recorded every 10 sec and the absorbance trace at 340 nm is 
used to calculate the initial velocity of the reaction.  
The reaction mixture is set-up into 1 ml quartz cuvette as follows: 
- add 0.5 ml of assay buffer and 0.49 ml of H2O; 
- mix and incubate at 25°C for 5 min; 
- add 10 μl of 10 mM NADPH (100 μM final concentration); 
- monitor the absorbance at 340 nm (for Cary100) or record the absorption spectra (for HP8453) for 2 
min; 
- add 1-10 μl of protein solution.  
The initial velocity is expressed as v/E in s
-1
, where v is the initial velocity of the reaction and E is the 
total enzyme concentration in the assay determined with the Bradford method and using the theoretical 
protein mass.  
Determination of kinetic parameters of the NADPH oxidase activity of MICAL forms  
Materials 
- HP 8453 diodearray  and Cary100 spectrophotometers connected to circulating bath set at 25°C.  
Solutions 
- Assay buffer: 40 mM Hepes/KOH, pH 7; 
- NADPH stock solution: 10 or 50 mM NADPH in 20 mM TrisOH; 
- NADPH 1-5 mM obtained by dilution of the 50 mM NADPH stock solution in H2O.  
Procedure  
To determine the apparent steady-state kinetic parameters kcat and Km for NADPH (KNADPH), the NADPH 
concentration was varied between 10-600 µM NADPH. For high NADPH concentrations 50 mM 
NADPH stock solution is used and care is taken to add less than 20 µl/ml assay mixture to avoid altering 
the pH of the reaction. Enzyme solutions are concentrated to add less than 50 µl/ml assay to start the 
reaction. The reaction was monitored at 340 nm for NADPH concentrations between 10 and 200 µM. For 
higher concentration of NADPH the reaction was monitored at 374 nm (ε360 = 2.1 mM
-1
cm
-1
) and at 380 
nm (ε380 = 1.3 mM
-1
cm
-1
). When the Cary100 spectrophotometer is used identical reactions are carried out 
and monitored at the two wavelengths in the overlapping range (with duplicates); when HP 8453 diode 
array spectrophotometer is used, the absorption spectra of the reaction are recorded every 10 s and the 
initial velocity of the reaction is calculated from the traces obtained at different wavelengths.   
After inspection of double reciprocal plots (Eq.1), the data of v/E were fitted to the Michaelis-Menten 
equation (Eq.2).  
Eq. 1 
catcat
m
kSk
K
v
E 11
*   
Eq.2 
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E
v
m
cat


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where: S is the varying substrate concentration; E is the total enzyme concentration in the assay with the 
protein concentration determined with the Bradford method and the known protein mass; kcat is the 
apparent turnover number and Km is the Michaelis-Menten constant for NADPH.   
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The Grafit 4.0 software (Erithacus Software Ltd, Horley, UK) was used to determine the kinetic 
parameters and the associated errors. The kcat/KNADPH was calculated with error propagation according to 
Bevington (1969).   
 
Effect of the ionic strength on the NADPH oxidase activity of MOCH 
 
Solutions 
- Assay buffer: 40 mM Hepes/KOH, pH 7; 
- NaCl: 1 M NaCl solution; 
- Na-acetate: 1M Na-acetate, pH 7; 
- Imidazole-acetate buffer: 200 mM imidazole/acetate, pH 7; 
- Tris-acetate buffer: 200 mM Tris/acetate, pH 7; 
- NADPH stock solution: 10 mM NADPH in 20 mM TrisOH; 
- NADPH 1 mM: 100 µl of NADPH 10 mM + 900 µl of  H2O. 
 
The effect of ionic strength on the NADPH oxidase activity of MOCH was studied by measuring the 
initial velocity of the reaction in the presence of varying concentration of NADPH and of (1) 20 mM 
Hepes/KOH buffer, pH 7 (I, 4.4 mM) + NaCl (10-100 mM; I, 29.4-104.4 mM) or Na-acetate (100-250 
mM; I, 104.4-254.4 mM), (2) imidazole-acetate buffer pH 7 (50-150 mM; I, 27-81 mM) and (3) Tris-
acetate buffer pH 7 (50-200 mM; I, 45-180 mM). The ionic strength of reaction medium was calculated as 
described in Ellis, K.J., et al 1982.  
The effect of imidazole-acetate buffer on the slope of double reciprocal plots (kcat /KNADPH)/(kcat /KNADPH)0 
as a function of ionic strength was well fitted to the limiting case of the Debye Hückel equation (Norby et 
al., 1997 and Eq 3),  
 
Eq. 3  0)/log(**)/log( McatSEMcat KkIzzKk   
Where: kcat/KM is the value of the parameter obtained in the presence of a given ionic strength (I); 
(kcat/KM)0 is the value of the parameter calculated at zero ionic strength; zE and zS are the charge of the 
enzyme acive site and that of ligand, respectively. For NADPH zS is -3 or -4 at pH 7.    
 
 
pH dependence of NADPH oxidase activity of MICAL forms 
Solutions 
- Mixed Buffer A 2x: 20 mM acetic acid, 10 mM Tris, 10 mM imidazole; 
- Mixed Buffer B 2x: 25 mM formic acid, 10 mM tris, 10 mM imidazole; 
- NADPH stock solution 10 or 50 mM in 20 mM TrisOH buffer.  
The pH dependence of the steady-state kinetic parameters of the NADPH oxidase activity of MICAL 
forms is studied in mixed buffer that ensures a constant ionic strength over the entire pH range explored 
(Ellis et al., 1982). In the light of the fact that the ionic strength of any single buffer significantly varies 
over its useful pH range. Figure 10.X show the plot of ionic strength of the single mixed buffer A as a 
function of pH to compare with that of complete mixed buffer A and B (Figure 10.X) in which the ionic 
strength is essentially constant over the pH range form 4.5 to 10. Moreover, the pKa value for a single 
buffer varies with temperature and thus, it is important to take into account temperature difference in the 
calculation of pKa values using the following relationship:  
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 DTTRTpKpK TRT   
Where RT, T and DT are: the required temperature, the temperature at which the determination was made 
and the change in pKa values per degree, respectively (Ellis and Morrison 1982).  
The NADPH oxidase activity of MICAL is very sensitive to ionic strength and ions composition, thus 
mixed buffer A and B are designed to maintain the ionic strength low and constant over the entire pH 
range investigated by calculating the total charge of the buffer and its ionic strength as a function of pH 
using the following formula and are indicated in Table 10.5:  
Total charge=                ''1'''1'1 ''1'''1'1 zCzHCzBzHBzAzHA zzzzzz    
 Ionic strength=                charge total''1'''1'15.0 2''21''2'21'221   zCzHCzBzHBzAzHA zzzzzz  
 
Figure 10.1. Plot of the ionic strength of the single components of 
mixed buffer A as a function of pH.  
○, 20 mM acetic acid; ●, 10 mM imidazole; □, 10 mM Tris.  
 
 
 
 
 
Figure 10.2. Plot of the ionic strength of mixed buffer A as a function 
of pH. Composition of mixed buffer A: 20 mM acetic acid, 10 mM 
imidazole, 10 mM Tris.   
.  
 
 
 
 
Figure 10.3. Plot of the ionic strength of mixed buffer B as a function 
of pH. Composition of mixed buffer B: 25 mM formic acid, 10 mM 
imidazole, 10 mM Tris.  
 
Na-acetate is added to maintain the ionic strength constant at 10 
and 12.5 mM for mixed buffer A and mixed buffer B, 
respectively. For mixed buffers A at pH >6.5 NaOH is added and small amount of HCl (<2 mM) is added 
to obtain pH 5-6. Mixed buffer B is designed to have an initial pH value of 4.3 in order to add only NaOH 
solution to reach the desired pH values.  
The kinetic parameters of the NADPH oxidation reaction catalyzed by MICAL forms are determined in 
mixed buffer A and mixed buffer B by varying NADPH concentration as described in the previously.  
The v/E values obtained at each pH are fitted to the Michaelis-Menten equation (Eq 2) and the resulting 
kinetic parameters (kcat, KNADPH and kcat/KNADPH) are fitted to the following equations to determine the pH 
dependence of the reaction.   
Eq 4: Y = [A1 * 10
-2pH
  + A2 * 10
-(pH + pKa1)
 + A3 * 10
-(pKa1+ pKa2)
]/[ 10
-(pKa1+ pKa2)
 + 10
-(pH + pKa1)
 + 10
-2pH
  ] 
Eq. 5 : Y = [A* 10 
(pH - pKa)
]/[1 + 10 
(pH - pKa)
] 
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Eq. 6:  Y = [A1 + A2 * 10
(pH-pKa)
]/[ 1 + 10
(pH-pKa)
] 
Eq. 7: Y = [A1 * 10
(pKa1-pH)
/ (1 + 10
(pKa1-pH)
) + A2 * 10
(pKa2-pH)
]/ (1 + 10
(pKa2-pH)
)] 
 
Eq 4. was used to describe the pH profile of the kcat of MO and MOCH. It describes the pH dependence 
of the parameter that increases from a non-zero value at low pH (A1) to a maximum (A2), as a group with 
pKa1 deprotonates, and decreases to another non-zero value (A3) as a second group with pKa2 
deprotonates.  
Eq.5 was used for the pH profile of the kcat calculated for MOCHLIM. The value of the parameter 
increases from zero to an upper limit (A) as one group deprotonates.  
Eq. 6 was used to describe the pH profile of the kcat calculated for MICAL. The value of the parameter 
decreases from un upper limit (A1) at low pH to a lower limit (A2) when a single group dissociates.  
Eq. 7 was used to describe the pH dependence of the kcat/KNADPH and 1/KNADPH for all MICAL forms. The 
value of the parameter decreases from an upper limit (A1+A2) at low pH to a second value (A2) as a group 
with pKa1 deprotonates and decreases to zero as a second group with pKa2 also deprotonates.   
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 Table 10.5. Composition of mixed buffer A (20 mM acetic acid, 10 mM imidazole, 10 mM Tris) and B (25 mM formic acid, 10 mM imidazole, 10 mM Tris)  stock solution:.  
A 
 
     pH 
 Concentration, mM pKa charge  5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 
Acetic acid 20 4.70 0 acid 6.72 2.76 0.96 0.32 0.10 0.03 0.01 0.00 0.00 0.00 0.00 
   -1 base 13.28 17.24 19.04 19.68 19.90 19.97 19.99 20.00 20.00 20.00 20.00 
                
Imidazole 10 7 1 acid 9.90 9.69 9.09 7.60 5.00 2.40 0.91 0.31 0.10 0.03 0.01 
   0 base 0.10 0.31 0.91 2.40 5.00 7.60 9.09 9.69 9.90 9.97 9.99 
                
Tris 10 8.09 1 acid 9.99 9.97 9.92 9.75 9.25 7.95 5.51 2.80 1.09 0.37 0.12 
   0 base 0.01 0.03 0.08 0.25 0.75 2.05 4.49 7.20 8.91 9.63 9.88 
                
    charge 6.62 2.43 -0.03 -2.34 -5.65 -9.61 -13.57 -16.89 -18.81 -19.59 -19.87 
    \charge\ 6.62 2.43 0.03 2.34 5.65 9.61 13.57 16.89 18.81 19.59 19.87 
    Ionic strength, mM 19.89 19.67 19.04 19.68 19.90 19.97 19.99 20.00 20.00 20.00 20.00 
    NaAcetate, mM 0.11 0.33 0.96 0.32 0.10 0.03 0.01 0.003 0.001 0.000 0.000 
    I total, mM 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 
 
B 
 
     pH 
 Concentration, mM pKa charge  5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 
Formic acid 25 3.75 0 acid 1.33 0.44 0.14 0.04 0.014 0.004 0.0014 0.0004 0.00014 4.45E-05 1.41E-05 
   -1 base 23.67 24.56 24.86 24.95 24.98 24.99 24.99 24.99 24.99 24.99 24.99 
                
Imidazole 10 7 1 acid 9.90 9.69 9.09 7.60 5 2.40 0.90 0.31 0.1 0.031 0.01 
   0 base 0.099 0.31 0.91 2.40 5 7.60 9.09 9.69 9.90 9.97 9.99 
                
Tris 10 8.09 1 acid 9.99 9.97 9.92 9.75 9.25 7.95 5.51 2.80 1.09 0.37 0.12 
   0 base 0.008 0.026 0.081 0.25 0.75 2.05 4.48 7.20 8.91 9.63 9.87 
                
    charge -3.77 -4.89 -5.85 -7.61 -10.73 -14.64 -18.58 -21.89 -23.81 -24.59 -24.86 
    \charge\ 3.77 4.89 5.85 7.61 10.73 14.64 18.58 21.89 23.81 24.59 24.86 
    Ionic strength, mM 23.67 24.56 24.86 24.95 24.98 24.99 24.99 24.99 24.99 24.9 24.99 
    NaAcetate, mM 1.33 0.44 0.14 0.044 0.014 0.0044 0.0014 0.0045 0.0001 4.45E-05 1.41E-05 
    I total, mM 25 25 25 25 25 25 25 25 25 25 25 
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Effect of viscosity on the NADPH oxidase reaction of MICAL-MOCH  
 
Solutions 
- Buffer stock solution: 80 mM Hepes/KOH, pH 7; 
- Assay buffer: 40 mM Hepes/KOH, pH 7 (25 g buffer stock solution + 25 g H2O); 
- Assay buffer + 10, 20, 30, 40, 50% glycerol (w/w);  
- NADPH stock solution: 10 or 50 mM NADPH in 20 mM TrisOH; 
- NADPH 2 mM: NADPH stock solution is diluted in H2O.  
 
The v/E values obtained by varying NADPH concentration in the presence of different glycerol 
concentrations were fitted to Eq (8) (Eser and Fitzpatrick, 2010). The relative viscosity (ηrel) values for 
glycerol have been obtained from the literature (Sheely, 1932).  
 
Eq. 8 
µ)*]*n(1*Sµ)*1(*[
*


mK
Sk
E
v
m
cat  
 
Where µ = (ηrel - 1); m and n are the effect of viscosity on kcat/Km and kcat respectively. The m*µ and n*µ 
values correspond to (kcat/Km)0/(kcat/Km)η and (kcat)0/(kcat)η  respectively, calculated at different relative 
viscosity values, which indicate the ratio of the value of the parameter in the absence and in the presence 
of viscogen at a given concentration. Note that in the original equation µ was (ηrel
2
 - 1), due to a printing 
error.     
 
Study the effect of F-actin on the NADPH oxidation reaction catalyzed by MICAL forms 
Materials  
-  HP8453 diode array and Cary100 spectrophotometers connected to theromostatted  bath at 25°C.  
Solutions 
- F-buffer (9.5 mM Tris/HCl, pH 7.7, 45 mM KCl, 0.18 mM CaCl2, 1.18 MgCl2, 1.1 mM ATP, 1.33 mM 
DTT); 
- NADPH 10 mM in 20 mM TrisOH;  
- F-actin solution (0.2 or 1.3 mg/ml, 4 or 30 μM); 
- MICAL proteins stock solutions (2-4 mg/ml) stored in buffer.   
Procedure  
F-actin solutions were prepared as described previously and maintained on ice during the experiments.  
To determine the intial velocity of the NADPH oxidation reaction catalyzed by MICAL forms in the 
presence of F-actin the enzyme solutions were diluted in buffer B (50 mM Na-phosphate, pH 7.5, 100 
mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT). MOCH dilution (0.03 mg/ml, 0.4 µM) is prepared 
for each single assay carried out in the presence of F-actin due to the instability of the enzyme at this 
concentration. MOCHLIM is diluted to 0.2 mg/ml, 2 µM and MICAL to 1.3 mg/ml, 10 µM in buffer B. 
For all MICAL forms the standard NADPH oxidase activity is measured in a Cary100 spectrophotometer 
in parallel to the assay carried out with HP8453 diode array spectrophotometer in the presence of F-actin 
to verify the stability of their activity under standard conditions and eventually, to correct the intial 
velocity measured in the presence of F-actin by taking into the account the partial loss of the activity due 
to the low concentration of protein solutions required to carry out the assys in the presence of F-actin. 
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To determine the effect of F-actin on the apparent steady-state kinetic parameters kcat and Km for NADPH 
of MICAL forms, the initial velocity of the NADPH consumption is determined  by varying NADPH 
concentration (10-400 μM) in the presence of a fixed concentration of F-actin (4 μM). The NADPH 
oxidation is monitored by recording the absorption spectra of the reaction every 10 s to detect the 
formation of turbidity and/or aggregates over time, which would affected the calculation of the reaction 
velocities. The v/E values are calculated from  the absorbance changes at 340 nm.  
To determine the apparent Km for F-actin the v/E values are determined in the presence of a fixed 
concentration of NADPH (200 μM) by varying F-actin concentration (1-30 μM) in F-buffer.  
An example of the experimental set-up to measure the rate of NADPH consumption in the presence of F-
actin is described:  
In a 0.2 ml cuvette:  
- add 120 μl of F-actin solution; 
- record the absorption spectrum for 2 min; 
- add 2.5 μl of 10 mM NADPH (200 μM final concentration) and mix gently;  
- record the absorption spectrum and incubate for 3 min;  
- add 1 μl of the enzyme dilution and mix gently;  
- record the absorption spectra every 10 s;  
- calculate the v/E value from the absorbance trace at 340 nm.  
 
The calculated v/E values are fitted to the Michaelis-Menten equation (Eq.2) after inspection of double 
reciprocal plots (Eq.1).  
 
 
10.12. Study of the interaction between MICAL-MO or MOCH and CRMP/8-525 
 
Study of the interaction by Ni-NTA affinity chromatography 
Method 1 
Materials 
- Ni-NTA Sepharose resin HisPur Ni-NTA Resin (Thermo Fisher Scientific); 
- HP 8453 diode array spectrophotometer. 
Solutions  
- buffer A: 20 mM Hepes/KOH buffer, pH 7;  
- buffer A + 100 mM NaCl pH 7;  
- buffer A + 20, 40, 60, 80, 100, 120, 140, 160, 200 and 500 mM imidazole, prepared by mixing buffer A 
and buffer A + 500 mM imidazole (pH 7).  
Sample preparation 
- gel filter CRMP and MO on a Sepharose G25 (medium) column (PD10) in buffer A, as previously 
described; 
- record the absorption spectrum of the individual fractions; 
- pool the fractions enriched in the protein; 
For MO-only and CRMP-only samples:  
- dilute the protein solution to 1 mg/ml in buffer A and a final volume of 1 ml; 
- record the absorption spectrum;  
For MO+CRMP sample: 
- add to 0.5 ml of MO solution (2 mg/ml) to 0.5 ml of CRMP solution (2 mg/ml);  
- record the absorption spectrum.  
Set-up of interaction assay 
- distribute in three eppendorf tubes 1 ml of Ni-NTA Sepharose 50% suspension in buffer A+ 100 mM 
NaCl; 
- let the resin settle and remove the supernatant;  
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- add 1 ml of MO-only, CRMP-only and MO+CRMP solutions to each tube;  
For each sample:  
- resuspend the resin by gently mixing;  
- incubate on a wheel for 1h at 6 rpm and 4°C; 
- pour the suspension into an empty column;  
- let the resin pack under flow and collect the flow-through (FT); 
- apply:  
 buffer A + 100 mM NaCl     5x0.5 ml 
 buffer A + 100 mM NaCl + 20 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 40 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 60 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 80 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 100 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 120 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 140 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 160 mM imidazole  1x0.5 ml 
 buffer A + 100 mM NaCl + 200 mM imidazole  2x0.5 ml 
 buffer A + 100 mM NaCl + 500 mM imidazole  4x0.5 ml 
 
- collect 0.5 ml fractions; 
- analyze 20 μl of each fraction by SDS-PAGE.  
Method 2 
Materials 
- Ni-NTA Sepharose resin HisPur Ni-NTA Resin, Thermo Fisher Scientific); 
- HP 8453 spectrophotometer. 
Solutions  
- buffer A: 20 mM Hepes/KOH buffer, pH 7, 20 mM imidazole;  
- buffer A + 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200 and 500 mM NaCl. 
- buffer A + 500 mM NaCl, 500 mM imidazole.  
Sample preparation 
MO and CRMP solutions are gel filtered on PD10 column in buffer A. 
Prepare MO and CRMP solutions to a final concentration of 0.5 mg/ml (1 ml).  
Set-up of interaction assay 
- distribute 1 ml aliquots of Ni-NTA Sepharose 50% suspension in buffer A in three eppendorf tubes;  
- let the resin to settle and remove the supernatant;  
To two resin aliquots: 
- add 1 ml of 0.5 mg/ml MO; 
- incubate on a wheel for 1 h at 6 rpm and 4°C; 
For each suspension, to remove any unbound proteins:  
- pour the suspension in an empty chromatography column;  
- let the resin pack under flow and collect the flow-through; 
- wash with 5x0.5 ml buffer A; 
- resuspend the resin in 0.5 ml of buffer A;  
- transfer the suspension into eppendorf tubes; 
- let the resin settle and discard the supernatant;  
To one aliquot of resin add 0.5 ml of buffer A and this will be the MO-only sample.  
To the second aliquot add 0.5 ml of CRMP (0.5 mg/ml) and this will be the MO+CRMP sample. 
To the third Ni-NTA Sepharose aliquot that had been set aside at the beginning of the experiment, add 0.5 
ml of CRMP (0.5 mg/ml in buffer A) and this will be the CRMP-only sample.  
For each one of the three samples:  
- mix gently;  
- incubate on a wheel for 1 h at 6 rpm and 4°C; 
- pour the suspension into an empty column, let the resin pack collecting the flow-through;  
- wash with 5x0.5 ml buffer A; 
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- apply 0.5 ml each of buffer A containing 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200 and 500 mM 
NaCl;  
- apply 5x0.5 ml buffer A + 500 mM NaCl, 500 mM imidazole; 
- collect 0.5 ml fractions and analyze 20 μl by SDS-PAGE.  
 
Study of the interaction between MO or MOCH and CRMP1/8-525  by measuring the NADPH oxidase 
activity of MICAL forms 
 
The interaction between MO or MOCH and CRMP/8-525 is also studied by measuring the NADPH 
oxidation reaction catalyzed by MICAL forms in the presence of CRMP/8-525 under different conditions.  
Protein preparations  
Prior each experiment aliquots of CRMP/8-525 preparation obtained by GSH-Sepharose chromatography 
were gel filtered in 20 mM Hepes/KOH buffer, pH 7 supplemented with 10, 25, 50, 100 mM NaCl or in 
“F-buffer no ATP” (9.5 mM Tris/HCl, pH 7.7, 45 mM KCl, 0.18 mM CaCl2, 1.18 mM MgCl2, 1.33 mM 
DTT) on a Superose12 column to remove the small amounts of aggregates and contaminating proteins 
and to transfer CRMP into the desired buffer, MICAL forms preparations stored at -80°C after gel 
filtration on a Superose12 column in buffer B (50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% 
glycerol, 1 mM EDTA, 1 mM DTT) were used. Buffer exchange of enzyme solutions was not required to 
due to the addition of a small volume of enzyme to the reaction mixture (1 μl to 120 μl).  
 
NADPH oxidase activity assays in the presence of CRMP/8-525  
Materials 
- HP8453 diode array spectrophotometer at 25°C.  
Solutions  
- 20 mM Hepes/KOH buffer, pH 7; 
- 20 mM Hepes/KOH buffer, pH 7 + 10, 25, 50, 100, 200 mM NaCl;  
- F-buffer; 
- NADPH 10 mM in 20 mM TrisOH.  
Procedure 
The NADPH oxidase activity of MO and MOCH is measured in the presence of a fixed concentration of 
NADPH (100 μM) and by varying CRMP concentration (1-50 μM) in the indicated buffers. Every 1-1.5 h 
the standard NADPH oxidase activity of MO and MOCH is measured.  
 
The activity assay is set-up in 0.2 ml cuvette as follows:  
- add 120 μl of CRMP solution or dilute CRMP solution at desired concentration in the same buffer to a 
total volume of 120 μl; 
- record the absorption spectrum for 2 min; 
- add 1.5 μl of 10 mM NADPH solution (100 μM final concentration) and incubate for 3 min;  
- add 1-2 μl of MO or MOCH solution; 
- record the absorption spectrum of the reaction every 10 sec.   
 
The v/E values are calculated as described before.  
 
To determine the apparent Kd for MO- or MOCH-CRMP complex when CRMP has an inhibitory effect, 
the v/E values measured in the presence of CRMP are subtracted to that measured in its absence, vice-
versa when a stimulatory effect is observed. The resulting v/E values are fitted to the following equation:  
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Eq.9  
 
tot
tottotdtottotdtottot
E
LEKLEKLE
EL
2
4
2

  
 
Where Etot is the total enzyme concentration; L is the total concentration of the ligand; EL is the concentration of the 
enzyme-ligand complex; Kd is the dissociation constant for the enzyme-ligand complex. The increase or decrease of 
v/E is taken as proportional to EL concentration so that Etot is the maximum value of v/E.   
 
 
10.13. Miscellaneous techniques  
 
Determination of the protein concentration with the Bradford method   
Preparation of the Bradford reagent  
Solutions 
- 85% (w/v) phosphoric acid; 
- 100% methanol;  
- H2O; 
- Coomassie Brilliant Blue G-250.  
Procedure for 1 l of Bradford reagent solution 
- dissolve 100 mg of Coomassie Brilliant Blue in 50 ml 100% methanol; 
- add 100 ml 85% phosphoric acid; 
- add 850 ml of H2O; 
- mix under stirring at least for 2 h at RT;  
- filter the solution through a 0.22 µm filter paper and store at 4°C.  
Preparation of standard curve and protein samples  
Solutions   
- Bradford reagent; 
- 0.15 M NaCl; 
- BSA 0.5 mg/ml.  
Materials 
- Cary100 spectrophotometer.  
Procedure 
A range of BSA concentrations (0-6 mg) is used to draw the calibration curve.  
In eppendorf tubes: 
- add 100 ul (for blank) or 100-x ul of 0.15 M NaCl; 
- add 0-x ul of BSA; 
- add 1 ml of Bradford reagent; 
- incubate for 15-20 min at RT; 
- record the A595; 
- plot the A595 as a function of the µg of BSA present in each assay to draw the calibration curve;  
- set-up the sample as described for BSA by using aliquots of different volumes for each sample;  
- record the A595 values; 
- check the reproducibility and linearity of the A595 values as a function of sample volume added; 
- determine the protein concentration of sample using the equation obtained from the linear portion of the 
calibration curve.  
 
 Polyacrylamide Gel Electrophoresis in the presence of Sodium Dodecyl Sulfate (SDS-PAGE)  
 
Materials 
- SE 260 electrophoretic apparatus for SDS-PAGE (Amersham, GE); 
- dual gel caster SE 245 (Hoefer-Amersham, GE); 
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Solutions 
- 30%AcA+bisAcA: 29.9% (w/v) acrylamide, 0.8% (w/v) N-methylenbisacrylamide; 
- 0.5 M Tris/HCl buffer, pH 6.8; 
- 1.5 M Tris/HCl buffer, pH 8.8; 
- 10% SDS: 10% (w/v) SDS in H2O;  
- AxS: 10% (w/v) ammonium persulphate in H2O;  
- TEMED: N,N,N’,N’-tetramethylethylenediamine 
- Running buffer 10X: 250 mM Tris, 1.92 M glycine, pH 8.2;  
- Running buffer: 10-fold dilution of running buffer 10x in H2O supplemented with 0.1% SDS (w/v); 
- SB4X: 0.5 M Tris/HCl, pH 6.8, 8% SDS (w/v), 40% glycerol (v/v), 20% 2-ME (v/v), 0.005% 
bromophenol blue (w/v), stored at -20°C;  
- staining solution: 40% methanol (v/v), 10% acetic acid (v/v), 0.1% Comassie Blue R-250 (w/v); 
- destaining solution: 40% methanol (v/v), 10% acetic acid (v/v).   
 
Procedure 
- set-up the following mixture to prepare the running gel for two mini gels (8x10 cm or 10x10 cm; 1 mm 
thinck) 
 
 AcA+bisAcA 
 10% 12% 
H2O, ml 8.1 6.7 
1.5 M Tris/HCl pH 8.8, ml 5 5 
AcA+bisAcA, ml 6.6 8 
SDS, ml 0.2 0.2 
TEMED, ml 0.01 0.01 
AxS, ml 0.1 0.1 
 
When the running gel is polymerized 
- set-up the following mixture to prepare the stacking gels 
 
 AcA+bisAcA 
 4% 
H2O, ml 6.1 
0.5 M Tris/HCl pH 6.8, ml 2.5 
AcA+bisAcA, ml 1.3 
SDS, ml 0.1 
TEMED, ml 0.01 
AxS, ml 0.05 
 
At the end of the polymerization: 
- place the gel onto apparatus for electrophoresis; 
- fill the upper and lower chambers of the apparatus with running buffer;  
- load the samples; 
- apply 20 mA per gel until the BBF reaches the running gel; 
- apply 40 mM until the BBF is at the end of running gel;  
- incubate the gel in the staining solution for at least 1 h under stirring; 
- transfer the gel in the destaining solution.  
 
Blot transfer onto polyvinylidene difluoride (Immobilon) membrane 
Materials 
The material being used is washed with ultrapure water and the electrophoretic apparatus is also rinsed 
with 100% methanol followed by water.  
- Whatman paper 3 MM (Millipore);  
- polyvinylidene difluoride membrane (Immobilon P, Millipore); 
- SE 260 electrophoretic apparatus (Amersham); 
- Mini-Trans Blot (BioRad 170-3930);  
 224 
Solutions 
All the solution are freshly prepared immediately before the experiment.  
- 1.5 M Tris/HCl buffer, pH 8.8 (filter the aliquot to use through 0.22 μm filter);  
- 0.5 M Tris/HCl buffer, pH 6.8 (filter the aliquot to use through 0.22 μm filter); 
- AcA + bisAcA 30% (use ultrapure AcA and bisAcA and filter the aliquot to use through a 0.22 μm 
filter); 
- SDS 10% (w/v); 
- Running buffer 10X: 0.25 M Tris, 1.9 M glycine; 
- Running buffer 1X: dilute running buffer 10X 10-fold with H2O and add 0.1% SDS; 
- Mercaptoacetic acid; 
- Methanol 100% (MetOH 100%); 
- Transfer buffer: 10 mM CAPS, pH 11, 10% methanol, 0.25 mM DTT (DTT is added just before use);  
- Staining solution: 40% methanol (v/v), 10% acetic acid (v/v) and 0.1% Comassie Blue R-250 (w/v); 
- Destaining solution: 40% methanol (v/v), 10% acetic acid (v/v);  
Procedure  
- prepare the polyacrilamide gel at the desired % of AcA+bisAcA;  
- store overnight at 4°C to ensure that all radical species are decayed;  
- set-up the electrophoretic apparatus; 
- add mercaptoacetic acid (2 mM) to the running buffer 1X and transfer it only in the upper chamber; 
- load the sample (at least 30 µg of protein for the N-terminal sequencing) and carry out the 
electrophoresis as described previously;  
At the end of the electrophoretic migration:  
- equilibrate the gel in transfer buffer for 15 min at RT under gentle shaking;  
- equilibrate filter papers (2 for 1 gel) in transfer buffer;  
- activate the immobilon membrane:  
 soak by capillarity in 100%MetOH and equilibrate for 3 min; 
 transfer the membrane in ultrapure H2O for 3 min; 
 transfer the membrane in transfer buffer for 3 min;  
For the electrotransfer: 
- place on the gel cassette holder: filter pad/filter paper/gel/immobilon membrane/filter paper/filter pad;  
- close the cassette firmly, being careful not to move the sandwich;  
- transfer into the buffer tank of the minitrans blot apparatus; 
- add the frozen Bio-Ice cooling unit;  
- fill the tank with transfer buffer stored at 4°C; 
- add a stir bar and place on a magnetic stirrer to help maintain even buffer temperature and ion 
distribution in the tank; 
- put on the lid and apply 60 V for 2 h.  
At the end of the electrotransfer: 
- disassemble the blotting sandwich and remove the membrane; 
- soak the membrane into staining solution for 5 min under gentle shaking; 
- transfer the gel into staining solution to verify the efficacy of the electrotransfer; 
- transfer the membrane into a small aliquots of the destaining solution  and remove the unbound dye by 
replacing the destaining solution every few minutes until no Coomassie blue is released; 
- wash thoroughly the membrane with several aliquots of  ultrapure H2O until no trace of acetic acid is 
detected; 
- dry the membrane; 
- place the membrane between two layers of filter paper and store at -20°C until analysis.  
 
10.14. Technical notes 
Ni-NTA Sepharose affinity chromatography  
Preparation and regeneration(1) 
Materials   
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- HisPur Ni-NTA Resin (Thermo Fisher Scientific); 
- column (2x9 cm). 
Solutions 
- H2O; 
- equilibration buffer; 
- MES buffer: 20 mM MES, pH 5, 100 mM NaCl; 
- 20% EtOH: 20% ethanol (v/v).  
The solutions are filtered with 0.22 µm and degassed.  
Procedure  
To equilibrate the resin: 
- transfer the desired volume of  50% suspension of Ni-NTA Sepharose resin stored in 20%EtOH in an 
empty column and pack the resin; 
- wash with at least 5 volumes of H2O; 
- equilibrate by flowing 5 volumes equilibration buffer; 
- resuspend the resin in 1 volume equilibration buffer; 
- transfer in a test tube; 
- store at 4°C.  
After usage to regenerate the resin flow: 
- 5 volumes H2O; 
- 5 volumes MES buffer; 
- 3 volumes 20%EtOH;  
Resuspend the resin in 1 volume 20%EtOH, transfer to a plastic bottle and store at 4°C.  
Preparation and regeneration(1) 
Materials  
- Ni-NTA Sepharose resin (Ni Sepharose 6 Fast Flow, GE Healthcare); 
- XK16 column (1.6x19 cm, Amersham Pharmacia); 
- peristaltic pump Pump P-1 (Amersham Pharmacia). 
Solutions 
- H2O; 
- equilibration buffer; 
- Na-phosphate buffer + EDTA: 20 mM Na-phosphate buffer, pH 7.5, 500 mM NaCl, 50 mM EDTA; 
- Na-phosphate buffer: 20 mM Na-phosphate buffer, pH 7.5; 
- NiSO4: 0.1 M NiSO4; 
- 20% EtOH: 20% ethanol (v/v). 
The solutions are filtered with 0.22 µm and degassed.  
Procedure  
To equilibrate the resin: 
- transfer the Ni-NTA Sepharose 50% suspension in 20%EtOH (30-60 ml) in a vacuum flask; 
- wash 5 times with 1 volume H2O; 
- wash twice with 1 volume equilibration buffer; 
- add 1 volume equilibration buffer; 
- resuspend the resin and degas for ≈1 h; 
- resuspend the resin and pour into the column containing 5 ml of degassed equilibration buffer; 
- let the resin settle for ≈10 min, open the column and let the resin pack; 
- flow 4 volumes equilibration buffer with a peristaltic pump at a flow rate of 150 ml/h; 
- store the column at 4°C.  
To regenerate the resin flow:  
- 5 volumes Na-phosphate buffer + EDTA; 
- 5 volumes Na-phosphate buffer;  
- 5 volumes H2O; 
- 0.5 volumes NiSO4;  
- 5 volumes H2O;  
- 3 volumes 20%EtOH;  
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Resuspend the resin in 1 volume 20%EtOH, transfer into a plastic bottle and store at 4°C.    
 
Gel filtration-Superose12 column 
Materials 
- Superose12 column for FPLC, fractionation range 10000-30000, stationary phase 24ml of dextran and 
agarose granules (microsphere diameter 8-12 μm) (Amersham Pharmacia); 
- FPLC Akta apparatus (GE Healthcare). 
Solutions  
- 20% EtOH: 20% ethanol (v/v); 
- H2O; 
- equilibration buffer.  
The solutions are filtered under vaccum though 0.22 µm filter and degassed.  
Procedure 
- wash the FPLC pumps A and B with 20% EtOH;  
- connect the column at a flow rate of 0.1 ml/min (50% B); 
- flow 50 ml of EtOH 20%; 
- wash pump A with H2O; 
- flow 50 ml water (0% B) at flow rate between 0.1 and 0.5 ml/min until the conductivity value is stable; 
- wash pump A with equilibration buffer; 
- flow equilibration (0% B) at flow rate between 0.1 and 0.5 ml/min at least 75 ml after that the 
conductivity value is stable; 
- load the sample (200-500 µl) in the loading loop (500 µl); 
- inject the sample and elute at a flow rate of 0.5 ml/min collecting 0.5 ml fractions. 
At the end of the chromatography: 
- wash the FPLC pump A with H2O; 
- flow 50 ml water (0% B) at flow rate between 0.1 and 0.5 ml/min until the conductivity value is stable; 
- wash the FPLC pump A with 20% EtOH; 
- flow 100 ml 20%EtOH (0% B) at flow rate between 0.1 and 0.3 ml/min until the conductivity value is 
stable; 
- disconnect the column at a flow rate of 0.1 ml/min.  
 
Calibration with standard proteins  
Solutions  
- standard proteins from the HMW and LMW Gel Filtration Calibration Kits (GE Healthcare): bovine 
thyroid thyroglobulin, 667000 Da; horse spleen ferritin, 395000 Da; rabbit muscle aldolase 191000 Da; 
bovine serum albumin BSA, 66000; hen egg ovoalbumin, 49400; 
- buffer B: 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT. 
Procedure 
- prepare protein standard solutions at a concentration of 10 mg/ml in buffer B; 
- set-up the following protein standard mixtures: 
 
 
Protein stock, μl   
Thyroglobulin   200 
BSA  200 
Buffer 200 
Total volume, μl 600 
  
 
Protein stock, μl  
Ferritin  200 
Ovoalbumin  200 
Buffer 200 
Total volume, μl 600 
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Protein stock, μl   
Aldolase  200 
Buffer 400 
Total volume, μl 600 
 
- inject 400 μl of one of the protein standard mixtures onto equilibrated Superose12 column and eluted 
with buffer B at 0.5 ml/min and collecting 0.5 ml fractions; 
- draw the calibration curve using the elution volume of the standard proteins (Table 10.x) by plotting the 
Log of their mass as a function of the elution volume; 
 
Table 10.6. Gel filtration of the standard proteins on a Superose12 column equilibrated and eluted with buffer B. 
The proteins were gel filtered in buffer B and their elution volume and molecular mass were used to draw the 
calibration curve shown in Figure 5.4.  
 
Protein Molecular mass, Da Elution volume, ml 
Thyroglobulin 667000 7.64 
Ferritin 395000 10.48 
Aldolase 191000 12.23 
BSA 69800 12.99 
Ovoalbumin 49400 13.44 
 
Gel filtration-Superdex200 column 
Materials  
- Superdex 200 prep grade resin (GE Healthcare);  
- XK16column (1.6x100 cm, Amersham Pharmacia); 
- Packing reservoir (Amersham Pharmacia);   
- peristaltic pump Pump P-1 (Amersham Pharmacia); 
- Bromma 2111 Multirac fraction collector (LBK, Uppsala).  
Solutions  
- H2O; 
- EtOH 20%: 20% ethanol (v/v); 
- buffer B + 1 mM PMSF: 50 mM Na-phosphate buffer, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM 
EDTA, 1 mM DTT, 1 mM PMSF;  
- Tween 20. 
The solutions are filtered with 0.22 µm and degassed.  
 Procedure 
- transfer 150 ml of Superdex 200 resin into a vacuum flask; 
- wash in batch 5-10 times with 1 volume H2O; 
- wash with 475 ml of water + 300 μl of Tween 20;  
- resuspend the resin and degas for 30 min; 
- attach packing reservoir to the column; 
- resuspend the resin, pour the suspension into the column in a single step and cap the packing reservoir; 
-  connect the pump outlet to the inlet of the packing reservoir and open the column;  
- flow buffer B + 1 mM PMSF at a flow rate of 2 ml/min for 2 h and 10 ml/min for 1 h; 
- transfer at 4°C; 
- load the sample; 
- flow buffer B + 1 mM PMSF at 0.5 ml/min; 
- collect 1.5-3 ml fractions; 
- analyze the fraction by recording the absorption spectrum and by SDS-PAGE.  
 
After use:  
- flow at least 5 volumes H2O at of 1-2 ml/min;  
- flow 3 volumes  20% EtOH at 0.5 ml/min; 
- resuspend the resin in 1 volume 20% EtOH, transfer in a plastic bottle and store at 4°C.  
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Anion exchange chromatography - MonoQ column connected to FPLC 
Materials 
- MonoQ anion exchanger column (Amersham Pharmacia);  
- FPLC Akta apparatus (GE Healthcare, Little Chalfont, UK); 
Solutions 
- 20%EtOH: 20% ethanol (v/v); 
- H2O; 
- buffer A: 20 or 50 mM Na-phosphate, pH 7.5; 
- buffer A + 1 M NaCl. 
The solutions are filtered with 0.22 µm and degassed.  
Procedure 
The MonoQ column is connected to FPLC Akta apparatus as described for Superose12 column in 
EtOH20%:   
- fill pump A and B with 20% EtOH;  
- flow 10 ml 20%EtOH (50% B) at a flow rate between 0.1 and 0.5 ml/min; 
- fill pump A and B with 20% H2O;  
- flow 10 ml H2O (50% B) at flow rate between 0.1 and 0.5 ml/min; 
- wash pump A with buffer A; 
- wash pump B with buffer A + 1 M NaCl; 
- flow 5 ml of starting buffer (2 or 10 %B); 
- equilibrate the column as follows:  
Volume, ml %B ml/min Note 
0-5 2 or 10 0.5  %B depends on the 
starting NaCl 
concentration desired 
 
5-8 gradient up to 100 0.3 
8-13 100 0.3 
13-16 Gradient down to 2or 10 0.3 
16-25 2-10 0.5 
At the end of the chromatography: 
- apply a linear gradient from 100 to 2-10% buffer B in 10 ml; 
- wash pump A and B with H2O; 
- flow 10 ml H2O (50%B) at 0.5 ml/min; 
- wash pump A and B with 20%EtOH; 
- flow 10 ml 20%EtOH (50%B) at 0.3 ml/min; 
- disconnect the column at a flow rate of 0.1 ml/min.  
 
Anion exchange chromatography - Large-scale purification on Q-Sepharose resin 
Materials 
- Q-Sepharose Fast Flow resin (GE Healthcare); 
- XK16 column (1.6x10 cm, GE Healthcare); 
- Akta apparatus for FPLC (GE Healthcare). 
Solutions 
- 20%EtOH: 20% ethanol (v/v); 
- H2O; 
- buffer A: 50 mM Na-phosphate, pH 7.5, 1 mM EDTA, 1 mM PMSF, 1 mM DTT (DTT and PMSF are 
added prior the use); 
- buffer A + 1 M  NaCl; 
- equilibration buffer (buffer A + 100 mM NaCl) : 50 mM Na-phosphate, pH 7.5, 100 mM NaCl, 1 mM 
EDTA, 1 mM PMSF, 1 mM DTT;  
The solutions are filtered with 0.22 µm and degassed.  
Procedure 
To equilibrate the resin: 
- transfer the required amount of resin (50% suspension in 20% EtOH) into a vacuum flask; 
- wash in batch with 1 volume H2O 5 times; 
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- wash in batch with 1 volume equilibration buffer 3 times; 
- resuspend in 1 volume of equilibration buffer; 
- degas for ≈1 h; 
- transfer into the column and let the resin settle; 
- connect the column to the FPLC apparatus flowing buffer A+ 100 mM NaCl (10%B) at 0.1 ml/min; 
- equilibrate the column as described for 10 ml of resin:  
Volume, ml %B ml/min 
0-40 10 1.5 
40-70 gradient up to 100 1.5 
70-120 100 1.5 
120-150 Gradient up to 2or 10 1.5 
150-230 10 1.5 
- transfer the column at 4°C in the cold room. 
For the chromatography of sample: 
 - load the sample and wash with 2 volumes of the equilibration buffer through gravity and collect 
fractions in the cold room; 
- connect the column to a bath thermostatted at 10°C and to the FPLC apparatus;  
- apply the following gradient (for a 10 ml column): 
Volume, ml % B Flow rate, ml/min 
0-50 2 or 10 1-1.2 
50-650 gradient up to 50 1-1.2 
650-750 gradient up to 100 1-1.2 
750-760 100 1-1.2 
- collect 5-2 ml fractions; 
At the end of chromatography to regenerate the resin:  
- apply a linear gradient from 100% to 10% buffer B in 5 volumes ml with a flow rate of 1-2 ml/min; 
- flow 3 volumes equilibration buffer ; 
- flow at least 5 volumes water; 
- flow 5 volumes 20% EtOH; 
- resuspend in 1 volume 20% EtOH, transfer into a plastic bottle and store at 4°C. 
Glutathione-Sepharose affinity chromatography  
Materials 
- Glutathione(GSH)-Sepharose resin (Glutathione agarose, GE Healthcare); 
- column (1.7xh 14 cm, BioRad); 
Solutions  
- H2O; 
- equilibration buffer (Lysis Buffer): 50 mM Hepes/KOH, pH 7.5, 150 mM KCl; 
- Regeneration Buffer: 6 M guanidine hydrochloride solution in water; 
- PBS: 10 mM Na2HPO4, 1.8 mM KH2PO4, 140 mM NaCl, pH 7.3, 2.7 mM KCl; 
- 20% EtOH: 20% ethanol (v/v).  
Procedure 
To equilibrate the resin: 
- transfer the resin (50% suspension in 20%EtOH) into the column;  
- flow 5 volumes H2O; 
- flow 5 volumes equilibration buffer; 
- resuspend the resin in 1 volume of equilibration buffer;  
- transfer in a falcon tube and store at 4°C. 
To regenerate the resin, flow:  
- 3 volumes regeneration buffer; 
- 3 volumes PBS; 
- 3 volumes H2O2; 
- flow 3 volumes of EtOH 20%; 
Resuspend the resin in 1 volume of 20% EtOH, transfer in a plastic bottle and store at 4°C.  
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